Unity Biotechnology, Inc.

 
 
  
UNITED STATES 
SECURITIES AND EXCHANGE COMMISSION 
Washington, D.C. 20549
 
FORM 10-K 
 
(Mark One) 
☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 
For the fiscal year ended December 31, 2024
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION 
PERIOD FROM                      TO                     
Commission File Number 001-38470 
 
Unity Biotechnology, Inc.
(Exact name of Registrant as specified in its Charter) 
 
 
Delaware
26-4726035
( State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer

Identification No.)
285 East Grand Ave. 
South San Francisco, CA
94080
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (650) 416-1192
 
 
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, par value $0.0001
UBX
The Nasdaq Global Select Market
 
Securities registered pursuant to Section 12(g) of the Act: None 
Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES ☐ NO ☒
Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YES ☐ NO ☒ 
Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 
months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☒ NO ☐ 
Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of 
this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). YES ☒ NO ☐ 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. 
See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer
  ☐ 
Accelerated filer
  ☐
Non-accelerated filer
  ☒ 
Smaller reporting company
  ☒
Emerging growth company
  ☐ 
 
   
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial 
accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the Registrant has filed a report on and attestation to its management assessment of the effectiveness of its internal control over financial reporting 
under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of 
an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s 
executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐
Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☐ NO ☒
The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on The 
Nasdaq Global Select Market on June 30, 2024 was $22,509,406. 
The number of shares of Registrant’s Common Stock outstanding as of March 6, 2025 was 16,867,647. 
DOCUMENTS INCORPORATED BY REFERENCE
Portions of the Registrant’s Definitive Proxy Statement relating to the 2025 Annual Meeting of Shareholders, scheduled to be held on June 20, 2025, are incorporated by reference into 
Part III of this Report. Such proxy statement will be filed with the Securities and Exchange Commission within 120 days of the end of the fiscal year covered by this Annual Report on 
Form 10-K.
 

 
2
Table of Contents
 
 
 
Page
PART I
 
 
Item 1.
Business
6
Item 1A.
Risk Factors
32
Item 1B.
Unresolved Staff Comments
75
Item 1C. 
Cybersecurity
75
Item 2.
Properties
76
Item 3.
Legal Proceedings
76
Item 4.
Mine Safety Disclosures
77
 
 
 
PART II
 
 
Item 5.
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
78
Item 6.
[Reserved]
78
Item 7.
Management’s Discussion and Analysis of Financial Condition and Results of Operations
79
Item 7A.
Quantitative and Qualitative Disclosures About Market Risk
94
Item 8.
Financial Statements and Supplementary Data
95
Item 9.
Changes in and Disagreements With Accountants on Accounting and Financial Disclosure
132
Item 9A.
Controls and Procedures
132
Item 9B.
Other Information
133
Item 9C.
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
133
 
 
 
PART III
 
 
Item 10.
Directors, Executive Officers and Corporate Governance
134
Item 11.
Executive Compensation
134
Item 12.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
134
Item 13.
Certain Relationships and Related Transactions, and Director Independence
134
Item 14.
Principal Accounting Fees and Services
134
 
 
 
PART IV
 
 
Item 15.
Exhibits, Financial Statement Schedules
135
Item 16.
Form 10-K Summary
139
 
Signatures
140
 

 
3
Special Note Regarding Forward-Looking Statements
This Annual Report on Form 10-K contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as 
amended, or the Exchange Act. All statements other than statements of historical facts contained in this Annual Report on Form 10-K are statements that 
could be deemed forward-looking statements reflecting the current beliefs and expectations of management with respect to future events or to our future 
financial performance and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance or 
achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. 
These statements are often identified by the use of words such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” 
“estimate,” “expect,” “goal,” “if,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would,” 
“until,” and similar expressions or variations. Forward-looking statements contained in this Annual Report on Form 10-K include, but are not limited to, 
statements about:
•
our plans to develop and commercialize UBX1325 (foselutoclax) or any future product candidates;
•
our expectations regarding the potential benefits, activity, effectiveness, and safety of our drug candidates;
•
our ongoing and planned clinical trials, including expectations with regard to the results of our clinical studies, preclinical studies and 
research and development programs, including the timing and availability of data from such studies;
•
our predictions about the results of future or ongoing clinical trials, including predictions based on results from a clinical trial;
•
our preclinical, clinical and regulatory development plans for our drug candidates, including the timing or likelihood of regulatory filings and 
approvals for our drug candidates;
•
our expectations with regard to our ability to acquire, discover and develop additional drug candidates and advance such drug candidates into, 
and successfully complete, clinical studies;
•
our ability to raise substantial additional funds to achieve our goals;
•
our expectations regarding the potential market size and size of the potential patient populations for our drug candidates, if approved for 
commercial use;
•
our intentions and our ability to establish collaborations and/or partnerships;
•
the timing and amount of any milestone payments we are obligated to make pursuant to our existing license agreements and any future 
license or collaboration agreements that we may enter into;
•
our commercialization, marketing and manufacturing capabilities and expectations;
•
our intentions with respect to the commercialization of our drug candidates;
•
the pricing and reimbursement of our drug candidates, if approved;
•
the implementation of our business model and strategic plans for our business and drug candidates, including additional indications that we 
may pursue;
•
the scope of protection we are able to establish and maintain for intellectual property rights covering our drug candidates, including the
projected terms of patent protection;
•
estimates of our expenses, future revenue, capital requirements, our needs for additional financing, and our ability to obtain additional 
capital;
•
our ability to maintain compliance with the minimum required closing bid price and the other standards for continued listing on the Nasdaq 
Global Select Market;
•
our ability to remediate a material weakness in our internal control over financial reporting;
•
developments and projections relating to our competitors and our industry, including competing therapies;
•
our financial performance;

 
4
•
macroeconomic trends and uncertainty, including high interest rates, rising inflation, tariffs, and the potential for local and/or global 
economic recession; and
•
other risks and uncertainties, including those listed under the caption “Risk Factors”.
We caution you that the foregoing list may not contain all of the forward-looking statements made in this Annual Report on Form 10-K.
Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or 
achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. We 
discuss these risks in greater detail in “Risk Factors” and elsewhere in this Annual Report on Form 10-K. Given these uncertainties, you should not place 
undue reliance on these forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the 
date of this Annual Report on Form 10-K. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to 
update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes 
available in the future. 
This Annual Report on Form 10-K also contains estimates, projections, and other information concerning our industry, our business and the 
markets for certain drugs, including data regarding the estimated size of those markets, their projected growth rates, and the incidence of certain medical 
conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties, and actual events or 
circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this 
industry, business, market, and other data from reports, research surveys, studies, and similar data prepared by third parties, industry, medical and general 
publications, government data, and similar sources. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, 
when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph 
is derived from the same sources, unless otherwise expressly stated or the context otherwise requires.
Trademarks
This Annual Report on Form 10-K includes trademarks, service marks, and trade names owned by us or other companies. All trademarks, service 
marks and trade names included in this Annual Report on Form 10-K are the property of their respective owners.
Risk Factor Summary
Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all 
of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under 
the heading “Risk Factors” and should be carefully considered, together with other information in this Annual Report on Form 10-K and our other filings 
with the Securities and Exchange Commission, or SEC, before making investment decisions regarding our common stock.
•
We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale. We have 
incurred significant losses since our inception, and we anticipate that we will continue to incur losses for the foreseeable future, which, 
together with our limited operating history, make it difficult to assess our future viability.
•
Our financial condition raises substantial doubt as to our ability to continue as a going concern.
•
We will require substantial additional financing to achieve our goals, and a failure to obtain this capital when needed on acceptable terms, or 
at all, could force us to delay, limit, reduce or terminate our product development programs, other operations or commercialization efforts.
•
We may not be able to maintain compliance with the continued listing requirements of Nasdaq and, if so, we would be subject to delisting.

 
5
•
Our core therapeutic approach to slow, halt, or reverse diseases of aging is based on our understanding of cellular senescence. Utilizing 
senolytic molecules to treat diseases of aging is a novel therapeutic approach, which exposes us to unforeseen risks and makes it difficult to 
predict the time and cost of drug development and potential for regulatory approval.
•
Our business is currently dependent on the successful development of UBX1325, which is in Phase 2 of clinical development.
•
Other than UBX1325, all of our other programs are preclinical and face significant development risk.
•
We rely on third-party suppliers to manufacture supplies of our drug candidates and we intend to continue to rely on third parties to produce 
such preclinical and clinical supplies as well as commercial supplies of any approved product. The loss of these suppliers, or their failure to 
comply with applicable regulatory requirements or to provide us with sufficient quantities at acceptable quality levels or prices, or at all, 
would materially and adversely affect our business.
•
We face significant competition in an environment of rapid technological and scientific change, and our drug candidates, if approved, will 
face significant competition and our failure to effectively compete may prevent us from achieving significant market penetration. Most of our 
competitors have significantly greater resources than we do, and we may not be able to successfully compete.
•
Our senolytic medicine platform and any future products that we commercialize could be alleged to infringe patent rights and other 
proprietary rights of third parties, which may require costly litigation and, if we are not successful, could cause us to pay substantial damages 
and/or limit our ability to commercialize our products.
•
We have identified a material weakness in our internal control over financial reporting.  This material weakness could continue to adversely 
affect results of operations and financial condition.  In the future, we may identify additional material weaknesses or otherwise fail to
maintain an effective system of internal control over financial reporting or adequate disclosure controls and procedures, which may result in 
material errors in our financial statements or cause us to fail to meet our period reporting obligations.
 

 
6
PART I
Item 1. Business. 
Overview
We are a biotechnology company engaged in researching and developing therapeutics to slow, halt, or reverse diseases of aging. Our initial focus 
is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat diseases of aging, such as ophthalmologic diseases, with the 
opportunity to explore neurology and other therapeutic areas. 
Diseases of aging cause considerable economic, personal, and societal burden. As individuals age, the prevalence of chronic disease increases, 
with 80% of older Americans having at least one chronic disease and 50% having two or more. Diseases of aging negatively impact quality of life, are 
typically chronic, and progress from the time of onset until death. It is estimated that providing healthcare for people over the age of 65 costs four to five 
times more than for younger individuals. According to the United States Census Bureau, this elderly population of Americans is expected to increase nearly 
50% by 2050, increasing the economic burden of aging dramatically. Any success increasing longevity without treating underlying diseases of aging would 
only serve to increase this burden. 
We believe that by creating medicines that target fundamental aging mechanisms, we can reduce the economic, personal, and societal burden of 
aging and enhance quality of life.
In February 2022 and in May 2023, we announced restructuring efforts to align resources to focus on our ongoing clinical programs and deliver on 
key development milestones. These actions to prioritize our ophthalmology programs and implement cost saving measures were designed to enable us to 
achieve multiple key clinical data readouts for UBX1325 with all other pipeline programs paused to focus resources on these advanced programs.
Targeting Cellular Senescence and Other Biologies of Aging
We believe that the accumulation of senescent cells is a fundamental mechanism of aging and a driver of many common diseases of aging and 
beyond. Cellular senescence can also occur independent of age and be triggered by factors such as cellular damage provoked by stressors such as 
hyperglycemia (elevated glucose), uncontrolled cellular division (such as cancer), irradiation and non-resolving inflammation. Cells that become senescent 
remain alive and keep residing in a tissue yet are no longer able to properly communicate with neighboring cells and can no longer contribute to tissue 
function. Senescent cells secrete large quantities of more than 100 proteins, including inflammatory factors, proteases, fibrotic factors, and growth factors, 
that disturb the tissue micro-environment. This collection of secreted proteins is referred to as the Senescence Associated Secretory Phenotype, or SASP. In 
addition to its effects on tissue function, the SASP contains factors that induce senescence in neighboring cells, setting off a cascade of events that 
culminates in the formation of the functionally aged and/or diseased tissue that underlies a variety of age-related diseases. 
We are developing senolytic medicines to eliminate senescent cells from organs damaged by old age or damaged by diseases such as diabetes. By 
removing senescent cells from a sick tissue, we believe we can allow healthy cells to regenerate and potentially repair the affected organs and as well as 
lower the production of the SASP, which we believe addresses a root cause of age-related diseases. Many existing therapeutics, such as antibodies, target 
single SASP factors, but fail to remove the cells that continually produce these factors. By stopping the production of the SASP at its source, we believe 
senolytic medicines could have a more durable impact by slowing, halting, or reversing particular diseases of aging, and shift the treatment paradigm from 
chronic to intermittent dosing. Less frequent dosing may also improve drug tolerability and patient adherence.  
While our primary focus is on programs targeting cellular senescence, we are exploring other biologies of aging that may have a major impact on 
diseases of aging. For instance, we have a preclinical program targeting Tie2 signaling. Tie2 is a receptor tyrosine kinase that is implicated in regulating 
barrier function in blood vessels of the eye, which are affected in several prevalent eye diseases. Tie2 is also implicated in kidney disease. We also have a 
preclinical program targeting both Tie2 and VEGF (Tie2/VEGF bispecific) designed to neutralize VEGF and activate Tie2, two major pathways involved 
in retinal disease. We have outlicensed our program in α-Klotho, a protein that has been implicated in human cognition and may provide benefits in age-
related cognitive dysfunctions.

 
7
Our Pipeline 
We are targeting specific biological mechanisms implicated in diseases of aging. Our core therapeutic approach targets cellular senescence, and 
we are currently advancing senolytic programs primarily in ophthalmologic disorders. In addition, we have other programs based on other biologies of 
aging to include an agonistic antibody to the Tie2 receptor and a Tie2/VEGF bispecific to treat vascular eye disease.  
Ophthalmology Program
UBX1325 is our most advanced lead drug candidate for age-related diseases of the eye, including diabetic macular edema, or DME. UBX1967 is 
our back-up compound to UBX1325. Each of these drug candidates are potent small molecule inhibitors of BCL-xL, a member of the BCL-2 family of 
apoptosis regulating proteins, and have shown distinct tissue residence time profiles in preclinical studies. UBX1325 and UBX1967 are designed to inhibit 
the function of proteins that senescent cells rely on for survival. In our preclinical studies, we have demonstrated that targeting BCL-xL with UBX1325 and 
UBX1967 preferentially eliminated senescent cells from diseased tissue while sparing cells in healthy tissue. 
In July 2020, we filed an Investigational New Drug application, or IND, to commence a Phase 1, first-in-human, open-label, single-ascending dose 
study of UBX1325 (foselutoclax) in patients with advanced DME and neovascular age-related macular degeneration, or nAMD. Our current goal with 
UBX1325 is to transformationally improve outcomes for patients with DME. In October 2020, the Phase 1, first-in-human, clinical study of UBX1325 
commenced. That study, an open-label, single ascending dose clinical trial, evaluated doses from 0.5 – 10 µg administered as a single intra-vitreal injection 
in up to 8 patients with DME and 11 patients with nAMD all of whom had been off all anti-VEGF treatment due to lack of benefit for at least 6 months. 
The results of this study demonstrated acceptable safety and tolerability without any dose-limiting toxicities; no evidence of intraocular inflammation; and 
mean improvement in Best Corrected Visual Acuity (BCVA) of up to 9.5 ETDRS letters in those patients with DME receiving higher doses (5 and 10 µg) 
and a mean improvement in BCVA of 3.2 ETDRS letters in evaluable patients with nAMD at all doses, both at 24 weeks after treatment with UBX1325.
In May 2021, we initiated our Phase 2 BEHOLD study of UBX1325 in patients with DME and dosed our first patient in June 2021. This study 
was a multi-center, randomized, double-masked, sham-controlled study designed to evaluate the safety, tolerability, efficacy and durability of a single 10 
µg dose of UBX1325 (foselutoclax) in patients with DME evaluated though 24 weeks. Patients had the option of rolling over to a 48-week long term 
extension and a majority of patients who completed their 24-week visits opted to remain in the study. A total of 65 patients were enrolled, randomized 
evenly between UBX1325 and sham-injected patients. These patients were being actively treated with anti-VEGF for at least 6 months prior to being
randomized into the BEHOLD study (mean of 4.03 injections in the 6 months preceding randomization), and had persistent visual acuity deficits (73 
ETDRS letters or worse, approximately 20/40 or worse, mean of 61.4 letters at baseline) and residual retinal fluid (≥300 µm of central subfield thickness on 
optical coherence tomography, mean of approximately 439.6 µm). At the time of randomization, patients were taken off of their anti-VEGF treatment, and 
instead treated with UBX1325 or a sham procedure. Endpoints explored in the study included safety and tolerability, changes in BCVA, CST, SRF/IRF, 
proportion of patients requiring rescue treatment, and durability of effects.
In August 2022, we announced positive 12- and 18-week data in our Phase 2 BEHOLD study, including that a single injection of UBX1325 led to 
a progressive, statistically significant, and clinically meaningful improvement in mean BCVA compared to sham treatment. At Week 18, the mean change 
from baseline of BCVA for UBX1325-treated subjects was an increase of 6.1 ETDRS letters that represented a difference of +5.0 ETDRS letters compared 
to sham-treated subjects (p=0.0368). In addition, patients treated with UBX1325 maintained central subfield thickness (CST) (+3.2 microns) compared to 
sham-treated patients who had progressive worsening (increase) in CST through 18 weeks (+53.5 microns) (p=0.0719). 
In November 2022, we announced positive 24-week data in our BEHOLD study, showing that a single injection of UBX1325 led to a statistically
significant and clinically meaningful improvement in BCVA of +6.2 ETDRS letters from baseline and +7.6 ETDRS letters compared to sham treatment 
(p=0.0084). Inclusive of rescue data, patients treated with UBX1325 had a mean improvement in BCVA of +6.4 ETDRS letters from baseline and +5.2 
ETDRS letters compared to sham (p=0.0068). At 24 weeks, patients treated with UBX1325 had a mean change in CST of -5.4 microns from baseline 
compared to a worsening (increase) of +34.6 microns in sham-treated patients (p=0.1244). The proportion of rescue-free patients at 24 weeks was greater 
on UBX1325 (59.4%) as compared to sham (37.5%) with fewer total rescues and longer time-to-rescue in UBX1325-treated patients as compared to sham. 

 
8
UBX1325 demonstrated a favorable safety and tolerability profile with no cases of intraocular inflammation, retinal artery occlusion, endophthalmitis, or 
vasculitis. Patients were followed through 48 weeks post-treatment in a long-term follow-up.
In April 2023, we announced positive 48-week data from this long-term follow-up in our BEHOLD study in 50 patients who participated in the 
48-week extension study, showing that a single injection of UBX1325 led to a statistically significant and clinically meaningful improvement in vision 
lasting for the duration of the study (48 weeks), marked by a gain of +6.2 ETDRS letters from baseline, representing a difference of +5.6 ETDRS letters 
compared to sham-treated patients. In addition, patients treated with UBX1325 maintained stable CST compared to worsening in sham-treated patients 
(p=0.1198). Approximately 50% of UBX1325-treated patients did not require any additional injections through 48 weeks, compared to only 22% of 
patients in the sham arm. Retinal structure, as measured by central subfield thickness (CST), was maintained in UBX1325-treated patients throughout the 
duration of the study. UBX1325 continued to show a favorable safety and tolerability profile with no evidence of intraocular inflammation.
In December 2023, we announced that the first patients have been dosed in our Phase 2b ASPIRE study, designed to evaluate UBX1325 
(foselutoclax) head-to-head against aflibercept in previously treated patients with active DME who are not achieving optimal benefit from standard of care. 
In August 2024, we completed enrollment of patients into the ASPIRE study in DME, which is a multi-center, randomized, double-masked, active-
controlled study designed to evaluate the safety and efficacy of UBX1325 in comparison to aflibercept. Patients are randomized 1:1 to receive either 10 μg 
UBX1325, or 2 mg of aflibercept control injections every eight weeks for six months. We completed enrollment of 52 participants with DME who have 
residual visual acuity deficits and excess fluid in the retina despite having received at least three anti-VEGF injections in the preceding sixteen weeks. All 
participants received three monthly doses of 2 mg aflibercept as a “run-in” prior to randomization. The primary efficacy endpoint will be mean change 
from baseline in BCVA to week 24. Secondary endpoints will include change in BCVA over time, CST change from baseline to week 24, proportion of 
participants who do not require rescue, and percentage of participants with one or more treatment-emergent ocular adverse events during the course of the 
study.
In April 2024, we announced that the ongoing Phase 2b ASPIRE study of UBX1325 has been extended from 24 to 36 weeks to assess safety, 
efficacy, and potentially greater durability compared to aflibercept. There will be no scheduled treatments in either arm between 24 and 36 weeks to allow 
direct comparison of durability to effect between the two treatment arms. We completed enrollment in August 2024 and anticipate receiving topline data 
from the ASPIRE study in two data readouts: 24-week primary endpoint data in the first quarter of 2025, and 36-week long-term extension data in the 
second quarter of 2025.
From August through September 2024, we had a Type C interaction with the U.S. Food and Drug Administration (FDA) regarding the 
development of UBX1325 (foselutoclax) or DME. The objectives of this meeting were to obtain FDA input regarding the design of the pivotal trial and 
endpoint for regulatory approval. Based on the interaction, we expect the pivotal study would need to be a non-inferiority trial comparing UBX1325 to an 
approved anti-VEGF agent. The primary endpoint is expected to be the change in baseline in BCVA, as assessed by the ETDRS scale with a non-inferiority 
margin of four letters.
In age-related macular degeneration (AMD), in March 2022, we enrolled our first patient in the Phase 2 ENVISION study. This study was a 
prospective, multicenter, randomized, double-masked, active-controlled study to assess the safety, tolerability, and evidence of activity of a repeat 
intravitreal injection of UBX1325 (foselutoclax) in patients with neovascular AMD. In September 2022, the study completed enrollment of 51 patients with 
nAMD who have had at least two intravitreal injections of anti-VEGF therapy in the preceding six months and who still have active choroidal 
neovascularization and residual sub- or intra-retinal fluid. Patients were to have received their last anti-VEGF treatment approximately 4-8 weeks prior to 
screening, and all patients were followed for approximately 24 weeks after dosing with either UBX1325 or aflibercept. 
In March 2023, we announced 16-week and 24-week data in Part A of our ENVISION study, in which UBX1325 monotherapy did not achieve 
non-inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain at week two in the anti-VEGF control arm. UBX1325 maintained visual 
acuity in patients with ongoing active disease through 24 weeks with less than one letter mean decrease from baseline (−0.8 ETDRS letters at 24 weeks 
compared to +3.1 ETDRS letters in the aflibercept control arm). Of UBX1325-treated patients, 52% did not require anti-VEGF treatment through 24 
weeks. UBX1325 demonstrated a favorable safety and tolerability profile with no cases of intraocular inflammation, retinal artery occlusion, 
endophthalmitis, or vasculitis.

 
9
In September 2023, we announced 48-week data in Part B of our ENVISION study, in which UBX1325 demonstrated a favorable safety and 
tolerability profile in the combination and monotherapy arms with no cases of significant intraocular inflammation, retinal artery occlusion or 
endophthalmitis. Patients switched from every 8-week aflibercept to a combination of aflibercept and UBX1325 at week 24 maintained vision gains 
achieved with aflibercept alone through week 48. Patients in a pre-specified subgroup with poor visual acuity at baseline (≤60 ETDRS letters) gained 3.2 
ETDRS letters on combination treatment between weeks 24 and 48. In the UBX1325 monotherapy arm, patients maintained visual acuity for the duration 
of the study, with a mean change of +0.1 ETDRS letters at the 24-week time point and a mean change of −1.5 ETDRS letters at 48 weeks. 40% of 
UBX1325-treated patients did not need anti-VEGF rescue through 48 weeks and 64% of the patients achieved an anti-VEGF treatment-free period of over 
24-weeks. The median time to first anti-VEGF rescue was 32 weeks.
Under our current amended license agreement with Ascentage Pharma Group Corp. Limited, or Ascentage, we have, among other things, 
exclusive worldwide development and commercialization rights and non-exclusive manufacturing rights to UBX1325 outside of Greater China (China, 
Hong Kong, Macau and Taiwan) in all non-oncology indications. Inside Greater China, we have the right to negotiate a joint venture with Ascentage to 
develop, manufacture and commercialize UBX1325. See “Licenses and Collaborations.” 
We also have a Tie2/VEGF bispecific program. Tie2 is a receptor tyrosine kinase that is implicated in regulating barrier function in blood vessels 
of the eye, which are affected in several prevalent eye diseases. Tie2 is an important key regulator of the vascular endothelium in the eye and dysregulation 
of this pathway leads to loss of barrier integrity and healthy vasculature. Preliminary studies suggest that cellular senescence in aging eyes may induce 
Ang-2 and therefore deactivate Tie2, leading to ocular edema.
The Tie2/VEGF bispecific has dual functionality on two validated targets for retinal diseases. In addition to direct activation of Tie2, the bispecific 
candidate is designed to neutralize VEGF-A and VEGF-B. We believe that direct agonism of Tie2 may be superior to antagonism of Ang2 which relies on 
adequate levels of endogenous Ang1 to activate the Tie2 pathway. We have identified Tie2/VEGF bispecific molecules that have pharmacological activity 
on Tie2 and VEGF with potencies relevant for clinical benefit. Based on supporting preclinical data, we designated an Advanced Candidate in July 2022. 
The program is currently paused to focus our development efforts on UBX1325.
UBX2050 is our investigational, fully human anti-Tie2 agonist monoclonal antibody. Tie2 dysregulation is implicated in eye disease as well as 
other indications. UBX2050 is derived from an asset that was acquired from Achaogen, Inc. in June 2020 through an Asset Purchase Agreement. UBX2050 
was selected based on its potential to activate the Tie2 receptor in vitro and has demonstrated encouraging activity in preclinical models of ocular disease. 
We believe UBX2050 may be an orthogonal approach to restoring barrier function and vascular function and have explored a number of indications for 
UBX2050. The program is currently paused to focus our development efforts on UBX1325.
Neurology Program
We believe cellular senescence may play a fundamental role in neurodegeneration. Multiple lines of evidence suggest that senescent cells 
accumulate in the nervous system during normal aging and neurodegenerative diseases. Several third-party preclinical proof of concept studies in mouse 
models of aging and neurodegeneration have provided preliminary evidence that the removal of senescent cells via senolytic drugs or genetic methods have 
the potential to improve brain function. 
UBX2089, an α-Klotho hormone drug candidate, is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain,
which is being researched for multiple neurology indications. Human genetic evidence links α-Klotho to cognitive function, and we have observed pro-
cognitive activity of recombinant α-Klotho in multiple preclinical rodent and non-human primate models. Our work focused on investigating the effect of 
UBX2089 on engaging CNS circuits in preclinical animal models with the intent of advancement to clinical studies, and in December 2021, we announced 
an exclusive licensing agreement of our α-Klotho asset to Jocasta Neuroscience, Inc. for development and commercialization.

 
10
Our Approach to Slowing, Halting, or Reversing Diseases of Aging
Targeting Cellular Senescence 
Cellular senescence is a natural biological state in which a cell permanently halts division or loses its ability to function properly subsequent to 
some form of unresolvable cellular stress. These cellular stress events result in the activation of the tumor suppressor protein p53, which drives the 
production of two cell-cycle dependent kinase inhibitors, or CDK inhibitors, p21 and p16. These two molecules are required for the establishment and 
subsequent maintenance of the senescent cell state. The first CDK inhibitor to be produced is p21, which works through subsequent pathways to block the 
production of numerous proteins that cells need to divide. The initial p21-driven signal is an acute response to cell damage and eventually decreases. In 
contrast, p16 permanently locks the cell into a non-dividing state and the production of p16 continues as long as the cell lives. Given that p16 production, in 
most cases, continues indefinitely and is believed to be produced almost exclusively in senescent cells, it is a widely used marker to identify and quantify 
senescent cells. 
The process through which stress mechanisms can induce cells to become senescent is illustrated in the figure below. 
 
Figure 1: Illustration of induction of the senescent state and secretion of factors that can damage the microenvironment
How Senescent Cells Drive Diseases of Aging 
Once cells become senescent, they begin secreting large quantities of proteins, including pro-inflammatory factors that recruit the immune system, 
proteases that remodel the extra-cellular matrix, pro-fibrotic factors that drive the formation of dysfunctional matrix, and growth factors that perturb the 
function of the tissue micro-environment. This collection of secreted proteins is referred to as the Senescence Associated Secretory Phenotype, or SASP. In 
addition to affecting normal tissue function, the SASP contains factors that induce senescence in neighboring cells, setting off a cascade of events that 
ultimately culminates in the formation of a functionally aged and/or diseased tissue that underlies a variety of age-related diseases. 
Numerous SASP factors have been implicated as potentially contributing to human disease and it is now believed that the SASP is the primary 
means by which senescent cells drive specific diseases of aging. For example, a variety of single SASP factors (e.g., TNF-α and VEGF-A) have been 
demonstrated to drive human diseases by themselves and have been the target of well-known antibody therapeutics, including HUMIRA® and EYLEA®. 
While these antibodies are able to modify human disease by removing the activity of a single factor, we believe the clearance of senescent cells will remove 
the source of numerous SASP factors, providing improvement in both efficacy and duration-of-effect.  

 
11
Our Therapeutic Paradigm 
We were founded on the principle that the selective elimination of senescent cells and their accompanying SASP has the potential to slow, halt, or 
reverse diseases of aging. Our insights into senescent cell biology allow us to identify senescence-driven diseases, target the senescent cells driving a 
particular disease, and selectively eliminate these cells. The figure below illustrates this process. 
 
Figure 2: Illustration of the senolytic therapeutic hypothesis
In developing this approach, we have acquired significant expertise with respect to senescent cell survival pathways, which are the signaling 
systems that senescent cells rely on for survival. When these pathways are targeted with specifically designed molecules, senescent cells undergo 
programmed cell death. Through our research, we have identified several of these mechanistically distinct survival pathways, which differ depending on 
cell type and the tissue in which the senescent cells reside. 
Advantages of Our Approach 
We believe that senolytic medicines that selectively eliminate senescent cells from diseased tissues may have several advantages over other efforts 
to treat diseases of aging: 
•
Senolytic medicines target a root cause of diseases of aging. We believe that the accumulation of senescent cells is a root cause of many diseases 
of aging. Unlike treatments that inhibit the activity of a single factor (such as antibodies targeting single pro-inflammatory proteins), we believe a 
senolytic medicine that eliminates accumulated senescent cells and consequently also their associated SASP, could blunt the activity of numerous 
factors contributing to disease. As a result, senolytic medicines could have improved efficacy because they target diseases at their source and 
therefore may be able to normalize tissue levels of numerous disease-causing factors simultaneously. 
•
Senolytic medicines can be dosed intermittently. The administration of senolytic medicines would remove senescent cells from diseased tissue. 
As new senescent cells may take months or perhaps years to re-accumulate, senolytic medicines could potentially be dosed infrequently. 
Intermittent dosing may also improve drug tolerability and patient adherence when compared to chronic therapies.
•
Senolytic medicines restore tissues to a healthy state. We believe senescent cells generally do not accumulate in young individuals and that the 
accumulation of senescent cells in older individuals interferes with normal tissue function. Our goal for the administration of senolytic medicines 
is to restore tissue to a functionally younger state. 

 
12
Our Programs
Ophthalmology Programs Targeting Cellular Senescence
Unmet Need and Therapeutic Rationale 
The majority of significant eye diseases are age-related, with the prevalence of vision-threatening disease increasing significantly over the age of 
75. Of the 285 million individuals worldwide living with visual impairment, 65% are over the age of 50. The individual diseases that are associated with 
these figures include age-related macular degeneration, diabetic macular edema, and diabetic eye diseases, all of which have a high prevalence and 
significant unmet need in either prevention or therapeutic options. The diseases we are evaluating as initial target indications for local administration of 
senolytic therapy in the eye include diabetic macular edema and diabetic retinopathy. 
Diabetic Macular Edema 
Diabetic macular edema is a condition in which the metabolic abnormalities associated with diabetes, including high levels of blood glucose, or 
hyperglycemia, damage blood vessels in the central portion of the retina, or the macula, causing those vessels to leak fluid. The leaking fluid leads to 
swelling and subsequently to abnormalities of vision. The prevalence of diabetic macular edema, or DME, in the United States ranges from approximately 
4.0% to 6.8% of people with diabetes who are 40 years of age or older. In 2019, it was estimated that more than 20 million people worldwide are affected 
by DME. There is a high burden of DME among non-Hispanic blacks and robust associations with higher hemoglobin A1c and longer duration of 
underlying diabetes.
Despite the success achieved with anti-VEGF treatment for retinal disease like AMD that involve the proliferation of abnormal blood vessels, or 
neovascularization, the impact of such treatment in DME has been more limited. This is due to the challenging nature of the therapeutic regimen (which 
entails monthly and or bimonthly IVT injections for up to two years), the number of cases that are refractory to anti-VEGF treatment (approximately 50% 
of DME patients), and the long-term complications of increased ischemia and retinal fibrosis associated with long-term treatment with anti-VEGF 
injections. As a result, there is an unmet need in this group of patients. Although VEGF has been identified as a major factor for neovascular disease, other 
factors, which we believe include SASP factors, are present in DME, including IL-1ß, TNF-, IL-6, and TGF-ß, among others. Due to the multifactorial
nature of the disease, a significant opportunity exists to develop a more comprehensive approach to the treatment of DME, such as senolysis, that targets 
the root cause of the disease.
Diabetic Retinopathy 
Diabetic retinopathy, or DR, is estimated to affect over 90 million people globally and approximately 28 million have vision-threatening stages of 
disease. It is a leading cause of vision loss in middle-aged and elderly people and impacts 8% of the U.S. population over age 65. Due to the increasing 
diabetic population arising from lifestyle changes in developing countries, the disease incidence is predicted to climb. 
Diabetic retinopathy is a complex multifactorial disease, characterized by progression through a series of stages of increasing severity. The 
metabolic abnormalities associated with diabetes incite a variety of inflammatory and metabolic stress-induced events which leads to proliferation of new 
blood vessels and subsequent bleeding and swelling, which in turn causes scarring and vision loss or may lead to blood vessel occlusion, limiting blood 
flow and leading to damage to the retinal photoreceptors and nerves supplied by those vessels. The risk of developing diabetic retinopathy and its severity 
increases with the duration of underlying diabetes. It is also associated with poor glycemic control and the presence of additional coexistent diseases, such 
as high blood pressure, high cholesterol levels, and impaired kidney function. 
Current standard of care for diabetic retinopathy, which includes blood sugar control, anti-VEGF drugs, steroid injections, and laser therapy, is 
modestly effective. The limitations of existing therapy include general challenges with achieving diabetes control, the need for frequent intravitreal 
injections for the administration of anti-VEGF therapy, a significant percentage of patients not completing or being non-responsive to anti-VEGF therapy, 
and tissue destruction with permanent side effects from laser therapy. This presents a significant opportunity to design and develop a treatment paradigm, 
such as senolytic medications like UBX1325, that treats a root cause of the disease. 

 
13
Evidence suggests that diabetic retinopathy is driven by the accumulation of senescent cells that are a direct result of elevated glucose levels in 
patients with diabetes. These senescent cells are triggered by local stresses in the retina and their accumulation drives the production of the accompanying 
ocular SASP factors, VEGF and platelet-derived growth factor, or PDGF. Overproduction of VEGF and IL-6 leads to ocular inflammation and abnormal 
blood vessel growth, key signatures of diabetic retinopathy. In addition, senescent cells within vascular units of the retina are unable to form proper 
junctions and thus blood vessels with heavy senescence burden are more prone to leak. Thus, a senolytic approach could target multiple aspects of the 
underlying causes of diabetic retinopathy and ideally lead to greater therapeutic coverage in a wider range of patients. This elimination of senescent cell 
accumulation and accompanying SASP factors could limit further disease progression, reduce vessel leakage and inflammation, and prevent vision loss. 
Evidence for Senescence Burden in Human Disease and Human Biomarker Discovery: AMD, DR and DME
We evaluated the presence of senescent cells by IHC staining for p16 in post-mortem retinal donor tissue from individuals who carried a pre-
mortem diagnosis of AMD, DR/DME, or neither. We believe the resulting data support our hypothesis that the accumulation of senescent cells is linked to 
AMD and DR/DME.  Quantification of IHC images indicated a significant increase in senescent cell burden (as measured by p16+ cells) in both AMD and 
DR patient globes (Figure 3).  
 
Figure 3: Quantification of senescent cell burden in AMD and DR/DME
We also compared the presence of senescence in human retinal microvascular endothelial cells, or HRMEC, versus retinal donor tissue from 
human DME/DR patients by evaluating the gene expression of several disease-relevant factors. Quantitative polymerase chain reaction, or qPCR, 
demonstrated elevations in the SASP factors VEGF, PDGF, IL1B, and TNF in senescent HRMEC, relative to non-senescent cells. These disease-relevant 
mediators have been reported to be elevated in DME/DR patients. We believe this data is consistent with our hypothesis that senescent cell accumulation 
and SASP factors play a central role in both DME and DR. 
Mechanism of Action of UBX1325 (Inhibitors of the BCL-2 Family) 
UBX1325, our lead drug candidate (along with our backup compound in our ophthalmology program, UBX1967) is a potent and selective small 
molecule inhibitor of BCL-xL, a specific member of the BCL-2 family of apoptosis regulating proteins. The B-cell lymphoma 2, or BCL-2, gene family 
encodes more than 20 proteins that regulate the intrinsic apoptosis pathway and are fundamental to the balance between cell survival and cell death. 
Inhibition of certain BCL-2 family proteins results in cell death in certain cell types. Targeting this pathway has been studied extensively in connection 
with the search for new oncology medicines.  

 
14
In Vitro and In Vivo Pharmacology Studies with UBX1325 
We conducted an in vitro assessment of binding and efficacy of UBX1325 to determine both its potency for the BCL-2 family protein targets and 
its potency at eliminating senescent cells. Biochemical assays for BCL-2, BCL-xL, and BCL-w yielded binding affinities in the sub-nanomolar range, but 
with a higher affinity for BCL-xL. UBX1325 is a phosphate pro-drug that releases the active parent molecule known as UBX0601. In order to assess the 
activity of UBX0601 on senescent cells, we used a cell-based assay with radiation-induced senescence. Senescent cells were exposed to increasing 
concentrations of UBX0601 for 72 hours. In this study, UBX0601 showed potent, concentration-dependent senolytic activity against human fetal lung 
cells, or IMR90, primary human umbilical vein endothelial cells, or HUVEC, and HRMEC as measured by reduction of senescent cell survival. UBX0601 
also demonstrated selectivity for elimination of senescent HRMEC over non-senescent HRMEC which is observed as decreased potency in the non-
senescent HRMEC (Figure 4).
Figure 4: Concentration- dependent induction of apoptosis in HRMEC cells by UBX0601 in vitro
We next studied the effects of UBX1325 in the retina in an in vivo model. We employed the mouse oxygen-induced retinopathy, or OIR, model, 
which provides an in vivo model of retinopathy of prematurity, or ROP, and DR. In this model, UBX1325 demonstrated a statistically significant 
improvement in the degree of retinal neovascularization (Figure 5).
 
Figure 5:  Intravitreal injection of UBX1325 reduced retinal neovascularization in the mouse OIR model
Based on these results in this key OIR model, we believe a single ocular injection of UBX1325 has the potential to functionally inhibit 
neovascularization and promote vascular repair. We believe the efficacy of UBX1325 in this OIR model is due to elimination of senescent cells and 
accompanying SASP that propagates senescence in retinal cells and promotes neovascularization of retinal vessels.

 
15
We then studied the in vivo efficacy of UBX1325 in a streptozotocin-induced diabetic mouse, or STZ, model to understand its effects in a diabetic 
retina, which shows phenotypes similar to the human diseased condition. In this STZ model, UBX1325 demonstrated a significant reduction in vascular 
leakage as measured by Evans Blue dye permeation (Figure 6A). UBX1325 also demonstrated an improvement in the electroretinogram, or ERG, as a 
measure of retinal/photoreceptor function (Figure 6B). At a dose of 200 pmol delivered per eye, UBX1325 led to significant increase in the amplitude of 
both the A- and B-waves (p<0.01 and p<0.0001, respectively) of the ERG when compared to the vehicle control group. Lastly, the expression of several 
disease-relevant cytokines was elevated in the diabetic retina, but attenuation of those factors was not observed after administration of UBX1325.
 
Figure 6:  Streptozotocin-induced diabetic mice have increased retinal vascular leakage (6A) and decreased A-wave amplitude in ERG (6B). Administration of UBX1325 
attenuated each of these disease-relevant endpoints.
 
Non-clinical toxicology studies of UBX1325, as well as its manufacturing and associated testing, have been completed to support the evaluation of 
the safety, tolerability, and pharmacokinetics of this molecule in further clinical studies.  
UBX1325 Clinical Data and Development Plan 
In July 2020, we filed an IND, to commence a Phase 1, first-in-human, open-label, single-ascending dose study of UBX1325 (foselutoclax) in 
patients with DME, and nAMD. Our current goal with UBX1325 is to transformationally improve outcomes for patients with DME. In October 2020, the 
Phase 1, first-in-human, clinical study of UBX1325 commenced. That study, an open-label, single ascending dose clinical trial, evaluated doses from 0.5 – 
10 µg administered as a single intra-vitreal injection in up to 8 patients with DME and 11 patients with nAMD all of whom had been off all anti-VEGF 
treatment due to lack of benefit for at least 6 months. The results of this study demonstrated acceptable safety and tolerability without any dose-limiting 
toxicities; no evidence of intraocular inflammation; and mean improvement in Best Corrected Visual Acuity (BCVA) of up to 9.5 ETDRS letters in those 
patients with DME receiving higher doses (5 and 10 µg) and a mean improvement in BCVA of 3.2 ETDRS letters in evaluable patients with nAMD at all 
doses, both at 24 weeks after treatment with UBX1325.
In May 2021, we initiated our Phase 2 BEHOLD study of UBX1325 in patients with DME and dosed our first patient in June 2021. This study 
was a multi-center, randomized, double-masked, sham- controlled study designed to evaluate the safety, tolerability, efficacy and durability of a single 10 
µg dose of UBX1325 (foselutoclax) in patients with DME evaluated though 24 weeks. Patients have the option of rolling over to a 48-week long term 
extension and a majority of patients who have completed their 24-week visits have opted to remain in the study. A total of 65 patients were enrolled, 
randomized evenly between UBX1325 and sham-injected patients. These patients were being actively treated with anti-VEGF for at least 6 months prior to 
being randomized into the BEHOLD study (mean of 4.03 injections in the 6 months preceding randomization), and had persistent visual acuity deficits (73 
ETDRS letters or worse, approximately 20/40 or worse) and residual retinal fluid (≥300 µm of central subfield thickness on optical coherence tomography, 
mean of approximately 439.6 µm). At the time of randomization, patients were taken off of their anti-VEGF treatment, and instead treated with UBX1325 
or a sham procedure. Endpoints explored in the study 

 
16
include safety and tolerability, changes in BCVA, CST, SRF/IRF, proportion of patients requiring rescue treatment, and durability of effects.
In August 2022, we announced positive 12- and 18-week data in our Phase 2 BEHOLD study, including that a single injection of UBX1325 led to 
a progressive, statistically significant, and clinically meaningful improvement in mean BCVA compared to sham treatment. At Week 18, the mean change 
from baseline of BCVA for UBX1325-treated subjects was an increase of 6.1 ETDRS letters that represented a difference of +5.0 ETDRS letters compared 
to sham-treated subjects (p=0.0368). In addition, patients treated with UBX1325 maintained central subfield thickness (CST) (+3.2 microns) compared to 
sham-treated patients who had progressive worsening (increase) in CST through 18 weeks (+53.5 microns) (p=0.0719).
In November 2022, we announced positive 24-week data in our BEHOLD study, showing that a single injection of UBX1325 led to a statistically
significant and clinically meaningful improvement in BCVA of +6.2 ETDRS letters from baseline and +7.6 ETDRS letters compared to sham treatment 
(p=0.0084). Inclusive of rescue data, patients treated with UBX1325 had a mean improvement in BCVA of +6.4 ETDRS letters from baseline and +5.2 
ETDRS letters compared to sham (p=0.0068). At 24 weeks, patients treated with UBX1325 had a mean change in CST of -5.4 microns from baseline 
compared to a worsening (increase) of +34.6 microns in sham-treated patients (p=0.1244). The proportion of rescue-free patients at 24 weeks was greater 
on UBX1325 (59.4%) as compared to sham (37.5%) with fewer total rescues and longer time-to-rescue in UBX1325-treated patients as compared to sham. 
UBX1325 demonstrated a favorable safety and tolerability profile with no cases of intraocular inflammation, retinal artery occlusion, endophthalmitis, or 
vasculitis. Patients were followed through 48 weeks post-treatment in a long-term follow-up.
In April 2023, we announced positive 48-week data from this long-term follow-up in our BEHOLD study in 50 patients who participated in the 
48-week extension study, showing that a single injection of UBX1325 led to a statistically significant and clinically meaningful improvement in vision 
lasting for the duration of the study (48 weeks), marked by a gain of +6.2 ETDRS letters from baseline, representing a difference of +5.6 ETDRS letters 
compared to sham-treated patients. In addition, patients treated with UBX1325 maintained stable CST compared to worsening in sham-treated patients 
(p=0.1198). Approximately 50% of UBX1325-treated patients did not require any additional injections through 48 weeks, compared to only 22% of 
patients in the sham arm. Retinal structure, as measured by central subfield thickness (CST), was maintained in UBX1325-treated patients throughout the 
duration of the study. UBX1325 continued to show a favorable safety and tolerability profile with no evidence of intraocular inflammation.
	
In December 2023, we announced that the first patients have been dosed in our Phase 2b ASPIRE study, designed to evaluate UBX1325 (foselutoclax) 
head-to-head against aflibercept in previously treated patients with active DME who are not achieving optimal benefit from standard of care. In August 
2024, we completed enrollment of patients into the ASPIRE study in DME, which is a multi-center, randomized, double-masked, active-controlled study 
designed to evaluate the safety and efficacy of UBX1325 in comparison to aflibercept. Patients are randomized 1:1 to receive either 10 μg UBX1325, or 2 
mg of aflibercept control injections every eight weeks for six months. We completed enrollment of 52 participants with DME who have residual visual 
acuity deficits and excess fluid in the retina despite having received at least three anti-VEGF injections in the preceding sixteen weeks. All participants 
received three monthly doses of 2 mg aflibercept as a “run-in” prior to randomization. The primary efficacy endpoint will be mean change from baseline in 
BCVA to week 24. Secondary endpoints will include change in BCVA over time, CST change from baseline to week 24, proportion of participants who do 
not require rescue, and percentage of participants with one or more treatment-emergent ocular adverse events during the course of the study.
	
In March 2022, we enrolled our first patient in Phase 2 of the ENVISION study. In September 2022, the study has completed enrollment of patients 
with nAMD who have had at least two intravitreal injections of anti-VEGF therapy in the preceding six months and who still have active choroidal 
neovascularization and residual sub- or intra-retinal fluid. Patients have received their last anti-VEGF treatment approximately 4-8 weeks prior to 
screening, and all patients will be followed for approximately 24 weeks after dosing with either UBX1325 or aflibercept. 
In March 2023, we announced 16-week and 24-week data in Part A of our ENVISION study, in which UBX1325 monotherapy did not achieve 
non-inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain at week two in the anti-VEGF control arm. UBX1325 maintained visual 
acuity in patients with ongoing active disease through 24 weeks with less than one letter mean decrease from baseline (−0.8 ETDRS letters at 24 weeks 
compared to +3.1 ETDRS letters in the aflibercept control arm). Of UBX1325-treated patients, 52% did not require anti-VEGF 

 
17
treatment through 24 weeks. UBX1325 demonstrated a favorable safety and tolerability profile with no cases of intraocular inflammation, retinal artery 
occlusion, endophthalmitis, or vasculitis.
	
In September 2023, we announced 48-week data in Part B of our ENVISION study, in which UBX1325 demonstrated a favorable safety and  
tolerability profile in the combination and monotherapy arms with no cases of significant intraocular inflammation, retinal artery occlusion or 
endophthalmitis. Patients switched from every 8-week aflibercept to a combination of aflibercept and UBX1325 at week 24 maintained vision gains 
achieved with aflibercept alone through week 48. Patients in a pre-specified subgroup with poor visual acuity at baseline (≤60 ETDRS letters) gained 3.2 
ETDRS letters on combination treatment between weeks 24 and 48. In the UBX1325 monotherapy arm, patients maintained visual acuity for the duration 
of the study, with a mean change of +0.1 ETDRS letters at the 24-week time point and a mean change of −1.5 ETDRS letters at 48 weeks. 40% of 
UBX1325-treated patients did not need anti-VEGF rescue through 48 weeks and 64% of the patients achieved an anti-VEGF treatment-free period of over 
24-weeks. The median time to first anti-VEGF rescue was 32 weeks.
In addition to UBX1325, which targets BCL-xL, we have preclinical stage molecules that target senescent cells via alternate mechanisms and 
could be the basis of future pipeline programs.
Ophthalmology Program Targeting Tie2 Signaling
The angiopoietin-Tie2 signaling axis is believed to play a fundamental role in vascular biology. Dysregulation of the expression of Tie2-regulating 
ligands angiopoietin-2 (a context dependent Tie2 antagonist ligand) and angiopoietin-1 (a Tie2 agonist ligand) has been observed in the vitreous of patients 
with DME, AMD, and other ocular diseases. We believe that a highly specific and potent Tie2-activating antibody will restore Tie2 signaling in ocular 
tissues, potentially leading to decreased vascular leak, lower levels of pathogenic angiogenesis, and a restoration of healthy blood vessels in ischemic areas 
of the eye. UBX2050 is an investigational Tie2-specific agonist monoclonal antibody that was selected based on its optimal binding and functional 
properties observed in in vitro assays. In primary human endothelial cells, or HUVECs, UBX2050 treatment activated Tie2 as measured by increased levels 
of cellular phospho-Tie2, and potently activated downstream signal transduction pathways as measured by increased levels of phospho-Akt and phospho-
Erk1/2 by western blotting (Figure 7).
Figure 7. Anti-Tie2 agonist antibody Tie2-3 (UBX2050) activated Tie2 signaling with a potency comparable to angiopoietin-1 in primary endothelial cells in 
vitro.

 
18
The in vivo activity of UBX2050 has been explored in a laser-induced choroidal neovascularization model in mice. In this model, UBX2050 was 
administered to mice via the intraperitoneal route at a dose of 10 mg/kg, one day prior to laser-induced rupture of Bruch’s membrane. UBX2050 treatment, 
but not treatment with a non-specific isotype control antibody, significantly inhibited the area of choroidal neovascularization nine days post-injury as 
measured in retina/choroid flat mounts from treated animals (Figure 8). Based on this data, we believe UBX2050 has the potential to address pathogenic 
angiogenesis in the eyes of patients with ocular diseases such as AMD and DME.
Figure 8. UBX2050 treatment significantly inhibited choroidal neovascularization in a laser-induced injury model in mice.
 
We believe that the investigational Tie2 antibody (UBX2050) may be an orthogonal approach to restoring barrier function and vascular function; 
however, this program is currently paused to focus our development efforts on UBX1325.
Tie2/VEGF bispecific program
Tie2 is a receptor tyrosine kinase that is implicated in regulating barrier function in blood vessels of the eye, which are affected in several 
prevalent eye diseases. Tie2 is an important key regulator of the vascular endothelium in the eye and dysregulation of this pathway leads to loss of barrier 
integrity and healthy vasculature. Preliminary studies suggest that cellular senescence in aging eyes may induce Ang-2 and therefore deactivate Tie2, 
leading to ocular edema. The Tie2/VEGF bispecific has dual functionality on two validated targets for retinal diseases. In addition to direct activation of 
Tie2, the bispecific candidate is designed to neutralize VEGF-A and VEGF-B. We believe that direct agonism of Tie2 may be superior to antagonism of 
Ang2 which relies on adequate levels of endogenous Ang1 to activate the Tie2 pathway. We have identified Tie2/VEGF bispecific molecules that have 
pharmacological activity on Tie2 and VEGF with potencies relevant for clinical benefit. Based on supporting preclinical data, we designated an Advanced 
Candidate in July 2022; however, this program is currently paused to focus our development efforts on UBX1325.
Neurology Program
UBX2089, a α-Klotho hormone drug candidate, is a circulating hormone primarily produced in the kidneys and choroid plexus of the brain, 
which is being researched for multiple neurology indications. Human genetic evidence links α-Klotho to cognitive function, and we have observed pro-
cognitive activity of recombinant α-Klotho in multiple preclinical rodent and non-human primate models. Our work focused on investigating the effect of 
UBX2089 on engaging CNS circuits in preclinical animal models with the intent of advancement to clinical studies, and in December 2021, we announced 
an exclusive licensing agreement of our α-Klotho asset to Jocasta Neuroscience, Inc. for development and commercialization.

 
19
Manufacturing
Our success will depend on our ability to deliver reliable, high-quality preclinical and clinical drug supply. As we mature and approach 
commercial stage operations, securing reliable high-quality commercial drug supply will be critical. We contract with third parties for the manufacture of 
our drug candidates for clinical studies. Because we rely on contract manufacturers, we employ personnel with extensive technical, manufacturing, 
analytical, and quality experience. Our staff has strong project management discipline to oversee contract manufacturing and testing activities, and to 
compile manufacturing and quality information for our regulatory submissions. 
Manufacturing is subject to extensive regulation that imposes various procedural and documentation requirements and that governs record 
keeping, manufacturing processes and controls, personnel, quality control and quality assurance, and more. Our systems and our contractors are required to 
be in compliance with these regulations, and compliance is assessed regularly through monitoring of performance and a formal audit program. 
Our current supply chains for our lead drug candidates involve several manufacturers that specialize in specific operations of the manufacturing 
process, specifically, raw materials manufacturing, drug substance manufacturing, drug product manufacturing, and drug product labeling, packaging, and 
storage. We currently operate under purchase order programs for our drug candidates with Material Service Agreements in place, and we intend to establish 
long-term supply agreements in the future. We believe our current manufacturers have the scale, the systems, and the experience to supply all planned 
clinical studies. 
We do not currently require commercial manufacturing capabilities. Should our needs change, we will likely need to scale up our manufacturing 
processes to enable commercial launch. To ensure continuity in our supply chain, we plan to establish supply arrangements with alternative larger scale 
suppliers for certain portions of our supply chain, as appropriate. 
Commercialization Plan
We do not currently have, nor do we expect to have in the near term, any FDA-approved drugs in our portfolio. Therefore, we have not yet built an 
infrastructure for sales, marketing, or commercial distribution. 
Should any of our drug candidates move into pivotal clinical trials intended to support an application for market authorization, we intend to 
develop a plan to commercialize them in the United States and other key markets, through an internal infrastructure or external partnerships. 
Competition
The biotechnology and pharmaceutical industries, including the field of research in aging, are typically rife with rapid technological developments, 
bold competition, and dependence on intellectual property. Like any biotechnology company, we face competition from multiple sources, including large 
or established pharmaceutical, biotechnology, and wellness companies, academic research institutions, government agencies, and private institutions. We 
believe our drug candidates will prevail amid the competitive landscape through their efficacy, safety, administration methods and convenience, cost, 
public and institutional demand, intellectual property portfolio, and treatment of the root cause of many diseases of aging. 
We are aware of other companies seeking to develop treatments to prevent or treat diseases of aging through various biological pathways, 
including several large pharmaceutical companies that have exploratory programs as well as a number of earlier-stage companies. Most of these companies 
are either in early stages of discovery research in senescence or have not yet disclosed pipeline candidates or mechanisms of interest, and those companies 
that have disclosed pipeline candidates are targeting other pathways. Hence, we believe that we currently have the most advanced program addressing 
cellular senescence. 
Our drug candidates are likely to compete against current therapies from a wide range of companies and technologies, including therapies for 
ophthalmology diseases: current standard of care treatments include anti-VEGF antibodies (bevacizumab, ranibizumab, aflibercept, brolucizumab); 
VEGF/Ang2 bispecific antibodies (faricimab); intravitreal steroid (dexamethasone); pan-retinal photocoagulation by laser for both neovascular AMD, DR, 
and DME; and complement inhibitors (e.g., pegcetacoplan) for the geographic atrophy form of AMD.
	
Many of our competitors, either alone or with strategic partners, have substantially greater financial, technical, and human resources than we do. 
Accordingly, our competitors may be more successful in obtaining 

 
20
approval for treatments and achieving widespread market acceptance, rendering our treatments obsolete or non-competitive. Accelerated merger and 
acquisition activity in the biotechnology and biopharmaceutical industries may result in even more resources concentrated among a smaller number of our 
competitors. These companies also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical study 
sites, patient registration for clinical studies, and acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage 
companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Our 
commercial opportunity could be substantially limited in the event that our competitors develop and commercialize products that are more effective, safer, 
more tolerable, more convenient, or less expensive than our comparable products. In geographies that are critical to our commercial success, competitors 
may also obtain regulatory approvals before us, resulting in our competitors building a strong market position in advance of our products’ entry. We 
believe the factors determining the success of our programs will be the efficacy, safety, and convenience of our drug candidates. 
Intellectual Property
Our success depends in large part upon our ability to obtain and maintain proprietary protection for our products and technologies and to operate
without infringing the proprietary rights of others. Our policy is to protect our proprietary position by, among other methods, filing U.S. and foreign patent 
applications that relate to our proprietary technologies, inventions and improvements that are important to the development and implementation of our 
business. We also rely on trademarks, know-how, continuing technological innovation and licensing opportunities to develop and maintain our proprietary 
position. 
Patent Portfolio 
Our patent portfolio consists of a combination of issued and allowed patents and pending patent applications that are owned or co-owned by us 
and/or licensed to us from third parties. The majority of these patents and applications cover our cellular senescence program, and others pertain to our 
programs that target aging mechanisms beyond cellular senescence, including the administration of a Tie2 receptor agonist or α-Klotho hormone. As of 
March 1, 2025, we own, co-own, or have an exclusive license in certain fields of use to approximately 172 patents and pending applications in the United 
States and foreign jurisdictions. This portfolio includes approximately 33 issued or allowed U.S. patents and applications and 70 granted or allowed foreign 
patents and applications. A composition of matter patent directed to the chemical structure of UBX1325 is expected to extend our loss of exclusivity on this 
molecule in the U.S. to 2039, not including any patent term extensions to which it may be entitled.
In general, patents have a term of 20 years from the earliest claimed non-provisional priority date. The patent term may be extendible by up to five 
years in certain countries by means of patent term extension depending on the regulatory pathway and the remaining term upon marketing approval. 
Certain other patents and patent applications directed to our patent portfolio, if they were to issue, may have later expiration dates. Any pending U.S. 
provisional application is not eligible to become an issued patent until, among other things, we file a non-provisional patent application within 12 months 
of filing the related provisional patent application. If we do not timely file any non-provisional patent application, we may lose our priority date with 
respect to our provisional patent application and any patent protection on the inventions disclosed in our provisional patent application.
Ophthalmology Programs 
We have a license with Ascentage to two patent families that include patents and applications directed to the composition of matter of our specific 
BCL-xL inhibitors including UBX0601, the active parent molecule of our lead drug candidate, UBX1325. This license grants us exclusive development 
and commercialization rights and non-exclusive manufacturing rights to UBX1325 for all non-oncology indications outside of Greater China (China, Hong 
Kong, Macau and Taiwan). Inside Greater China, we have the right to negotiate a joint venture with Ascentage to develop, manufacture and commercialize 
UBX1325. Patents in these two patent families have been granted in the United States, South Korea, New Zealand, South Africa, Australia, Canada, China, 
India, Singapore, Japan and Europe, and applications are pending in India and Singapore. Granted patents and patents that may issue from pending 
applications in these two patent families are expected to expire between 2032 and 2034, excluding any potential patent term adjustments or extensions. 

 
21
Our license agreement with Ascentage also grants us the right to continue our preclinical development efforts with UBX1967 (our back-up 
compound to UBX1325) until the time we wish to submit an IND for UBX1967, at which point we would be required to enter into a separate license 
agreement with Ascentage covering UBX1967.  
We co-own a patent family encompassing the use of BCL-2 and BCL-xL inhibitors generally to treat various age-related eye diseases by targeting 
senescent cells (which also covers aspects of our neurology programs) with the Buck Institute and the Mayo Clinic. We have exclusive licenses from each 
of the Buck Institute and the Mayo Clinic to this patent family in the field of senescence. Patents in this patent family have been granted in the U.S., 
Canada, Europe, Israel, New Zealand, Hong Kong, Mexico, South Korea, and South Africa. These patents include claims that are directed to treating age 
related eye diseases, including age-related macular degeneration, and expire in 2035, excluding any patent term adjustments or extensions. Patent 
applications in this patent family are pending in the United States, Australia, Brazil, Israel, Japan, and Singapore.
We also solely own a patent family that specifically claims the composition of matter of UBX1325 and closely related compounds, as well as 
general methods of use of UBX1325. As of March 1, 2025, this family includes three issued U.S. patents and one pending U.S. application, issued patents 
in Europe, Hong Kong, and South Korea, and pending applications in Australia, Canada, China, Europe, and Japan. Granted patents from this family are 
expected to expire in 2039, excluding any potential patent term adjustments and patent term extensions.
We solely own a patent family that specifically covers the sequence, epitope, alternative antibody formats, and use of UBX2050 not only for 
ophthalmic diseases, but also other indications, including kidney. We have a granted patent in the U.S. and an allowed patent application in Japan, and 
patent applications pending in Australia, Canada, China, Europe, Hong Kong, Japan, South Korea, and the U.S. Granted patents from this family expire in 
2040, excluding any patent term adjustments and patent term extensions. We also solely own a patent family that specifically covers the sequences of our 
Tie2/VEGF bispecific UBX2048 and variants for many indications, including ocular. Future patents issuing from this family are expected to expire in 
2043, excluding any patent term adjustments and patent term extensions.
Neurology Program
We have an exclusive license with The Regents of the University of California for a patent family directed to methods of treatment and the use of 
α-Klotho hormone for the development of human therapeutics to treat cognitive decline. As of March 1, 2025, our patent portfolio includes four issued U.S. 
patents, and issued patents in Australia, Belgium, Europe, France, Germany, India, Ireland, Italy, Japan, Luxembourg, Switzerland, and the United 
Kingdom, and pending patent applications in Canada, China, and Hong Kong. Patents that issue from this family are expected to expire in 2036, excluding 
any patent term adjustments and patent term extensions. In December 2021, we announced an exclusive agreement licensing our α-Klotho asset to Jocasta 
Neuroscience, Inc. for development and commercialization.
We co-own a patent family encompassing the use of BCL-2/xL inhibitors generally to treat neurodegenerative diseases by targeting senescent cells 
(which also covers aspects of our ophthalmology program) with the Buck Institute and the Mayo Clinic. We have exclusive licenses from each of the Buck 
Institute and the Mayo Clinic to this patent family in the field of senescence. Currently, we co-own an issued U.S. patent and a pending U.S. patent 
application for the use of BCL-xL inhibition to eliminate senescent cells to treat neurodegenerative disorders. Patents that issue from this family are 
expected to expire in 2035, excluding any patent term adjustments and patent term extensions.
Other Intellectual Property 
Our continuing research and development, technical know-how, and contractual arrangements supplement our intellectual property protection to 
maintain our competitive position. Our policy is to require inventors who are identified on any Company-owned patent applications to assign rights to us. 
We also have confidentiality agreements with our employees, consultants, and other advisors to protect our proprietary information. Our policy is to require 
third parties that receive material UNITY confidential information to enter into confidentiality agreements with us. 
We also protect our brand through procurement of trademark rights. As of March 1, 2025, the mark UNITY BIOTECHNOLOGY® and the 
UNITY BIOTECHNOLOGY® design logo are registered in the United States, the European Union, or EU, China, and in Japan, as well as other foreign 
jurisdictions. The mark UNITY® is also registered in the United States and in the EU. In order to supplement protection of our brand, we have also 
registered several internet domain names.

 
22
Licenses and Collaborations
Description of Ascentage Agreements 
We were a party to three agreements, or the Commercial Agreements, with Ascentage Pharma: (a) a compound library and option agreement 
executed in February 2016, the Library Agreement, granting the Company the right to research and nominate an active compound from Ascentage’s library 
of BCL compounds and subsequently nominate a development candidate from any active compound in order to begin GLP toxicology work for indications
outside of oncology, which expired in February 2022; (b) a license agreement executed in February 2016 granting the Company rights to an Ascentage
Pharma compound known as APG1252, or the APG1252 License Agreement, which the Company terminated in July 2020 due to the Company’s decision 
to prioritize the progression of UBX1325; and (c) a second license agreement executed in January 2019 granting the Company world-wide rights to 
develop and commercialize UBX0601, the active parent molecule of our lead drug candidate UBX1325, outside of Greater China, or the Original BCL 
Agreement, for indications outside of oncology. 
The Commercial Agreements referenced above include cash payments of up to $70.3 million as well as the equity payments of up to an aggregate 
of (a) 93,333 shares of common stock in the event there is only one licensed product; and (b) 133,333 shares of common stock in the event there are two or 
more licensed products, in each case to be issued based on the Company’s achievement of certain preclinical and clinical development and sales milestone 
events. The Company is required to make 80% of all equity payments to Ascentage Pharma and the remaining 20% to an academic institution from whom 
Ascentage Pharma had previously licensed the technology. The milestones include the advancement of additional compounds into IND, enabling studies, 
the filing of an IND, the commencement of clinical studies, Food and Drug Administration, or FDA, and/or European Medicines Agency approval, and a 
net sales threshold. The Original BCL License Agreement also includes tiered royalties in the low-single digits based on sales of licensed products.    
As of December 31, 2024, pursuant to the Commercial Agreements, the Company had issued 126,975 shares of common stock to Ascentage 
Pharma and 29,194 shares of common stock to the academic institution from whom Ascentage Pharma had previously licensed the technology. The 
Company had issued no additional shares pursuant to the Commercial Agreements during the year ended December 31, 2024. In May 2021, the Company 
initiated the BEHOLD study, a Phase 2 proof-of-concept study of UBX1325 in patients with diabetic macular edema. As a result of the first patient dosed 
in the Phase 2 proof-of-concept UBX1325 study in June 2021, the Company triggered a milestone payment of $2.0 million for Ascentage Pharma, which 
the Company elected to settle in shares of the Company’s common stock. At the instruction of Ascentage Pharma, the Company issued 29,477 shares of its 
common stock to Ascentage Pharma as of August 2021 with a fair market value of $1.1 million net of withholding taxes, and 10,527 shares of its common 
stock to the academic institution with a fair market value of $0.4 million at settlement date. The milestone payment was recognized as research and 
development expense in the Statement of Operations and Comprehensive Loss during the year ended December 31, 2021. The Company had previously 
issued 36,166 shares of its common stock with a value of $2.3 million to Ascentage Pharma as of December 31, 2020.
The Commercial Agreements included contingent consideration in the form of additional issuances of shares of the Company’s common stock 
based on the achievement of the specified milestones. Upon the July 2020 termination of the license to APG1252, the Company determined that the 
contingency no longer applied and adjusted the fair value of the contingent consideration liability to zero. To date, no royalties were due from the sales of 
licensed products.
Under the terms of the Original BCL Agreement, Ascentage granted us the following rights for all non-oncology indications outside of Greater 
China (China, Hong Kong, Macau and Taiwan): (i) exclusive worldwide development rights, and (ii) exclusive commercialization rights. Inside Greater 
China we have the right to negotiate a joint venture with Ascentage to develop, manufacture and commercialize UBX1325. The Original BCL Agreement 
also stipulates that Ascentage has the right to manufacture at least 50% of our supply requirements of the licensed compound, provided they achieve and 
maintain certain manufacturing quality standards. This Original BCL Agreement was amended in the fourth quarter of 2019 to remove certain field and 
territory limitations and to amend the schedule of licensed patents related to UBX1967, and then amended again in the first quarter of 2020 to further 
amend and restate the schedule of licensed patents. This Original BCL Agreement was amended a third time in June 2020 to switch the status of UBX1967 
from Licensed Compound to back-up compound, and conversely the status of UBX1325 from back-up to Licensed Compound. 

 
23
Additional License Agreements 
We are party to additional license agreements that support our senescence-related patent portfolio. These agreements are with an entity affiliated 
with the Mayo Clinic, or Mayo, and the Buck Institute for Research on Aging, or Buck, and provide us with a worldwide, exclusive, sublicensable license 
under those counter-parties’ rights to a patent family that is co-owned by Buck, Mayo and us to develop and commercialize licensed products, including for 
the treatment of senescence-related diseases in therapeutic areas including ophthalmology and neurological diseases. 
Under our June 2013 license with Mayo, we may be obligated to make development and sales milestone payments to Mayo of up to $10.8 million 
in the aggregate, to pay Mayo a percentage of certain sublicensing revenue that is between the high-single digits and the low-teens, and to pay Mayo 
running royalty payments ranging from less than 1% to low-single digit percentages on net sales of licensed products. Our obligation to pay running 
royalties to Mayo under the agreement is subject to a non-material minimum annual royalty and could potentially extend until January 1, 2037. We also 
issued 67,796 shares of our common stock to Mayo under this agreement. Our agreement with Mayo continues until the later of (i) the expiration of the last 
valid claim within the licensed patents and (ii) 13 years after first commercial sale of the first licensed product. We may terminate the agreement for 
convenience, and either party may terminate the agreement for the other party’s uncured material breach. 
Under our January 2017 license with Buck, which includes similar rights to a second patent family that is co-owned only by Buck and us, we may 
be obligated to make development and sales milestone payments to Buck of up to $5.4 million in the aggregate, to pay Buck a mid-single digit percentage 
of certain sublicensing revenue, and to pay Buck running royalty payments ranging from less than 1% to low-single digit percentages on net sales of 
licensed products. Our obligation to pay running royalties to Buck under the agreement is subject to a non-material minimum annual royalty and could 
potentially extend until January 1, 2037. We also issued 13,220 shares of our common stock to Buck under this agreement. The term of our license 
agreement with Buck continues until the expiration of all our payment obligations to Buck thereunder. We may terminate the agreement for convenience, 
and either party may terminate the agreement for the other party’s uncured material breach. 
We are also party to license agreements relating to our α-Klotho program. In May 2019, we entered into an exclusive license with The Regents of 
the University of California for intellectual property and know-how for the development of human therapeutics to treat cognitive decline in exchange for 
development and sales milestones and low single-digit percentages on net sales of licensed products. In December 2021, we signed an exclusive license 
agreement licensing our rights in the α-Klotho asset to Jocasta Neuroscience, Inc. for development and commercialization, under which we received a $5 
million upfront cash payment from Jocasta, and we will also receive additional payments based on development milestones, approval milestones, and sales-
based royalties, per indication. 
Government Regulation 
Government authorities in the United States (including federal, state and local authorities) and in other countries, extensively regulate, among 
other things, the manufacturing, research and clinical development, marketing, labeling and packaging, storage, distribution, post-approval monitoring and 
reporting, advertising and promotion, pricing, and export and import of pharmaceutical products, such as those we are developing. The process of obtaining 
regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of 
substantial time and financial resources. 
U.S. Government Regulation 
In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations, and 
biologics under the FDCA and the Public Health Service Act, or PHSA, and its implementing regulations. FDA approval is required before any new
unapproved drug or dosage form, including a new use of a previously approved drug, can be marketed in the United States. Drugs and biologics are also 
subject to other federal, state and local statutes and regulations. If we fail to comply with applicable FDA or other requirements at any time during the drug 
development process, clinical testing, the approval process or after approval, we may become subject to administrative or judicial sanctions. These 
sanctions could include the FDA’s refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, warning letters, 
product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties or criminal prosecution. 

 
24
The process required by the FDA before drug candidates may be marketed in the United States generally involves the following: 
•
completion of extensive preclinical laboratory tests and preclinical animal studies, all performed in accordance with GLP regulations; 
•
submission to the FDA of an IND, which must become effective before human clinical studies may begin; 
•
approval by an independent institutional review board, or IRB, or ethics committee representing each clinical site before each clinical study may 
be initiated; 
•
performance of adequate and well-controlled human clinical studies to establish the safety and efficacy, or in the case of a biologic, the safety, 
purity and potency, of the drug candidate for each proposed indication; 
•
preparation of and submission to the FDA of a new drug application, or NDA, or biologics license application, or BLA, after completion of all 
pivotal clinical studies; 
•
review of the product application by an FDA advisory committee, where appropriate and if applicable; 
•
a determination by the FDA within 60 days of its receipt of an NDA or BLA to file the application for review;  
•
satisfactory completion of an FDA pre-approval inspection of the manufacturing facilities where the drug candidate is produced to assess 
compliance with current Good Manufacturing Practices, or cGMP; and 
•
FDA review and approval of an NDA or BLA prior to any commercial marketing or sale of the drug or biologic in the United States. 
An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The central focus of an IND 
submission is on the general investigational plan and the protocol(s) for human studies. The IND also includes results of animal and in vitro studies 
assessing the toxicology, pharmacokinetics, pharmacology and pharmacodynamic characteristics of the product; chemistry, manufacturing and controls 
information; and any available human data or literature to support the use of the investigational new drug. An IND must become effective before human
clinical studies may begin. An IND will automatically become effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns 
or questions related to the proposed clinical studies. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve 
any outstanding concerns or questions before clinical studies can begin. Accordingly, submission of an IND may or may not result in the FDA allowing 
clinical studies to commence. 
Clinical Studies 
Clinical studies involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in 
accordance with Good Clinical Practice regulations, or GCPs, which include the requirement that all research subjects provide their informed consent for 
their participation in any clinical study. Clinical studies are conducted under protocols detailing, among other things, the objectives of the study, the 
parameters to be used in monitoring safety and the efficacy criteria to be evaluated. A protocol for each clinical study and any subsequent protocol 
amendments must be submitted to the FDA as part of the IND. Additionally, approval must also be obtained from each clinical study site’s IRB before the 
studies may be initiated, and the IRB must monitor the study until completed. There are also requirements governing the reporting of ongoing clinical 
studies and clinical study results to public registries. 
The clinical investigation of a drug or biologic is generally divided into three or four phases. Although the phases are usually conducted 
sequentially, they may overlap or be combined. 
•
Phase 1.	 The drug or biologic is initially introduced into healthy human subjects or patients with the target disease or condition. These studies are 
designed to evaluate the safety, dosage tolerance, metabolism and pharmacologic actions of the investigational new drug in humans, the side 
effects associated with increasing doses, and if possible, to gain early evidence on effectiveness. 
•
Phase 2.	 The drug or biologic is administered to a limited patient population to evaluate dosage tolerance and optimal dosage, identify possible 
adverse side effects and safety risks and preliminarily evaluate efficacy. 

 
25
•
Phase 3.	 The drug or biologic is administered to an expanded patient population, generally at geographically dispersed clinical study sites to 
generate enough data to statistically evaluate dosage, clinical effectiveness and safety, to establish the overall benefit-risk relationship of the 
investigational product and to provide an adequate basis for product approval. 
•
Phase 4.	 In some cases, the FDA may condition approval of an NDA or BLA for a drug candidate on the sponsor’s agreement to conduct
additional clinical studies after approval. In other cases, a sponsor may voluntarily conduct additional clinical studies after approval to gain more 
information about the drug. Such post-approval studies are typically referred to as Phase 4 clinical studies. 
A pivotal study is a clinical study that adequately meets regulatory agency requirements for the evaluation of a drug candidate’s efficacy and 
safety such that it can be used to justify the approval of the product. Generally, pivotal studies are Phase 3 studies, but the FDA may accept results from 
Phase 2 studies if the study design provides a well-controlled and reliable assessment of clinical benefit, particularly in situations where there is an unmet 
medical need, and the results are sufficiently robust. 
The FDA, the IRB or the clinical study sponsor may suspend or terminate a clinical study at any time on various grounds, including a finding that 
the research subjects are being exposed to an unacceptable health risk. Additionally, some clinical studies are overseen by an independent group of 
qualified experts organized by the clinical study sponsor, known as a data safety monitoring board or committee. This group provides authorization for 
whether or not a study may move forward at designated check points based on access to certain data from the study. A sponsor may also suspend or 
terminate a clinical study based on evolving business objectives and/or competitive climate.  
Submission of an NDA or BLA to the FDA 
Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, detailed investigational new 
drug product information is submitted to the FDA in the form of an NDA or BLA requesting approval to market the product for one or more indications. 
Under federal law, the submission of most NDAs and BLAs is subject to a substantial application user fee. Applications for orphan drug products are 
exempted from the NDA and BLA application user fees. 
An NDA or BLA must include all relevant data available from pertinent preclinical and clinical studies, including negative or ambiguous results as 
well as positive findings, together with detailed information relating to the product’s chemistry, manufacturing, controls and proposed labeling, among 
other things. Data can come from company-sponsored clinical studies intended to test the safety and effectiveness of a use of a product, or from a number 
of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and 
quantity to establish the safety and effectiveness of the investigational product to the satisfaction of the FDA. 
Once an NDA or BLA has been submitted, the FDA’s goal is to review the application within ten months after it accepts the application for filing,
or, if the application receives priority review, six months after the FDA accepts the application for filing. The review process is often significantly extended 
by FDA requests for additional information or clarification. 
Before approving an NDA or BLA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not 
approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to 
assure consistent production of the product within required specifications. Additionally, before approving an NDA or BLA, the FDA will typically inspect 
one or more clinical sites to assure compliance with GCP. 
The FDA is required to refer an application for a novel drug or biologic to an advisory committee or explain why such referral was not made. An 
advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a 
recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an 
advisory committee, but it considers such recommendations carefully when making decisions and typically follows such recommendations. 

 
26
The FDA’s Decision on an NDA or BLA 
After the FDA evaluates the NDA or BLA and conducts inspections of manufacturing facilities, it may issue an approval letter or a Complete 
Response Letter. An approval letter authorizes commercial marketing of the drug or biologic with specific prescribing information for specific indications. 
A Complete Response Letter indicates that the review cycle of the application is complete, and the application is not ready for approval. A Complete 
Response Letter may require additional clinical data and/or an additional pivotal Phase 3 clinical study(ies), and/or other significant, expensive and time-
consuming requirements related to clinical studies, preclinical studies or manufacturing. Even if such additional information is submitted, the FDA may 
ultimately decide that the NDA or BLA does not satisfy the criteria for approval. The FDA could also approve the NDA or BLA with a Risk Evaluation 
and Mitigation Strategy, or REMS, to mitigate risks, which could include medication guides, physician communication plans or elements to assure safe 
use, such as restricted distribution methods, patient registries and other risk minimization tools. The FDA also may condition approval on, among other 
things, changes to proposed labeling, development of adequate controls and specifications or a commitment to conduct one or more post-market studies or 
clinical studies. Such post-market testing may include Phase 4 clinical studies and surveillance to further assess and monitor the product’s safety and 
effectiveness after commercialization. Also, new government requirements, including those resulting from new legislation, may be established, or the 
FDA’s policies may change, which could delay or prevent regulatory approval of our products under development. 
Expedited Review and Accelerated Approval Programs 
The FDA has various programs, including fast track designation, breakthrough therapy designation, accelerated approval, and priority review, that 
are intended to expedite the development and approval of new drugs and biologics that address unmet medical needs in the treatment of serious or life-
threatening diseases and conditions. To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is 
intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA may review 
sections of the NDA for a fast-track product on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the 
submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays 
any required user fees upon submission of the first section of the NDA. 
The FDA may give a priority review designation to drugs or biologics that are designed to treat a serious condition and, if approved, would 
provide a significant improvement in safety or effectiveness compared to available therapies. A priority review means that the goal for the FDA to review 
an application is six months, rather than the standard review of ten months. These six- and 10-month review periods are measured from the “filing” date 
rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review and decision 
from the date of submission. Products that are eligible for fast-track designation may also be eligible for priority review. 
In addition, products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful 
therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis of adequate and well-controlled 
clinical studies establishing that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical 
endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or 
mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. 
As a condition of approval, the FDA may require a sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and 
describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug or biologic may be subject to expedited 
withdrawal procedures if the sponsor fails to conduct the required post-marketing studies, or such post-marketing studies fail to confirm the predicted 
clinical benefit. 
Moreover, under the provisions of the Food and Drug Administration Safety and Innovation Act, or FDASIA, passed in July 2012, a sponsor can 
request designation of a product candidate as a “breakthrough therapy.” A breakthrough therapy is defined as a drug or biologic that is intended, alone or in 
combination with one or more other drugs or biologics, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates 
that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial 
treatment effects observed early in clinical development. This designation includes all of the features of fast track designation, as well as more intensive 
FDA interaction and guidance. The breakthrough 

 
27
therapy designation is a distinct status from both accelerated approval and priority review, but these can also be granted to the same product candidate if the 
relevant criteria are met. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development 
and review of an application for approval of a breakthrough therapy.
Fast track designation, priority review, and breakthrough therapy designation do not change the standards for approval but may expedite the 
development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets 
the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. 
Post-Approval Requirements 
Drugs and biologics marketed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other 
things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse 
experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to 
prior FDA review and approval. There also are continuing, annual user fee requirements. 
Manufacturers are subject to periodic unannounced inspections by the FDA and state agencies for compliance with cGMP requirements. Changes 
to the manufacturing process are strictly regulated and, depending on the significance of the change, may require prior FDA approval before being 
implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation 
requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and 
effort in the area of production and quality control to maintain compliance with cGMP and other aspects of regulatory compliance. 
Discovery of previously unknown problems with a product or the failure to comply with applicable requirements may result in restrictions on a 
product, manufacturer or holder of an approved NDA or BLA, including withdrawal or recall of the product from the market or other voluntary, FDA-
initiated or judicial action that could delay or prohibit further marketing. Also, new government requirements, including those resulting from new 
legislation, may be established, or the FDA’s policies may change, which could delay or prevent regulatory approval of our products under development. 
The FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the 
product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or 
frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new 
safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other 
restrictions under a REMS program. Other potential consequences include, among other things: 
•
restrictions on the marketing or manufacturing of the product;  
•
complete withdrawal of the product from the market or product recalls; 
•
fines, warning letters or holds on post-approval clinical studies; 
•
refusal of the FDA to approve pending NDAs or BLAs or supplements to approved NDAs or BLAs, or suspension or revocation of product 
licenses or approvals; 
•
product seizure or detention, or refusal to permit the import or export of products; or 
•
injunctions or the imposition of civil or criminal penalties. 
The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only 
for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and 
regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to 
significant liability. 

 
28
Orphan Designation and Exclusivity 
Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a 
disease or condition with a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 
individuals in the United States and when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the 
United States will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a 
BLA or NDA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed 
publicly by the FDA. 
If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the disease for 
which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, 
including a full NDA or BLA, to market the same drug or biologic for the same indication for seven years, except in limited circumstances, such as a 
showing of clinical superiority to the product with orphan drug exclusivity or if FDA finds that the holder of the orphan drug exclusivity has not shown that 
it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was 
designated. Orphan drug exclusivity does not prevent the FDA from approving a different drug or biologic for the same disease or condition, or the same 
drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver 
of the BLA or NDA application user fee. 
A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it 
received orphan designation. In addition, orphan drug exclusive marketing rights in the United States may be lost if the FDA later determines that the 
request for designation was materially defective or, as noted above, if the second applicant demonstrates that its product is clinically superior to the 
approved product with orphan exclusivity or the manufacturer of the approved product is unable to assure sufficient quantities of the product to meet the 
needs of patients with the rare disease or condition. 
Biosimilars and Exclusivity 
The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or the Affordable Care Act, 
signed into law in 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated 
approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. To date, only a 
handful of biosimilars have been licensed under the BPCIA, although numerous biosimilars have been approved in Europe. The FDA has issued several 
guidance documents outlining an approach to review and approval of biosimilars. 
Biosimilarity, which requires that there be no clinically meaningful differences between the biological product and the reference product in terms 
of safety, purity and potency, can be shown through analytical studies, animal studies and a clinical study or studies. Interchangeability requires that a 
product is biosimilar to the reference product and the product must demonstrate that it can be expected to produce the same clinical results as the reference 
product in any given patient and, for products that are administered multiple times to an individual, the biologic and the reference biologic may be 
alternated or switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of 
the reference biologic. However, complexities associated with the larger, and often more complex, structures of biological products, as well as the 
processes by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being 
worked out by the FDA. 
Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference 
product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date 
on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the 
reference product if the FDA approves a full BLA for the competing product containing that applicant’s own preclinical data and data from adequate and 
well-controlled clinical studies to demonstrate the safety, purity and potency of its product. The BPCIA also created certain exclusivity periods for 
biosimilars approved as interchangeable products. At this juncture, it is unclear whether products deemed “interchangeable” by the FDA will, in fact, be 
readily substituted by pharmacies, which are governed by state pharmacy law. 

 
29
A biological product can also obtain pediatric market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to existing 
exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted 
based on the voluntary completion of a pediatric study in accordance with an FDA-issued “Written Request” for such a study. 
The BPCIA is complex and continues to be interpreted and implemented by the FDA. In addition, recent government proposals have sought to 
reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have 
also been the subject of recent litigation. As a result, the ultimate impact, implementation, and impact of the BPCIA is subject to significant uncertainty. 
Hatch-Waxman Amendments and Exclusivity 
Section 505 of the FDCA describes three types of marketing applications that may be submitted to the FDA to request marketing authorization for 
a new drug. A Section 505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A 505(b)(2) NDA is an 
application that contains full reports of investigations of safety and efficacy but where at least some of the information required for approval comes from 
investigations that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or 
for whom the investigations were conducted. This regulatory pathway enables the applicant to rely, in part, on the FDA’s prior findings of safety and 
efficacy for an existing product, or published literature, in support of its application. Section 505(j) establishes an abbreviated approval process for a 
generic version of approved drug products through the submission of an Abbreviated New Drug Application, or ANDA. An ANDA provides for marketing 
of a generic drug product that has the same active ingredients, dosage form, strength, route of administration, labeling, performance characteristics and 
intended use, among other things, to a previously approved product. ANDAs are termed “abbreviated” because they are generally not required to include 
preclinical (animal) and clinical (human) data to establish safety and efficacy. Instead, generic applicants must scientifically demonstrate that their product 
is bioequivalent to, or performs in the same manner as, the innovator drug through in vitro, in vivo or other testing. The generic version must deliver the 
same amount of active ingredients into a subject’s bloodstream in the same amount of time as the innovator drug and can often be substituted by 
pharmacists under prescriptions written for the reference listed drug. In seeking approval for a drug through an NDA, applicants are required to list with the 
FDA each patent with claims that cover the applicant’s drug or a method of using the drug. Upon approval of a drug, each of the patents listed in the 
application for the drug is then published in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the 
Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential competitors in support of approval of an ANDA or 505(b)(2) NDA. 
Upon submission of an ANDA or a 505(b)(2) NDA, an applicant must certify to the FDA that (1) no patent information on the drug product that is 
the subject of the application has been submitted to the FDA; (2) such patent has expired; (3) the date on which such patent expires; or (4) such patent is 
invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. Generally, the ANDA or 
505(b)(2) NDA cannot be approved until all listed patents have expired, except where the ANDA or 505(b)(2) NDA applicant challenges a listed patent 
through the last type of certification, also known as a paragraph IV certification. If the applicant does not challenge the listed patents or indicates that it is 
not seeking approval of a patented method of use, the ANDA or 505(b)(2) NDA application will not be approved until all of the listed patents claiming the 
referenced product have expired. 
If the ANDA or 505(b)(2) NDA applicant has provided a Paragraph IV certification to the FDA, the applicant must send notice of the Paragraph 
IV certification to the NDA and patent holders once the application has been accepted for filing by the FDA. The NDA and patent holders may then initiate 
a patent infringement lawsuit in response to the notice of the paragraph IV certification. If the paragraph IV certification is challenged by an NDA holder or 
the patent owner(s) asserts a patent challenge to the paragraph IV certification, the FDA may not approve that application until the earlier of 30 months 
from the receipt of the notice of the paragraph IV certification, the expiration of the patent, when the infringement case concerning each such patent was 
favorably decided in the applicant’s favor or settled, or such shorter or longer period as may be ordered by a court. This prohibition is generally referred to 
as the 30-month stay. In instances where an ANDA or 505(b)(2) NDA applicant files a paragraph IV certification, the NDA holder or patent owner(s) 
regularly take action to trigger the 30-month stay, recognizing that the related patent litigation may take many months or years to resolve. 
The FDA also cannot approve an ANDA or 505(b)(2) application until all applicable non-patent exclusivities listed in the Orange Book for the 
branded reference drug have expired. For example, a pharmaceutical manufacturer 

 
30
may obtain five years of non-patent exclusivity upon NDA approval of a new chemical entity, or NCE, which is a drug containing an active moiety that has 
not been approved by FDA in any other NDA. An “active moiety” is defined as the molecule responsible for the drug substance’s physiological or 
pharmacologic action. During that five-year exclusivity period, the FDA cannot accept for filing (and therefore cannot approve) any ANDA seeking 
approval of a generic version of that drug or any 505(b)(2) NDA that relies on the FDA’s approval of the drug, provided that that the FDA may accept an 
ANDA four years into the NCE exclusivity period if the ANDA applicant also files a Paragraph IV certification. 
A drug, including one approved under Section 505(b)(2), may obtain a three-year period of exclusivity for a particular condition of approval, or 
change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical studies (other than bioavailability 
or bioequivalence studies) was essential to the approval of the application and was conducted/sponsored by the applicant. Should this occur, the FDA 
would be precluded from approving any ANDA or 505(b)(2) application for the protected modification until after that three-year exclusivity period has run. 
However, unlike NCE exclusivity, the FDA can accept an application and begin the review process during the exclusivity period.
Other Healthcare Laws and Compliance Requirements
Pharmaceutical companies are subject to additional healthcare regulation and enforcement by the federal government and by authorities in the 
states and foreign jurisdictions in which they conduct their business. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, 
false claims, and physician sunshine laws and regulations. If their operations are found to be in violation of any of such laws or any other governmental 
regulations that apply, they may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, the curtailment or 
restructuring of operations, exclusion from participation in federal and state healthcare programs and individual imprisonment. 
Coverage and Reimbursement
Sales of any product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state and foreign 
government healthcare programs, commercial insurance and managed healthcare organizations and the level of reimbursement for such product by third-
party payors. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. These third-party 
payors are increasingly reducing reimbursements for medical products, drugs and services. For products administered under the supervision of a physician, 
obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. In addition, the 
U.S. government, state legislatures and foreign governments have continued implementing cost-containment programs, including price controls, 
restrictions on coverage and reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment 
measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit sales of any product. Decreases 
in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand 
for the product and also have a material adverse effect on sales. 
Healthcare Reform
In March 2010, former President Obama signed the Affordable Care Act, which substantially changed the way healthcare is financed by both 
governmental and private insurers in the United States, and significantly affected the pharmaceutical industry. The Affordable Care Act contains a number 
of provisions, including those governing enrollment in federal healthcare programs, reimbursement adjustments and fraud and abuse changes. Additionally, 
the Affordable Care Act increases the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%; requires 
collection of rebates for drugs paid by Medicaid managed care organizations; requires manufacturers to participate in a coverage gap discount program, 
under which they must agree to offer 70 percent point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their 
coverage gap period, as a condition for the manufacturer’s outpatient drugs to be covered under Medicare Part D; and imposes a non-deductible annual fee 
on pharmaceutical manufacturers or importers who sell “branded prescription drugs” to specified federal government programs. 

 
31
Since its enactment, there have been judicial and Congressional challenges to certain aspects of the Affordable Care Act, and we expect there will 
be additional challenges and other efforts to repeal or replace the Affordable Care Act in the future. Other legislative changes have been proposed and 
adopted since the Affordable Care Act was enacted, including aggregate reductions of Medicare payments to providers of 2% per fiscal year and reduced 
payments to several types of Medicare providers. Moreover, there has recently been heightened governmental scrutiny over the manner in which 
manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other 
things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government 
program reimbursement methodologies for drug products. Individual states in the United States have also become increasingly active in implementing 
regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain 
product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and 
bulk purchasing. 
Data Privacy and Security Laws
Numerous state, federal and foreign laws, including consumer protection laws and regulations, govern the collection, dissemination, use, access to, 
confidentiality and security of personal information, including health-related information. In the United States, numerous federal and state laws and 
regulations, including data breach notification laws, health information privacy and security laws and consumer protection laws and regulations that govern 
the collection, use, disclosure, and protection of health-related and other personal information and could apply to our operations or the operations of our 
partners. In addition, certain foreign laws govern the privacy and security of personal data, including health-related data, many of which differ from each 
other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can 
result in the imposition of significant civil and/or criminal penalties and private litigation.  Privacy and security laws, regulations, and other obligations are 
constantly evolving, may conflict with each other to complicate compliance efforts, and can result in investigations, proceedings, or actions that lead to 
significant civil and/or criminal penalties and restrictions on data processing.
Employees and Human Capital Resources
As of December 31, 2024, we had 16 employees, all of whom were full-time. Approximately 25% of our employees hold advanced degrees. In 
February 2022, and again on May 4, 2023, we announced a restructuring to align resources to focus on our ongoing clinical programs and deliver on key 
development milestones. 
The majority of our employees work in our corporate headquarters. None of our employees are represented by a labor union or a collective 
bargaining agreement and we consider our relationship with our employees to be good.
Our human capital resources objectives are, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and 
additional employees. As such, we expend considerable time, attention, and financial resources on these activities. Our corporate culture, which is 
underpinned by our company values, is the overarching framework we use to make decisions related to people practices, including total compensation, 
short and long-term incentives, health and wellness, and employee engagement.
Facilities
Our corporate headquarters are located in South San Francisco, California, where we currently lease approximately 62,000 square feet of office 
and laboratory space pursuant to a lease dated February 28, 2019, of which approximately 23,000 square feet was subleased from June 2021 through July 
2024, and approximately 15,000 square feet was subleased as of July 2022 through June 2026 with an additional 17,000 square feet subleased as of 
September 2023 through June 2026. The majority of our employees work at our corporate headquarters. 
Legal Proceedings
We are not currently involved in any litigation or legal proceedings that, in management’s opinion, are likely to have any material adverse effect 
on our company. While we know of no imminent legal action in which we are 

 
32
likely to be involved, we may in the future become engaged in litigation or other legal proceedings. Regardless of the outcome, litigation can have an 
adverse impact due to defense fees, settlement costs, demands on management attention, and other concerns. 
About UNITY
We were incorporated in the State of Delaware on March 30, 2009. Our registered trademarks include UNITY BIOTECHNOLOGY®. Other 
service marks, trademarks and trade names referred to in this document are the property of their respective owners.
Available Information
We are subject to the information requirements of the Securities Exchange Act of 1934, as amended and we therefore file periodic reports, proxy 
statements and other information with the SEC, relating to our business, financial statements and other matters. The SEC maintains an Internet site, 
www.sec.gov, that contains reports, proxy statements and other information regarding issuers such as UNITY.
For more information about UNITY, including free access to our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on 
Form 8-K and amendments to those reports, visit our website, www.unitybiotechnology.com. The information found on or accessible through our website is 
not incorporated into, and does not form a part of, this Annual Report on Form 10-K. 
Item 1A. Risk Factors
This Annual Report on Form 10-K contains forward-looking information based on our current expectations. Because our business is subject to many risks 
and our actual results may differ materially from any forward-looking statements made by or on behalf of us, this section includes a discussion of important 
factors that could affect our business, operating results, financial condition and the trading price of our common stock. This discussion should be read in 
conjunction with the other information in this Annual Report on Form 10-K, including our financial statements and the notes accompanying those financial 
statements and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” The occurrence of any of the events or 
developments described below could have a material adverse effect on our business, results of operations, financial condition, prospects and stock price.
Risks Related to Our Limited Operating History, Financial Condition, and Capital Requirements
We are a clinical-stage biopharmaceutical company with a limited operating history and no products approved for commercial sale. We have incurred 
significant losses since our inception, and we anticipate that we will continue to incur losses for the foreseeable future, which, together with our limited 
operating history, make it difficult to assess our future viability.
We are a clinical-stage biopharmaceutical company with a limited operating history. Biopharmaceutical product development is a highly speculative 
undertaking and involves a substantial degree of risk. We have not yet sought approval for commercial sale of any products and therefore have no products 
approved for commercial sale and have not generated any product revenue and have incurred losses in each year since our inception in March 2009. We 
have only a limited operating history upon which you can evaluate our business and prospects. In addition, we have limited experience and have not yet 
demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving 
fields, particularly in the biopharmaceutical industry. 
 
We have had significant operating losses since our inception. Our net loss for the years ended December 31, 2024 and 2023 was approximately $26.0 
million and $39.9 million, respectively. As of December 31, 2024, we had an accumulated deficit of $510.3 million. Substantially all of our losses have 
resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our 
operations. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will 

 
33
increase as we continue to develop our drug candidates, conduct clinical studies and pursue research and development activities. Even if we achieve 
profitability in the future, we may not be able to sustain profitability in subsequent periods. Our prior losses, combined with expected future losses, have 
had and will continue to have an adverse effect on our stockholders’ equity and working capital.
Our financial condition raises substantial doubt as to our ability to continue as a going concern.
Based on our current operating plans, we expect our existing capital resources will fund our planned operating expenses into the fourth quarter of 2025, 
which will be used to advance UBX1325 (foselutoclax). Since our capital resources will fund operations less than 12 months from the date of this Annual 
Report on Form 10-K, we concluded that these conditions raise substantial doubt about our ability to continue as a going concern. We expect to continue to 
incur net operating losses for at least the next several years as we continue our research and development efforts, advance our drug candidates through 
preclinical and clinical development, seek regulatory approval, prepare for and, if approved, proceed to commercialization. We do not expect to generate 
revenue from any drug candidates that we develop until we obtain regulatory approval for one or more of such drug candidates and commercialize our 
products or enter into collaborative agreements with third parties. 
While our financial statements have been prepared assuming that we will continue to operate as a going concern, which contemplates the realization of 
assets and the satisfaction of liabilities in the normal course of business, and have successful development of UBX1325, which is in Phase 2 of clinical 
development, we will need to raise additional funds.
There is no assurance that funding will be available to us, will be obtained on terms favorable to us or will provide us with sufficient funds to meet our 
objectives. Failure to raise additional financing may adversely impact our ability to achieve our intended business objectives because without substantial 
additional capital, we may not be able to complete pivotal trials necessary to advance our product development and our programs. If we become unable to 
continue as a going concern, we may have to liquidate our assets and the values we receive for our assets in liquidation or dissolution could be significantly 
lower than the values reflected in our financial statements, and may be sooner than the fourth quarter of 2025.
The reaction of investors to the inclusion of a going concern statement by our auditors may materially adversely affect our share price and our ability to 
raise new capital or enter into partnerships.
We will require substantial additional financing to achieve our goals, and a failure to obtain this capital when needed on acceptable terms, or at all, 
could force us to delay, limit, reduce or terminate our product development, other operations or commercialization efforts.
Since our inception, we have invested a significant portion of our efforts and financial resources in research and development activities. Preclinical studies 
and clinical studies for our drug candidates and additional research and development activities to discover and develop new drug candidates will require 
substantial funds to complete. As of December 31, 2024, we had capital resources consisting of cash, cash equivalents, and marketable securities of  $23.2 
million. We believe that we will continue to expend substantial resources for the foreseeable future in connection with our programs, including the clinical 
development of UBX1325, and the development of any other drug candidates we may choose to pursue. These expenditures will include costs associated 
with conducting preclinical studies and clinical studies, obtaining regulatory approvals, and manufacturing and supply, as well as marketing and selling any 
products approved for sale. In addition, other unanticipated costs may arise. Because the outcome of any preclinical study or clinical study is highly 
uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our current 
drug candidates or any future drug candidates.
In February 2022, and again on May 4, 2023, we announced restructuring efforts to align resources to focus on our ongoing clinical programs and deliver 
on key development milestones. These actions to prioritize our ophthalmology programs, optimize resource allocation, extend our runway, and implement 
cost saving measures were designed to enable us to achieve multiple key clinical data readouts for UBX1325. As part of the May 2023 restructuring 
actions, we reduced our headcount by a total of nine employees, or approximately 29%, effective as of May 31, 2023, with three employees who departed 
as of June 30, 2023.

 
34
While our financial statements have been prepared assuming that we will continue to operate as a going concern, which contemplates the realization of 
assets and the satisfaction of liabilities in the normal course of business, and have successful development of UBX1325, which is in Phase 2 of clinical 
development, we will need to raise additional funds.
Based on our current operating plans, we expect our existing capital resources will fund our planned operating expenses into the fourth quarter of 2025, 
which will be used to advance UBX1325. Since our capital resources will fund operations less than 12 months from the date of this Annual Report on Form 
10-K, we concluded that these conditions raise substantial doubt about our ability to continue as a going concern. If we become unable to continue as a
going concern, we may have to liquidate our assets and the values we receive for our assets in liquidation or dissolution could be significantly lower than 
the values reflected in our financial statements, and maybe sooner than the fourth quarter of 2025.
The reaction of investors to the inclusion of a going concern statement by our auditors may materially adversely affect our share price and our ability to 
raise new capital or enter into partnerships.
We will need substantial additional capital to operate our business and continue our development activities and without substantial additional capital, we 
may not be able to complete pivotal trials necessary to advance our product development and our programs. If funding is only available on less desirable 
terms or not available at all for companies in the life sciences industry or if we are unable to access our cash deposits held at financial institutions due any 
liquidity concerns at such financial institutions, our business and operations would be adversely affected and we may be required to cease operations.
To date, we have primarily financed our operations through the sale of equity securities. For example, in March 2022, we filed a Registration Statement on 
Form S-3 covering the offering of up to $125.0 million of common stock, preferred stock, debt securities, warrants and units, which was declared effective 
by the SEC in May 2022, or the March 2022 Shelf Registration Statement. In March 2022, we also entered into a sales agreement, or the March 2022 Sales 
Agreement, with Cowen and Company, LLC, or Cowen, (now TD Securities (USA) LLC) as sales agent to sell shares of our common stock, from time to 
time, with aggregate gross sales proceeds of up to $25.0 million pursuant to the March 2022 Shelf Registration Statement as an “at-the-market” offering 
under the Securities Act, or the March 2022 ATM Offering Program. Further, in October 2022, we filed a Registration Statement on Form S-3 covering the 
offering of up to $250.0 million of common stock, preferred stock, debt securities, warrants and units, or the October 2022 Shelf Registration Statement 
and, together with the March 2022 Shelf Registration Statement, the shelf registration statements. In October 2022, we also entered into a sales agreement 
with Cowen as sales agent to sell shares of our common stock, from time to time, with aggregate gross sales proceeds of up to $50.0 million pursuant to the 
October 2022 Shelf Registration Statement as an “at-the-market” offering under the Securities Act, or the October 2022 ATM Offering Program, and, 
together with the March 2022 ATM Offering Program, the ATM Offering Programs. 
We will be required to seek additional funding in the future and currently intend to do so through collaborations, public or private equity offerings or debt 
financings, credit or loan facilities or a combination of one or more of these funding sources. Such financing may result in dilution to stockholders and the 
terms of any financing may adversely affect the rights of our stockholders. In addition, as a condition to providing additional funds to us, future investors 
may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, is likely to involve restrictive covenants 
limiting our flexibility in conducting future business activities, and, in the event of insolvency, debt holders would be repaid before holders of our equity 
securities received any distribution of our corporate assets.
Our ability to raise additional funds will depend on financial, economic and other factors, many of which are beyond our control. For example, financial 
markets have been negatively affected by high interest rates, rising inflation, tariffs, and the potential for local and/or global economic recession. Such
impacts may be exacerbated by unforeseen events, changes in government administrations, or public health emergencies. Adequate funding may not be 
available to us on acceptable terms, or at all, particularly in light of these conditions. In addition, we may seek additional capital due to favorable market 
conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. 

 
35
We currently have shelf registration statements effective and existing ATM Offering Programs, however, our ability to raise capital under these registration 
statements and through these ATM Offering Programs may be limited by, among other things, SEC rules and regulations impacting the eligibility of 
smaller companies to use Form S-3 for primary offerings of securities. Based on our public float, as of the date of the filing of this Annual Report on Form 
10-K, we are only permitted to utilize a shelf registration statement, including the registration statements under which our ATM Offering Programs are
operated, subject to Instruction I.B.6 to Form S-3, which is referred to as the “baby shelf” rule. For so long as our public float is less than $75.0 million, we 
may not sell more than the equivalent of one-third of our public float during any 12 consecutive months pursuant to the baby shelf rules. Although 
alternative public and private transaction structures may be available, these may require additional time and cost, may impose operational restrictions on us, 
and may not be available on attractive terms. 
Our future capital requirements depend on many factors, including:
•
the results of our ongoing clinical trials of UBX1325 (foselutoclax);
•
our ability to reduce our operating expenses;
•
the scope, progress, results and costs of researching and developing our drug candidates, and conducting preclinical studies and clinical 
studies;
•
potential delays in or an increase in costs associated with our ongoing or planned preclinical studies or clinical trials;
•
the timing of, and the costs involved in, obtaining regulatory approvals for our current drug candidates or any future drug candidates;
•
the number and characteristics of any additional drug candidates we develop or acquire;
•
the timing and amount of any milestone payments we are required to make pursuant to our license agreements;
•
the cost of manufacturing our current drug candidates or any future drug candidates and any products we successfully commercialize;
•
the cost of commercialization activities if our current drug candidates or any future drug candidates are approved for sale, including 
marketing, sales and distribution costs;
•
our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any 
such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement;
•
any product liability or other lawsuits related to our products;
•
the costs associated with being a public company;
•
the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing our intellectual property portfolio; 
•
our ability to utilize our ATM Offering Programs and raise additional capital; 
•
whether we can maintain compliance with the continued listing requirements of Nasdaq; and
•
the timing, receipt and amount of sales of any future approved products, if any.
Additional and sufficient funds may not be available when we need them, on terms that are acceptable to us, or at all. If adequate funds are not available to 
us on a timely basis and if we do not manage discretionary spending, we may be required to:
•
delay, limit, reduce or terminate preclinical studies, clinical studies or other development activities for our current drug candidates or any 
future drug candidate;
•
delay, limit, reduce or terminate our research and development activities;

 
36
•
delay, limit, reduce or terminate our efforts to establish manufacturing and sales and marketing capabilities or other activities that may be 
necessary to commercialize our current drug candidates or any future drug candidate, or reduce our flexibility in developing or maintaining 
our sales and marketing strategy; or
•
liquidate assets where possible, cease operations or file for bankruptcy protection.
We also could choose or be required to seek funds through arrangements with collaborators or others that may require us to relinquish rights to some of our 
technologies or drug candidates that we would otherwise pursue on our own. We do not expect to realize revenue from sales of products or royalties from 
licensed products in the foreseeable future, if at all, and unless and until our drug candidates are clinically tested, approved for commercialization and 
successfully marketed.
We may not be able to maintain compliance with the continued listing requirements of Nasdaq, and, if so, we would be subject to delisting. 
Our common stock is currently listed for trading on the Nasdaq Global Select Market under the symbol “UBX”. The continued listing of our common stock 
on Nasdaq is subject to our compliance with a number of listing standards. On June 3, 2022, we received a letter from the Listing Qualifications Staff of 
The Nasdaq Stock Market LLC indicating that for the last 30 consecutive business days, the closing bid price of our common stock was below $1.00 per 
share, which is the minimum required closing bid price for continued listing on the Nasdaq Global Select Market pursuant to Listing Rule 5450(a)(1). We 
had 180 calendar days, or until November 30, 2022, to regain compliance. To regain compliance, the closing bid price of our common stock needed to be at 
least $1.00 per share for a minimum of ten consecutive business days. On October 19, 2022, we effected a 1-for-10 reverse stock split of our common stock 
seeking to regain compliance with Nasdaq Global Select Market's continued listing standards. From October 20, 2022 to November 2, 2022 (10 
consecutive business days), the closing bid price of our common stock exceeded $1.00 per share. Accordingly, on November 3, 2022, we received a notice 
from Nasdaq indicating that we have regained compliance with Listing Rule 5450(a)(1) as of such date. 
Although we currently comply with the minimum bid requirement following the reverse stock split, our bid price could fall below $1.00 per share again in 
the future, in which event we would receive another deficiency notice from Nasdaq advising us that we have 180 days to regain compliance by maintaining 
a minimum bid price of at least $1.00 for a minimum of ten consecutive business days. Under certain circumstances, Nasdaq could require that the 
minimum bid price exceed $1.00 for more than ten consecutive days before determining that a company complies. If we fail to satisfy the Nasdaq’s 
continued listing requirements, we may transfer to the OTC Bulletin Board. Having our common stock trade on the OTC Bulletin Board could adversely 
affect the liquidity of our common stock. Any such transfer could make it more difficult to dispose of, or obtain accurate quotations for the price of, our 
common stock, and there also would likely be a reduction in our coverage by securities analysts and the news media, which could cause the price of our 
common stock to decline further and adversely impact the ability of stockholders to sell our common stock. We may also face other material adverse 
consequences in such event such as negative publicity, a decreased ability to obtain additional financing, diminished investor and/or employee confidence, 
and the loss of business development opportunities, any of which may contribute to a further decline in our stock price.
Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to 
fall below expectations.
Our quarterly and annual operating results may fluctuate significantly, making it difficult for us to predict our future operating results. These fluctuations 
may occur due to a variety of factors, many of which are outside of our control and may be difficult to predict, including:
•
the timing, cost and level of investment in research, development and, if approved, commercialization activities relating to our drug 
candidates, which may change from time to time;
•
the timing and status of enrollment for our clinical studies;
•
the cost of manufacturing our drug candidates, as well as building out our supply chain, which may vary depending on the quantity of 
production and the terms of our agreements with manufacturers;

 
37
•
expenditures we may incur to acquire, develop or commercialize additional drug candidates and technologies;
•
timing and amount of any milestone, royalty or other payments due under any collaboration or license agreement;
•
future accounting pronouncements or changes in our accounting policies;
•
the timing and success or failure of preclinical studies and clinical studies for our drug candidates or competing drug candidates, or any other 
change in the competitive landscape of our industry, including consolidation among our competitors or partners;
•
the timing of receipt of approvals for our drug candidates from regulatory authorities in the United States and internationally;
•
coverage and reimbursement policies with respect to our drug candidates, if approved, and potential future drugs that compete with our
products;
•
the level of demand for our products, if approved, which may vary significantly over time; and
•
potential disruption caused by unforeseen events and public health emergencies.
The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, 
comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our 
future performance.
This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If 
our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts 
we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price 
decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide.
Risks Related to Our Business and Product Development
Our core therapeutic approach to slow, halt, or reverse diseases of aging is based on our understanding of cellular senescence. Utilizing senolytic 
molecules to treat diseases of aging is a novel therapeutic approach, which exposes us to unforeseen risks and makes it difficult to predict the time and 
cost of drug development and potential for regulatory approval.
Our foundational science and lead drug candidate are based on senescence biology. We believe that we can develop drug candidates capable of eliminating 
or modulating accumulated senescent cells, when administered locally. In our development efforts we intend to explore senolytic medicines that use 
multiple modalities. However, our approach to treating diseases of aging is novel and the scientific research that forms the basis of our efforts to develop 
senolytic medicines is ongoing. We have only recently begun testing our senolytic molecules in humans and the majority of our current data supporting our 
hypothesis regarding senescence biology is limited to pre-clinical animal models and in vitro cell lines, the results of which may not translate into humans. 
We currently have no conclusive evidence in humans, that the accumulation or modulation of senescent cells is the underlying cause of tissue damage and 
dysfunction associated with many diseases of aging. For example, in August 2020, we announced the 12-week results from our Phase 2 study of UBX0101 
in patients with moderate-to-severe painful OA of the knee. There was no statistically significant difference between any arm of UBX0101 and placebo at 
the 12-week primary endpoint for change from baseline in WOMAC-A, an established measurement of pain in OA. Given these results, we decided not to 
progress UBX0101 into pivotal studies and have narrowed our near-term focus mainly to our ongoing ophthalmologic disease programs.
Our current program, UBX1325 (foselutoclax), is a BCL-xL inhibitor, and is intended to target senescent cells in the eye. While cellular senescence is a 
naturally occurring biological process, the administration of senolytic medicines to eliminate or cause the elimination or modulation of accumulated 
senescent cells in humans has not been widely 

 
38
tested and may potentially harm healthy tissue or result in unforeseen safety events or fail to achieve the intended therapeutic purpose entirely. We may 
also ultimately discover that our senolytic molecules do not possess certain properties required for therapeutic effectiveness, or that even if found to be 
effective in one type of tissue, that such molecules will be effective in other tissues. In addition, given the novel nature of this therapeutic approach, 
designing preclinical and clinical studies to demonstrate the effect of senolytic medicines is complex and exposes us to unforeseen risks. In addition, the 
scientific evidence to support the feasibility of developing systemic senolytic medicines is based primarily on preclinical data and not human clinical trials. 
We may spend substantial funds attempting to develop these drug candidates and never succeed in doing so.
No regulatory authority has granted approval for a senolytic medicine. As such, we believe the U.S. Food and Drug Administration, or the FDA, has 
limited experience with senescence, which may increase the complexity, uncertainty and length of the clinical development and regulatory approval 
process for our drug candidates. We may never receive approval to market and commercialize any drug candidate. Even if we obtain regulatory approval, 
the approval may be for targets, disease indications or patient populations that are not as broad as we intended or desired or may require labeling that 
includes significant use or distribution restrictions or safety warnings. We may be required to perform additional or unanticipated clinical studies to obtain 
approval or be subject to post-marketing testing requirements to maintain marketing authorization. If our other senolytic molecules prove to be ineffective, 
unsafe or commercially unviable, our entire senolytic platform and pipeline would have little, if any, value, which would have a material and adverse effect 
on our business, financial condition, results of operations and prospects.
Our business is currently dependent on the successful development of UBX1325, which is in Phase 2 of clinical development.
We have no products approved for sale and all of our drug candidates are in early stages of development. We have one product candidate, UBX1325, in 
clinical development and are focused on advancing our ophthalmology program. In particular, in October 2020, we initiated a Phase 1 clinical study of 
UBX1325 in patients with DME or nAMD for whom anti-VEGF therapy was no longer considered beneficial, and in July, October, and November 2021, 
we announced positive data up to 24 weeks from this Phase 1 study. We initiated a Phase 2 proof-of-concept clinical study of UBX1325 in DME 
(BEHOLD) in May 2021, dosed the first patient in June 2021 and announced positive 24-week safety and efficacy data in November 2022, and announced 
positive 48-week safety and efficacy data in April 2023. In April 2022 we also dosed our first patient in our Phase 2 proof-of-concept study in nAMD 
(ENVISION), and we shared 16- and 24-week data in March 2023, and 48-week data in September 2023. We completed enrollment in our head-to-head 
Phase 2b (ASPIRE) study to explore the efficacy of UBX1325 in patients with DME compared to the current standard of care, aflibercept. We anticipate 
receiving topline data from the ASPIRE study in two data readouts: 24-week primary endpoint data in the first quarter of 2025, and 36-week long-term 
extension data in the second quarter of 2025.
In February 2022, and again on May 4, 2023, we announced restructuring efforts to align resources to focus on our ongoing clinical programs and deliver 
on key development milestones. These actions to prioritize our ophthalmology programs, optimize resource allocation, extend our runway, and implement 
cost saving measures were designed to enable us to achieve multiple key clinical data readouts for UBX1325. As a result, our business, including our 
ability to finance our company and generate any revenue in the future, is currently dependent on the successful development of UBX1325. If UBX1325 
does not demonstrate clinical benefit, we may be required to significantly delay or abandon its development. In the event UBX1325 is not successful in 
clinical development, we have limited resources and capital with which to develop additional drug candidates and we may be forced to sell or liquidate our 
business. 
The clinical and commercial success of UBX1325, and any other future drug candidates, will depend on a number of factors, including the following:
•
our ability to raise any additional required capital on acceptable terms, or at all;
•
our ability to complete IND-enabling studies and successfully submit an IND or comparable applications in foreign jurisdictions;
•
timely completion of our preclinical studies and clinical studies, which may be significantly slower, or cost more than we currently anticipate 
and will depend substantially upon the performance of third-party 

 
39
contractors, some of whom could be adversely impacted by unforeseen events such as pandemics and public health emergencies;
•
whether we are required by the FDA or similar foreign regulatory agencies to conduct additional clinical studies or other studies beyond 
those planned to support the approval and commercialization of our drug candidates or any future drug candidates;
•
acceptance of our proposed indications and primary endpoint assessments relating to the proposed indications of our drug candidates by the 
FDA and similar foreign regulatory authorities;
•
our ability to demonstrate to the satisfaction of the FDA and similar foreign regulatory authorities the safety, efficacy, and acceptable risk-to-
benefit profile of our current drug candidates or any future drug candidates;
•
the prevalence, duration and severity of potential side effects or other safety issues experienced with our drug candidates or future approved 
products, if any;
•
the timely receipt of necessary marketing approvals from the FDA and similar foreign regulatory authorities;
•
achieving and maintaining, and, where applicable, ensuring that our third-party contractors achieve and maintain compliance with our 
contractual obligations and with all regulatory requirements applicable to our current drug candidates or any future drug candidates or 
approved products, if any;
•
the willingness of physicians, professional societies, operators of clinics, hospitals, and patients to recommend, utilize, or adopt any of our 
future drug candidates to treat diseases of aging;
•
the ability of third parties with whom we contract to manufacture adequate clinical study and commercial supplies of our current drug 
candidates or any future drug candidates, to remain in good standing with regulatory agencies and develop, validate and maintain 
commercially viable manufacturing processes that are compliant with current good manufacturing practices, or cGMP;
•
our ability to successfully develop a commercial strategy and thereafter commercialize our drug candidates or any future drug candidates in 
the United States, and internationally, if approved for marketing, reimbursement, sale and distribution in such countries and territories, 
whether alone or in collaboration with others;
•
the convenience of our treatment or dosing regimen;
•
acceptance by physicians, payors, and patients of the benefits, safety, and efficacy of our drug candidates or any future drug candidates, if 
approved, including relative to alternative and competing treatments;
•
patient demand for our drug candidates, if approved;
•
our ability to establish and enforce intellectual property rights in and to our drug candidates or any future drug candidates; and 
•
our ability to avoid third-party patent interference, intellectual property challenges, or intellectual property infringement claims.
These factors, many of which are beyond our control, could cause us to experience significant delays or be unable to obtain regulatory approvals or 
commercialize our drug candidates. Even if regulatory approvals are obtained, we may never achieve success in commercializing any of our drug 
candidates. Accordingly, we cannot provide assurances that we will be able to generate sufficient revenue through the sale of our drug candidates or any 
future drug candidates to continue our business or achieve profitability.
Other than UBX1325, all of our other programs are preclinical and face significant development risk.   
Other than UBX1325, all of our other programs are in preclinical and early research stage. In addition, we have limited resources for which to develop any 
products other than UBX1325. Given the early stage nature of these programs, each of the drug candidates and programs faces substantial development 
risk. UBX1325 is the only current drug candidate that we have administered to humans, and as such, we face significant translational risk with our earlier 

 
40
stage drug candidates. We may also be required by the FDA or similar foreign regulatory agencies to conduct additional preclinical studies beyond those 
planned to support the commencement of additional clinical trials. Accordingly, there can be no assurance that we are able to bring any of our preclinical 
product candidates or development programs into the clinic or otherwise successfully develop them.
Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive 
of future trial results.
Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure or delay can occur at any time during the 
clinical study process. Success in preclinical studies and early clinical studies does not ensure that later clinical studies will be successful. A number of 
companies in the biotechnology, and pharmaceutical industries have suffered significant setbacks in clinical studies, even after positive results in earlier 
preclinical studies or clinical studies. These setbacks have been caused by, among other things, preclinical findings made while clinical studies were 
underway and safety or efficacy observations made in clinical studies, including previously unreported adverse events. The results of our preclinical animal 
studies or studies in ex vivo human tissues may not be predictive of the results of outcomes in human clinical studies. For example, our senolytic molecules 
may demonstrate different chemical and pharmacological properties in patients than they do in laboratory studies or may interact with human biological 
systems in unforeseen or harmful ways.
Drug candidates in later stages of clinical studies may fail to show the desired pharmacological properties or safety and efficacy traits despite having 
progressed through preclinical studies and initial clinical studies. Notwithstanding any promising results in earlier studies, we cannot be certain that we will 
not face similar setbacks. Even if we are able to initiate and complete clinical studies, the results may not be sufficient to obtain regulatory approval for our 
drug candidates.
We cannot be certain that studies or trials for our drug candidates will begin on time, not require redesign, enroll an adequate number of subjects on time or 
be completed on schedule, if at all. Future pandemics or public health emergencies could cause or exacerbate these factors. For example, for our Phase 2 
studies for UBX1325 and future studies, clinical sites may be unable to recruit and retain investigators and study staff, screen and enroll patients, patients 
may be unable to adhere to the study visit schedule, and the completion of the study could be delayed. Clinical studies can be prolonged, delayed or 
terminated for a variety of reasons, including:
•
the FDA or comparable foreign regulatory authorities disagreeing with or requiring changes to the design or implementation of our clinical 
studies;
•
delays in obtaining regulatory approval to commence or continue a trial;
•
reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical study sites, the terms of 
which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;
•
obtaining institutional review board, or IRB, approval at each trial site;
•
recruiting an adequate number of suitable patients to participate in a trial;
•
having subjects complete a trial or return for post-treatment follow-up;
•
encountering difficulties in gathering the range of biological data from patients needed to fully assess the impact of our drug candidates;
•
clinical sites deviating from trial protocol or dropping out of a trial;
•
addressing subject safety concerns that arise during the course of a trial;
•
adding a sufficient number of clinical study sites; or
•
obtaining sufficient product supply of drug candidate for use in preclinical studies or clinical studies from third-party suppliers some of 
whom could be adversely impacted by unforeseen events such as pandemics and public health emergencies.

 
41
We may experience numerous adverse or unforeseen events during, or as a result of, preclinical studies and clinical studies that could delay or prevent our 
ability to receive marketing approval or commercialize our drug candidates, including:
•
clinical studies of our drug candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to 
modify clinical study design, conduct additional clinical studies or abandon drug development programs, including all of our senolytic 
programs;
•
the number of patients required for clinical studies of our drug candidates may be larger than we anticipate, enrollment in these clinical 
studies may be slower than we anticipate, or participants may drop out of these clinical studies at a higher rate than we anticipate;
•
our third-party contractors may fail to comply with regulatory requirements, fail to maintain adequate quality controls, or be unable to 
provide us with sufficient product supply to conduct and complete preclinical studies or clinical studies of our drug candidates in a timely 
manner, or at all;
•
we or our investigators might have to suspend or terminate clinical studies of our drug candidates for various reasons, including 
noncompliance with regulatory requirements, a finding that our drug candidates have undesirable side effects or other unexpected 
characteristics, a finding that the participants are being exposed to unacceptable health risks, or due to unforeseen events such as pandemics 
and public health emergencies;
•
the cost of clinical studies of our drug candidates may be greater than we anticipate;
•
the quality of our drug candidates or other materials necessary to conduct preclinical studies or clinical studies of our drug candidates may be 
inadequate;
•
regulators may revise the requirements for approving our drug candidates, or such requirements may not be as we anticipate; and
•
future collaborators may conduct clinical studies in ways they view as advantageous to them but that are suboptimal for us.
If we are required to conduct additional clinical studies or other testing of our drug candidates beyond those that we currently contemplate, if we are unable
to successfully complete clinical studies of our drug candidates or other testing, if the results of these trials or tests are not positive or are only moderately 
positive, or if there are safety concerns, we may:
•
incur unplanned costs;
•
be delayed in obtaining marketing approval for our drug candidates or fail to obtain marketing approval at all;
•
obtain marketing approval in some countries and not in others;
•
obtain marketing approval for indications or patient populations that are not as broad as intended or desired;
•
obtain marketing approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed 
warnings;
•
be subject to additional post-marketing testing requirements; or
•
have the treatment removed from the market after obtaining marketing approval.
We could also encounter delays if a clinical study is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, 
by the Data Safety Monitoring Board, or DSMB, for such trial or by the FDA or other regulatory authorities. Such authorities may suspend or terminate a 
clinical study due to a number of factors, including failure to conduct the clinical study in accordance with regulatory requirements or our clinical 
protocols, inspection of the clinical study operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, 
unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from 

 
42
using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical study.
Further, conducting clinical studies in foreign countries, as we may do for certain of our drug candidates, presents additional risks that may delay 
completion of our clinical studies. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of 
differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as 
political and economic risks relevant to such foreign countries, including those caused by unforeseen events such as pandemics and public health 
emergencies similar to the COVID-19 pandemic.
Moreover, in September 2024, the U.S. House of Representatives passed a version of the BIOSECURE Act (H.R. 8333), however, the Senate did not 
approve that legislation. If Congress takes up the legislation again and it is passed and enacted into law, the BIOSECURE Act would have the potential to 
restrict the ability of U.S. biopharmaceutical companies like us to purchase services or products from, or otherwise collaborate with, certain Chinese 
biotechnology companies “of concern” without losing the ability to contract with, or otherwise receive funding from, the U.S. government. We do business 
with companies in China, and it is possible some of our contractual counterparties could be impacted by this legislation.
Principal investigators for our clinical studies may serve as scientific advisors or consultants to us from time to time and may receive cash or equity 
compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or a 
regulatory authority concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the 
applicable clinical study site may be questioned and the utility of the clinical study itself may be jeopardized, which could result in the delay or rejection of 
the marketing application we submit. Any such delay or rejection could prevent or delay us from commercializing our current or future drug candidates.
If we experience termination or delays in the completion of any preclinical study or clinical study of our drug candidates, the commercial prospects of our 
drug candidates may be harmed, and our ability to generate revenues from any of these drug candidates will be delayed or unrealized. In addition, any 
delays in completing our clinical studies may increase our costs, slow down our drug candidate development and approval process and jeopardize our 
ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business, financial condition and prospects. 
In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical studies may also ultimately lead to the denial 
of regulatory approval of our drug candidates. If one or more of our drug candidates or our senescence technology generally prove to be ineffective, unsafe 
or commercially unviable, our platform and pipeline would have significantly diminished value, which would have a material and adverse effect on our 
business, financial condition, results of operations and prospects and we may be forced to sell or liquidate our business.
If we encounter difficulties enrolling patients in our clinical studies, our clinical development activities could be delayed or otherwise adversely 
affected.
The timely completion of clinical studies in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of 
patients who remain in the study until its conclusion. We may experience difficulties in patient enrollment in our clinical studies for a variety of reasons. 
The enrollment of patients depends on many factors, including:
•
the patient eligibility criteria defined in the protocol;
•
the size of the patient population required for analysis of the trial’s primary endpoints;
•
the proximity of patients to trial sites;
•
patients’ fear of visiting or traveling to trial sites due to pandemics and public health emergencies;
•
the design of the trial;
•
our ability to recruit clinical study investigators with the appropriate competencies and experience;

 
43
•
clinicians’ and patients’ perceptions as to the potential advantages of the drug candidate being studied in relation to other available therapies, 
including any new drugs that may be approved for the indications we are investigating; and
•
our ability to obtain and maintain patient consents.
In addition, our clinical studies may compete with other clinical studies for drug candidates that are in the same therapeutic areas as our drug candidates. 
This competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may 
instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we may conduct 
some of our clinical studies at the same clinical study sites that some of our competitors use, which will reduce the number of patients who are available for 
our clinical studies in such clinical study site.
Further, the administration of senolytic medicines designed to eliminate or cause the elimination of senescent cells and thereby modulate their associated 
SASP may result in unforeseen events, including by harming healthy tissues. As a result, it is possible that safety concerns could negatively affect patient
enrollment among the patient populations that we intend to treat, including among those in indications with a low risk of mortality. Delays in patient 
enrollment may result in increased costs or may affect the timing or outcome of the planned clinical studies, which could prevent completion of these trials 
and adversely affect our ability to advance the development of our drug candidates.
Interim, “top-line” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data 
become available and are subject to audit and verification procedures that could result in material changes in the final data.
From time to time, we may publicly disclose top-line or preliminary data from our clinical trials, which is based on a preliminary analysis of then-available 
data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular 
study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had 
the opportunity to fully and carefully evaluate all data. As a result, the top-line or preliminary results that we report may differ from future results of the 
same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Top-line or 
preliminary data also remain subject to audit and verification procedures that may result in the final data being materially different from the top-line or 
preliminary data we previously published. As a result, top-line and preliminary data should be viewed with caution until the final data is available.
From time to time, we may also disclose interim data from our preclinical studies and clinical trials. Interim data from clinical trials that we may conduct 
are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data becomes 
available. Adverse differences between interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us 
or by our competitors could result in volatility in the price of our common stock.
Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may 
interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the 
particular product candidate or product, our ability to make certain claims about our products, and our company in general. In addition, the information we 
choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree 
with what we determine is material or otherwise appropriate information to include in our disclosure.
If the interim, top-line or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the 
conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, 
operating results, prospects or financial condition.
Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain, 
or deploy key leadership and other personnel, or otherwise prevent products 

 
44
from being developed, approved, or commercialized in a timely manner or at all, which may adversely affect our business. 
The ability of the FDA and other government agencies to review and approve new products can be affected by a variety of factors, including government 
budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. In 
addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is 
inherently fluid and unpredictable. Disruptions at the FDA and other agencies, including a prolonged government shutdown, may cause significant 
regulatory delays and, therefore, delay our efforts to seek approvals and adversely affect our business, financial condition, results of operations, or cash 
flows. For example, in recent years, the U.S. government has shut down several times, and certain regulatory agencies, such as the FDA, have had to 
furlough critical employees and stop critical activities.
Our drug candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the 
commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.
Undesirable side effects caused by our drug candidates could cause us or regulatory authorities to interrupt, delay or halt clinical studies and could result in 
a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. Other than our clinical 
studies of UBX0101 and UBX1325 (foselutoclax), senolytic medicines designed to eliminate or cause the elimination of senescent cells have never been 
tested in humans. As a result, although UBX1325 has been well tolerated in our Phase 1 and Phase 2 clinical studies with no adversities that would prevent 
advancement into later stage clinical trials as of the date of this Annual Report on Form 10-K, UBX1325 could reveal a high and unacceptable severity and 
prevalence of side effects, and it is possible that patients enrolled in such clinical studies could respond in unexpected ways. For instance, in preclinical in 
vivo animal and ex vivo human tissue studies, our senolytic molecules have exhibited clearance of senescent cells; however, the elimination of 
accumulated senescent cells may result in unforeseen events, including harming healthy cells or tissues. In addition, the entry by cells into a senescent state 
is a natural biological process that we believe may have protective effects, such as halting the proliferation of damaged cells. The treatment of tissues with 
senolytic molecules could interfere with such protective processes.
If unacceptable side effects arise in the development of our drug candidates, we, the FDA, the IRBs at the institutions in which our studies are conducted, 
or the DSMB could suspend or terminate our clinical studies, or the FDA or comparable foreign regulatory authorities could order us to cease clinical 
studies or deny approval of our drug candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the 
ability of enrolled patients to complete any of our clinical studies or result in potential product liability claims. In addition, these side effects may not be 
appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our drug candidates to understand 
the side effect profiles for our clinical studies and upon any commercialization of any of our drug candidates. Inadequate training in recognizing or 
managing the potential side effects of our drug candidates could result in patient injury or death. Any of these occurrences may harm our business, financial 
condition and prospects significantly.
In addition, even if we successfully advance any of our drug candidates into and through clinical studies, such trials will likely only include a limited 
number of subjects and limited duration of exposure to our drug candidates. As a result, we cannot be assured that adverse effects of our drug candidates 
will not be uncovered when a significantly larger number of patients are exposed to the drug candidate. Further, clinical studies may not be sufficient to 
determine the effect and safety consequences of taking our drug candidates over a multi-year period. There can be no assurance that it will demonstrate a 
similarly favorable safety profile in subsequent clinical trials.
If any of our drug candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of 
potentially significant negative consequences could result, including:
•
regulatory authorities may withdraw their approval of the product;
•
we may be required to recall a product or change the way such product is administered to patients;

 
45
•
additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any 
component thereof;
•
regulatory authorities may require the addition of labeling statements, such as a “black box” warning or a contraindication;
•
we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a Medication Guide outlining the risks of 
such side effects for distribution to patients;
•
we could be sued and held liable for harm caused to patients;
•
the product may become less competitive; and
•
our reputation may suffer.
Any of the foregoing events could prevent us from achieving or maintaining market acceptance of the particular drug candidate, if approved, and result in 
the loss of significant revenues to us, which would materially and adversely affect our results of operations and business. In addition, if one or more of our 
drug candidates or our senescence approach generally prove to be unsafe, our entire platform and pipeline could be affected, which would have a material 
and adverse effect on our business, financial condition, results of operations and prospects.
We may not be successful in our efforts to continue to create a pipeline of drug candidates or to develop commercially successful products. If we fail to 
successfully identify and develop additional drug candidates, our commercial opportunity may be limited.
We are committed to developing senolytic medicines that slow, halt, or reverse diseases of aging, and we are committed to advancing multiple senolytic 
molecules to address a variety of diseases of aging, focusing on ophthalmologic disorders. As senolytic medicines are not limited to intervention by a single 
mode of action or molecular target, we believe that we can modulate a number of biologic pathways in order to trigger the beneficial elimination of 
senescent cells. However, our core therapeutic approach is based on our belief that senescent cells drive diseases of aging, and that hypothesis has not yet 
been proven. In addition, we do not know if we will be able to develop medicines that selectively eliminate senescent cells or whether the elimination of 
such senescent cells will mitigate the effects of or effectively treat any diseases.
In addition, identifying, developing, obtaining regulatory approval and commercializing drug candidates for the treatment of diseases of aging, including in 
ophthalmology, will require substantial additional funding and is prone to the risks of failure inherent in drug development. Research programs to identify 
drug candidates also require substantial technical, financial and human resources, regardless of whether or not any drug candidates are ultimately identified, 
and even if our preclinical research programs initially show promise in identifying potential drug candidates, they may fail to yield drug candidates for 
clinical development.
While we have a number of drug discovery programs targeting senescent cells, we do not know whether these will be successful, or whether we will be 
able to identify novel senolytic mechanisms to continue to build our pipeline. We also cannot provide any assurance that we will be able to successfully 
identify or acquire additional drug candidates, advance any of these additional drug candidates through the development process, successfully 
commercialize any such additional drug candidates, if approved, or assemble sufficient resources to identify, acquire, develop or, if approved, 
commercialize additional drug candidates. If we are unable to successfully identify, acquire, develop and commercialize additional drug candidates, our 
commercial opportunities may be limited.
We may be unable to obtain regulatory approval for our drug candidates under applicable regulatory requirements. The denial or delay of any such 
approval would delay commercialization of our drug candidates and adversely impact our potential to generate revenue, our business and our results of 
operations.
To gain approval to market our drug candidates, we must provide the FDA and foreign regulatory authorities with clinical data that adequately demonstrate 
the safety and efficacy of the drug candidate for the intended indication applied for in the applicable regulatory filing. For our senolytic medicines, we must 
also demonstrate that eliminating or causing the elimination of senescent cells and modulating relevant associated SASP factors will lead to the 
improvement of well-defined and measurable endpoints.

 
46
We have not previously submitted an NDA, or biologics license application, or BLA, to the FDA, or similar approval filings to comparable foreign 
regulatory authorities. An NDA, BLA or other relevant regulatory filing must include extensive preclinical and clinical data and supporting information to 
establish that the drug candidate is safe and effective, or that a biological drug candidate is safe, pure and potent for each desired indication. The NDA, 
BLA or other relevant regulatory submission must also include significant information regarding the chemistry, manufacturing and controls for the product.
The research, testing, manufacturing, labeling, approval, sale, marketing, and distribution of drug and biologic products are subject to extensive regulation 
by the FDA and other regulatory authorities in the United States and other countries, and such regulations differ from country to country. We are not 
permitted to market our drug candidates in the United States or in any foreign countries until they receive the requisite approval from the applicable 
regulatory authorities of such jurisdictions.
The FDA or any foreign regulatory bodies can delay, limit or deny approval of our drug candidates for many reasons, including:
•
our inability to demonstrate to the satisfaction of the FDA or the applicable foreign regulatory body that any of our drug candidates is safe 
and effective for the requested indication;
•
the FDA’s or the applicable foreign regulatory agency’s disagreement with our trial protocol or the interpretation of data from preclinical 
studies or clinical studies;
•
our inability to demonstrate that the clinical and other benefits of any of our drug candidates outweigh any safety or other perceived risks;
•
the FDA’s or the applicable foreign regulatory agency’s requirement for additional preclinical studies or clinical studies;
•
the FDA’s or the applicable foreign regulatory agency’s failure to approve the formulation, labeling or specifications of our current or future 
drug candidates, including UBX1325;
•
the FDA’s or the applicable foreign regulatory agency’s failure to approve the manufacturing processes or facilities of third-party 
manufacturers upon which we rely; or
•
the potential for approval policies or regulations of the FDA or the applicable foreign regulatory agencies to significantly change in a manner 
that renders our clinical data insufficient for approval.
Of the large number of biopharmaceutical and pharmaceutical products in development, only a small percentage successfully complete the FDA or other 
regulatory approval processes and are commercialized.
Even if we eventually complete clinical testing and receive approval from the FDA or applicable foreign agencies for any of our drug candidates, the FDA 
or the applicable foreign regulatory agency may grant approval contingent on the performance of costly additional clinical studies which may be required 
after approval. The FDA or the applicable foreign regulatory agency also may approve our current drug candidates for limited indications or narrower 
patient populations than we originally requested, and the FDA, or applicable foreign regulatory agency, may not approve our drug candidates with the 
labeling that we believe is necessary or desirable for the successful commercialization of such drug candidates.
Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of our drug candidates and would 
materially adversely impact our business and prospects.
Even if our current drug candidates or any future drug candidates obtain regulatory approval, they may fail to achieve the broad degree of physician 
and patient adoption and use necessary for commercial success.
Even if one or more of our drug candidates receive FDA or other regulatory approvals, the commercial success of any of our current or future drug 
candidates will depend significantly on the broad adoption and use of the resulting product by physicians and patients for approved indications. Our drug 
candidates may not be commercially successful for a variety of reasons, including: competitive factors, pricing or physician preference, reimbursement by 
insurers, and the 

 
47
degree and rate of physician and patient adoption of our current or future drug candidates. If approved, the commercial success of our drug candidates will 
depend on a number of factors, including:
•
the clinical indications for which the product is approved and patient demand for approved products that treat those indications;
•
the safety and efficacy of our product as compared to other available therapies;
•
the availability of coverage and adequate reimbursement from managed care plans, insurers and other healthcare payors for any of our drug 
candidates that may be approved;
•
acceptance by physicians, operators of clinics, and patients of the product as a safe and effective treatment;
•
physician and patient willingness to adopt a new therapy over other available therapies to treat approved indications;
•
overcoming any biases physicians or patients may have toward particular therapies for the treatment of approved indications;
•
proper training and administration of our drug candidates by physicians and medical staff;
•
public misperception regarding the use of our therapies, or public bias against “anti-aging” companies;
•
patient satisfaction with the results and administration of our drug candidates and overall treatment experience, including, for example, the 
convenience of any dosing regimen;
•
the cost of treatment with our drug candidates in relation to alternative treatments and reimbursement levels, if any, and willingness to pay 
for the product, if approved, on the part of insurance companies and other third-party payers, physicians and patients;
•
the willingness of patients to pay for certain of our products, if approved;
•
the revenue and profitability that our products may offer a physician as compared to alternative therapies;
•
the prevalence and severity of side effects;
•
limitations or warnings contained in the FDA-approved labeling for our products;
•
the willingness of physicians, operators of clinics and patients to utilize or adopt our products as a solution;
•
any FDA requirement to undertake a REMS;
•
the effectiveness of our sales, marketing and distribution efforts;
•
adverse publicity about our products or favorable publicity about competitive products; and
•
potential product liability claims.
We cannot assure you that our current or future drug candidates, if approved, will achieve broad market acceptance among physicians and patients. Any 
failure by our drug candidates that obtain regulatory approval to achieve market acceptance or commercial success would adversely affect our results of 
operations.
We rely on third-party suppliers to manufacture supplies of our drug candidates and we intend to continue to rely on third parties to produce such 
preclinical and clinical supplies as well as commercial supplies of any approved product. The loss of these suppliers, or their failure to comply with 
applicable regulatory requirements or to provide us with sufficient quantities at acceptable quality levels or prices, or at all, would materially and 
adversely affect our business.
We do not have the infrastructure or capability internally to manufacture supplies of our drug candidates or the materials necessary to produce our drug 
candidates for use in the conduct of our clinical studies, and we lack the internal resources and the capability to manufacture any of our drug candidates on 
a clinical or commercial scale. The facilities used by our contract manufacturers to manufacture our drug candidates are subject to various regulatory 
requirements and may be subject to the inspection of the FDA or other regulatory authorities. We do not control the manufacturing process of, and are 
completely dependent on, our contract manufacturing partners for compliance with 

 
48
the regulatory requirements, known as cGMPs. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications 
and the strict regulatory requirements of the FDA or comparable regulatory authorities in foreign jurisdictions, we may not be able to rely on their 
manufacturing facilities for the manufacture or our drug candidates. In addition, we have limited control over the ability of our contract manufacturers to 
maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds these facilities 
inadequate for the manufacture of our drug candidates or if such facilities are subject to enforcement action in the future or are otherwise inadequate, we 
may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our 
drug candidates.
We currently intend to supply all of our drug candidates in all territories for our planned clinical development programs. We currently rely on third parties 
at key stages in our supply chain. For instance, the supply chains for our current drug candidates involve several manufacturers that specialize in specific 
operations of the manufacturing process, specifically, raw materials manufacturing, drug substance manufacturing and drug product manufacturing. As a 
result, the supply chain for the manufacturing of our drug candidates is complicated and we expect the logistical challenges associated with our supply 
chain to grow more complex as our drug candidates progress through the clinical trial process. Some of these third parties have in the past and may in the 
future also be adversely impacted by unforeseen events and public health emergencies. For example, one of the manufacturers in our supply chain for 
UBX0101 experienced a two-week shutdown in April 2020 due to a COVID-19 related incident. While this incident did not impact our supply of 
UBX0101 for clinical studies being conducted in April 2020, there can be no assurance that our supply chain for any of our candidates and clinical trials 
will not be disrupted in the future due to such incidents.
We do not have any control over the process or timing of the acquisition or manufacture of materials by our manufacturers. Further, we have not yet 
engaged any manufacturers for the commercial supply of our current drug candidates. Although we intend to enter into such agreements prior to 
commercial launch of any of our drug candidates, we may be unable to enter into any such agreement or do so on commercially reasonable terms, which 
could have a material adverse impact upon our business. We generally do not begin a preclinical study and we do not intend to initiate any clinical studies 
unless we believe we have access to a sufficient supply of a drug candidate to complete such study or trial. In addition, any significant delay in, or quality 
control problems with respect to, the supply of a drug candidate, or the raw material components thereof, for an ongoing study or trial could considerably 
delay completion of our preclinical studies or future clinical studies, product testing and potential regulatory approval of our drug candidates.
Moreover, if there is a disruption to one or more of our third-party manufacturers’ or suppliers’ relevant operations, or if we are unable to enter into 
arrangements for the commercial supply of our drug candidates, we will have no other means of producing our current drug candidates until they restore 
the affected facilities or we or they procure alternative manufacturing facilities or sources of supply. Our ability to progress our preclinical and clinical 
programs could be materially and adversely impacted if any of the third-party suppliers upon which we rely were to experience a significant business 
challenge, disruption or failure due to issues such as financial difficulties or bankruptcy, issues relating to other customers such as regulatory or quality 
compliance issues, or other financial, legal, regulatory or reputational issues.
Additionally, any damage to or destruction of our third-party manufacturers’ or suppliers’ facilities or equipment may significantly impair our ability to 
manufacture our drug candidates on a timely basis.
Further, to manufacture our current drug candidates in the quantities that we believe would be required to meet anticipated market demand, our third-party 
manufacturers would likely need to increase manufacturing capacity and, in some cases, we would need to secure alternative sources of commercial supply, 
which could involve significant challenges and may require additional regulatory approvals. In addition, the development of commercial-scale 
manufacturing capabilities may require us and our third-party manufacturers to invest substantial additional funds and hire and retain the technical 
personnel who have the necessary manufacturing experience. Neither we nor our third-party manufacturers may successfully complete any required 
increase to existing manufacturing capacity in a timely manner, or at all. If our manufacturers or we are unable to purchase the raw materials necessary for 
the manufacture of our drug candidates on acceptable terms, at sufficient quality levels, or in adequate quantities, if at all, the commercial launch of our 
current drug candidates or any future drug candidates would be delayed or there would be 

 
49
a shortage in supply, which would impair our ability to generate revenues from the sale of such drug candidates, if approved.
If we fail to attract and retain key personnel, we may be unable to successfully develop our current drug candidates or any future drug candidates, 
conduct our clinical studies and commercialize our current or any future drug candidates.
Our success depends in part on our continued ability to attract, retain and motivate highly qualified management and employees. In February 2022, and 
again on May 4, 2023, we announced restructuring actions to advance corporate strategy and focus on key ophthalmology programs and, as of May 2023, 
the UBX1325 program in DME in particular. As a result of the restructuring and other factors, additional unplanned loss of personnel may occur despite 
our efforts to retain management and employees. Additionally, continued disruption caused by the transition or by the loss of ongoing services of any other 
members of our management or employees could delay or prevent the successful development of our ongoing programs, initiation or completion of our 
planned clinical studies or the commercialization of our current drug candidates or any future drug candidates. Competition for qualified personnel in the 
biotechnology and pharmaceuticals field is intense due to the limited number of individuals who possess the skills and experience required by our industry,
and we may not be able to adequately address attrition, including unplanned, attrition, and as a result, the timely completion of our clinical trials could be 
jeopardized. Further, our ability to attract and retain highly qualified management and employees relies in part on our ability to offer competitive 
compensation and equity packages to such key personnel. We use restricted stock units, or RSUs, and stock options as a key component of compensation 
for key employees in order to align employee interests with the interests of our stockholder, provide competitive compensation packages, and encourage 
employee retention. Our stock price volatility or lack of positive performance may cause periods of time during which option exercise prices might be less 
than the sale price of our common stock or the value of RSUs might be less competitive, which may lessen the retentive attributes of these awards. We are 
also limited as to the number of equity awards that we may grant under our stock plans, and we are unsure how effective different stock-based awards with 
different vesting schedules will be to retain key employees. As a result, we may have to incur increased compensation costs, change our equity 
compensation strategy, or find it difficult to attract, retain and motivate employees.
We depend on third-party suppliers for key raw materials used in our manufacturing processes, and the loss of these third-party suppliers or their 
inability to supply us with adequate raw materials could harm our business.
We rely on third-party suppliers for the raw materials required for the production of our drug candidates. Our dependence on these third-party suppliers and 
the challenges we may face in obtaining adequate supplies of raw materials involve several risks, including limited control over pricing, availability, and 
quality and delivery schedules. As a small company, our negotiation leverage is limited, and we are likely to get lower priority than our competitors who 
are larger than we are. We cannot be certain that our suppliers will continue to provide us with the quantities of these raw materials that we require or 
satisfy our anticipated specifications and quality requirements. Any supply interruption in limited or sole sourced raw materials could materially harm our 
ability to manufacture our drug candidates until a new source of supply, if any, could be identified and qualified. We may be unable to find a sufficient 
alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on the part of our suppliers could delay the 
development and potential commercialization of our drug candidates, including limiting supplies necessary for clinical studies and regulatory approvals, 
which would have a material adverse effect on our business.
We rely on third parties in the conduct of critical portions of our preclinical studies and intend to rely on third parties in the conduct of critical portions of 
our future clinical studies. If these third parties do not successfully carry out their contractual duties, fail to comply with applicable regulatory requirements 
or meet expected deadlines, we may be unable to obtain regulatory approval for our drug candidates. Some of these third parties may also be adversely 
impacted by unforeseen events and public health emergencies.
We currently do not have the ability to independently conduct preclinical studies that comply with the regulatory requirements known as good laboratory 
practice, or GLP, requirements. We also do not currently have the ability to independently conduct any clinical studies. The FDA and regulatory authorities 
in other jurisdictions require us to comply with regulations and standards, commonly referred to as good clinical practice, or GCP, requirements for 
conducting, monitoring, recording and reporting the results of clinical studies, in order to ensure that the data and 

 
50
results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical studies. We 
rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct GLP-compliant preclinical studies 
and GCP-compliant clinical studies on our drug candidates properly and on time. While we have agreements governing their activities, we control only 
certain aspects of their activities and have limited influence over their actual performance. The third parties with whom we contract for execution of our 
GLP-compliant preclinical studies and our GCP-compliant clinical studies play a significant role in the conduct of these studies and trials and the 
subsequent collection and analysis of data. These third parties are not our employees and, except for restrictions imposed by our contracts with such third 
parties, we have limited ability to control the amount or timing of resources that they devote to our programs. Although we rely on these third parties to 
conduct our GLP-compliant preclinical studies and GCP-compliant clinical studies, we remain responsible for ensuring that each of our GLP preclinical 
studies and clinical studies is conducted in accordance with its investigational plan and protocol and applicable laws and regulations, and our reliance on 
the CROs does not relieve us of our regulatory responsibilities.
Many of the third parties with whom we contract may also have relationships with other commercial entities, potentially including our competitors, for 
whom they may also be conducting clinical studies or other drug development activities that could harm our competitive position. If the third parties 
conducting our preclinical studies or our clinical studies do not adequately perform their contractual duties or obligations, experience significant business 
challenges, disruptions or failures, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy 
of the data they obtain is compromised due to their failure to adhere to our protocols or to GCPs, or for any other reason, we may need to enter into new 
arrangements with alternative third parties. This could be difficult, costly or impossible, and our preclinical studies or clinical studies may need to be 
extended, delayed, terminated or repeated. As a result, we may not be able to obtain regulatory approval in a timely fashion, or at all, for the applicable 
drug candidate, our financial results and the commercial prospects for our drug candidates would be harmed, our costs could increase, and our ability to 
generate revenues could be delayed.
We face significant competition in an environment of rapid technological and scientific change, and our drug candidates, if approved, will face 
significant competition and our failure to effectively compete may prevent us from achieving significant market penetration. Most of our competitors 
have significantly greater resources than we do, and we may not be able to successfully compete.
The biotechnology and pharmaceutical industries in particular are characterized by rapidly advancing technologies, intense competition and a strong 
emphasis on developing proprietary therapeutics. Numerous companies are engaged in the development, patenting, manufacturing and marketing of 
healthcare products competitive with those that we are developing. We face competition from a number of sources, such as pharmaceutical companies, 
generic drug companies, biotechnology companies and academic and research institutions, many of which have greater financial resources, marketing 
capabilities, sales forces, manufacturing capabilities, research and development capabilities, clinical study expertise, intellectual property portfolios, 
experience in obtaining patents and regulatory approvals for drug candidates and other resources than we do. Some of the companies that offer competing 
products also have a broad range of other product offerings, large direct sales forces and long-term customer relationships with our target physicians, which 
could inhibit our market penetration efforts. Mergers and acquisitions in the pharmaceutical industry may result in even more resources being concentrated 
among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through 
collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific 
and management personnel and establishing clinical study sites and patient registration for clinical studies, as well as in acquiring technologies 
complementary to, or necessary for, our programs. In addition, certain of our drug candidates, if approved, may compete with other products that treat 
diseases of aging, including over the counter, or OTC, treatments, for a share of some patients’ discretionary budgets and for physicians’ attention within 
their clinical practices.
We are aware of other companies seeking to develop treatments to prevent or treat diseases of aging through various biological pathways. Within our lead 
senolytic program in ophthalmology diseases, our drug candidates would compete against current therapies from a wide range of companies and 
technologies, including current standard of care treatments such as anti-VEGF antibodies (bevacizumab, ranibizumab, aflibercept, brolucizumab), 
bispecific antibodies (faricimab), intravitreal steroid (dexamethasone), high-dose EYLEA®, complement inhibitors (e.g., pegcetacoplan) for the geographic 
atrophy form of AMD, and pan-retinal photocoagulation by laser. There are also 

 
51
potentially disease-modifying therapeutics being developed by several pharmaceutical and biotechnology companies, including Roche/Genentech and 
Regeneron.
Further, we believe that potential competitors may be able to develop senolytic medicines utilizing well-established molecules and pathways, which could 
enable the development of competitive drug candidates utilizing the same cellular senescence biological theories.
Certain alternative treatments offered by competitors may be available at lower prices and may offer greater efficacy or better safety profiles. Furthermore, 
currently approved products could be discovered to have application for treatment of diseases of aging generally, which could give such products 
significant regulatory and market timing advantages over any of our drug candidates. Our competitors also may obtain FDA, EMA or other regulatory 
approval for their products more rapidly than we may obtain approval for ours and may obtain orphan product exclusivity from the FDA for indications our 
drug candidates are targeting, which could result in our competitors establishing a strong market position before we are able to enter the market. Newly 
developed systemic or non-systemic treatments that replace existing therapies that currently are only utilized in patients suffering from severe disease may 
also have lessened side effects or reduced prices compared to current therapies, which make them more attractive for patients suffering from mild to 
moderate disease. Even if a generic or OTC product is less effective than our drug candidates, it may be more quickly adopted by physicians and patients 
than our competing drug candidates based upon cost or convenience.
The successful commercialization of our drug candidates will depend in part on the extent to which governmental authorities and health insurers 
establish adequate coverage, reimbursement levels and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our 
drug candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.
The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health 
insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as our drug candidates, assuming 
FDA approval. Our ability to achieve acceptable levels of coverage and reimbursement for products by governmental authorities, private health insurers 
and other organizations will have an effect on our ability to successfully commercialize our drug candidates. Assuming we obtain coverage for our drug 
candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find 
unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the European Union or elsewhere will be available for our 
drug candidates or any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.
Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to 
provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar or a less expensive therapy is available. 
It is possible that a third-party payor may consider our drug candidates as substitutable and only offer to reimburse patients for the cost of the less 
expensive product. Even if we show improved efficacy or improved convenience of administration with our drug candidates, pricing of existing third-party 
therapeutics may limit the amount we will be able to charge for our drug candidates. These payors may deny or revoke the reimbursement status of a given 
product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in 
our drug candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our drug 
candidates and may not be able to obtain a satisfactory financial return on our investment in the development of drug candidates.
There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, 
including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new 
drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and 
other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval 
of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. We cannot predict at 
this time what third-party payors will decide with respect to the coverage and reimbursement for our drug candidates.

 
52
No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and 
reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and 
costly process that will require us to provide scientific and clinical support for the use of our drug candidates to each payor separately, with no assurance 
that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding 
reimbursement change frequently, in some cases on short notice, and we believe that changes in these rules and regulations are likely.
Outside the United States, international operations are generally subject to extensive governmental price controls and other market regulations, and we 
believe the increasing emphasis on cost-containment initiatives in Europe and other countries have and will continue to put pressure on the pricing and 
usage of our drug candidates. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health 
systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits.
Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our drug candidates. 
Accordingly, in markets outside the United States, the reimbursement for our drug candidates may be reduced compared with the United States and may be 
insufficient to generate commercially reasonable revenue and profits.
Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such 
organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate 
payment for our drug candidates. We expect to experience pricing pressures in connection with the sale of our drug candidates due to the trend toward 
managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on 
healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, 
increasingly high barriers are being erected to the entry of new products.
We currently have no sales organization. If we are unable to establish sales capabilities on our own or through third parties, we may not be able to 
market and sell our drug candidates effectively in the U.S. and foreign jurisdictions, if approved, or generate product revenue.
We currently do not have a marketing or sales organization. In order to commercialize our drug candidates in the United States and foreign jurisdictions, 
we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these 
services, and we may not be successful in doing so. If any of our drug candidates receive regulatory approval, we expect to establish a sales organization 
with technical expertise and supporting distribution capabilities to commercialize each such drug candidate, which will be expensive and time consuming. 
We have no prior experience in the marketing, sale and distribution of pharmaceutical products and there are significant risks involved in building and 
managing a sales organization, including our ability to hire, retain, and incentivize qualified individuals, generate sufficient sales leads, provide adequate 
training to sales and marketing personnel, and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the
development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may choose 
to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution 
systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements on acceptable terms or at all, we may 
not be able to successfully commercialize our drug candidates. If we are not successful in commercializing our drug candidates or any future drug 
candidates, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we 
would incur significant additional losses.
If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our current 
or future drug candidates.
We face an inherent risk of product liability as a result of the clinical testing of our drug candidates and will face an even greater risk if we commercialize 
any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing, 
manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, and a failure to 

 
53
warn of dangers inherent in the product, negligence, strict liability, and a breach of warranty. Claims could also be asserted under state consumer protection 
acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit 
commercialization of our drug candidates.
Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims 
may result in:
•
decreased demand for our current or future drug candidates;
•
injury to our reputation;
•
withdrawal of clinical study participants;
•
costs to defend the related litigation;
•
a diversion of management’s time and our resources;
•
substantial monetary awards to trial participants or patients;
•
regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;
•
loss of revenue; and
•
the inability to commercialize our current or any future drug candidates.
Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential product 
liability claims could prevent or inhibit the commercialization of our current or any future drug candidates we develop. We currently carry product liability 
insurance covering our clinical studies. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or 
settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance 
policies also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to 
pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we 
may not have, or be able to obtain, sufficient funds to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a 
reasonable cost or in sufficient amounts to protect us against losses. If and when we obtain approval for marketing any of our drug candidates, we intend to 
expand our insurance coverage to include the sale of such drug candidate; however, we may be unable to obtain this liability insurance on commercially 
reasonable terms or at all.
Our existing collaborations as well as additional collaboration arrangements that we may enter into in the future may not be successful, which could 
adversely affect our ability to develop and commercialize our drug candidates.
We utilize external collaborations and currently maintain several active early-stage research and discovery focused collaborations. In the future, we may 
seek additional collaboration arrangements for the commercialization, or potentially for the development, of certain of our drug candidates depending on 
the merits of retaining commercialization rights for ourselves as compared to entering into collaboration arrangements. To the extent that we decide to enter 
into additional collaboration agreements in the future, we may face significant competition in seeking appropriate collaborators. Moreover, collaboration 
arrangements are complex and time-consuming to negotiate, document, implement and maintain and challenging to manage. We may not be successful in 
our efforts to prudently manage our existing collaborations or to enter new ones should we chose to do so. The terms of new collaborations, or other 
arrangements that we may establish may not be favorable to us.
The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators and partners. Collaborations are subject 
to numerous risks, which may include risks that:
•
collaborators and partners have significant discretion in determining the efforts and resources that they will apply to collaborations, and they 
may not devote the level of effort or resources we expect;
•
collaborators may not pursue development and commercialization of our drug candidates or may elect not to continue or renew development 
or commercialization programs based on clinical study results, changes 

 
54
in their strategic focus due to their acquisition of competitive products or their internal development of competitive products, availability of 
funding or other external factors, such as a business combination that diverts resources or creates competing priorities;
•
collaborators may delay clinical studies, provide insufficient funding for a clinical study program, stop a clinical study, abandon a drug 
candidate, repeat or conduct new clinical studies or require a new formulation of a drug candidate for clinical testing;
•
collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or 
drug candidates;
•
a collaborator with marketing, manufacturing, and distribution rights to one or more products may not commit sufficient resources to or 
otherwise not perform satisfactorily in carrying out these activities;
•
we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;
•
collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary 
information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or 
proprietary information or expose us to potential liability;
•
disputes may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of 
our current or future drug candidates or that result in costly litigation or arbitration that diverts management attention and resources;
•
collaborations may be terminated, resulting in a need for additional capital to pursue further development or commercialization of the 
applicable current or future drug candidates;
•
collaborators may own or co-own intellectual property covering products that results from our collaborating with them, and in such cases, we 
would not have the exclusive right to develop or commercialize such intellectual property;
•
disputes may arise with respect to the ownership of any intellectual property developed pursuant to our collaborations;
•
a collaborator’s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal 
proceedings; and
•
collaborators may be adversely impacted by unforeseen events and public health emergencies.
Risks Related to Intellectual Property
Our senolytic medicine platform and any future products that we commercialize could be alleged to infringe patent rights and other proprietary rights 
of third parties, which may require costly litigation and, if we are not successful, could cause us to pay substantial damages and/or limit our ability to 
commercialize our products.
Our commercial success depends on our ability to develop, manufacture and market our senolytic medicines and future drug candidates and use our 
proprietary technology without infringing the patents and other proprietary rights of third parties. Intellectual property disputes can be costly to defend and 
may cause our business, operating results and financial condition to suffer. We operate in an industry with extensive intellectual property litigation. As the 
biopharmaceutical and pharmaceutical industries expand and more patents are issued, the risk increases that there may be patents issued to third parties that 
relate to our products and technology of which we are not aware or that we may need to challenge to continue our operations as currently contemplated.
Whether merited or not, we may face allegations that we have infringed the trademarks, copyrights, patents and other intellectual property rights of third 
parties, including patents held by our competitors or by non-practicing entities. We may also face allegations that our employees have misappropriated the 
intellectual property rights of their former employers or other third parties.

 
55
Litigation may make it necessary to defend ourselves by determining the scope, enforceability, and validity of third-party proprietary rights, or to establish 
our proprietary rights. Regardless of whether claims that we are infringing patents or other intellectual property rights have merit, the claims can be time 
consuming, divert management attention and financial resources and are costly to evaluate and defend. Results of any such litigation are difficult to predict 
and may require us to stop treating certain conditions, obtain licenses or modify our products and features while we develop non-infringing substitutes, or 
may result in significant settlement costs. For example, litigation can involve substantial damages for infringement (and if the court finds that the 
infringement was willful, we could be ordered to pay treble damages and the patent owner’s attorneys’ fees), and the court could prohibit us from selling or 
licensing our products unless the third-party licenses rights to us, which it is not required to do at a commercially reasonable price or at all. If a license is 
available from a third party, we may have to pay substantial royalties, upfront fees or grant cross-licenses to intellectual property rights for our products. 
We may also have to redesign our products so they do not infringe third-party intellectual property rights, which may not be possible at all or may require 
substantial monetary expenditures and time, during which our products may not be available for manufacture, use, or sale.
In addition, patent applications in the United States and many international jurisdictions are typically not published until 18 months after the filing of 
certain priority documents (or, in some cases, are not published until they issue as patents) and publications in the scientific literature often lag behind 
actual discoveries. Thus, we cannot be certain that others have not filed patent applications or made public disclosures relating to our technology or our 
contemplated technology. A third party may have filed, and may in the future file, patent applications covering our products or technology similar to ours. 
Any such patent application may have priority over our patent applications or patents, which could further require us to obtain rights to issued patents
covering such technologies. If another party has filed a U.S. patent application on inventions similar to ours, depending on whether the timing of the filing 
date falls under certain patent laws, we may have to participate in a priority contest (such as an interference proceeding) declared by the U.S. Patent and 
Trademark Office, to determine priority of invention in the United States. The costs of patent and other proceedings could be substantial, and it is possible 
that such efforts would be unsuccessful if it is determined that the other party had independently arrived at the same or similar invention prior to our own 
invention, resulting in a loss of our U.S. patent position with respect to such inventions.
From time to time, we may be subject to legal proceedings and claims in the ordinary course of business with respect to intellectual property. Although we 
are not currently subject to any claims from third parties asserting infringement of their intellectual property rights, in the future, we may receive claims 
from third parties asserting infringement of their intellectual property rights. Future litigation may be necessary to establish our intellectual property rights 
or to defend ourselves by determining the scope, enforceability and validity of third-party intellectual property rights. There can be no assurance with 
respect to the outcome of any current or future litigation brought by or against us, and the outcome of any such litigation could have a material adverse 
impact on our business, operating results and financial condition. Litigation is inherently unpredictable, and outcomes are uncertain. Further, as the costs 
and outcomes of these types of claims and proceedings can vary significantly, it is difficult to estimate potential losses that may occur. Accordingly, we are 
unable at this time to estimate the effects of these potential future lawsuits on our financial condition, operations or cash flows.
Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater 
resources. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant 
expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements 
of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, 
it could have a material adverse effect on the price of our common stock. Finally, any uncertainties resulting from the initiation and continuation of any 
litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations.
If we are unable to obtain, maintain and enforce intellectual property protection directed to our senolytic medicine platform and any future 
technologies that we develop, others may be able to make, use, or sell products substantially the same as ours, which could adversely affect our ability 
to compete in the market.
As of December 31, 2024, we own, co-own, or have an exclusive license in certain fields of use to more than 170 patents and pending applications in the 
United States and foreign jurisdictions. This portfolio includes 33 issued and allowed U.S. patents and applications and 68 granted and allowed foreign 
patents and applications, respectively. A 

 
56
composition of matter patent filing claiming the specific chemical structure of UBX1325 was issued in the U.S. on April 20, 2021, which will extend our 
loss of exclusivity on this molecule to 2039, not including any patent term adjustment or patent term extensions to which it may be entitled. 
We have not pursued or maintained, and may not pursue or maintain in the future, patent protection for our products in every country or territory in which 
we may sell our products. In addition, we cannot be sure that any of our pending patent applications or pending trademark applications will issue or that, if 
issued, they will issue in a form that will be advantageous to us. The U.S. Patent and Trademark Office (USPTO), international patent offices or judicial 
bodies may deny, or significantly narrow claims made under our patent applications and our issued patents may be successfully challenged, may be 
designed around, or may otherwise be of insufficient scope to provide us with protection for our commercial products. Further, the USPTO, international 
trademark offices or judicial bodies may deny our trademark applications and, even if published or registered, these trademarks may not effectively protect 
our brand and goodwill. Like patents, trademarks also may be successfully opposed or challenged.
We cannot be certain that the steps we have taken will prevent unauthorized use or unauthorized reverse engineering of our technology. Moreover, third 
parties may independently develop technologies that are competitive with ours and such competitive technologies may or may not infringe our intellectual 
property. The enforcement of our intellectual property rights also depends on the success of our legal actions against these infringers in the respective 
country or forum, but these actions may not be successful. As with all granted intellectual property, such intellectual property may be challenged, 
invalidated or circumvented, may not provide specific protection and/or may not prove to be enforceable in actions against specific alleged infringers.
The market for biopharmaceuticals, pharmaceuticals, and treatments for diseases of aging is highly competitive and subject to rapid technological change. 
Our success depends, in part, upon our ability to maintain a competitive position in the development and protection of technologies and products for use in 
these fields and upon our ability to obtain, maintain and enforce our intellectual property rights in connection therewith. We seek to obtain and maintain 
patents and other intellectual property rights to restrict the ability of others to market products that misappropriate our technology and/or infringe our 
intellectual property to unfairly and illegally compete with our products. If we are unable to protect our intellectual property and proprietary rights, our 
competitive position and our business could be harmed, as third parties may be able to make, use, or sell products that are substantially the same as ours 
without incurring the sizeable development and licensing costs that we have incurred, which would adversely affect our ability to compete in the market.
We use a combination of patents, trademarks, know-how, confidentiality procedures, and contractual provisions to protect our proprietary technology. 
However, these protections may not be adequate and may not provide us with any competitive advantage. For example, patents may not issue from any of 
our currently pending or any future patent applications, and our issued patents and any future patents that may issue may not survive legal challenges to 
their scope, validity or enforceability, or provide significant protection for us.
If we or one of our current or future collaborators were to initiate legal proceedings against a third party to enforce a patent covering one of our current 
drug candidates or future drug candidates, the defendant could counterclaim that our patent is invalid and/or unenforceable. In patent litigation in the 
United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace.
Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness or 
nonenablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant 
information from the USPTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before the USPTO, even 
outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable.
With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were 
unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and 
perhaps all, of the patent protection on our drug candidates. Such a loss of patent protection would have a material adverse impact on our business.

 
57
Even if our patents are determined by a court to be valid and enforceable, they may not be interpreted sufficiently broadly to prevent others from marketing
products similar to ours or designing around our patents. For example, third parties may be able to make products that are similar to ours but that are not 
covered by the claims of our patents. Third parties may assert that we or our licensors were not the first to make the inventions covered by our issued
patents or pending patent applications. The claims of our issued patents or patent applications when issued may not cover our proposed commercial 
technologies or the future products that we develop. We may not have freedom to commercialize unimpeded by the patent rights of others. Third parties 
may have dominating, blocking, or other patents relevant to our technology of which we are not aware. There may be prior public disclosures or art that 
could be deemed to invalidate one or more of our patent claims. Further, we may not develop additional proprietary technologies in the future, and, if we 
do, they may not be patentable.
Patent law can be highly uncertain and involve complex legal and factual questions for which important principles remain unresolved. In the United States 
and in many international jurisdictions, policy regarding the breadth of claims allowed in patents can be inconsistent. The U.S. Supreme Court and the 
Court of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the United States are interpreted. 
Similarly, international courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. 
We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by U.S. and international 
legislative bodies. Those changes may materially affect our patents, our ability to obtain patents or the patents and patent applications of our licensors. 
Patent reform legislation in the United States could increase the uncertainties and costs surrounding the prosecution of our patent applications and the 
enforcement or defense of our issued patents. For example, on September 16, 2011, the Leahy-Smith America Invents Act, or Leahy-Smith Act, was signed 
into law. The Leahy-Smith Act included a number of significant changes to U.S. patent law. These include provisions that affect the way patent 
applications are prosecuted, redefine prior art, may affect patent litigation, and switch the U.S. patent system from a “first-to-invent” system to a “first-to-
file” system. Under a “first-to-file” system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally 
will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. The U.S. Patent and Trademark Office 
recently developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law 
associated with the Leahy-Smith Act, and in particular, the first-to-file provisions, only became effective on March 16, 2013. The Leahy-Smith Act and its 
implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our 
issued patents, which could have a material adverse effect on our business and financial condition.
In addition, we have a number of international patents and patent applications and expect to continue to pursue patent protection in many of the significant 
markets in which we intend to do business. The laws of some international jurisdictions may not protect intellectual property rights to the same extent as 
laws in the United States, and many companies have encountered significant difficulties in obtaining, protecting, and defending such rights in international 
jurisdictions. If we encounter such difficulties or we are otherwise precluded from effectively protecting our intellectual property rights in international 
jurisdictions, our business prospects could be substantially harmed.
Varying filing dates in international countries may also permit intervening third parties to allege priority to certain technology.
Patent terms may be shortened or lengthened by, for example, terminal disclaimers, patent term adjustments, supplemental protection certificates, and 
patent term extensions. Patent term extensions and supplemental protection certificates, and the like, may be impacted by the regulatory process and may 
not significantly lengthen the patent term. Non-payment or delay in payment of patent fees or annuities, delay in patent filings or delay in extension filing 
(including any patent term extension or adjustment filing), whether intentional or unintentional, may also result in the loss of patent rights important to our 
business. Certain countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to other parties. In addition, 
many countries limit the enforceability of patents against other parties, including government agencies or government contractors. In these countries, the 
patent owner may have limited remedies, which could materially diminish the value of any patents.
In addition to the protection afforded by patents, we rely on confidentiality agreements to protect confidential information and proprietary know-how that is 
not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our drug candidate discovery and 
development processes that involve 

 
58
proprietary know-how, information or technology that is not covered by patents. We seek to protect our proprietary technology and processes, in part, by 
entering into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We cannot guarantee that we have entered 
into such agreements with each party that may have or have had access to our confidential information or proprietary technology and processes. We also 
seek to preserve the integrity and confidentiality of our data and other confidential information by maintaining physical security of our premises and 
physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, 
agreements or security measures may be breached and detecting the disclosure or misappropriation of confidential information and enforcing a claim that a 
party illegally disclosed or misappropriated confidential information is difficult, expensive and time-consuming, and the outcome is unpredictable. Further, 
we may not be able to obtain adequate remedies for any breach. In addition, our confidential information may otherwise become known or be
independently discovered by competitors, in which case we would have no right to prevent them, or those to whom they communicate it, from using that 
technology or information to compete with us. We may in the future rely on trade secret protection, which would be subject to the risks identified above 
with respect to confidential information.
Monitoring unauthorized use of our intellectual property is difficult and costly. From time to time, we review our competitors’ products, and may in the 
future seek to enforce our patents or other rights against potential infringement. However, the steps we have taken to protect our proprietary rights may not 
be adequate to prevent misappropriation of our intellectual property. We may not be able to detect unauthorized use of, or take appropriate steps to enforce, 
our intellectual property rights. Our competitors may also independently develop similar technology. Any inability to meaningfully protect our intellectual 
property could result in competitors offering products that incorporate our product or service features, which could reduce demand for our products. In 
addition, we may need to defend our patents from third-party challenges, such as (but not limited to) interferences, derivation proceedings, reexamination 
proceedings, post-grant review, inter partes review, third-party submissions, oppositions, nullity actions or other patent proceedings. We may need to 
initiate infringement claims or litigation.
Adverse proceedings such as litigation can be expensive, time consuming and may divert the efforts of our technical and managerial personnel, which 
could in turn harm our business, whether or not we receive a determination favorable to us. In addition, in an infringement proceeding, a court or other 
judicial body may decide that the patent we seek to enforce is invalid or unenforceable, or may refuse to stop the other party from using the technology at 
issue on the grounds that the patent in question does not cover the technology in question. An adverse result in any litigation could put one or more of our 
patents at risk of being invalidated or interpreted narrowly. Some of our competitors may be able to devote significantly more resources to intellectual 
property litigation and may have significantly broader patent portfolios to assert against us if we assert our rights against them. Further, because of the 
substantial discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be disclosed 
or otherwise compromised during litigation.
We may not be able to correctly estimate or control our future operating expenses in relation to obtaining intellectual property, enforcing intellectual
property and/or defending intellectual property, which could affect operating expenses. Our operating expenses may fluctuate significantly in the future as a 
result of a variety of factors, including the costs of preparing, filing, prosecuting, defending, and enforcing patent and trademark claims and other 
intellectual property-related costs, including adverse proceedings (such as litigation) costs.
Our intellectual property agreements with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of 
our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors.
Certain provisions in our intellectual property agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation 
disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology, or affect financial or other obligations 
under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects.
In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property 
to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact 
conceives or develops intellectual property that we regard as our own. Our assignment agreements may not be self-executing or may be breached, and we
may be 

 
59
forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual 
property.
If we are unable to protect the confidentiality of our proprietary information and know-how, the value of our technology and products could be 
adversely affected.
We may not be able to protect our proprietary information and technology adequately. Although we use reasonable efforts to protect our proprietary 
information, technology, and know-how, our employees, consultants, contractors and outside scientific advisors may unintentionally or willfully disclose 
our information to competitors. Enforcing a claim that a third party illegally obtained and is using any of our proprietary information, technology or know-
how is expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect 
proprietary information, technology, and know-how. We rely, in part, on non-disclosure and confidentiality agreements with our employees, consultants 
and other parties to protect our proprietary information, technology, and know-how. These agreements may be breached, and we may not have adequate 
remedies for any breach. Moreover, others may independently develop similar or equivalent proprietary information, and third parties may otherwise gain 
access to our proprietary knowledge.
Risks Related to Government Regulation
Even if we obtain regulatory approval for a drug candidate, our products will remain subject to regulatory scrutiny.
If our drug candidates are approved, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storage, advertising, 
promotion, sampling, record-keeping, conduct of post-marketing studies, and submission of safety, efficacy, and other post-market information, including 
both federal and state requirements in the United States and requirements of comparable foreign regulatory authorities.
Manufacturers and manufacturers’ facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, 
including ensuring that quality control and manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be 
subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any approved marketing application. 
Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including 
manufacturing, production, and quality control.
We will have to comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to 
prescription drugs and biologics are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product’s 
approved label. As such, we may not promote our products for indications or uses for which they do not have approval. The holder of an approved 
application must submit new or supplemental applications and obtain approval for certain changes to the approved product, product labeling, or 
manufacturing process. We could also be asked to conduct post-marketing clinical studies to verify the safety and efficacy of our products in general or in 
specific patient subsets. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval.
If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems 
with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, such regulatory agency may 
impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory 
requirements, a regulatory agency or enforcement authority may, among other things:
•
issue warning letters;
•
impose civil or criminal penalties;
•
suspend or withdraw regulatory approval;
•
suspend any of our clinical studies;
•
refuse to approve pending applications or supplements to approved applications submitted by us;

 
60
•
impose restrictions on our operations, including closing our contract manufacturers’ facilities; or
•
seize or detain products or require a product recall.
Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate 
negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and 
generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating 
results will be adversely affected.
Moreover, the policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that could 
prevent, limit or delay regulatory approval of our drug candidates. We cannot predict the likelihood, nature or extent of government regulation that may 
arise from future legislation or administrative or executive action, either in the United States or abroad. 
If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain 
regulatory compliance, we may be subject to enforcement action, and we may not achieve or sustain profitability.
If any of our small molecule drug candidates obtain regulatory approval, additional competitors could enter the market with generic versions of such 
drugs, which may result in a material decline in sales of affected products.
Under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, a pharmaceutical manufacturer may file an 
ANDA, seeking approval of a generic version of an approved, small molecule innovator product. Under the Hatch-Waxman Act, a manufacturer may also 
submit an NDA, under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act that references the FDA’s prior approval of the small molecule 
innovator product. A 505(b)(2) NDA product may be for a new or improved version of the original innovator product. The Hatch-Waxman Act also 
provides for certain periods of regulatory exclusivity, which preclude FDA approval (or in some circumstances, FDA filing and review) of an ANDA or 
505(b)(2) NDA. In addition to the benefits of regulatory exclusivity, an innovator NDA holder may have patents claiming the active ingredient, product 
formulation or an approved use of the drug, which would be listed with the product in the FDA publication, “Approved Drug Products with Therapeutic 
Equivalence Evaluations,” known as the Orange Book. If there are patents listed in the Orange Book for a product, a generic or 505(b)(2) applicant that 
seeks to market its product before expiration of the patents must include in their applications what is known as a “Paragraph IV” certification, challenging 
the validity or enforceability of, or claiming non-infringement of, the listed patent or patents. Notice of the certification must be given to the patent owner 
and NDA holder and if, within 45 days of receiving notice, either the patent owner or NDA holder sues for patent infringement, approval of the ANDA or 
505(b)(2) NDA is stayed for up to 30 months.
Accordingly, if any of our small molecule drug candidates, such as UBX1325, are approved, competitors could file ANDAs for generic versions of our 
small molecule drug products or 505(b)(2) NDAs that reference our small molecule drug products. If there are patents listed for our small molecule drug 
products in the Orange Book, those ANDAs and 505(b)(2) NDAs would be required to include a certification as to each listed patent indicating whether the 
ANDA applicant does or does not intend to challenge the patent. We cannot predict which, if any, patents in our current portfolio or patents we may obtain 
in the future will be eligible for listing in the Orange Book, how any generic competitor would address such patents, whether we would sue on any such 
patents, or the outcome of any such suit.
We may not be successful in securing or maintaining proprietary patent protection for products and technologies we develop or license. Moreover, if any of 
our owned or in-licensed patents that are listed in the Orange Book are successfully challenged by way of a Paragraph IV certification and subsequent 
litigation, the affected product could immediately face generic competition and its sales would likely decline rapidly and materially.
Any biologic, or large molecule, drug candidates for which we intend to seek approval may face competition sooner than anticipated.
If we are successful in achieving regulatory approval to commercialize any biologic drug candidate faster than our competitors, such drug candidates may 
face competition from biosimilar products. In the United States, large molecule 

 
61
drug candidates are regulated by the FDA as biologic products subject to approval under the biologics license application, or BLA, pathway. The Biologics 
Price Competition and Innovation Act of 2009, or BPCIA, creates an abbreviated pathway for the approval of biosimilar and interchangeable biologic 
products following the approval of an original BLA. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve 
biosimilar biologics, including the possible designation of a biosimilar as “interchangeable” based on its similarity to an existing brand product. Under the 
BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the original branded product was approved under a 
BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are 
subject to uncertainty.
Moreover, the extent to which a biosimilar product, once approved, will be substituted for any one of our reference products in a way that is similar to 
traditional generic substitution for non-biologic products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still 
developing. In addition, a competitor could decide to forego the biosimilar approval path and submit a full BLA after completing its own preclinical studies 
and clinical studies. In such cases, any exclusivity to which we may be eligible under the BPCIA would not prevent the competitor from marketing its 
product as soon as it is approved.
If competitors are able to obtain marketing approval for biosimilars referencing our large molecule drug candidates, if approved, such products may 
become subject to competition from such biosimilars, with the attendant competitive pressure and potential adverse consequences. Such competitive 
products may be able to immediately compete with us in each indication for which our drug candidates may have received approval.
Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our drug 
candidates and may affect the prices we may set.
In the United States, the European Union and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and 
regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and 
continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For 
example, in March 2010, the Patient Protection and ACA, as amended by the Health Care and Education Reconciliation Act, or collectively the Affordable 
Care Act, was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers. It is unclear how other 
healthcare reform measures of the Trump administration or other efforts, if any, to challenge, repeal or replace the ACA will impact our business. Among 
the provisions of the ACA, those of greatest importance to the pharmaceutical and biotechnology industries include the following:
•
an annual, non-deductible fee payable by any entity that manufactures or imports certain branded prescription drugs and biologic agents 
(other than those designated as orphan drugs), which is apportioned among these entities according to their market share in certain 
government healthcare programs;
•
a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 70% point-of-sale discounts off 
negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer’s 
outpatient drugs to be covered under Medicare Part D;
•
an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the 
average manufacturer price for branded and generic drugs, respectively;
•
a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are 
inhaled, infused, instilled, implanted or injected;
•
extension of a manufacturer’s Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care 
organizations;
•
expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to certain 
individuals with income at or below 133% of the federal poverty level, thereby potentially increasing a manufacturer’s Medicaid rebate 
liability;

 
62
•
a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness 
research, along with funding for such research;
•
creation of the Independent Payment Advisory Board, which, once empaneled, will have the authority to recommend certain changes to the 
Medicare program that could result in reduced payments for prescription drugs and those recommendations could have the effect of law 
unless overruled by a supermajority vote of Congress; and
•
establishment of a Center for Medicare Innovation at the Centers for Medicare & Medicaid Services, or CMS, to test innovative payment and 
service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending.
Since its enactment, there have been judicial and Congressional challenges to certain aspects of the Affordable Care Act. For example, the Tax Cuts and 
Jobs Act of 2017, or the Tax Act, includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the 
ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the “individual 
mandate”. In addition, there may be other efforts to challenge, repeal or replace the ACA that may impact our business or financial condition.
In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. In August 2011, the 
Budget Control Act of 2011, among other things, led to aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions 
went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a 
temporary suspension from May 1, 2020 through December 31, 2021, unless additional action is taken by Congress. In addition, in January 2013, the 
American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, 
including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover 
overpayments to providers from three to five years.
Individual states in the United States have also become increasingly aggressive in passing legislation and implementing regulations designed to control 
pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and 
marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. 
Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial 
condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what 
pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate 
demand for our drug candidates or put pressure on our product pricing. Moreover, payment methodologies may be subject to changes in healthcare 
legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. In addition, 
recently there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products.
In the European Union, similar political, economic and regulatory developments may affect our ability to profitably commercialize our drug candidates, if 
approved. In addition to continuing pressure on prices and cost containment measures, legislative developments at the EU or member state level may result 
in significant additional requirements or obstacles that may increase our operating costs. The delivery of healthcare in the European Union, including the 
establishment and operation of health services and the pricing and reimbursement of medicines, is almost exclusively a matter for national, rather than EU, 
law and policy. National governments and health service providers have different priorities and approaches to the delivery of health care and the pricing 
and reimbursement of products in that context. In general, however, the healthcare budgetary constraints in most European Union member states have 
resulted in restrictions on the pricing and reimbursement of medicines by relevant health service providers. Coupled with ever-increasing EU and national 
regulatory burdens on those wishing to develop and market products, this could prevent or delay marketing approval of our drug candidates, restrict or 
regulate post-approval activities and affect our ability to commercialize our drug candidates, if approved. In markets outside of the United States and 
European Union, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on 
specific products and therapies.

 
63
We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United 
States, the European Union or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing 
requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our drug 
candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.
Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient 
organizations and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.
Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient 
organizations and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the 
business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our 
drug candidates, if approved.
Such laws include:
•
the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, 
offering, receiving or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, 
in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or 
recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under U.S. federal and state 
healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific 
intent to violate it in order to have committed a violation;
•
the U.S. federal false claims and civil monetary penalties laws, including the civil False Claims Act, which, among other things, impose 
criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, 
or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, 
using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false 
statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert 
that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent 
claim for purposes of the False Claims Act;
•
the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, 
among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or 
knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the 
delivery of, or payment for, healthcare benefits, items or services; similar to the U.S. federal Anti-Kickback Statute, a person or entity does 
not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
•
the FDCA, which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;
•
the U.S. Public Health Service Act, which prohibits, among other things, the introduction into interstate commerce of a biological product 
unless a biologics license is in effect for that product;
•
the U.S. Physician Payments Sunshine Act and its implementing regulations, which require certain manufacturers of drugs, devices, biologics 
and medical supplies that are reimbursable under Medicare, Medicaid, or the Children’s Health Insurance Program to report annually to the 
government information related to certain payments and other transfers of value to physicians (defined to include doctors, dentists, 
optometrists, podiatrists and chiropractors), certain other healthcare providers starting in 2022, and teaching hospitals, as well as ownership 
and investment interests held by the physicians described above and their immediate family members;

 
64
•
analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, 
including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services 
reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the 
pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal 
government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws and 
regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and 
other remuneration and items of value provided to healthcare professionals and entities; and
•
similar healthcare laws and regulations in the European Union and other jurisdictions, including reporting requirements detailing interactions 
with and payments to healthcare providers.
Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will 
involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, 
regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in 
violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant 
penalties, including civil, criminal and administrative penalties, damages, fines, exclusion from government-funded healthcare programs, such as Medicare 
and Medicaid or similar programs in other countries or jurisdictions, disgorgement, individual imprisonment, contractual damages, reputational harm, 
diminished profits and the curtailment or restructuring of our operations. Further, defending against any such actions can be costly, time-consuming and 
may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our 
business may be impaired.
U.S. tax legislation and future changes to applicable U.S. tax laws and regulations may have a material adverse effect on our business, financial 
condition and results of operations.
New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, or interpreted, changed, modified or 
applied adversely to us, any of which could adversely affect our business operations and financial performance. We are currently unable to predict whether 
such changes will occur and, if so, the ultimate impact on our business. To the extent that such changes have a negative impact on us, our suppliers or our 
customers, including as a result of related uncertainty, these changes may materially and adversely impact our business, financial condition, results of 
operations and cash flows.
 
Risks Related to Ownership of Our Common Stock 
Our stock price may be volatile and you may not be able to resell shares of our common stock at or above the price you paid.
The trading price of our common stock has been and may continue to be highly volatile and may be subject to wide fluctuations in response to various 
factors, some of which are beyond our control.
These factors include those discussed in this “Risk Factors” section of this report and others such as:
•
results from, and any delays in, commencing, conducting or completing our clinical studies for our current drug candidates, or any other 
future clinical development programs;
•
announcements by academic or other third parties challenging the fundamental premises underlying our approach to treating diseases of 
aging and/or drug development;
•
announcements of regulatory approval or disapproval of our current or any future drug candidates;
•
failure or discontinuation of any of our research and development programs;
•
announcements relating to future licensing, collaboration, or development agreements;

 
65
•
our ability to raise substantial additional funds to achieve our goals;
•
our ability to maintain compliance with Nasdaq listing standards;
•
delays in the commercialization of our current or any future drug candidates;
•
public misperception regarding the use of our therapies, or public bias of against “anti-aging” companies;
•
acquisitions and sales of new products, technologies, or businesses;
•
manufacturing and supply issues related to our drug candidates for clinical studies or future drug candidates for commercialization;
•
quarterly variations in our results of operations or those of our future competitors;
•
changes in earnings estimates or recommendations by securities analysts;
•
announcements by us or our competitors of new products, significant contracts, commercial relationships, acquisitions, or capital 
commitments;
•
developments with respect to intellectual property rights;
•
our commencement of, or involvement in, litigation;
•
changes in financial estimates or guidance, including our ability to meet our future revenue and operating profit or loss estimates or guidance; 
•
any major changes in our board of directors or management;
•
new legislation in the United States relating to the sale or pricing of pharmaceuticals;
•
FDA or other U.S. or foreign regulatory actions affecting us or our industry;
•
product liability claims or other litigation or public concern about the safety of our drug candidates;
•
market conditions in the pharmaceutical, biopharmaceutical and biotechnology sectors; and
•
general economic conditions in the United States and abroad, including high interest rates, rising inflation, tariffs, liquidity concerns at 
financial institutions, and the potential for local and/or global economic recession.
In addition, the stock markets in general, and the markets for pharmaceutical, biopharmaceutical, and biotechnology stocks in particular, have experienced 
extreme volatility as a result of the economic uncertainty and increased interest rates, inflation, tariffs, and liquidity concerns at financial institutions that 
may be unrelated to the operating performance of the issuer. These broad market fluctuations may adversely affect the trading price or liquidity of our 
common stock. In the past, when the market price of a stock has been volatile, holders of that stock have sometimes instituted securities class action 
litigation against the issuer. If any of our stockholders were to bring such a lawsuit against us, we could incur substantial costs defending the lawsuit and 
the attention of our management would be diverted from the operation of our business.
On October 19, 2022, we effected a 1-for-10 reverse stock split of our common stock seeking to regain compliance with Nasdaq Global Select Market's 
continued listing standards. As a result of the reverse stock split, the split-adjusted per share market price of our common stock increased and, from 
October 20, 2022 to November 2, 2022 (10 consecutive business days), the closing bid price of our common stock exceeded $1.00 per share. Accordingly, 
on November 3, 2022, we received a notice from Nasdaq indicating that we have regained compliance with Listing Rule 5450(a)(1) as of such date. See the 
risk factor titled “We may not be able to maintain compliance with the continued listing requirements of Nasdaq and, if so, we would be subject to 
delisting.” for additional information about our ability to maintain compliance with the continued listing requirements of Nasdaq. Although we currently 
comply with the minimum bid requirement following the reverse stock split, we cannot assure you that we will be able to maintain compliance with the
continued listing requirements of Nasdaq and any delisting would adversely affect our stock price and the liquidity of our common stock. 

 
66
An active, liquid and orderly market for our common stock may not be maintained.
Although our common stock is listed on the Nasdaq Global Select Market, an active trading market for our common stock may never be sustained on the 
Nasdaq Global Select Market or any other exchange in the future. On October 19, 2022, we effected a 1-for-10 reverse stock split of our common stock 
seeking to bring us into compliance with the minimum required losing bid price for continued listing on the Nasdaq Global Select Market and to regain 
compliance with Nasdaq Global Select Market's continued listing standards. While we have regained compliance, we cannot assure that we will continue to 
meet the minimum required closing bid price for continued listing on the Nasdaq Global Select Market in the future or that we will be able to maintain our 
listing on the Nasdaq Global Select Market or any other exchange. See the risk factor titled “We may not be able to maintain compliance with the continued 
listing requirements of Nasdaq and, if so, we would be subject to delisting.” for additional information about our ability to maintain compliance with the 
continued listing requirements of Nasdaq. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a 
price that you consider reasonable. An inactive market may also impair our ability to raise capital by selling shares and may impair our ability to acquire 
other businesses, applications, or technologies using our shares as consideration. 
If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our 
stock, our stock price and trading volume could decline.
The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our business. In 
the event any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock 
performance, or if our clinical studies and operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or more of 
these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our 
stock price or trading volume to decline. If our public float stays below $75.0 million, the risk that analysts cease to cover our stock may increase.
If we sell shares of our common stock in future financings, stockholders may experience immediate dilution and, as a result, our stock price may 
decline.
We have and may from time to time issue additional shares of common stock at a discount from the current trading price of our common stock. As a result, 
our stockholders would experience immediate dilution upon the purchase of any shares of our common stock sold at such discount. For example, we may 
issue additional shares from time to time pursuant to our shelf registration statements and ATM Offering Programs. In addition, as opportunities present 
themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt securities, preferred stock or common stock. 
However, for so long as our public float is less than $75.0 million, under our shelf registration statements, we may not sell more than the equivalent of one-
third of our public float during any 12 consecutive months pursuant to the baby shelf rules.
Sales of substantial amounts of shares of our common stock or other securities by our stockholders, by us under our shelf registration statements or the 
ATM Offering Programs or through any other means could also lower the market price of our common stock and impair our ability to raise capital through 
the sale of equity or equity-related securities.
We have identified a material weakness in our internal control over financial reporting. This material weakness could continue to adversely affect our 
results of operations and financial condition. In the future, we may identify additional material weaknesses or otherwise fail to maintain an effective 
system of internal control over financial reporting or adequate disclosure controls and procedures, which may result in material errors in our financial 
statements or cause us to fail to meet our period reporting obligations.
 Our management is responsible for establishing and maintaining adequate internal control over financial reporting, evaluating the effectiveness of our 
internal controls and disclosing any changes or material weaknesses identified through such evaluation. A material weakness is a deficiency, or a 
combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual 
or interim financial statements will not be prevented or detected on a timely basis.

 
67
 In March 2024, we determined that we incorrectly classified certain warrants that were issued to investors in connection with a Follow-On offering of our 
common stock in August 2022. Our management subsequently concluded that a material weakness existed and our internal control over financial reporting 
was not effective as of August 2022. The material weakness was due to the inadequate design and implementation of controls to evaluate the accounting for 
warrant classification between liability and equity.
As a result, we determined that there were material errors in the financial statements that required a restatement of the December 31, 2022 financial 
statements and for our Forms 10-Q for the quarterly periods ended September 30, 2022, March 31, 2023, June 30, 2023 and September 30, 2023. Those 
restatements are included in the Annual Report on Form 10-K for the year ended December 31, 2023. This was due to the inadequate design and 
implementation of controls to evaluate the accounting for warrant classification between liability and equity. 
Management is implementing enhanced internal controls to remediate the material weakness. Specifically, we are in the process of expanding and 
improving our review process for complex security transactions and related accounting standards. We plan to improve this process by specifically 
incorporating the review of the accounting conclusions for each significant relevant contractual term, by using a robust accounting literature tool, and 
engaging third-party subject matter experts with relevant experience to determine the appropriate accounting for complex security transactions. The 
elements of our remediation plan can only be accomplished over time, and we can offer no assurance that these initiatives will ultimately have the intended 
effects.
Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls 
and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their 
implementation, could cause us to fail to meet our reporting obligations. If we are not able to comply with the requirements of the Sarbanes-Oxley Act or if 
we are unable to maintain effective internal control over financial reporting, we may not be able to produce timely and accurate financial statements or 
guarantee that information required to be disclosed by us in the reports that we file with the SEC, is recorded, processed, summarized, and reported within 
the time periods specified in SEC rules and forms. Any failure of our internal control over financial reporting or disclosure controls and procedures could 
cause our investors to lose confidence in our publicly reported information, cause the market price of our stock to decline, expose us to sanctions or 
investigations by the SEC or other regulatory authorities, or impact our results of operations.
Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited.
We have incurred substantial losses during our history and may never achieve profitability. To the extent that we continue to generate taxable losses, 
unused losses will carry forward to offset a portion of future taxable income, if any, until such unused losses expire, if ever. Under Sections 382 and 383 of 
the Internal Revenue Code of 1986, as amended, if a corporation undergoes an “ownership change,” generally defined as a greater than 50 percentage point 
change (by value) in its equity ownership by certain stockholders over a three-year period, the corporation’s ability to use its pre-change net operating loss 
carryforwards, or NOLs, and other pre-change tax attributes (such as research and development tax credits) to offset its post-change income or taxes may 
be limited. We may have experienced ownership changes in the past and may experience ownership changes in the future as a result of subsequent shifts in 
our stock ownership (some of which shifts are outside our control). As a result, if we earn net taxable income, our ability to use our pre-change NOLs to 
offset such taxable income could be subject to limitations. Similar provisions of state tax law may also apply. As a result, even if we achieve profitability, 
we may be unable to use a material portion of our NOLs and other tax attributes.
Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to 
entrenchment of management.
Our amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent changes in control or 
changes in our management without the consent of our board of directors. These provisions include the following:
•
a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a 
majority of our board of directors;

 
68
•
no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates;
•
the exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of the board of directors or the 
resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors;
•
the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those 
shares, including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a 
hostile acquiror;
•
the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval;
•
the required approval of at least 66 2/3% of the shares entitled to vote at an election of directors to adopt, amend or repeal our amended and 
restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of 
directors;
•
a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our 
stockholders;
•
the requirement that a special meeting of stockholders may be called only by the chief executive officer or the president or the board of 
directors, which may delay the ability of our stockholders to force consideration of a proposal or to take action, including the removal of 
directors; and
•
advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters 
to be acted upon at a stockholders’ meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to 
elect the acquiror’s own slate of directors or otherwise attempting to obtain control of us.
We are also subject to the anti-takeover provisions contained in Section 203 of the Delaware General Corporation Law. Under Section 203, a corporation 
may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three 
years or, among other exceptions, the board of directors has approved the transaction.
Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may 
reduce the amount of money available to us.
Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in each 
case to the fullest extent permitted by Delaware law.
In addition, as permitted by Section 145 of the Delaware General Corporation Law, our amended and restated bylaws and our indemnification agreements
that we have entered into with our directors and officers provide that:
•
We will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the 
fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good 
faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any 
criminal proceeding, had no reasonable cause to believe such person’s conduct was unlawful.
•
We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.
•
We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such 
directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification. 
We will not be obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that 
person against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a 
right to indemnification.

 
69
•
The rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements 
with our directors, officers, employees and agents and to obtain insurance to indemnify such persons.
•
We may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers, 
employees and agents.
We do not currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend 
on appreciation in the price of our common stock.
We do not currently intend to pay any cash dividends on our common stock for the foreseeable future. We currently intend to invest our future earnings, if 
any, to fund our growth. Therefore, you are not likely to receive any dividends on your common stock for the foreseeable future. Since we do not intend to 
pay dividends, your ability to receive a return on your investment will depend on any future appreciation in the market value of our common stock. There is 
no guarantee that our common stock will appreciate or even maintain the price at which our holders have purchased it.  
General Risk Factors
Unfavorable global economic or political conditions could adversely affect our business, financial condition or results of operations.
Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. Furthermore, the 
market for products with the potential to treat diseases of aging, particularly those affecting large populations in a wide range of geographic locations, may 
be particularly vulnerable to unfavorable economic conditions. A global financial crisis or a global or regional political disruption have caused and could 
continue to cause extreme volatility in the capital and credit markets. A severe or prolonged economic downturn or political disruption could result in a 
variety of risks to our business, including weakened demand for our current drug candidates or any future drug candidates, if approved, and our ability to 
raise additional capital when needed on acceptable terms, if at all. A weak or declining economy or political disruption could also strain our manufacturers 
or suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. Weakened or declining economic
conditions could be caused by a number of factors, including high interest rates, rising inflation, tariffs, liquidity concerns at financial institutions, and the 
potential for local and/or global economic recession. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the 
political or economic climate and financial market conditions could adversely impact our business.
We or the third parties upon whom we depend may be adversely affected by earthquakes, other natural disasters or unforeseen pandemics and public 
health emergencies, such as the COVID-19 pandemic, and our business continuity and disaster recovery plans may not adequately protect us from a 
serious disaster.
Our corporate headquarters and other facilities are located in the San Francisco Bay Area, which in the past has experienced both severe earthquakes and 
wildfires. Although we carry earthquake insurance, it is limited in scope. Earthquakes, wildfires or other natural disasters could severely disrupt our 
operations, and have a material adverse effect on our business, results of operations, financial condition and prospects.
If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical 
infrastructure, such as our enterprise financial systems or manufacturing resource planning and enterprise quality systems, or that otherwise disrupted 
operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and 
business continuity plans we have in place currently are limited and are unlikely to prove adequate in the event of a serious disaster or similar event. We 
may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly when taken 
together with our lack of earthquake insurance, could have a material adverse effect on our business. 

 
70
Furthermore, integral parties in our supply chain are similarly vulnerable to natural disasters or other sudden, unforeseen and severe adverse events. If such 
an event were to affect our supply chain, it could have a material adverse effect on our business.
Significant disruptions of information technology systems or deficiencies in our cybersecurity could materially adversely affect our business, results of 
operations and financial condition.
We collect and maintain information in digital form that is necessary to conduct our business, and we are increasingly dependent on information 
technology systems and infrastructure to operate our business. In the ordinary course of our business, we collect, store and transmit large amounts of 
confidential information, including intellectual property, proprietary business information and personal information. It is critical that we do so in a secure 
manner to maintain the confidentiality and integrity of such confidential information. We have established physical, electronic and organizational measures 
to safeguard and secure our systems to prevent a data compromise, and rely on commercially available systems, software, tools, and monitoring to provide 
security for our information technology systems and the processing, transmission and storage of digital information. We have also outsourced elements of 
our information technology infrastructure, and as a result a number of third-party vendors may or could have access to our confidential information. 
Our information technology systems and infrastructure, and those of our current and any future collaborators, contractors and consultants and other third 
parties on which we rely, are vulnerable to attack, interruption and damage from computer viruses, malware (e.g. ransomware), natural disasters, terrorism, 
war, telecommunication and electrical failures, cyberattacks or cyber-intrusions over the Internet, phishing attacks and other social engineering schemes, 
employee theft or misuse, human error, fraud, denial or degradation of service attacks, sophisticated nation-state and nation-state-supported actors or 
unauthorized access or use by persons inside our organization, or persons with access to systems inside our organization.
The risk of a security breach or disruption, particularly through cyberattacks or cyber-intrusion, including by computer hackers, “phishing” attacks, foreign 
governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the
world have increased. In addition, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, 
which could lead to the loss of confidential information or other intellectual property. We may face increased cybersecurity risks due to our reliance on 
internet technology and the number of our employees that work or may work remotely, which may create additional opportunities for cybercriminals to 
exploit vulnerabilities. 
Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until 
launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security 
breaches that may remain undetected for an extended period. Even if identified, we may be unable to adequately investigate or remediate incidents or 
breaches due to attackers increasingly using tools and techniques that are designed to circumvent controls, to avoid detection, and to remove or obfuscate 
forensic evidence.  The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities 
could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to 
address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service and other harm to 
our business and our competitive position. 
We and certain of our service providers are from time to time subject to cyberattacks and security incidents. While we do not believe that we have 
experienced any significant system failure, accident or security breach to date, if such an event were to occur and cause interruptions in our operations, it 
could result in a material disruption of our product development programs. For example, the loss of clinical study data from completed or ongoing or 
planned clinical studies could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.
Moreover, if a security breach affects our systems, or those of our current and any future collaborators, contractors and consultants and other third parties 
on which we rely, or results in the unauthorized release of personally identifiable information, our reputation could be materially damaged. In addition, 
such a breach may require notification to governmental agencies, the media or individuals pursuant to various federal and state privacy and security laws. 
We 

 
71
would also be exposed to a risk of loss or litigation and potential liability, which could materially adversely affect our business, results of operations and 
financial condition. We maintain cyber liability insurance; however, this insurance may not be sufficient to cover the financial, legal, business or 
reputational losses that may result from an interruption or breach of our systems.
Our employees and independent contractors, including principal investigators, consultants, commercial collaborators, service providers and other 
vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could 
have an adverse effect on our results of operations.
We are exposed to the risk that our employees and independent contractors, including principal investigators, consultants, any future commercial 
collaborators, service providers and other vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include 
intentional, reckless and/or negligent conduct or other unauthorized activities that violate the laws and regulations of the FDA and other similar regulatory 
bodies, including those laws that require the reporting of true, complete and accurate information to such regulatory bodies; manufacturing standards; U.S. 
federal and state healthcare fraud and abuse, data privacy laws and other similar non-U.S. laws; or laws that require the true, complete and accurate 
reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the 
course of clinical studies, the creation of fraudulent data in our preclinical studies or clinical studies, or illegal misappropriation of product, which could 
result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other 
third-parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in 
protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. In
addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are 
instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business 
and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, 
disgorgements, possible exclusion from participation in Medicare, Medicaid and other U.S. healthcare programs, individual imprisonment, other sanctions, 
contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our 
ability to operate our business and our results of operations.
Our business involves the use of hazardous materials, and we and our third-party manufacturers and suppliers must comply with environmental laws 
and regulations, which can be expensive and restrict how we do business.
Our research and development activities and our third-party manufacturers’ and suppliers’ activities involve the controlled storage, use and disposal of 
hazardous materials owned by us, including the components of our product and drug candidates and other hazardous compounds. We and any third-party 
manufacturers and suppliers we engage are subject to numerous federal, state and local environmental, health and safety laws, regulations and permitting 
requirements, including those governing laboratory procedures; the generation, handling, use, storage, treatment, and disposal of hazardous and regulated 
materials and wastes; the emission and discharge of hazardous materials into the ground, air and water; and employee health and safety. Our operations 
involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce 
hazardous waste. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers’ facilities 
pending their use and disposal. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of 
contamination, which could cause an interruption of our commercialization efforts, research and development efforts and business operations, 
environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of 
these materials and specified waste products.
Although we believe that the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials generally comply 
with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or 
injury from these materials. Under certain environmental laws, we could be held responsible for costs relating to any contamination at our current or past 
facilities and at third-party facilities. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and 
state or federal or other applicable authorities may curtail our use of certain materials and/or 

 
72
interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more 
stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance.
Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair 
our research, product development and manufacturing efforts. In addition, we cannot entirely eliminate the risk of accidental injury or contamination from 
these materials or wastes. Although we maintain workers’ compensation insurance to cover us for costs and expenses, we may incur due to injuries to our 
employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not carry 
specific biological or hazardous waste insurance coverage, and our property, casualty, and general liability insurance policies specifically exclude coverage 
for damages and fines arising from biological or hazardous waste exposure or contamination. Accordingly, in the event of contamination or injury, we 
could be held liable for damages or be penalized with fines in an amount exceeding our resources, and our clinical studies or regulatory approvals could be 
suspended, which could have a material adverse effect on our business, results of operations and financial condition.
We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual 
property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such 
claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect 
on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and distraction to management and 
other employees.
We may not be able to protect our intellectual property rights throughout the world.
Filing, prosecuting and defending patents on drug candidates in all countries throughout the world would be prohibitively expensive, and our intellectual 
property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign 
countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to 
prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our 
inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent 
protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but 
enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights 
may not be effective or sufficient to prevent them from competing.
Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems 
of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly 
those relating to biopharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in 
violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our 
efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent 
applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the 
damages or other remedies awarded, if any, may not be commercially meaningful.
Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from 
the intellectual property that we develop or license.

 
73
Actual or perceived failures to comply with U.S. and foreign privacy and data protection laws, regulations and standards may adversely affect our 
business, operations and financial performance.
We are subject to or affected by numerous federal, state and foreign laws and regulations, as well as regulatory guidance, governing the collection, use, 
disclosure, retention, and security of personal information, such as information that we collect about patients and healthcare providers in connection with 
clinical trials in the United States and abroad. The global data protection landscape is rapidly evolving, and implementation standards and enforcement 
practices are likely to remain uncertain for the foreseeable future. This evolution may create uncertainty in our business, affect our or any service 
providers’, contractors’ or future collaborators’ ability to operate in certain jurisdictions or to collect, store, transfer use and share personal information, 
necessitate the acceptance of more onerous obligations in our contracts, result in liability or impose additional costs on us. The cost of compliance with 
these laws, regulations and standards is high and is likely to increase in the future. Any failure or perceived failure by us or our collaborators, service 
providers and contractors to comply with federal, state or foreign laws or regulation, our internal policies and procedures or our contracts governing 
processing of personal information could result in negative publicity, diversion of management time and effort and proceedings against us by governmental 
entities or others. In many jurisdictions, enforcement actions and consequences for noncompliance are rising.
In the United States, HIPAA imposes privacy, security and breach reporting obligations with respect to individually identifiable health information upon 
“covered entities” (health plans, health care clearinghouses and certain health care providers), and their respective business associates, individuals or 
entities that create, receive, maintain or transmit protected health information in connection with providing a service for or on behalf of a covered entity. 
Most healthcare providers, including research institutions from which we obtain patient health information, are subject to privacy and security regulations 
promulgated under HIPAA. While we do not believe that we are currently acting as a covered entity or business associate under HIPAA and thus are not 
directly regulated under HIPAA, any person may be prosecuted under HIPAA’s criminal provisions either directly or under aiding-and-abetting or 
conspiracy principles. Consequently, depending on the facts and circumstances, we could face substantial criminal penalties if we knowingly receive 
individually identifiable health information from a HIPAA-covered healthcare provider or research institution that has not satisfied HIPAA’s requirements 
for disclosure of individually identifiable health information.
In addition, certain state laws govern the privacy and security of personal information, including health-related information. For example, the California 
Consumer Privacy Act, or the CCPA went into effect on January 1, 2020. The CCPA gives California residents expanded rights to access and delete their 
personal information, opt out of certain personal information sharing, and receive detailed information about how their personal information is used. The 
CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that has increased the likelihood, and risks associated 
with data breach litigation. Further, the California Privacy Rights Act, or the CPRA generally went into effect on January 1, 2023, and significantly amends 
the CCPA. It imposes additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data 
uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It also creates a new California data protection agency 
authorized to issue substantive regulations and could result in increased privacy and information security enforcement. Additional compliance investment 
and potential business process changes may also be required. Similar laws have passed in Virginia, Colorado, Connecticut and Utah, and have been 
proposed in other states and at the federal level, reflecting a trend toward more stringent privacy legislation in the United States. The enactment of such 
laws could have potentially conflicting requirements that would make compliance challenging. In the event that we are subject to or affected by HIPAA, 
the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could 
adversely affect our financial condition.
Our operations abroad may also be subject to increased scrutiny or attention from data protection authorities. Many countries in these regions have 
established or are in the process of establishing privacy and data security legal frameworks with which we, our collaborators, service providers, including 
our CRO, and contractors must comply. For example, the European Union General Data Protection Regulation, or GDPR, went into effect in May 2018 
and imposes strict requirements for processing the personal information of subjects within the European Economic Area, or EEA, including clinical trial 
data. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data
protection requirements and potential fines for noncompliance of up to €20 million or 4% of the annual global revenues of the noncompliant company, 
whichever 

 
74
is greater. Further, recent legal developments in Europe have created complexity and compliance uncertainty regarding certain transfers of personal data 
from the EEA. On July 16, 2020, the Court of Justice of the European Union, or the CJEU, invalidated the EU-U.S. Privacy Shield Framework, or the 
Privacy Shield, under which personal data could be transferred from the EEA to United States entities who had self-certified under the Privacy Shield 
scheme, and imposed further restrictions on use of the standard contractual clauses, or SCCs. In March 2022, the US and EU announced a new regulatory 
regime intended to replace the invalidated regulations; however, this new EU-US Data Privacy Framework has not been implemented beyond an executive 
order signed by President Biden on October 7, 2022 on Enhancing Safeguards for United States Signals Intelligence Activities. European court and 
regulatory decisions subsequent to the CJEU decision of July 16, 2020 have taken a restrictive approach to international data transfers. As supervisory 
authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or start taking 
enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer 
personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical 
location or segregation of our relevant systems and operations, and could adversely affect our financial results.
Further, beginning January 1, 2021, companies have had to comply with the GDPR and also the United Kingdom GDPR, or UK GDPR, which, together 
with the amended UK Data Protection Act 2018, retains the GDPR in United Kingdom national law. The UK GDPR mirrors the fines under the GDPR, i.e., 
fines up to the greater of €20 million (£17.5 million) or 4% of global turnover.  As we continue to expand into other foreign countries and jurisdictions, we 
may be subject to additional laws and regulations that may affect how we conduct business.
We incur increased costs as a result of operating as a public company, and our management devote substantial time to new compliance initiatives. We 
may fail to comply with the rules that apply to public companies, including Section 404 of the Sarbanes-Oxley Act of 2002, which could result in 
sanctions or other penalties that would harm our business.
We have incurred and will continue to incur significant legal, accounting and other expenses as a public company, including costs resulting from public 
company reporting obligations under the Exchange Act and regulations regarding corporate governance practices. The listing requirements of the Nasdaq 
Global Select Market and the rules of the Securities and Exchange Commission, or SEC, require that we satisfy certain corporate governance requirements 
relating to director independence, filing annual and interim reports, stockholder meetings, approvals and voting, soliciting proxies, conflicts of interest and 
a code of conduct. Our management and other personnel have devoted and will need to devote a substantial amount of time to ensure that we comply with 
all of these requirements. Moreover, the reporting requirements, rules and regulations will increase our legal and financial compliance costs and will make 
some activities more time-consuming and costlier. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our 
obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential 
litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on our
board of directors or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors’ and officers’ insurance, 
on acceptable terms.
We are subject to Section 404 of The Sarbanes-Oxley Act of 2002, or Section 404, and the related rules of the SEC, which generally require our 
management and independent registered public accounting firm to report on the effectiveness of our internal control over financial reporting. Section 404 
requires an annual management assessment of the effectiveness of our internal control over financial reporting. Once we are considered an "accelerated 
filer" or "larger accelerated filer" under SEC rules, we will be required to include an opinion from our independent registered public accounting firm on the 
effectiveness of our internal controls over financial reporting.
During the course of our review of our internal controls we may identify deficiencies in our internal controls that we must remediate. If we identify a 
material weakness in our internal controls over financial reporting, we may not detect errors on a timely basis and our financial statements may be 
materially misstated. We or our independent registered public accounting firm may not be able to conclude on an ongoing basis that we have effective 
internal control over financial reporting, which could harm our operating results, cause investors to lose confidence in our reported financial information 
and cause the trading price of our stock to fall. In addition, as a public company we will be required to file accurate and timely quarterly and annual reports 
with the SEC under the Exchange Act. In order to report our 

 
75
results of operations and financial statements on an accurate and timely basis, we will depend in part on CROs to provide timely and accurate notice of 
their costs to us. Any failure to report our financial results on an accurate and timely basis could result in sanctions, lawsuits, delisting of our shares from 
The Nasdaq Global Select Market or other adverse consequences that would materially harm to our business.
We have recorded, and may be required to record in the future, significant charges if our long-lived assets become impaired.
We test long-lived assets for impairment if changes in circumstances or the occurrence of events suggest impairment exists. Any significant change in 
market conditions, including a sustained decline in our stock price, that indicate a reduction in carrying value may give rise to impairment in the period that 
indicators are present. For example, as a result of the sustained decline in our stock price and related market capitalization and a general decline in equity 
values in the biotechnology industry, we performed an impairment assessment of long-lived assets in connection with the preparation of the financial 
statements required to be included in our Annual Report on Form 10-K for the year ended December 31, 2023. Based on this assessment, we recognized a 
non-cash long-lived asset impairment charge of $5.6 million during the year ended December 31, 2023. 
It is possible that changes in circumstances, many of which are outside of our control, or in the numerous variables associated with the assumptions and 
estimates used in assessing the appropriate valuation of our long-lived assets, could in the future result in an impairment to our long-lived assets, requiring 
us to record impairment charges, which would adversely affect our business, financial condition and results of operations.
 
Item 1B. Unresolved Staff Comments. 
None.
Item 1C. Cybersecurity 
 
Cybersecurity Risk Management and Strategy
 
We have developed and implemented a cybersecurity risk management program intended to protect the confidentiality, integrity, and availability of our 
critical systems and information. Our cybersecurity risk management program includes a cybersecurity incident response plan. 
 
We design and assess our cybersecurity program based on the National Institute of Standards and Technology (NIST) Cybersecurity Framework.  This 
does not imply that we meet any particular technical standards, specifications, or requirements, only that we use the NIST Cybersecurity Framework as a 
guide to help us identify, assess, and manage cybersecurity risks relevant to our business.
 
Our cybersecurity risk management program is integrated into our overall enterprise risk management program, and shares common methodologies, 
reporting channels and governance processes that apply across the enterprise risk management program to other legal, compliance, strategic, operational, 
and financial risk areas.
 
Our cybersecurity risk management program includes:
•
risk assessments designed to help identify material cybersecurity risks to our critical systems, information, products, services, and our 
broader enterprise IT environment;
•
a security team principally responsible for managing (1) our cybersecurity risk assessment processes, (2) our security controls, and (3) our 
response to cybersecurity incidents;
•
the use of external service providers, where appropriate, to assess, test or otherwise assist with aspects of our security controls;
•
cybersecurity awareness training of our employees, incident response personnel, and senior management; 

 
76
•
a cybersecurity incident response plan that includes procedures for responding to cybersecurity incidents; and
•
a third-party risk management process for service providers, suppliers, and vendors.
 
We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or 
are reasonably likely to materially affect us, including our operations, business strategy, results of operations, or financial condition.
 
Cybersecurity Governance
 
Our Board considers cybersecurity risk as part of its risk oversight function and has delegated to the Audit Committee oversight of cybersecurity and other 
information technology risks. The Audit Committee oversees management’s implementation of our cybersecurity risk management program. 
 
The Audit Committee receives regular reports from management on our cybersecurity risks. In addition, management updates the Audit Committee, as 
necessary, regarding any material cybersecurity incidents, as well as any incidents with lesser impact potential. 
 
The Audit Committee reports to the full Board regarding its activities, including those related to cybersecurity. The full Board also receives briefings from 
management on our cyber risk management program.  Board members receive presentations on cybersecurity topics from our Head of Information 
Technology, internal security staff or external experts as part of the Board’s continuing education on topics that impact public companies.
 
Our management team, including our Chief Legal Officer and Head of Operations and external IT consultants, is responsible for assessing and managing 
our material risks from cybersecurity threats. Our Chief Legal Officer is a former federal prosecutor and deputy chief of cybercrime in the U.S. Attorney's 
Office for the Eastern District of Virginia, as well as a former law firm partner conducting and overseeing investigations, prosecutions, and cases relating to 
cybercrime, hacking, trade secrets, large-scale identity theft, national security, data breaches, and related cybersecurity and data privacy matters.  The team 
has primary responsibility for our overall cybersecurity risk management program and supervises both our internal cybersecurity personnel and our retained 
external cybersecurity consultants. Our management team’s experience, in close cooperation with external IT consultants, includes significant experience 
of leading and managing IT infrastructure and security operations teams for various sized global companies across several different industries. 
 
Our management team supervises efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means, which may 
include briefings from internal security personnel; threat intelligence and other information obtained from governmental, public or private sources, 
including external consultants engaged by us; and alerts and reports produced by security tools deployed in the IT environment.  
Item 2. Properties. 
Our corporate headquarters are located in South San Francisco, California, where we currently lease approximately 62,000 square feet of office and 
laboratory space pursuant to a lease dated February 28, 2019, of which approximately 23,000 square feet was subleased from June 2021 through July 2024 
and approximately 15,000 square feet was subleased as of July 2022 through June 2026 with an additional 17,000 square feet subleased as of September 
2023 through June 2026. The majority of our employees work at our corporate headquarters.
Item 3. Legal Proceedings. 
We are not currently a party to any material litigation or other material legal proceedings.

 
77
Item 4. Mine Safety Disclosures.
Not applicable.

 
78
PART II
Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. 
Market Information for Common Stock
Our common stock has been listed on the Nasdaq Global Select Market under the symbol “UBX” since May 3, 2018. As of March 1, 2025, there were 40 
holders of record of our common stock. Because many of our shares of common stock are held by brokers and other institutions on behalf of stockholders, 
we are unable to estimate the total number of beneficial owners of our common stock represented by these record holders.
Dividend Policy
We have never declared or paid any cash dividends on our common stock or any other securities. We anticipate that we will retain all available funds and 
any future earnings, if any, for use in the operation of our business and do not anticipate paying cash dividends in the foreseeable future. In addition, future 
debt instruments may materially restrict our ability to pay dividends on our common stock. Payment of future cash dividends, if any, will be at the 
discretion of the board of directors after taking into account various factors, including our financial condition, operating results, current and anticipated 
cash needs, the requirements of current or then-existing debt instruments and other factors the board of directors deems relevant.
Sales of Unregistered Equity Securities
There were no sales of unregistered securities during the year ended December 31, 2024 that were not previously reported in a quarterly report on Form 10-
Q or current report on Form 8-K.
Repurchase of Shares or of Company Equity Securities
None.
Item 6. [Reserved] 
 

 
79
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations. 
You should read the following discussion and analysis of our financial condition and results of operations together with the section entitled “Selected 
Financial Data” and our audited financial statements and related notes included elsewhere in this report. This discussion and other parts of this report 
contain forward-looking statements that involve risks and uncertainties, such as our plans, objectives, expectations, intentions and beliefs. Our actual 
results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, 
but are not limited to, those identified below and those discussed in the section entitled “Risk Factors” included elsewhere in this report. 
Overview
We are a biotechnology company engaged in researching and developing therapeutics to slow, halt, or reverse diseases of aging. Our initial focus is on 
creating senolytic medicines to selectively eliminate senescent cells and thereby treat diseases of aging, such as ophthalmologic diseases.
In July 2020, we filed an Investigational New Drug application, or IND, to commence a Phase 1, first-in-human, open-label, single-ascending dose study of 
UBX1325 (foselutoclax) in patients with advanced diabetic macular edema, or DME, and neovascular age-related macular degeneration, or nAMD. Our 
goal with UBX1325 is to transformationally improve outcomes for patients with DME. In October 2020, the Phase 1, first-in-human, clinical study of 
UBX1325 commenced. That study, an open-label, single ascending dose clinical trial, evaluated doses from 0.5 – 10 µg administered as a single intra-
vitreal injection in up to 8 patients with DME and 11 patients with nAMD all of whom had been off all anti-VEGF treatment due to lack of benefit for at 
least 6 months. The results of this study demonstrated acceptable safety and tolerability without any dose-limiting toxicities; no evidence of intraocular 
inflammation; and mean improvement in best corrected visual acuity (BCVA) of up to 9.5 ETDRS letters in those patients with DME receiving higher 
doses (5 and 10 µg) and a mean improvement in BCVA of 3.2 ETDRS letters in evaluable patients with nAMD at all doses, both at 24 weeks after 
treatment with UBX1325.
In May 2021, we initiated our Phase 2 BEHOLD study of UBX1325 in patients with DME and dosed our first patient in June 2021. This study was a multi-
center, randomized, double-masked, sham-controlled study designed to evaluate the safety, tolerability, efficacy and durability of a single 10 µg dose of 
UBX1325 (foselutoclax) in patients with DME evaluated though 24 weeks. Patients had the option of rolling over to a 48-week long term extension and a 
majority of patients who completed their 24-week visits opted to remain in the study. A total of 65 patients were enrolled, randomized evenly between 
UBX1325 and sham-injected patients. These patients were being actively treated with anti-VEGF for at least 6 months prior to being randomized into the 
BEHOLD study (mean of 4.03 injections in the 6 months preceding randomization), and had persistent visual acuity deficits (requirement of 73 ETDRS 
letters or worse, equal to Snellen equivalent of approximately 20/40 or worse, where the mean of 61.4 letters at baseline was observed) and residual retinal 
fluid (requirement of ≥300 µm of central subfield thickness on optical coherence tomography, where the mean of approximately 439.6 µm at baseline was 
observed). At the time of randomization, patients were taken off of their anti-VEGF treatment, and instead treated with UBX1325 or a sham procedure. 
Endpoints explored in the study included safety and tolerability, changes in BCVA, CST, presence of SRF/IRF, proportion of patients requiring rescue 
treatment, and durability of effects.
In August 2022, we announced positive 12- and 18-week data in our Phase 2 BEHOLD study, including that a single injection of UBX1325 led to a 
progressive, statistically significant, and clinically meaningful improvement in mean BCVA compared to sham treatment. At Week 18, the mean change 
from baseline of BCVA for UBX1325-treated subjects was an increase of 6.1 ETDRS letters that represented a difference of +5.0 ETDRS letters compared 
to sham-treated subjects (p=0.0368). In addition, patients treated with UBX1325 maintained central subfield thickness (CST) (+3.2 microns) compared to 
sham-treated patients who had progressive worsening (increase) in CST through 18 weeks (+53.5 microns) (p=0.0719). 
In November 2022, we announced positive 24-week data in our BEHOLD study, showing that a single injection of UBX1325 led to a statistically 
significant and clinically meaningful improvement in BCVA of +6.2 ETDRS letters from baseline and +7.6 ETDRS letters compared to sham treatment 
(p=0.0084). Inclusive of rescue data, patients treated with UBX1325 had a mean improvement in BCVA of +6.4 ETDRS letters from baseline and +5.2 
ETDRS 

 
80
letters compared to sham (p=0.0068). At 24 weeks, patients treated with UBX1325 had a mean change in CST of −5.4 microns from baseline compared to 
a worsening (increase) of +34.6 microns in sham-treated patients (p=0.1244). The proportion of rescue-free patients at 24 weeks was greater on UBX1325 
(59.4%) as compared to sham (37.5%) with fewer total rescues and longer time-to-rescue in UBX1325-treated patients as compared to sham. UBX1325 
demonstrated a favorable safety and tolerability profile with no cases of intraocular inflammation, retinal artery occlusion, endophthalmitis, or vasculitis. 
Patients were followed through 48 weeks post-treatment in a long-term follow-up.
In April 2023, we announced positive 48-week data from this long-term follow-up in our BEHOLD study in 50 patients who participated in the 48-week 
extension study, showing that a single injection of UBX1325 led to a statistically significant and clinically meaningful improvement in vision lasting for 
the duration of the study (48 weeks), marked by a gain of +6.2 ETDRS letters from baseline, representing a difference of +5.6 ETDRS letters compared to 
sham-treated patients (p=0.1198). In addition, patients treated with UBX1325 maintained stable CST (-13.7 µm) compared to worsening in sham-treated 
patients (+24.2 µm) that did not lead to a statistical significant difference (p=0.2289). Approximately 50% of UBX1325-treated patients did not require any 
additional injections through 48 weeks, compared to only 22% of patients in the sham arm. Retinal structure, as measured by central subfield thickness 
(CST), was maintained in UBX1325-treated patients throughout the duration of the study. UBX1325 continued to show a favorable safety and tolerability 
profile with no evidence of intraocular inflammation.
In December 2023, we announced that the first patients have been dosed in our Phase 2b ASPIRE study, designed to evaluate UBX1325 (foselutoclax) 
head-to-head against aflibercept in previously treated patients with active DME who are not achieving optimal benefit from standard of care. In August 
2024, we completed enrollment of patients into the ASPIRE study in DME, which is a multi-center, randomized, double-masked, active-controlled study 
designed to evaluate the safety and efficacy of UBX1325 in comparison to aflibercept. Patients are randomized 1:1 to receive either 10 μg UBX1325, or 2 
mg of aflibercept control injections every eight weeks for six months. We completed enrollment of 52 participants with DME who have residual visual 
acuity deficits and excess fluid in the retina despite having received at least three anti-VEGF injections in the preceding sixteen weeks. All participants 
received three monthly doses of 2 mg aflibercept as a “run-in” prior to randomization. The primary efficacy endpoint will be mean change from baseline in 
BCVA to week 24. Secondary endpoints will include change in BCVA over time, CST change from baseline to week 24, proportion of participants who do 
not require rescue, and percentage of participants with one or more treatment-emergent ocular adverse events during the course of the study.
In April 2024, we announced that the ongoing Phase 2b ASPIRE study of UBX1325 has been extended from 24 to 36 weeks to assess safety, efficacy, and 
potentially greater durability compared to aflibercept. There will be no scheduled treatments in either arm between 24 and 36 weeks to allow direct 
comparison of durability of effect between the two treatment arms. We completed enrollment in August 2024 and anticipate receiving topline data from the 
ASPIRE study in two data readouts: 24-week primary endpoint data in the first quarter of 2025, and 36-week long-term extension data in the second 
quarter of 2025. 
From August through September 2024, we had a Type C interaction with the U.S. Food and Drug Administration, or FDA, regarding the development of 
UBX1325 (foselutoclax) for DME. The objectives of this meeting were to obtain FDA input regarding the design of the pivotal trial and endpoint for 
regulatory approval. Based on the interaction, we expect the pivotal study would need to be a non-inferiority trial comparing UBX1325 to an approved 
anti-VEGF agent. The primary endpoint is expected to be the change in baseline in BCVA, as assessed by the ETDRS scale with a non-inferiority margin 
of four letters. 
In age-related macular degeneration (AMD), in March 2022, we enrolled our first patient in the Phase 2 ENVISION study. This study was a prospective, 
multicenter, randomized, double-masked, active-controlled study to assess the safety, tolerability, and evidence of activity of a repeat intravitreal injection 
of UBX1325 (foselutoclax) in patients with neovascular AMD. In September 2022, the study completed enrollment of 50 patients with nAMD who have 
had at least two intravitreal injections of anti-VEGF therapy in the preceding six months and who still have active choroidal neovascularization and residual 
sub- or intra-retinal fluid. Patients were to have received their last anti-VEGF treatment approximately 4-8 weeks prior to screening, and all patients were 
followed for approximately 24 weeks after dosing with either UBX1325 or aflibercept. 

 
81
In March 2023, we announced 16-week and 24-week data in Part A of our ENVISION study, in which UBX1325 monotherapy did not achieve non-
inferiority through 24 weeks due, in part, to an unexpected 3.5 letter gain at week two in the anti-VEGF control arm. UBX1325 maintained visual acuity in 
patients with ongoing active disease through 24 weeks with less than one letter mean decrease from baseline (−0.8 ETDRS letters at 24 weeks compared to 
+3.1 ETDRS letters in the aflibercept control arm). Of UBX1325-treated patients, 52% did not require anti-VEGF treatment through 24 weeks. UBX1325 
demonstrated a favorable safety and tolerability profile with no cases of intraocular inflammation, retinal artery occlusion, endophthalmitis, or vasculitis.
In September 2023, we announced 48-week data in Part B of our ENVISION study, in which UBX1325 demonstrated a favorable safety and tolerability 
profile in the combination and monotherapy arms with no cases of significant intraocular inflammation, retinal artery occlusion or endophthalmitis. Patients 
switched from every 8-week aflibercept to a combination of aflibercept and UBX1325 at week 24 maintained vision gains achieved with aflibercept alone 
through week 48. Patients in a pre-specified subgroup with poor visual acuity at baseline (≤60 ETDRS letters) gained 3.2 ETDRS letters on combination 
treatment between weeks 24 and 48. In the UBX1325 monotherapy arm, patients maintained visual acuity for the duration of the study, with a mean change 
of +0.1 ETDRS letters at the 24-week time point and a mean change of −1.5 ETDRS letters at 48 weeks. 40% of UBX1325-treated patients did not need 
anti-VEGF rescue through 48 weeks and 64% of the patients achieved an anti-VEGF treatment-free period of over 24-weeks. The median time to first anti-
VEGF rescue was 32 weeks.
In February 2022, and again on May 4, 2023, we announced restructuring efforts to align resources to focus on our ongoing clinical programs and deliver 
on key development milestones. These actions to prioritize our ophthalmology programs, optimize resource allocation, extend our runway, and implement 
cost saving measures were designed to enable us to achieve multiple key clinical data readouts for UBX1325. As part of the May 2023 restructuring 
actions, we reduced our headcount by a total of nine employees, or approximately 29%, effective as of May 31, 2023, with three employees who departed 
as of June 30, 2023. 
On November 9, 2023, we entered into an Inducement Offer with certain holders, or Holders of existing warrants, or Existing Warrants, to purchase up to 
an aggregate of 2,143,000 shares of common stock, which warrants were issued to the Holders on August 22, 2022, having an exercise price of $8.50 per 
share. The Holders agreed to exercise for cash their Existing Warrants to purchase an aggregate of 2,143,000 shares of common stock at a reduced exercise 
price of $2.045 per share, or the Exercise, in consideration of our agreement to issue new warrants, or the New Warrants to purchase up to an aggregate of 
2,143,000 shares of common stock, or the New Warrant Shares. Each New Warrant has an exercise price equal to $1.92 per share. We received aggregate 
gross proceeds of approximately $4.4 million from the Exercise, before deducting $0.6 million in placement agent fees and other offering expenses payable 
by us. We also issued to the placement a, H.C. Wainwright & Co., LLC, warrants to purchase up to 128,580 shares of common stock with an exercise price 
equal to $2.5563 per share. We are using the net proceeds from the Inducement Offer for working capital, operating expenses to include clinical trial 
progression, and general corporate purposes. The resale of the New Warrant Shares and the shares underlying the warrants issued to the placement agent 
was registered on a Registration Statement on Form S-3 initially filed on December 6, 2023 pursuant to the terms of the Inducement Offer.
Since the commencement of our operations, we have invested a significant portion of our efforts and financial resources in research and development 
activities, and we have incurred net losses each year since inception. Our net losses were $26.0 million, $39.9 million, and $44.5 million for the years 
ended December 31, 2024, 2023, and 2022, respectively. We do not have any products approved for sale, and we have never generated any product 
revenue. As of December 31, 2024, we had an accumulated deficit of $510.3 million, and we do not expect positive cash flows from operations in the 
foreseeable future. 
Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and 
administrative costs associated with our operations. Based on our current operating plans, we expect our existing capital resources will fund our planned 
operating expenses into the fourth quarter of 2025, which will be used to advance UBX1325. Since our capital resources will fund operations less than 12 
months from the date of this Annual Report on Form 10-K, we concluded that these conditions raise substantial doubt about our ability to continue as a 
going concern. We will need to raise additional capital; however, adequate funding may not be available to us on acceptable terms, or at all, particularly in 
light of the current economic uncertainty, high interest rates, rising inflation, tariffs, and the potential for local and/or global economic recession. We 
expect to 

 
82
continue to look for opportunities to secure such financing in the near future, in addition to using our existing 2022 ATM Offering Programs (as defined 
below). If sufficient funds on acceptable terms are not available when needed, we could be required to significantly reduce our operating expenses and 
delay, reduce the scope of, or eliminate one or more of our development programs or liquidate assets where possible, cease operations or file for 
bankruptcy protection.
While our financial statements have been prepared assuming that we will continue to operate as a going concern, which contemplates the realization of 
assets and the satisfaction of liabilities in the normal course of business, and have successful development of UBX1325, which is in early stages of clinical 
development, we will need to raise additional funds.
If we become unable to continue as a going concern, we may have to liquidate our assets and the values we receive for our assets in liquidation or 
dissolution could be significantly lower than the values reflected in our financial statements, and maybe sooner than the fourth quarter of 2025.
We expect to continue to incur net operating losses for at least the next several years as we continue our research and development efforts, advance our 
drug candidates through preclinical and clinical development, seek regulatory approval, prepare for and, if approved, proceed to commercialization. We do 
not expect to generate revenue from any drug candidates that we develop until we obtain regulatory approval for one or more of such drug candidates and 
commercialize our products or enter into collaborative agreements with third parties.
We rely on third parties in the conduct of our preclinical studies and clinical trials and for manufacturing and supply of our drug candidates. We have no 
internal manufacturing capabilities, and we will continue to rely on third parties, many of whom are single-source suppliers, for our preclinical and clinical 
trial materials, as well as the commercial supply of our products. In addition, we do not yet have a marketing or sales organization or commercial 
infrastructure. Accordingly, we will incur significant expenses to develop a marketing and sales organization and commercial infrastructure in advance of 
generating any product sales.
 
Reverse Stock Split
  
On October 18, 2022, at a special meeting of stockholders, or the Special Meeting, our stockholders approved a proposal authorizing our board of directors, 
in its discretion, to effect a reverse stock split of our outstanding shares of common stock at a ratio ranging from 1-for-6 to 1-for-12 to be determined by the 
board of directors in its discretion following the Special Meeting and prior to the Company’s annual meeting of stockholders to be held in 2023. On 
October 19, 2022, our board of directors approved a 1-for-10 reverse stock split of our outstanding common stock. A Certificate of Amendment to the 
Amended and Restated Certificate of Incorporation effecting the reverse stock split was filed with the Secretary of State of the State of Delaware on 
October 19, 2022 and the reverse stock split became effective at 5:00 p.m., Eastern Time, on October 19, 2022. At the effective time, every 10 shares of 
common stock issued and outstanding was automatically reclassified into one new share common stock without any action on the part of the holders. No 
fractional shares of common stock were issued in the reverse stock split, but in lieu thereof, each holder of common stock who would otherwise have been 
entitled to a fraction of a share in the reverse stock split received a cash payment. Proportionate adjustments were made to the exercise prices and the 
number of shares underlying the Company’s outstanding equity awards, as applicable, and warrants exercisable for shares of common stock, as well as to 
the number of shares issuable under the Company’s equity incentive plans and certain existing agreements. The common stock issued pursuant to the 
reverse stock split remain fully paid and non-assessable. The reverse stock split affected all stockholders of our common stock uniformly, and did not affect 
any stockholder’s percentage of ownership interest. Unless otherwise noted, all share and per share information included in this Annual Report on Form 
10-K has been adjusted to give effect to the reverse stock split.
  
The reverse stock split did not affect the number of authorized shares of common stock or the par value of our common stock.
 

 
83
Components of Our Results of Operations 
Research and Development Expenses
Research and development expenses consist primarily of costs incurred for the development of our drug candidates, which include: 
•
personnel-related expenses, including salaries, benefits, severance, and stock-based compensation for personnel contributing to research and 
development activities;
•
laboratory expenses including supplies and services;
•
clinical trial expenses;
•
expenses incurred under agreements with third-party contract manufacturing organizations, contract research organizations, research and 
development service providers, academic research institutions, and consultants;
•
expenses related to license and sponsored research agreements; and 
•
facilities and other allocated expenses, including expenses for rent and facilities maintenance, and depreciation and amortization. 
We expect our research and development expenses to increase as we advance our drug candidates into and through preclinical and clinical trials and pursue 
regulatory approval of our drug candidates. The process of conducting the clinical trials required to obtain regulatory approval is costly and time-
consuming. Clinical trials generally become larger and more costly to conduct as they advance into later stages, and we are required to make estimates for 
expense accruals related to clinical trial expenses. The actual probability of success for our drug candidates may be affected by a variety of factors 
including: the safety and efficacy of our drug candidates, early clinical data, investment in our clinical program, the ability of collaborators, if any, to 
successfully develop any drug candidates we license to them, competition, manufacturing capability and commercial viability. We may never succeed in 
achieving regulatory approval for any of our drug candidates. Program costs that are direct external expenses are tracked on a program-by-program basis 
once they enter clinical studies. As a result of the uncertainties discussed above, we are unable to determine the duration and completion costs of our 
research and development projects or when and to what extent we will generate revenue from the commercialization and sale of our drug candidates.
General and Administrative Expenses
Our general and administrative expenses consist primarily of personnel costs, allocated facilities costs and other expenses for outside professional services, 
including legal, audit and accounting services, and depreciation and amortization expense related to property and equipment. Personnel costs consist of 
salaries, benefits, severance, and stock-based compensation. We expect to continue to incur additional expenses associated with operating as a public 
company, including expenses related to compliance with the rules and regulations of the Securities and Exchange Commission and standards applicable to 
companies listed on a national securities exchange, additional insurance expenses, investor relations activities, and other administrative and professional 
services. 
Interest Income 
Interest income is primarily related to interest earned on our marketable securities.  
Interest Expense
Interest expense relates to interest on the Hercules Loan Agreement (as defined below) entered into on August 3, 2020 which was subsequently 
extinguished on September 6, 2023.

 
84
Gain or Loss on Warrant Liability 
Gain or loss is primarily related to the non-cash changes in the estimated fair value of the warrants associated with the Follow-On Offering of our common 
stock in August 2022 and the Inducement Offer in November 2023.
 
Impairment of long-lived assets
	
Impairment charges relate to the right-of-use asset and related leasehold improvements upon subleasing our office space located in South San Francisco, 
California.
Other Expense, Net
 
Other expense, net includes property and other taxes and foreign exchange losses from payments to international vendors, and sale of laboratory equipment.
In 2023, Other expense, net included, in addition to the items above, the debt extinguishment loss associated with the unamortized debt discount. 
Results of Operations
Comparison of the Years Ended December 31, 2024 and 2023
The following table sets forth the significant components of our results of operations (in thousands):
 
 
 
Year ended December 31,
   
 
 
 
 
2024
   
2023
   
Change
 
Summary of Operations Data:
 
    
    
   
Operating expenses:
 
    
    
   
Research and development
  $
13,006    $
20,099    $
(7,093)
General and administrative
   
15,460     
18,966     
(3,506)
Impairment of long-lived assets
   
2,705     
5,602     
(2,897)
Total operating expenses
   
31,171     
44,667     
(13,496)
Loss from operations
   
(31,171)    
(44,667)    
13,496 
Interest income
   
1,733     
2,874     
(1,141)
Interest expense
   
—     
(2,452)    
2,452 
Gain (loss) on warrant liability
   
3,713     
6,215     
(2,502)
Other expense, net
   
(265)    
(1,830)    
1,565 
Net loss
  $
(25,990)   $
(39,860)   $
13,870 
Research and Development
Research and development expenses decreased by $7.1 million, to $13.0 million for the year ended December 31, 2024 from $20.1 million for 
the year ended December 31, 2023. The decrease was primarily due to decreases of $3.5 million in personnel costs due to our reduced headcount and the 
reduction in force, $2.7 million in direct research and development expenses mainly due to the completion of our UBX1325 BEHOLD and ENVISION 
studies, and $0.9 million in facilities-related costs primarily due to the sublease of our East Grand facility.
General and Administrative
General and administrative expenses decreased by $3.5 million, to $15.5 million for the year ended December 31, 2024 from $19.0 million for 
the year ended December 31, 2023. The decrease was primarily due to decreases of $2.5 million in personnel costs due to our reduced headcount and 
reduction in force, $0.4 million in professional fees, and $0.6 million in facilities-related costs primarily due to the sublease of our East Grand facility.

 
85
 
Impairment of Long-Lived Assets
 
Impairment charges consisted of impairment of long-lived assets. During the year ended December 31, 2024, we recorded an impairment charge
of $2.7 million after evaluating the right-of-use asset and related leasehold improvements upon ongoing vacancy in our office space. In December 31, 2023, 
we recorded an impairment charge of $5.6 million after evaluating the right-of-use asset and related leasehold improvements upon subleasing our office 
space located in South San Francisco, California. 
 
Interest Income 
Our interest income was $1.7 million for the year ended December 31, 2024, as compared to $2.9 million for the year ended December 31, 2023.
The decrease is primarily attributable to continued decreases in market yields during the year and the total interest bearing instruments held. 
 
Interest Expense
Our interest expense of $2.4 million for the year ended December 31, 2023, was related to the Hercules Loan Agreement. We did not have 
interest expense for the year ended December 31, 2024.
 
Gain or Loss on Warrant Liability
 
Our unrealized gain was $3.7 million and $6.2 million for the years ended December 31, 2024 and 2023, respectively. Gain is attributable to the 
subsequent non-cash changes in the estimated fair value of the warrants associated with the Follow-On Offering of our common stock in August 2022 and 
the Inducement Offering in November 2023.
Other Expense, Net
Other expense, net, was $0.3 million for the year ended December 31, 2024 which comprised of $0.3 million in property and other taxes. Other 
expense, net, was $1.8 million for the year ended December 31, 2023 which includes $1.0 million in issuance costs and loss on extinguishment of Existing 
Warrants, $0.5 million in debt extinguishment loss associated with the unamortized debt discount, and $0.3 million in property and other taxes. 
Comparison of the years ended December 31, 2023 and 2022
The following table sets forth the significant components of our results of operations (in thousands): 
 
 
 
Year ended December 31,
   
 
 
 
 
2023
    2022 (Restated)    
Change
 
Summary of Operations Data:
 
    
    
   
Licensing revenue – related party
  $
—    $
236    $
(236)
Operating expenses:
 
    
    
   
Research and development
   
20,099     
36,859     
(16,760)
General and administrative
   
18,966     
20,949     
(1,983)
Impairment of long-lived assets
   
5,602     
—     
5,602 
Total operating expenses
   
44,667     
57,808     
(13,141)
Loss from operations
   
(44,667)    
(57,572)    
12,905 
Interest income
   
2,874     
1,220     
1,654 
Interest expense
   
(2,452)    
(3,558)    
1,106 
Gain (loss) on warrant liability
   
6,215     
16,843     
(10,628)
Other expense, net
   
(1,830)    
(1,402)    
(428)
Net loss
  $
(39,860)   $
(44,469)   $
4,609 
 

 
86
Licensing Revenue – Related Party
In December 2021, we entered into a licensing agreement with Jocasta Neuroscience, Inc. (“Jocasta”) pursuant to which we exclusively licensed all of our 
rights to UBX2089, our α-Klotho asset. The agreement provided for an upfront fee of $5.0 million. We recognized revenue of zero and $0.2 million for the 
years ended December 31, 2023 and 2022, respectively, related to the delivery of the know-how performance obligation under the license agreement 
entered into with Jocasta in December 2021.
Research and Development
Research and development expenses decreased by $16.8 million, to $20.1 million for the year ended December 31, 2023 from $36.9 million for the year 
ended December 31, 2022. The decrease was primarily due to decreases of $7.3 million in direct research and development expenses mainly due to the 
completion of our UBX1325 BEHOLD and ENVISION studies, $7.2 million in personnel costs due to our reduced headcount and reduction in force, $2.0 
million in facilities-related costs primarily due to the sublease of our East Grand facility, and $0.3 million in laboratory supplies.
General and Administrative
General and administrative expenses decreased by $1.9 million, to $19.0 million for the year ended December 31, 2023 from $21.0 million for the year 
ended December 31, 2022. The decrease was primarily due to decreases of $2.5 million in personnel costs due to our reduced headcount and reduction in 
force, partially offset by an increase of $0.6 million in professional fees.
 
Impairment of Long-Lived Assets
 
Impairment charges consisted of impairment of long-lived assets. During the year ended December 31, 2023, we recorded an impairment charge of $5.6 
million after evaluating the right-of-use asset and related leasehold improvements upon subleasing our office space located in South San Francisco, 
California. There were no impairment charges during the year ended December 31, 2022. 
 
Interest Income 
Our interest income was $2.9 million for the year ended December 31, 2023, as compared to $1.2 million for the year ended December 31, 2022. The 
increase is primarily attributable to continued increases in market yields during the year. 
 
Interest Expense
Our interest expense of $2.4 million and $3.5 million for the years ended December 31, 2023 and 2022, respectively, was related to the Hercules Loan 
Agreement. 
 
Gain or Loss on Warrant Liability
 
Our unrealized gain was $6.2 million and $16.8 million for the years ended December 31, 2023 and 2022, respectively. Gain is attributable to the 
subsequent non-cash changes in the estimated fair value of the warrants associated with the Follow-On Offering of the Company’s common stock in 
August 2022 and the Inducement Offering in November 2023.
Other Expense, Net
Other expense, net, was $1.8 million for the year ended December 31, 2023 which includes $1.0 million in issuance costs and loss on extinguishment of 
Existing Warrants, $0.5 million in debt extinguishment loss associated with the unamortized debt discount, and $0.3 million in property and other taxes. 
Other expense was immaterial for the year ended December 31, 2022 which includes $0.2 million in recognized gains resulting from the extinguishment of 
the 

 
87
derivative related to long term debt and $0.1 million from the gains on sale of assets, offset by $0.3 million property and other tax expense.
Liquidity, Capital Resources and Capital Requirements
Sources of Liquidity
We have incurred net losses each year since inception. We do not have any products approved for sale and have never generated any revenue from product 
sales. Historically, we have incurred operating losses as a result of ongoing efforts to develop our drug candidates, including conducting ongoing research 
and development, preclinical studies and providing general and administrative support for these operations. Our net losses were $26.0 million and $39.9 
million for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024, we had an accumulated deficit of $510.3 million, and we 
do not expect positive cash flows from operations in the foreseeable future. Our future viability is dependent on our ability to raise additional capital to
finance our operations. Although we have been successful in raising capital in the past, there is no assurance that we will be successful in obtaining such 
additional financing. If sufficient funds on acceptable terms are not available when needed, we could be further required to significantly reduce our 
operating expenses and delay, reduce the scope of, or eliminate our lead development program. Failure to manage discretionary spending or raise additional 
financing, as needed, may adversely impact our ability to achieve our intended business objectives, or we may be forced to liquidate assets where possible, 
cease operations or file for bankruptcy protection. 
Based on our current operating plans, we expect our existing capital resources will fund our planned operating expenses into the fourth quarter of 2025, 
which will be used to advance UBX1325. Since our capital resources will fund operations less than 12 months from the date of this Annual Report on Form 
10-K, we concluded that these conditions raise substantial doubt about our ability to continue as a going concern. 
While our financial statements have been prepared assuming that we will continue to operate as a going concern, which contemplates the realization of 
assets and the satisfaction of liabilities in the normal course of business, and have successful development of UBX1325, which is in early stages of clinical 
development, we will need to raise additional funds.
There is no assurance that funding will be available to us, will be obtained on terms favorable to us or will provide us with sufficient funds to meet our 
objectives. Failure to raise additional financing may adversely impact our ability to achieve our intended business objectives because without substantial 
additional capital, we may not be able to complete pivotal trials necessary to advance our product development and our programs. If we become unable to 
continue as a going concern, we may have to liquidate our assets and the values we receive for our assets in liquidation or dissolution could be significantly 
lower than the values reflected in our financial statements, and maybe sooner than the fourth quarter of 2025.
We expect to incur operating losses and negative operating cash flows over at least the next several years as we continue our research and development 
activities, advance our drug candidate through preclinical and clinical testing and move into later and more costly stages of drug development, hire 
personnel and prepare for regulatory submissions and the commercialization of our drug candidates.
As a result, we will need to raise additional capital to finance its operations. Adequate funding may not be available to us on acceptable terms, or at all, 
particularly in light of the economic uncertainty, and potential for local and/or global economic recession. Further, if banks and financial institutions enter 
receivership or become insolvent in the future in response to financial conditions affecting the banking system and financial markets, our ability to access 
our existing cash, cash equivalents, and marketable securities may be threatened, which could have a material adverse effect on our business and financial 
condition. 
Further, based on our public float, as of the date of the filing of this Annual Report on Form 10-K, we are only permitted to utilize a shelf registration 
statement, including the registration statements under which our ATM Offering Programs are operated, subject to Instruction I.B.6 to Form S-3, which is 
referred to as the “baby shelf” rule. For so long as our public float is less than $75.0 million, we may not sell more than the equivalent of one-third of our 
public 

 
88
float during any 12 consecutive months pursuant to the baby shelf rules. Although alternative public and private transaction structures may be available, 
these may require additional time and cost, may impose operational restrictions on us, and may not be available on attractive terms. Failure to manage 
discretionary spending or raise additional financing, as needed, may adversely impact our ability to achieve our intended business objectives because 
without substantial additional capital, we may not be able to complete pivotal trials necessary to advance our product development and our programs.
We have historically financed our operations primarily through private placements of preferred stock and promissory notes, as well as public equity 
issuances, such as our initial public offering, and more recently through proceeds from the Hercules Loan Agreement, our prior and existing at-the-market 
offering programs, the Equity Purchase Agreement (as defined below), and the sale of common stock and warrants in the Follow-On Offering and the 
Inducement Offer (each as defined above) and we will continue to be dependent upon equity and/or debt financing to operate our business until we are able 
to generate positive cash flows from our operations.
In August 2020, we entered into a Loan and Security Agreement, as amended, restated, supplemented or otherwise modified, the "Hercules Loan 
Agreement") with Hercules Capital, Inc., or Hercules, as administrative agent and collateral agent for the lenders, and certain banks and other financial 
institutions or entities from time to time parties thereto, for an aggregate principal amount of up to $80.0 million secured term loan facility, or the Hercules 
Facility, subject to certain terms and conditions. $25.0 million was advanced to us on the date of execution of the Hercules Loan Agreement. In August 
2022, we met certain clinical and capital raising milestones, which extended the interest only period to March 2023. On January 25, 2023, we entered into a 
second amendment to the Hercules Loan Agreement whereas the amortization date was extended from March 1, 2023 to April 1, 2023. As such, we 
continued to make interest only payments up to the amended amortization date and were required to repay the principal balance and interest in equal 
monthly installments through August 1, 2024. In December 2021, we entered into an amendment to the Hercules Loan Agreement under the terms of 
which, Hercules (including any of its assignees) had the option for a period of six (6) months to convert up to $5.0 million of the outstanding principal 
under the existing loan into shares of our common stock. Under this amendment, the required cash reserve amount would be reduced by the principal 
amount of the converted loan to not less than $10 million. As of December 31, 2022, we had issued 435,497 shares of our common stock reducing our 
outstanding loan principal balance by $5.0 million and reducing the required cash reserve to $10 million. In addition, the interest-only period could extend 
an additional three months to June 1, 2023 if specific milestones related to our clinical trials and raising additional capital by April 1, 2023 were met; 
however, we did not meet all these criteria such that the amortization date remained April 1, 2023. There were no material adverse events in connection 
with the Hercules Loan Agreement. 
In September 2023, we and Hercules entered into a payoff letter for a voluntary prepayment with respect to the Hercules Loan Agreement, or the Payoff 
Letter. Pursuant to the Payoff Letter, we paid a total of $15.0 million to Hercules, representing the outstanding principal, accrued and unpaid interest, fees, 
costs and expenses due to Hercules under the Hercules Facility and the Hercules Loan Agreement and related loan documents, in repayment of our 
outstanding obligations under the Hercules Facility and the Hercules Loan Agreement and related loan documents, and thereby terminated the Hercules 
Loan Agreement and the Hercules Facility and related loan documents. 
 
On August 22, 2022, we closed an underwritten offering, or the Follow-On Offering, in which we issued and sold an aggregate of 6,428,571 shares of 
common stock together with warrants, or the Warrants, to purchase an up to aggregate of 6,428,572 shares of common stock at an offering price of $7.00 
per unit. The Warrants have an exercise price of $8.50 per share underlying the Warrant. The gross proceeds to us were approximately $45 million.
On November 9, 2023, we entered into an Inducement Offer with certain Holders of Existing Warrants to purchase up to an aggregate of 2,143,000 shares 
of common stock, which warrants were issued to the Holders on August 22, 2022, having an exercise price of $8.50 per share. The Holders agreed to 
exercise for cash their Existing Warrants to purchase an aggregate of 2,143,000 shares of common stock at a reduced exercise price of $2.045 per share in 
consideration of our agreement to issue New Warrants to purchase up to an aggregate of 2,143,000 shares of New Warrant Shares. Each New Warrant has 
an exercise price equal to $1.92 per share. We received aggregate gross proceeds of approximately $4.4 million from the Exercise, before deducting 
placement agent fees and other offering expenses payable by us. We also issued to the placement agent, H.C. Wainwright & Co., LLC, warrants to 
purchase up to 128,580 shares of common stock with an exercise price equal to $2.5563 per share. We expect to use the net proceeds from the Inducement 
Offer for working capital, operating expenses to include clinical trial progression, and 

 
89
general corporate purposes. The New Warrant Shares were registered on a Registration Statement on Form S-3 filed on December 6, 2023 pursuant to the 
terms of the Inducement Offer. 
Future Funding Requirements
To date we have not generated any product revenue. We expect to continue to incur significant losses for the foreseeable future, and we expect the losses to 
increase as we continue the development of, and seek regulatory approvals for, our drug candidates, and begin to commercialize any approved products. 
We are subject to all of the risks typically related to the development of new drug candidates, and we may encounter unforeseen expenses, difficulties, 
complications, delays, and other unknown factors that may adversely affect our business. Moreover, since becoming a public company, we continue to 
incur additional ongoing costs associated with operating as a public company. We anticipate that we will need substantial additional funding in connection 
with our continuing operations.  
Until we can generate a sufficient amount of revenue from the commercialization of our drug candidates or from collaborative agreements with third 
parties, if ever, we expect to finance our future cash needs through various means. We do not have any committed external source of funds. Additional 
capital may be raised through the sale of our equity securities through our ATM Offering Programs or otherwise, incurring debt, entering into licensing or 
collaboration agreements with partners, receiving research contributions, grants or other sources of financing to fund our operations. There can be no 
assurance that sufficient funds will be available to us on attractive terms or at all. If we are unable to obtain additional funding from these or other sources, 
it may be necessary to significantly reduce our rate of spending through reductions in staff and delaying, scaling back, or stopping certain research and 
development programs. Insufficient liquidity may also require us to relinquish rights to drug candidates at an earlier stage of development or on less 
favorable terms than we would otherwise choose.
We have based our projections of operating capital requirements on assumptions that may prove to be incorrect, and we may use all our available capital 
resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development, and commercialization of 
biotechnology products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on 
many factors, including, but not limited to:
•
the results of our ongoing clinical trials of UBX1325 (foselutoclax);
•
our ability to reduce our operating expenses;
•
the scope, progress, results and costs of researching and developing our drug candidates, and conducting preclinical studies and clinical 
studies;
•
potential delays in or an increase in costs associated with our ongoing or planned preclinical studies or clinical trials;
•
the timing of, and the costs involved in, obtaining regulatory approvals for our current drug candidates or any future drug candidates;
•
the number and characteristics of any additional drug candidates we develop or acquire;
•
the timing and amount of any milestone payments we are required to make pursuant to our license agreements;
•
the cost of manufacturing our current drug candidates or any future drug candidates and any products we successfully commercialize;
•
the cost of commercialization activities if our current drug candidates or any future drug candidates are approved for sale, including 
marketing, sales and distribution costs;
•
our ability to maintain existing, and establish new, strategic collaborations, licensing or other arrangements and the financial terms of any 
such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement;
•
any product liability or other lawsuits related to our products;
•
the costs associated with being a public company;

 
90
•
the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing our intellectual property portfolio;
•
our ability to utilize our ATM Offering Programs and raise additional capital;
•
whether or not we can maintain compliance with the continued listing requirements of Nasdaq; and
•
the timing, receipt and amount of sales of any future approved products, if any.
Cash Flows
The following table sets forth a summary of the primary sources and uses of cash and restricted cash for each of the periods presented below (in 
thousands):
 
 
 
Year ended December 31,
 
 
 
2024
   
2023
    2022 (Restated)  
Cash used in operating activities
  $
(20,865)   $
(37,088)   $
(52,414)
Cash provided by (used in) investing activities
   
8,565     
60,495     
(24,545)
Cash provided by (used in) financing activities
   
77     
(16,340)    
56,240 
Net increase (decrease) in cash and
   restricted cash
  $
(12,223)   $
7,067    $
(20,719)
Operating Activities
Cash used in operating activities of $20.9 million for the year ended December 31, 2024 consisted primarily of a net loss of $26.0 million adjusted for net 
non-cash charges of $1.8 million and net changes to our operating assets and liabilities of $3.3 million. Our non-cash charges consisted primarily of $4.0 
million in stock-based compensation, $2.7 million in impairment of long-lived assets, and $0.9 million in depreciation and amortization, partially offset by 
$3.7 million in gain on the warrant liability,  $1.3 million in non-cash rent expense, and $0.8 million in net accretion and amortization of premium and 
discounts on marketable securities. The net change in our operating assets and liabilities primarily consisted of decreases of $2.4 million in prepaid 
expenses combined with increases of $1.2 million in accrued liabilities and other current liabilities and $0.2 million in accrued compensation, partially 
offset by decreases of $0.5 million in accounts payable.
Cash used in operating activities of $37.1 million for the year ended December 31, 2023 consisted primarily of a net loss of $39.9 million adjusted for net 
non-cash charges of $7.2 million and net changes to our operating assets and liabilities of $4.4 million. Our non-cash charges consisted primarily of $7.4 
million in stock-based compensation, $5.6 million in impairment of long-lived assets, $1.2 million in depreciation and amortization, $0.7 million in 
amortization of debt issuance costs, $0.7 million in extinguishment loss and issuance costs on the warrants, and $0.5 million in debt extinguishment loss, 
partially offset by $6.2 million in gain on the warrant liability, $1.5 million in net accretion and amortization of premium and discounts on marketable 
securities, $1.1 million in non-cash rent expense, and $0.1 million in gain on the disposal of property and equipment. The net change in our operating assets 
and liabilities primarily consisted of increases of $1.7 million in prepaid expenses combined with decreases of $1.2 million in accrued compensation, $1.1 
million in accrued liabilities and other current liabilities, and $0.4 million in accounts payable.
Cash used in operating activities of $52.4 million for the year ended December 31, 2022 consisted primarily of a net loss of $44.5 million adjusted for net 
non-cash charges of $6.9 million and net changes to our operating assets and liabilities of $1.0 million. Our non-cash charges consisted primarily of $9.4 
million in stock-based compensation, $2.2 million in depreciation and amortization, and $1.3 million in amortization of debt issuance costs, partially offset 
by a $16.9 million unrealized gain on the warrant liability, $2.1 million in non-cash rent expense, $0.3 million in net accretion and amortization of premium 
and discounts on marketable securities, $0.3 million gain from disposal of property and equipment and $0.2 million gain from the extinguishment of the
derivative related to long term debt. The net change in our operating assets and liabilities primarily consisted of decreases of $1.0 million in accrued 

 
91
compensation, and $0.2 million in accounts payable, partially offset by decreases of $0.1 million in prepaid expenses and other current assets and $0.1 
million in other long-term assets. 
Investing Activities
Cash provided by investing activities of $8.6 million for the year ended December 31, 2024 was related to   maturities of marketable securities of $32.3 
million, partially offset by purchases of marketable securities of $23.7 million.
Cash provided by investing activities of $60.5 million for the year ended December 31, 2023 was related to   maturities of marketable securities of $89.0 
million and the sale of property and equipment of $0.1 million, partially offset by purchases of marketable securities of $28.6 million.
Cash used in investing activities of $24.5 million for the year ended December 31, 2022 was related to   purchases of marketable securities of $98.8 million 
and property and equipment of $0.1 million, partially offset by maturities of marketable securities of $74.0 million and the sale of $0.4 million of property 
and equipment.
Financing Activities
Cash used by financing activities of $0.1 million for the year ended December 31, 2024 was related to $0.1 million in proceeds from the issuance of 
common stock under the 2018 Employee Stock Purchase Plan.
Cash used by financing activities of $16.3 million for the year ended December 31, 2023 was related to $20.0 million principal repayment of long-term 
debt and $1.5 million of term loan issuance costs, partially offset by $4.4 million in proceeds from issuance of common stock and warrants from the 
Inducement Offer, $0.7 million in proceeds from the sale of common stock through our ATM Offering Program, net of issuance costs, and $0.1 million in 
proceeds from the issuance of common stock under the 2018 Employee Stock Purchase Plan.
Cash provided by financing activities of $56.2 million for the year ended December 31, 2022 was related to $45.0 million in proceeds from issuance of 
common stock and warrants from our Follow-On Offering, $12.2 million in proceeds from the sale of common stock through our ATM Offering Program, 
net of issuance costs, $0.9 million in proceeds from issuance of common stock to Lincoln Park Capital Fund, net of issuance costs, and $0.1 million in 
proceeds from the issuance of common stock under the 2018 Employee Stock Purchase Plan, partially offset by $2.0 million of issuance costs for the sale 
of common stock.
Contractual Obligations and Other Commitments 
Our contractual obligations and commitments relate primarily to our operating leases and non-cancelable purchase obligations under agreements 
with various research and development organizations and suppliers in the ordinary course of business. See Note 9, “Commitments and Contingencies” to 
our financial statements for further information. 
We are party to various license agreements pursuant to which we have in-licensed rights to various technologies, including patents, research 
“know-how” and proprietary research tools, for the discovery, research, development and commercialization of drug candidates to treat age-related 
diseases. The license agreements obligate us to make certain milestone payments related to specified clinical development and sales milestone events, as 
well as tiered royalties in the low-single digits based on sales of licensed products. See Note 6 to our financial statements “License Revenue, Agreements 
and Strategic Investment” for additional information. 
Indemnification
In the normal course of business, we enter into contracts and agreements that contain a variety of representations and warranties and provide for general 
indemnifications. Our exposure under these agreements is unknown because it involves claims that may be made against us in the future but have not yet 
been made. To date, we have not paid any claims or been required to defend any action related to our indemnification obligations. However, we may record 
charges in the future as a result of these indemnification obligations.

 
92
In accordance with our certificate of incorporation and bylaws, we have potential indemnification obligations to our officers and directors for specified 
events or occurrences, subject to some limits, while they are serving at our request in such capacities. There have been no claims to date, and we have 
director and officer insurance that may enable us to recover a portion of any amounts paid for future potential claims.
Off-Balance Sheet Arrangements
We have not entered into any off-balance sheet arrangements. 
Critical Accounting Policies and Estimates 
This discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in 
accordance with accounting principles generally accepted in the United States, or GAAP. The preparation of these financial statements requires us to make 
estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the 
financial statements, as well as the reported expenses incurred during the reporting periods. These items are monitored and analyzed by us for changes in 
facts and circumstances, and material changes in these estimates could occur in the future. Our estimates are based on our historical experience and on 
various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying 
value of assets and liabilities that are not readily apparent from other sources. Changes in estimates are reflected in reported results for the period in which 
they become known. Actual results may differ from these estimates under different assumptions or conditions. 
While our significant accounting policies are described in more detail in the notes to our financial statements included elsewhere in this prospectus, we 
believe that the following accounting policies are critical to understanding our historical and future performance, as these policies relate to the more 
significant areas involving management’s judgments and estimates. 
Research and Development Expenses and Accruals 
Costs related to research and development of drug candidates are charged to research and development expense as incurred. Research and development 
costs include, but are not limited to, payroll and personnel expenses for personnel contributing to research and development activities, laboratory supplies, 
outside services, licenses acquired to be used in research and development, manufacturing of clinical material, pre-clinical testing and consultants and 
allocated overhead, including rent, equipment, depreciation and utilities. Research and development costs are expensed as incurred unless there is an 
alternative future use in other research and development projects. Payments made prior to the receipt of goods or services to be used in research and 
development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Such payments are 
evaluated for current or long-term classification based on when they will be realized.
As part of the process of preparing our financial statements, we are required to estimate expenses resulting from our obligations under contracts with 
vendors and consultants and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to 
negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are 
provided under such contracts. Our objective is to reflect the appropriate expenses in our financial statements by matching those expenses with the period 
in which services and efforts are expended. We account for these expenses according to the progress of the production of clinical trial materials or based on 
progression of the clinical trial, as measured by patient progression and the timing of various aspects of the trial. We determine accrual estimates by taking 
into account discussion with applicable personnel and outside service providers as to the progress or state of consummation of goods and services, or the 
services completed. 
During the course of a clinical trial, we adjust the rate of expense recognition if actual results differ from our estimates. We make estimates of accrued 
expenses as of each balance sheet date in our financial statements based on the facts and circumstances known at that time. Our clinical trial accrual is 
dependent in part upon the timely and accurate reporting of contract research organizations, contract manufacturers and other third-party vendors. Although 
we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed 
relative to the actual status and timing of services performed may vary and may result 

 
93
in our reporting changes in estimates in any particular period. Adjustments to prior period estimates have not been material for the years ended December 
31, 2024 and 2023.
 
We provide enhanced transparency into key research and development initiatives, including expected timelines, projected expenditures, and potential risks 
associated with our drug development programs. We consider the impact of macroeconomic factors, regulatory changes, and competitive market conditions 
that may influence the pace and cost of our research and development efforts. Furthermore, we disclose any significant funding arrangements, government 
grants, or collaborations that materially affect our research and development investment strategy.
 
We continuously assess our research and development cost structure and expenditure trends to ensure alignment with corporate objectives and financial 
sustainability. Future expenses may be influenced by the outcome of clinical trials, regulatory approvals, and commercialization strategies. Any material 
deviations from our projected research and development expenditures are disclosed in our financial statements along with a discussion of underlying factors
contributing to such variances.
Warrant Liabilities
 
We have issued freestanding warrants to purchase shares of our common stock. Our outstanding common stock warrants are classified as liabilities in the 
balance sheet and are measured at fair value. We use the Monte Carlo option pricing model to value warrants, which requires management to estimate 
inputs including the probability of a fundamental transaction, expected volatility and the estimated term to exercise. These inputs are inherently subjective 
and require judgment to develop. The fair value of all warrants is re-measured at each financial reporting date with any changes in fair value being 
recognized as a gain or loss on warrant liability, in the Statements of Operations and Comprehensive Loss. 
Stock-Based Compensation 
We recognize compensation costs related to stock-based awards granted based on the estimated fair value of the awards on the date of grant, and we 
recognize forfeitures as they occur. For awards that vest solely based on service conditions or a combination of service and performance conditions, we 
estimate the grant date fair value, and the resulting stock-based compensation expense, using the Black-Scholes option-pricing model. The grant date fair 
value of the awards is generally recognized on a straight-line basis over the requisite service period, which is typically their vesting period. We recognize 
forfeitures as they occur. 
The market traded price of the shares of common stock underlying the stock-based awards is the fair value of our stock as reported on the Nasdaq Global 
Select Market on the grant date.
We have also granted stock options to certain key employees that vest in conjunction with certain market conditions. The Company uses the Monte-Carlo 
option-pricing model to estimate the fair value of stock option awards that contain only market conditions. The Monte-Carlo option pricing model uses 
similar input assumptions as the Black-Scholes model; however, it further incorporates into the fair-value determination the possibility that the market 
condition may not be satisfied.
For stock-based awards subject to ratable vesting, we recognize compensation cost on a straight-line basis over the service period for the entire award. In 
future periods, our stock-based compensation expense is expected to increase as a result of recognizing our existing unrecognized stock-based 
compensation for awards that will vest and as we issue additional stock-based awards to attract and retain our employees.

 
94
Recent Accounting Pronouncements 
See Note 3 to our Financial Statements “Summary of Significant Accounting Policies” for information. 
Item 7A. Quantitative and Qualitative Disclosures About Market Risk. 
Cash, Cash Equivalents and Marketable Securities
We are exposed to market risks in the ordinary course of our business. These risks primarily relate to interest rate sensitivities. We had cash, cash 
equivalents, and marketable securities of $23.2 million as of December 31, 2024, which consist of bank deposits, money market funds, and marketable 
securities. The primary objective of our investment activities is to preserve capital to fund our operations. We also seek to maximize income from our 
investments without assuming significant risk. Because our investments are primarily short-term in duration, we believe that our exposure to interest rate 
risk is not significant, and a 1% movement in market interest rates would not have a significant impact on the total value of our portfolio.
 
 

 
95
Item 8. Financial Statements and Supplementary Data. 
 
UNITY BIOTECHNOLOGY, INC. 
Index to Financial Statements
 
 
 
 
 
Page
 
   
Report of Independent Registered Public Accounting Firm (PCAOB ID 42)
 
96
 
 
 
Balance Sheets
 
98
 
 
 
Statements of Operations and Comprehensive Loss
 
99
 
 
 
Statements of Stockholders’ Equity
 
100
 
 
 
Statements of Cash Flows
 
101
 
 
 
Notes to the Financial Statements
 
102
 

 
96
Report of Independent Registered Public Accounting Firm
To the Stockholders and the Board of Directors of Unity Biotechnology, Inc. 
 
Opinion on the Financial Statements 
 
We have audited the accompanying balance sheets of Unity Biotechnology, Inc.  (the Company) as of December 31, 2024 and 2023, the related statements 
of operations and comprehensive loss, stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2024, and the 
related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the 
financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the 
period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.
The Company's Ability to Continue as a Going Concern
The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the 
financial statements, the Company has suffered recurring losses from operations, and has stated that substantial doubt exists about the Company’s ability to 
continue as a going concern. Management's evaluation of the events and conditions and management’s plans regarding these matters are also described in 
Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Basis for Opinion 
 
These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial 
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) 
(PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and 
regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable 
assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor 
were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of 
internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over 
financial reporting. Accordingly, we express no such opinion.
Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and 
performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in 
the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as 
evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
Critical Audit Matters 
 
The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or 
required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) 
involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion 
on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical 
audit matters or on the accounts or disclosures to which they relate.
 

 
97
 
Valuation of warrant liability
 
Description of the Matter
As discussed in Note 12 to the financial statements, the Company has issued warrants to purchase shares of its common 
stock in connection with financing activities. The Company accounted for the issuance of warrants as liabilities on the 
balance sheets and measures the warrants at fair value. The Company's warrant liability as of December 31, 2024 totaled 
$2.2 million. 
Auditing the fair value of the warrant liability was complex because of the probabilities associated with the occurrence of a 
prospective fundamental transaction used in the fair valuation of the warrant liability. 
How We Addressed the 
Matter in Our Audit
To test the Company’s fair value of warrants, our audit procedures included, among others, utilizing our valuation 
specialists to assist in evaluating the reasonableness of the Company’s valuation methodology and assumptions. Our 
procedures to test the probabilities of a fundamental transaction included reviewing the meeting minutes of those charged 
with governance, obtaining corroborative external evidences such as press releases of the Company, performing inquiries 
with Company executives and Board of Directors, and assessing consistency of the information with evidence obtained in 
other areas of our audit.
 
 
Impairment of Long-Lived Assets 
Description of the Matter
As discussed in Note 9 to the financial statements, the Company’s long-lived assets are assessed for recoverability 
whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. When 
indicators of impairment exist, the Company compares the estimated future undiscounted net cash flows to the carrying 
amount of the asset. If the carrying amount of the asset exceeds the future undiscounted cash flows, an impairment is 
measured based on the difference between the carrying amount of the asset and its fair value. An indicator of impairment 
was identified for the year ended December 31, 2024. As a result, the Company recorded an impairment charge of $2.7 
million for its right-of-use asset and related leasehold improvements. 
Auditing the Company’s impairment model was challenging due to the subjective assumption of market rental rates used 
as an input in determining the fair value of the right-of-use asset and related leasehold improvements.
How We Addressed the 
Matter in Our Audit
To test the Company’s accounting for the impairment over the right-of-use asset and related leasehold improvements, our 
audit procedures included, among others, utilizing our valuation specialists to assist in evaluating the reasonableness of the 
Company’s valuation methodology and the market rental rate assumption, performing an evaluation of market rental rates 
by benchmarking to other properties of similar type and within the geographic area, and testing the completeness and 
accuracy of the inputs within the model.
 
/s/ Ernst & Young LLP 
We have served as the Company’s auditor since 2017. 
San Mateo, California 
March 7, 2025

 
98
UNITY BIOTECHNOLOGY, INC. 
Balance Sheets 
(in thousands, except for share amounts and par value) 
 
 
 
December 31,
 
 
 
2024
   
2023
 
Assets
 
    
   
Current assets:
 
    
   
Cash and cash equivalents
 
$
7,580   
$
19,803 
Short-term marketable securities
 
 
15,650   
 
23,398 
Prepaid expenses and other current assets
 
 
1,037   
 
3,404 
Total current assets
 
 
24,267   
 
46,605 
Property and equipment, net
 
 
3,456   
 
5,082 
Operating lease right-of-use asset
 
 
8,900   
 
12,981 
Long-term restricted cash
 
 
896   
 
896 
Other long-term assets
 
 
143   
 
126 
Total assets
 
$
37,662   
$
65,690 
Liabilities and Stockholders’ Equity
 
    
   
Current liabilities:
 
    
   
Accounts payable
 
$
997   
$
1,380 
Accrued compensation
 
 
2,096   
 
1,841 
Accrued and other current liabilities
 
 
6,167   
 
4,619 
Total current liabilities
 
 
9,260   
 
7,840 
Operating lease liability, net of current portion
 
 
19,709   
 
23,539 
Warrant liability
 
 
2,199   
 
5,913 
Total liabilities
 
 
31,168   
 
37,292 
Commitments and contingencies (Note 9)
 
    
   
Stockholders’ equity:
 
    
   
Convertible preferred stock, $0.0001 par value; 10,000,000 shares
   authorized; no shares issued and outstanding
 
 
—   
 
— 
Common stock, $0.0001 par value; 300,000,000 shares
   authorized as of December 31, 2024 and 2023; 16,865,201 
   and 16,784,969 shares issued and outstanding as of 
   December 31, 2024 and 2023, respectively
 
 
2   
 
2 
Additional paid-in capital
 
 
516,820   
 
512,773 
Accumulated other comprehensive gain (loss)
 
 
15   
 
(24)
Accumulated deficit
 
 
(510,343)  
 
(484,353)
Total stockholders’ equity
 
 
6,494   
 
28,398 
Total liabilities and stockholders’ equity
 
$
37,662   
$
65,690 
 
See accompanying notes to the financial statements. 

 
99
UNITY BIOTECHNOLOGY, INC. 
Statements of Operations and Comprehensive Loss 
(in thousands, except share and per share amounts)
 
 
 
Year ended December 31,
 
 
 
2024
   
2023
   
2022 (Restated)
 
Licensing revenue – Related Party
  $
—    $
—    $
236 
Operating expenses:
 
    
    
   
Research and development
   
13,006     
20,099     
36,859 
General and administrative
   
15,460     
18,966     
20,949 
Impairment of long-lived assets
   
2,705     
5,602     
— 
Total operating expenses
   
31,171     
44,667     
57,808 
Loss from operations
   
(31,171)    
(44,667)    
(57,572)
Interest income
   
1,733     
2,874     
1,220 
Interest expense
   
—     
(2,452)    
(3,558)
Gain on warrant liability
   
3,713     
6,215     
16,843 
Other expense, net
   
(265)    
(1,830)    
(1,402)
Net loss
  $
(25,990)   $
(39,860)   $
(44,469)
Other comprehensive gain (loss)
 
    
    
   
Unrealized gain (loss) on marketable debt securities
   
39     
227     
(207)
Comprehensive loss
  $
(25,951)   $
(39,633)   $
(44,676)
Net loss per share, basic and diluted
  $
(1.54)   $
(2.70)   $
(4.68)
Weighted average number of shares used in computing 
net loss per share, basic and diluted 
   
16,827,038     
14,773,612     
9,494,421 
 
(1)  The Company effected a reverse stock split of its outstanding shares of common stock on October 19, 2022 where every ten shares of its common stock issued and outstanding was converted 
into one share of common stock. Any fractional post-split shares as a result of the reverse split were rounded up to the nearest whole post-split share. Shareholders of the Company previously 
authorized the Board of Directors to approve a reverse stock split at the annual meeting on October 18, 2022. All share amounts and per share amounts disclosed in this Annual Report on Form 
10-K have been restated to reflect the reverse stock split on a retroactive basis in all periods presented.
 
See accompanying notes to the financial statements.
(1)

 
100
 UNITY BIOTECHNOLOGY, INC. 
Statements of Stockholders’ Equity
(in thousands, except share amounts) 
 
 
 
Common Stock 
   
Additional
Paid-In
   
Accumulated
Other
Comprehensive
   
Accumulated
   
Total
Stockholders’
 
 
 
Shares
   
Amount
   
Capital
   
Gain (Loss)
   
Deficit
   
Equity
 
Balances at December 31, 2021
   
6,299,158     $
1     $
459,636     $
(44 )   $
(400,024 )   $
59,569  
Issuance of common stock, net of issuance costs, 
  under ATM equity offering program
   
1,019,046      
—      
12,155      
—      
—      
12,155  
Sale of common stock under Follow-On Offering, net of
   issuance costs (Restated)
   
6,428,571      
—      
15,426      
—      
—      
15,426  
Issuance of common stock to Lincoln Park 
   Capital Fund, net of issuance costs
   
90,000      
—      
910      
—      
—      
910  
Issuance of common stock to Hercules Capital,
   net of issuance costs
   
262,761      
—      
3,179      
—      
—      
3,179  
Issuance of common stock under 2018 ESPP
   
25,482      
—      
142      
—      
—      
142  
Vesting of restricted stock units
   
90,284      
—      
—      
—      
—      
—  
Stock-based compensation
   
—      
—      
9,379      
—      
—      
9,379  
Unrealized loss on available-for-sale marketable 
   securities
   
—      
—      
—      
(207 )    
—      
(207 )
Net loss (Restated)
   
—      
—      
—      
—      
(44,469 )    
(44,469 )
Balances at December 31, 2022 (Restated)
   
14,215,302     $
1     $
500,827     $
(251 )   $
(444,493 )   $
56,084  
Issuance of common stock, net of issuance costs, 
  under ATM equity offering program
   
274,781      
—      
725      
—      
—      
725  
Issuance of common stock under the warrant inducement 
   agreement, net of issuance costs
   
2,143,000      
1      
3,686      
—      
—      
3,687  
Issuance of common stock under 2018 ESPP
   
57,419      
—      
116      
—      
—      
116  
Vesting of restricted stock units
   
94,467      
—      
—      
—      
—      
—  
Stock-based compensation
   
—      
—      
7,419      
—      
—      
7,419  
Unrealized gain on available-for-sale marketable 
   securities
   
—      
—      
—      
227      
—      
227  
Net loss
   
—      
—      
—      
—      
(39,860 )    
(39,860 )
Balances at December 31, 2023
   
16,784,969     $
2     $
512,773     $
(24 )   $
(484,353 )   $
28,398  
Repurchase of early exercised shares
   
(3,336 )    
—      
—      
—      
—      
—  
Issuance of common stock under 2018 ESPP
   
61,448      
—      
77      
—      
—      
77  
Vesting of restricted stock units
   
22,120      
—      
—      
—      
—      
—  
Stock-based compensation
   
—      
—      
3,970      
—      
—      
3,970  
Unrealized gain on available-for-sale marketable 
   securities
   
—      
—      
—      
39      
—      
39  
Net loss
   
—      
—      
—      
—      
(25,990 )    
(25,990 )
Balances at December 31, 2024
   
16,865,201     $
2     $
516,820     $
15     $
(510,343 )   $
6,494  
 
(1) The Company effected a reverse stock split of its outstanding shares of common stock on October 19, 2022 where every ten shares of its common stock issued and outstanding was converted 
into one share of common stock. Any fractional post-split shares as a result of the reverse split were rounded down to the nearest whole post-split share. Shareholders of the Company previously 
authorized the Board of Directors to approve a reverse stock split at the annual meeting on October 18, 2022. All share amounts and per share amounts disclosed in this Annual Report on Form 
10-K have been restated to reflect the reverse stock split on a retroactive basis in all periods presented.
 
See accompanying notes to the financial statements.
(1)

 
101
UNITY BIOTECHNOLOGY, INC. 
Statements of Cash Flows 
(in thousands) 
 
 
 
Year ended December 31,
 
 
 
2024
   
2023
   
2022 (Restated)
 
Operating activities
 
     
     
   
Net loss
 
$
(25,990 )  
$
(39,860 )   $
(44,469 )
Adjustments to reconcile net loss to net cash used in operating activities:
 
     
     
   
Depreciation and amortization
 
 
867    
 
1,182      
2,180  
Amortization of debt issuance costs
 
 
—    
 
705      
1,318  
Debt extinguishment loss upon paydown of principal
 
 
—    
 
491      
—  
Debt extinguishment gain upon conversion to equity
 
 
—    
 
—      
(199 )
Net accretion and amortization of premium and discounts on marketable securities
 
 
(751 )  
 
(1,503 )    
(276 )
Gain on disposal of property and equipment
 
 
(23 )  
 
(114 )    
(346 )
Stock-based compensation
 
 
3,970    
 
7,419      
9,379  
Non-cash rent expense
 
 
(1,320 )  
 
(1,072 )    
(2,136 )
Impairment of long-lived assets
 
 
2,705    
 
5,602      
—  
Gain on warrant liability
 
 
(3,714 )  
 
(6,215 )    
(16,843 )
Extinguishment loss and non-cash issuance costs on warrant
 
 
—    
 
668      
—  
Changes in operating assets and liabilities:
 
     
     
   
Prepaid expenses and other current assets
 
 
2,367    
 
(1,664 )    
138  
Other long-term assets
 
 
(17 )  
 
(74 )    
39  
Accounts payable
 
 
(383 )  
 
(410 )    
(194 )
Accrued compensation
 
 
255    
 
(1,180 )    
(1,008 )
Accrued liabilities and other current liabilities
 
 
1,169    
 
(1,063 )    
26  
Other long-term liabilities
 
 
—    
 
—      
(23 )
Net cash used in operating activities
 
 
(20,865 )  
 
(37,088 )    
(52,414 )
Investing activities
 
     
     
   
Purchase of marketable securities
 
 
(23,711 )  
 
(28,609 )    
(98,827 )
Maturities of marketable securities
 
 
32,250    
 
89,000      
74,000  
Sale of property and equipment
 
 
26    
 
115      
378  
Purchase of property and equipment
 
 
—    
 
(11 )    
(96 )
Net cash provided by (used in) investing activities
 
 
8,565    
 
60,495      
(24,545 )
Financing activities
 
     
     
   
Payment of debt principal
 
 
—    
 
(20,000 )    
—  
Payment of debt issuance costs
 
 
—    
 
(1,563 )    
—  
Proceeds from issuance of common stock under ATM offering program, 
   net of issuance costs
 
 
—    
 
725      
12,155  
Proceeds from sale of common stock and warrants under Follow-On Offering
 
 
—    
 
—      
45,000  
Issuance costs for sale of common stock
 
 
—    
 
—      
(1,967 )
Proceeds from the issuance of common stock and warrants under the warrant 
   inducement agreement
 
 
—    
 
4,382      
—  
Proceeds from issuance of common stock to Lincoln Park Capital Fund, 
   net of issuance costs
 
 
—    
 
—      
910  
Proceeds from issuance of common stock under the 2018 ESPP
 
 
77    
 
116      
142  
Net cash provided by (used in) financing activities
 
 
77    
 
(16,340 )    
56,240  
Net increase (decrease) in cash, cash equivalents and restricted cash
 
 
(12,223 )  
 
7,067      
(20,719 )
Cash, cash equivalents and restricted cash at beginning of year
 
 
20,699    
 
13,632      
34,351  
Cash, cash equivalents and restricted cash at end of year
 
$
8,476    
$
20,699     $
13,632  
Supplemental Disclosures of Cash Flow Information:
 
     
     
   
Cash paid for interest
 
$
—    
$
1,969     $
2,204  
Supplemental Disclosures of Non-Cash Investing and Financing Activities
 
     
     
   
Issuance of common shares in payment of debt
 
$
—    
$
—     $
3,179  
 
See accompanying notes to the financial statements. 

 
102
UNITY BIOTECHNOLOGY, INC.
NOTES TO THE FINANCIAL STATEMENTS 
1. Organization 
Description of Business 
Unity Biotechnology, Inc. (the “Company”) is a biotechnology company engaged in the research and development of therapeutics to slow, halt, or reverse 
diseases of aging. The Company devotes substantially all of its time and efforts to performing research and development. The Company’s headquarters are 
located in South San Francisco, California. The Company was incorporated in the State of Delaware in 2009.
Liquidity
 
The Company’s financial statements have been prepared assuming that the Company will continue as a going concern, which requires the Company to 
continue successfully developing UBX1325, which is in Phase 2  of clinical development. This assumption contemplates the realization of assets and the 
settlement of liabilities and commitments in the normal course of business. 
 
The Company has incurred operating losses and has an accumulated deficit as a result of ongoing efforts to develop drug product candidates, including
conducting preclinical and clinical trials and providing general and administrative support for these operations. The Company had an accumulated deficit of 
$510.3 million as of December 31, 2024. During the year ended December 31, 2024, the Company incurred a net loss of $26.0 million and used $20.9 
million of cash in operating activities. To date, none of the Company’s drug product candidates have been approved for sale; therefore, the Company has 
not generated any product revenue. The Company anticipates operating losses and negative operating cash flows to continue for the foreseeable future. The 
Company has financed its operations primarily through private placements of preferred stock and promissory notes, public equity issuances and more 
recently, from its ATM Offering Programs, the sale of common stock and warrants under a Follow-On Offering and the Inducement Offer and will 
continue to be dependent upon equity and/or debt financing until the Company is able to generate positive cash flows from its operations.
The Company had cash, cash equivalents, and marketable securities of $23.2 million as of December 31, 2024. The Company expects that its cash, cash 
equivalents, and marketable securities as of December 31, 2024 will not be sufficient to fund its current business plan including related operating 
expenditure requirements through at least 12 months from the date of issuance of these financial statements are filed with the Securities and Exchange 
Commission (“SEC”). These conditions raise substantial doubt about the Company’s ability to continue as going concern. 
The Company plans to seek to address this condition by raising additional capital to finance its operations. Although the Company has been successful in 
raising capital in the past, there is no assurance that it will be successful in obtaining such additional financing. If sufficient funds on acceptable terms are 
not available when needed, the Company could be further required to significantly reduce its operating expenses and delay, reduce the scope of, or
eliminate one or more of its development programs. Failure to manage discretionary spending or raise additional financing, as needed, may adversely 
impact the Company’s ability to achieve its intended business objectives, or the Company may be forced to liquidate assets where possible, or to cease 
operations or file for bankruptcy protection. It is not considered probable that the Company’s plans to raise additional capital nor reduce discretionary 
spending will alleviate the substantial doubt regarding its ability to continue as a going concern. 
 
2. Restatement of Previously Issued Financial Statements
 
The Company has restated herein its audited financial statements for the fiscal year ended December 31, 2022, in accordance with Accounting Standards 
Codification (“ASC”) Topic 250, Accounting Changes and Error Corrections. In March 2024, the Company concluded the warrants issued in 2022 were 
incorrectly classified as equity and should have been recorded as liabilities. 
 
Historically, the Existing Warrants were reflected as a component of equity as opposed to liabilities on the Balance Sheet. Additionally, the Statements of 
Operations and Comprehensive Loss did not include changes in the fair value of the Existing Warrants. The Company reassessed its accounting for the 
Existing Warrants and determined they should have been classified as liabilities and measured at fair value upon issuance with subsequent changes in fair 

 
103
value, as well as the issuance costs associated with the Existing Warrants, reported in the Company's Statement of Operations and Comprehensive Loss.

 
104
3. Summary of Significant Accounting Policies 
Basis of Presentation 
These financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and 
the rules and regulations of the SEC. 
 
The Company effected a reverse stock split on October 19, 2022 of its outstanding shares of common stock at a ratio of 1-for-10 pursuant to a Certificate of 
Amendment to the Company's Certificate of Incorporation filed with the Secretary of State of the State of Delaware. The reverse stock split was reflected 
on the Nasdaq Global Select Market beginning with the opening of trading on October 20, 2022. Accordingly, an amount equal to the par value of the 
decreased shares resulting from the reverse stock split was reclassified from "Additional paid-in capital" to "Common stock". Any fractional post-split 
shares as a result of the reverse stock split were rounded down to the nearest whole post-split share. The reverse stock split did not change the par value of 
the Company's common stock or the authorized number of shares of the Company's common stock. All share amounts and per share amounts disclosed in 
this Annual Report on Form 10-K have been restated to reflect the reverse stock split on a retroactive basis in all periods presented.
 
Warrants
 
The Company determines the accounting classification of warrants that are issued, as either liability or equity, by first assessing whether the warrants meet 
liability classification in accordance with ASC 480-10, Distinguishing Liabilities from Equity, and then in accordance with ASC 815-40, Accounting for 
Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock. Under ASC 480-10, warrants are considered liability 
classified if the warrants are mandatorily redeemable, obligate the issuer to settle the warrants or the underlying shares by paying cash or other assets, or 
must or may require settlement by issuing variable number of shares.
 
If warrants do not meet liability classification under ASC 480-10, the Company assesses the requirements under ASC 815-40, which states that contracts 
that require or may require the issuer to settle the contract for cash are liabilities recorded at fair value, irrespective of the likelihood of the transaction 
occurring that triggers the net cash settlement feature. If the warrants do not require liability classification under ASC 815-40, in order to conclude equity 
classification, the Company assesses whether the warrants are indexed to its common stock and whether the warrants are classified as equity under ASC 
815-40 or other applicable principles of GAAP. After all relevant assessments are made, the Company concludes whether the warrants are classified as 
liability or equity. Liability classified warrants are required to be accounted for at fair value both on the date of issuance and on subsequent accounting 
periods with changes in fair value recorded in the Statements of Operations and Comprehensive Loss under "Gain or (loss) on warrant liability".
 
If warrants are issued together with the sale of common stock, for the issuance costs that are not specifically attributed to either the common stock or 
warrants issued, the Company allocates the issuance costs between the common stock and warrants based on their relative fair value. The Company 
expenses issuance costs allocated to the warrants that are classified as liabilities and the issuance costs allocated to common stock or warrants that are 
classified as equity are recognized as reduction to the equity.
 
Use of Estimates 
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts 
reported in the financial statements and accompanying notes. The Company bases its estimates on historical experience and market-specific or other 
relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s balance sheets 
and the amount of expenses and income reported for each of the periods presented are affected by estimates and assumptions, which are used for, but are 
not limited to, determining the fair value of assets and liabilities, the fair value of right-of-use assets and lease liabilities, and stock-based compensation. 
Actual results could differ from such estimates or assumptions.
Estimating fair values of liability-classified financial instruments requires the development of estimates that may, and are likely to, change over the 
duration of the instrument with related changes in internal and external market factors. As liability-classified financial instruments are initially and 
subsequently carried at fair value, the Company’s financial results will reflect the volatility in these estimate and assumption changes. Changes in estimated 
fair value are recognized as a component of "Gain (loss) on warrant liability" in the Statements of Operations and Comprehensive Loss.

 
105
Segments 
The Company has one operating segment and one reportable segment. The Company’s chief operating decision maker (CODM), its Chief Executive 
Officer, manages the Company’s operations on a consolidated basis for the purposes of allocating resources. The Company’s method for measuring 
profitability on a reportable segment basis is net profit or loss. Additional significant segment expenses are provided on a quarterly basis to the CODM to 
support the CODM’s decision making process. Refer to Note 18 for additional information.
 Cash, Cash Equivalents, and Restricted Cash 
The Company considers all highly liquid investments with original maturities of 90 days or less from the date of purchase to be cash equivalents. Cash 
equivalents primarily include money market funds that invest in U.S. Treasury obligations which are stated at fair value. 
The Company has issued letters of credit under its lease agreements which have been collateralized. This cash is classified as noncurrent restricted cash on 
the balance sheet based on the term of the underlying lease. 
The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheets that sum to the total of the 
same amounts shown in the statements of cash flows (in thousands).
 
 
 
December 31,
 
 
 
2024
   
2023
   
2022
 
Cash and cash equivalents
  $
7,580   $
19,803   $
12,736 
Restricted cash
   
896    
896    
896 
Total cash, cash equivalents, and restricted cash
  $
8,476   $
20,699   $
13,632 
Marketable Securities 
The Company generally invests its excess cash in investment grade, short to intermediate-term, fixed income securities. Such investments are considered 
available-for-sale debt securities and reported at fair value with unrealized gains and losses included as a component of stockholders’ equity. Marketable 
securities with original maturities of greater than 90 days from the date of purchase but less than one year from the balance sheet date that are available to 
be converted into cash to fund current operations are classified as short-term, while marketable securities with maturities in one year or beyond one year 
from the balance sheet date are classified as long-term. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of 
discounts to maturity, which is included in "Interest income" on the Statements of Operations and Comprehensive Loss. Realized gains and losses and 
declines in value judged to be other-than-temporary, if any, on marketable securities are included in "Other expense, net". The cost of securities sold is
determined using the specific identification method.
The Company periodically evaluates whether declines in fair values of its marketable securities below their book value are other-than-temporary. This 
evaluation consists of several qualitative and quantitative factors regarding the severity and duration of the unrealized loss as well as the Company’s ability 
and intent to hold the marketable security until a forecasted recovery occurs. Additionally, the Company assesses whether it has plans to sell the security or 
it is more likely than not it will be required to sell any marketable securities before recovery of its amortized cost basis. Factors considered include quoted 
market prices, recent financial results and operating trends, implied values from any recent transactions or offers of investee securities, credit quality of 
debt instrument issuers, other publicly available information that may affect the value of the marketable security, duration and severity of the decline in 
value, and management’s strategy and intentions for holding the marketable security. To date, the Company has not recorded any impairment charges on its 
marketable securities related to other-than-temporary declines in market value. 
Fair Value Measurements
The Company’s financial instruments during the periods presented consist of cash and cash equivalents, restricted cash, marketable securities, strategic 
investments, prepaid expenses and other current assets, accounts payable, accrued compensation, accrued and other current liabilities, derivative liabilities 
related to debt and long-term debt. Fair value estimates of these instruments are made at a specific point in time, based on relevant market information. 
Level 3 instruments incorporate certain unobservable inputs such as the selected discount rate of the related loan. These estimates may be subjective in 
nature and involve uncertainties and matters of judgment. 

 
106
Revenue Recognition 
The Company recognizes revenue in accordance with the provisions of Accounting Standards Codification Topic 606, Revenue from Contracts with 
Customers, or Topic 606. In determining the appropriate amount and timing of revenue to be recognized under this guidance, the Company performs the 
following five steps: (i) identifies the contract(s) with our customer; (ii) identifies the promised goods or services in the agreement and determine whether 
they are performance obligations, including whether they are distinct in the context of the agreement; (iii) measures the transaction price, including the 
constraint on variable consideration; (iv) allocates the transaction price to the performance obligations based on stand-alone selling prices; and (v) 
recognizes revenue when (or as) the Company satisfies each performance obligation. 
A performance obligation is a promise in an agreement to transfer a distinct good or service to the customer and is the unit of account in Topic 606. 
Significant management judgment is required to determine the level of effort required and the period over which completion of the performance obligations 
is expected under an agreement. If reasonable estimates regarding when performance obligations are either complete or substantially complete cannot be 
made, then revenue recognition is deferred until a reasonable estimate can be made. Revenue is then recognized over the remaining estimated period of 
performance using the cumulative catch-up method.
The Company allocates the total transaction price to each performance obligation based on the estimated relative stand-alone selling prices of the promised 
goods or services underlying each performance obligation. The total consideration which the Company expects to collect in exchange for the Company’s 
products is an estimate and may be fixed or variable. The Company constrains the estimated variable consideration when it assesses it is probable that a 
significant reversal in the amount of cumulative revenue recognized may occur in future periods. The transaction price is re-evaluated, including the 
estimated variable consideration included in the transaction price and all constrained amounts, in each reporting period and as uncertain events are resolved 
or other changes in circumstances occur. The allocation of the transaction price is performed based on standalone selling prices, which are based on 
estimated amounts that the Company would charge for a performance obligation if it were sold separately. Revenue is recognized when, or as, performance 
obligations in the contracts are satisfied, in the amount reflecting the expected consideration to be received from the goods or services transferred to the 
customers. Consideration received in advance are recorded as deferred revenue and are recognized as the related performance obligation is satisfied.
 
Following is a description of the principal activities from which the Company generates revenue. License revenue primarily represent amounts earned 
under agreements that license our intellectual property to other companies. See Note 5, “License Revenue, Agreements and Strategic Investment” for 
further detail. Consideration under these contracts generally includes a nonrefundable upfront payment, development, regulatory and commercial 
milestones and royalties based on net sales of approved products. 
 
Licenses of Intellectual Property. If the Company determines the license to intellectual property is distinct from the other performance obligations 
identified in the agreement and the licensee can use and benefit from the license, the Company recognizes revenue from the estimated transaction price that 
is allocated to the license. Licensing arrangements are analyzed to determine whether the promised goods or services, which may include licenses, transfer 
of know-how, transfer of materials, research and development services and governance committee services, are distinct or whether they must be accounted 
for as part of a combined performance obligation. If the license is considered not to be distinct, the license would then be combined with other promised 
goods or services as a combined performance obligation. If the Company is involved in a governance committee, it assesses whether its involvement 
constitutes a separate performance obligation. When governance committee services are determined to be separate performance obligations, the Company 
determines the fair value to be allocated to this promised service.
 
Milestone Payments: At the inception of each agreement that includes milestone payments, the Company evaluates whether the milestones are considered 
probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a 
significant revenue reversal would not occur, the value of the associated milestone is included in the transaction price. For milestones that the Company do 
not deem to be probable of being achieved, the associated milestone payments are fully constrained and the value of the milestone is excluded from the 
transaction price with no revenue being recognized. For example, milestone payments that are not within our control, such as regulatory-related 
accomplishments, are not considered probable of being achieved until those accomplishments have been communicated by the relevant regulatory 
authority. Once the assessment of probability of achievement becomes probable, the Company recognizes revenue for the milestone payment. At each 
reporting date, the Company assesses the probability of achievement of each milestone under our current agreements.
 

 
107
Royalties. For agreements with sales-based royalties, including milestone payments based on the level of sales, where the license is deemed to be the 
predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the 
performance obligation, to which some or all of the royalty has been allocated, has been satisfied (or partially satisfied). At each reporting date, the 
Company estimates the sales incurred by each licensee during the reporting period based on historical experience and accrues the associated royalty 
amount.
Concentrations of Risk 
Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, restricted 
cash, and marketable securities. Substantially all of the Company’s cash and cash equivalents and restricted cash is deposited in accounts with financial 
institutions that management believes are of high credit quality. Such deposits have and will continue to exceed federally insured limits. The Company 
maintains its cash with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. The Company has not experienced 
any losses on its cash deposits. 
The Company’s investment policy limits investments in marketable securities to certain types of securities issued by the U.S. government, its agencies and 
institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to 
credit risk in the event of a default by the financial institutions holding its cash, cash equivalents, restricted cash and marketable securities and issuers of 
marketable securities to the extent recorded on the balance sheets. As of December 31, 2024 and 2023, the Company had no off-balance sheet 
concentrations of credit risk. 
The Company depends on third-party suppliers for key raw materials used in its manufacturing processes and is subject to certain risks related to the loss of 
these third-party suppliers or their inability to supply the Company with adequate raw materials. 
Research and Development Expenses and Accruals
Costs related to research, design, and development of drug candidates are charged to research and development expense as incurred. Research and 
development costs include, but are not limited to, payroll and personnel expenses for personnel contributing to research and development activities, 
laboratory supplies, outside services, licenses acquired to be used in research and development, manufacturing of clinical material, pre-clinical testing and 
consultants and allocated overhead, including rent, equipment, depreciation, and utilities. Research and development costs are expensed as incurred unless 
there is an alternative future use in other research and development projects. Payments made prior to the receipt of goods or services to be used in research 
and development are deferred and recognized as expense in the period in which the related goods are received or services are rendered. Such payments are 
evaluated for current or long-term classification based on when they will be realized.
As part of the process of preparing its financial statements, the Company is required to estimate expenses resulting from its obligations under contracts with 
vendors and consultants and clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts are subject to 
negotiations which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are 
provided under such contracts. The Company’s objective is to reflect the appropriate expenses in its financial statements by matching those expenses with 
the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the production of clinical 
trial materials or based on progression of the clinical trial, as measured by patient progression and the timing of various aspects of the trial. The Company 
determines accrual estimates by taking into account discussion with applicable personnel and outside service providers as to the progress or state of 
consummation of goods and services, or the services completed. 
During the course of a clinical trial, the rate of expense recognition is adjusted if actual results differ from the Company’s estimates. The Company makes 
estimates of accrued expenses as of each balance sheet date in its financial statements based on the facts and circumstances known at that time. The clinical 
trial accrual is dependent in part upon the timely and accurate reporting of contract research organizations, contract manufacturers, and other third-party 
vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding of the status and 
timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting changes in estimates in any 
particular period. Adjustments to prior period estimates have not been material for the years ended December 31, 2024 and 2023.

 
108
Property and Equipment, Net 
Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful 
lives of the respective assets, generally three years. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful
lives or the term of the lease. Depreciation and amortization begin at the time the asset is placed in service. Maintenance and repairs are charged to expense 
as incurred and costs of improvement are capitalized. 
Leases 
 
The Company determines whether the arrangement is or contains a lease at the inception of the arrangement and if so, whether such a lease is classified as a 
financing lease or an operating lease. Operating leases are included in operating lease right-of-use asset, (“ROU asset”), operating lease liabilities, net of 
current portion, and accrued and other current liabilities on the Company’s balance sheets. The Company has elected not to recognize on the balance sheets 
leases with terms of one year or less. Operating lease ROU assets represent the Company’s right to use an underlying asset for the lease term and are 
considered long-lived assets for purposes of identifying, recognizing and measuring impairment. Operating lease liabilities represent the Company’s 
obligation to make lease payments arising from the lease. Operating lease ROU assets and operating lease liabilities are recognized based on the present 
value of lease payments over the expected lease term. As the Company’s leases do not provide an implicit rate, the Company uses its incremental 
borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar 
economic environment, in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made or 
incentives received and impairment charges if the Company determines the ROU asset is impaired and excludes lease incentives. The Company’s lease 
terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options to extend or terminate 
the lease. Lease expense for lease payments is recognized on a straight-line basis over the lease term. 
The Company has elected to not separate lease and non-lease components for its leased assets and accounts for all lease and non-lease components of its 
agreements as a single lease component.  The lease components resulting in a ROU asset have been recorded on the balance sheets and are amortized as 
lease expense on a straight-line basis over the lease term.
The Company has subleased a majority of its South San Francisco, California facility under agreements considered to be operating leases according to ASC 
842. The Company has not been legally released from its primary obligations under the original leases and therefore it continues to account for the original 
leases as it did before commencement of the subleases. The Company records both fixed and variable payments received from the sublessee in its 
statements of operations on a straight-line basis as an offset to rent expense.
Impairment of Long-Lived Assets 
 
The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not 
be fully recoverable. If indicators of impairment exist and the undiscounted future cash flows that the assets are expected to generate are less than the 
carrying value of the assets, the Company reduces the carrying amount of the assets through an impairment charge, to their estimated fair value based on a 
discounted cash flow approach or, when available and appropriate, to comparable market values. See Note 9, “Commitments and Contingencies”.
 
Determining estimated discounted cash flows for purposes of an impairment analysis requires the Company to make estimates and assumptions regarding 
the amount of market rent, timing of sublease income, and risk-adjusted discount rates. There are often risks and uncertainties associated with the intent to 
sublease offices and laboratory space. Consequently, the eventual realized sublease income may vary from estimates as of the impairment testing date and 
adjustments may occur in future periods.
Stock-Based Compensation 
The Company measures compensation expense for all stock-based awards based on their grant date fair value. For stock-based awards with service 
conditions only, stock-based compensation expense is recognized over the requisite service period using the straight-line method. For awards with 
performance conditions, the Company evaluates the probability of achieving performance condition at each reporting date. The Company begins to 
recognize stock-based 

 
109
compensation expense using an accelerated attribution method when it is deemed probable that the performance condition will be met. Forfeitures are 
recognized as they occur. 
The Company uses the Black-Scholes option-pricing model to estimate the fair value of stock option awards that do not contain market conditions. The 
Black-Scholes option-pricing model requires the use of highly subjective assumptions to determine the fair value of stock-based awards. These 
assumptions include: 
•
Expected term—The expected term represents the period that the stock-based awards are expected to be outstanding. We use, due to 
insufficient historical data, the simplified method to determine the expected term, which is based on the average of the time-to-vesting and 
the contractual life of the options. 
•
Expected volatility—Due to our limited trading history for our common stock, the expected volatility is estimated based on the average 
historical volatilities of common stock of comparable publicly traded entities over a period equal to the expected term of the stock option 
grants. The comparable companies are chosen based on their size, stage in the product development cycle or area of specialty. We will 
continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes 
available. 
•
Risk-free interest rate—The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero-coupon U.S. 
Treasury notes with maturities approximately equal to the expected term of the awards. 
•
Expected dividend—We have never paid dividends on our common stock and have no plans to pay dividends on our common stock. 
Therefore, we used an expected dividend yield of zero. 
The Company has used the Monte-Carlo option-pricing model to estimate the fair value of stock option awards that contain only market conditions. The 
Monte-Carlo option pricing model uses similar input assumptions as the Black-Scholes model; however, it further incorporates into the fair-value 
determination the possibility that the market condition may not be satisfied.
Embedded Derivatives of the Loan Agreement
The Company measures derivative liability related to debt at fair value. Estimated fair value of the derivative liability related to debt, initially measured and 
recorded on the date of the amendment of the loan and security agreement, is considered to be a Level 3 instrument. The fair value of the derivative liability 
related to debt is based on the term loan principal, the date of maturity, the contractual term loan interest rate, the convertible discount factor, and the 
selected discount rate of the loan. The derivative liability related to debt is recorded at fair value at the end of each reporting period with changes in 
estimated fair values recognized as a component of "Other expense, net" in the Statements of Operations and Comprehensive Loss.
 
Restructuring
The Company recognizes restructuring charges related to reorganization plans that have been committed to by management and when liabilities have been 
incurred. In connection with these activities, the Company records restructuring charges at fair value for a) contractual employee termination benefits when 
obligations are associated to services already rendered, rights to such benefits have vested, and payment of benefits is probable and can be reasonably 
estimated, and b) one-time employee termination benefits when management has committed to a plan of termination, the plan identifies the employees and 
their expected termination dates, the details of termination benefits are complete, it is unlikely changes to the plan will be made or the plan will be 
withdrawn and communication to such employees has occurred.
 
One-time employee termination benefits are recognized in their entirety when communication has occurred, and future services are not required. Contract 
termination costs to be incurred over the remaining contract term without economic benefit are recorded in their entirety when the contract is canceled. 
 
The recognition of restructuring charges requires the Company to make certain judgments and estimates regarding the nature, timing and amount of costs 
associated with the planned reorganization plan. At the end of each reporting period, the Company evaluates the remaining accrued restructuring balances 
to ensure that no excess accruals are retained, and the utilization of the provisions are for their intended purpose in accordance with developed restructuring 
plans.

 
110
Income Taxes 
The Company uses the asset and liability method of accounting for income taxes, in which deferred tax assets and liabilities are recognized for future tax 
consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax 
bases. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary 
differences are expected to be reversed. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that 
includes the enactment date. A valuation allowance is established if it is more likely than not that all or a portion of the deferred tax asset will not be 
realized. 
The Company’s tax positions are subject to income tax audits. The Company recognizes the tax benefit of an uncertain tax position only if it is more likely 
than not that the position is sustainable upon examination by the taxing authority, based on the technical merits. The tax benefit recognized is measured as 
the largest amount of benefit which is more likely than not to be realized upon settlement with the taxing authority. The Company recognizes interest 
accrued and penalties related to unrecognized tax benefits in its tax provision. The Company evaluates uncertain tax positions on a regular basis. The 
evaluations are based on a number of factors, including changes in facts and circumstances, changes in tax law, correspondence with tax authorities during 
the course of the audit, and effective settlement of audit issues. The provision for income taxes includes the effects of any accruals that the Company 
believes are appropriate, as well as the related net interest and penalties. 
Net Loss per Common Share 
Basic net loss per share is calculated by dividing net loss by the weighted average number of shares outstanding for the period. Diluted net loss per share is 
calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding plus the effect of 
dilutive potential common shares outstanding during the period determined using the treasury-stock method.
In all periods presented, the Company’s outstanding stock options, convertible preferred stock, early exercised common stock subject to future vesting, 
warrants and presumed issuance of additional shares as contingent consideration were excluded from the calculation of diluted net loss per share because 
their effects were antidilutive.
Comprehensive Loss 
Comprehensive loss includes net loss and certain changes in stockholders’ equity that are excluded from net loss, primarily unrealized losses on the 
Company’s marketable securities.
Recently Adopted Accounting Pronouncements
 
In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) 2023-07, Segment Reporting (Topic 
280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which requires all public entities, including public entities with a single 
reportable segment, to provide in interim and annual periods one or more measures of segment profit or loss used by the chief operating decision maker to 
allocate resources and assess performance. Additionally, the standard requires disclosures of significant segment expenses and other segment items as well 
as incremental qualitative disclosures. The guidance in this update is effective for fiscal years beginning after December 15, 2023, and interim periods after 
December 15, 2024. We adopted ASU 2023-07 on January 1, 2024 and the adoption resulted in enhanced required disclosures, as described in Note 18, 
"Segment Reporting".
Recently Issued Accounting Pronouncements Not Yet Adopted 
 
In December 2023, the Financial Accounting Standards Board (FASB) issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax 
Disclosures, which enhances the disclosures required for income taxes in the Company’s annual financial statements. ASU 2023-09 is effective for the 
Company in its annual reporting for fiscal 2025 on a prospective basis. Early adoption and retrospective reporting are permitted. The Company does not 
plan to adopt this standard early. The adoption of this standard is not expected to have a material impact on the Company’s financial statements.
 
In November 2024, the Financial Accounting Standards Board (FASB) issued ASU 2024-03, Reporting Comprehensive Income (Topic 220): 
Disaggregation of Income Statement Expenses which requires disaggregated disclosure of income statement expenses for public entities. The ASU does not 
change the expense captions an 

 
111
entity presents on the face of the income statement; rather, it requires disaggregation of certain expense captions into specified categories in disclosures 
within the footnotes to the financial statements. ASU 2024-03 is effective for the Company in its annual reporting for fiscal 2025 on a prospective basis. 
The Company does not plan to adopt this standard early. The adoption of this standard is not expected to have a material impact on the Company’s 
financial statements.
4. Fair Value Measurements 
The Company determines the fair value of financial and non-financial assets and liabilities based on the assumptions that market participants would use in 
pricing the asset or liability in an orderly transaction between market participants at the measurement date. The identification of market participant 
assumptions provides a basis for determining what inputs are to be used for pricing each asset or liability. A fair value hierarchy has been established which 
gives precedence to fair value measurements calculated using observable inputs over those using unobservable inputs. This hierarchy prioritized the inputs 
into three broad levels as follows:
•
Level 1: Quoted prices in active markets for identical instruments 
•
Level 2: Other significant observable inputs (including quoted prices in active markets for similar instruments) 
•
Level 3: Significant unobservable inputs (including assumptions in determining the fair value of certain investments) 
The carrying amounts of financial instruments such as cash and cash equivalents, restricted cash, prepaid expenses and other current assets, accounts 
payable, accrued compensation, accrued and other current liabilities approximate to their related fair values due to the short-term nature of these
instruments.
The Company’s financial assets and liabilities subject to fair value measurements on a recurring basis and the level of inputs used in such measurements 
were as follows (in thousands):
 
 
 
December 31, 2024
 
 
 
Total
   
Level 1
   
Level 2
   
Level 3
 
Assets:
 
    
    
    
   
Cash equivalents:
 
    
    
    
   
Money market funds
  $
6,418    $
6,418    $
—    $
— 
Total cash equivalents
   
6,418     
6,418     
—     
— 
Short-term marketable securities:
 
    
    
    
   
U.S. treasuries
   
10,429     
—     
10,429     
— 
U.S. government debt securities
   
5,221     
—     
5,221     
— 
Total short-term marketable securities
   
15,650    
—    
15,650    
— 
Restricted Cash equivalents:
 
     
     
     
   
Money market funds
   
896     
896     
—     
— 
Total restricted cash equivalents
   
896     
896     
—     
— 
Total assets subject to fair value measurements
   on a recurring basis
  $
22,964    $
7,314    $
15,650    $
— 
 
 
    
    
    
   
Liabilities:
 
    
    
    
   
Warrant Liability
  $
2,199    $
—    $
—    $
2,199 
Total liabilities subject to fair value measurements
   on a recurring basis
   
2,199     
—     
—     
2,199 
 

 
112
 
 
 
December 31, 2023
 
 
 
Total
   
Level 1
   
Level 2
   
Level3
 
Assets:
 
    
    
    
   
Cash equivalents:
 
    
    
    
   
Money market funds
  $
12,864    $
12,864    $
—    $
— 
U.S. treasuries
   
2,989     
—     
2,989     
— 
Total cash equivalents
   
15,853     
12,864     
2,989     
— 
Short-term marketable securities:
 
    
    
    
   
U.S. treasuries
   
7,849     
—     
7,849     
— 
U.S. government debt securities
   
15,549     
—     
15,549     
— 
Total short-term marketable securities
   
23,398    
—    
23,398    
— 
Restricted Cash equivalents:
 
     
     
     
   
Money market funds
   
896     
896     
—     
— 
Total restricted cash equivalents
   
896     
896     
—     
— 
Total assets subject to fair value measurements
   on a recurring basis
  $
40,147    $
13,760    $
26,387    $
— 
 
 
    
    
    
   
Liabilities:
 
    
    
    
   
Warrant Liability
  $
5,913    $
—    $
—    $
5,913 
Total liabilities subject to fair value measurements
   on a recurring basis
   
5,913     
—     
—     
5,913 
 
The Company estimates the fair value of its money market funds, U.S. treasuries, and U.S. government debt securities by taking into consideration 
valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income and market-
based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate fair value. These inputs include reported trades of 
and broker/dealer quotes on the same or similar securities, issuer credit spreads; benchmark securities; prepayment/default projections based on historical 
data; and other observable inputs. See Note 5, “Marketable Securities,” for further information regarding the carrying value of the Company's financial 
instruments. 
 
August 2022 Warrants ("Existing Warrants")
The common stock warrants are classified as a liability on the Balance Sheets and are measured at fair value with the change in fair value recorded within 
“Gain (loss) on warrant liability” on the Statement of Operations and Comprehensive Loss. The estimated fair value of the outstanding common stock 
warrants was $0.8 million and $2.8 million as of December 31, 2024 and 2023, respectively.
 
The Company estimates the fair value of its warrant liability using a Monte Carlo simulation model based on significant inputs not observable in the 
market, which represents a Level 3 measurement. The Company used the following key assumptions within its valuation. In all scenarios, the Company 
also applied the likelihood of a fundamental transaction and the related impact on the Company’s common stock price and volatility.  
 
 
 
December 31, 2024
   
December 31, 2023
 
Common stock price
  $  
0.98 
 $  
1.93 
Exercise price per share
  $  
8.50 
 $  
8.50 
Expected volatility
   
 
90.0%  
  
80.0%
Risk-free interest rate
   
 
4.26%  
  
3.85%
Contractual term (in years)
   
 
2.64 
 
  
3.64 
November 2023 Inducement Offer ("New Warrants")
 
In November 2023, the Company issued common stock warrants to purchase an aggregate of 2,143,000 shares of common stock at an exercise price of 
$1.92 per warrant. Additionally, 128,580 common stock warrants were issued to the Placement Agent ("Placement Agent Warrants") at an exercise price of 
$2.5563 per warrant. The New Warrants and Placement Agent Warrants are recorded as a liability on the Balance Sheet and are adjusted to estimated fair 
value at period end within “Gain (loss) on warrant liability” on the Statement of Operations and Comprehensive Loss. The 

 
113
estimated fair value of the New Warrants was $1.4 million and $3.1 million as of December 31, 2024 and 2023, respectively.
 
The Company estimates the fair value of its Level 3 warrant liabilities using a Monte Carlo simulation model. The Company used the following key 
assumptions within its valuation. In all scenarios, the Company also applied the likelihood of a fundamental transaction and the related impact on the 
Company’s common stock price and volatility.  
 
 
 
December 31, 2024
   
December 31, 2023
 
Common stock price
  $  
0.98 
 $  
1.93 
Exercise price per share
  $
1.92-2.5563    $
1.92-2.5563  
Expected volatility
   
 
95.0%  
  
80.0%
Risk-free interest rate
   
 
4.32%  
  
3.85%
Contractual term (in years)
   
 
3.87 
 
  
4.87 
 
The following is a roll forward of the fair value of Level 3 warrants:
 
 
 
Warrant Liability 
Fair Value
 
Balance at December 31, 2022 (Restated)
 
$
10,765 
Warrants issued
 
 
2,724 
Warrants exercised
 
 
(1,361)
Gain from change in fair value
 
 
(6,215)
Balance at December 31, 2023
 
 
5,913 
Warrants issued
 
 
— 
Warrants exercised
 
 
— 
Gain from change in fair value
 
 
(3,714)
Balance at December 31, 2024
 
$
2,199 
 
5. Marketable Securities
Marketable securities, which are classified as available-for-sale, consisted of the following (in thousands):
 
 
 
December 31, 2024
 
 
 
Amortized
Cost Basis
   
Unrealized
Gains
   
Unrealized
Losses
   
Fair
Value
 
Cash equivalents:
 
    
    
    
   
Money market funds
  $
6,418    $
—    $
—    $
6,418 
Total cash equivalents
   
6,418     
—     
—     
6,418 
Short-term marketable securities:
 
    
    
    
   
U.S. treasuries
   
10,414     
16     
(1)    
10,429 
U.S. government debt securities
   
5,221     
3     
(3)    
5,221 
Total short-term marketable securities
   
15,635     
19     
(4)    
15,650 
Restricted Cash equivalents:
 
     
     
     
   
Money market funds
   
896     
—     
—     
896 
Total restricted cash equivalents
   
896     
—     
—     
896 
Total
  $
22,949    $
19    $
(4)   $
22,964 
 

 
114
 
 
 
December 31, 2023
 
 
 
Amortized
Cost Basis
   
Unrealized
Gains
   
Unrealized
Losses
   
Fair
Value
 
Cash equivalents:
 
    
    
    
   
Money market funds
  $
12,864    $
—    $
—    $
12,864 
U.S. treasuries
   
2,989     
—     
—     
2,989 
Total cash equivalents
   
15,853     
—     
—     
15,853 
Short-term marketable securities:
 
    
    
    
   
U.S. treasuries
   
7,853     
4     
(8)    
7,849 
U.S. government debt securities
   
15,570     
1     
(22)    
15,549 
Total short-term marketable securities
   
23,423     
5     
(30)    
23,398 
Restricted Cash equivalents:
 
     
     
     
   
Money market funds
   
896     
—     
—     
896 
Total restricted cash equivalents
   
896     
—     
—     
896 
Total
  $
40,172    $
5    $
(30)   $
40,147 
 
 
At December 31, 2024, the remaining contractual maturities of available-for-sale debt securities were less than a year. There have been no significant 
realized gains or losses on available-for-sale debt securities for the periods presented. As of December 31, 2024, the Company held two securities in an 
unrealized loss position and did not hold any individual securities in an unrealized loss position for 12 months or greater. The Company has the ability and 
intent to hold all marketable securities that have been in a continuous loss position until maturity or recovery. No significant facts or circumstances have 
arisen to indicate that there has been any significant deterioration in the creditworthiness of the issuers of the securities held by the Company. The 
Company considered the current and expected future economic and market conditions and determined that the estimate of credit losses was not 
significantly impacted. Thus, there has been no change in estimate of expected credit loss during the year ended December 31, 2024 and no allowance for 
credit loss was recorded at December 31, 2024.  The Company will continue to assess the current and expected future economic and market conditions as 
further development arises.
 
See Note 4, “Fair Value Measurements,” for further information regarding the fair value of the Company's financial instruments. 
6. License Revenue, Agreements and Strategic Investment
In accordance with the license agreements, the Company recognized revenue as follows:
 
 
 
Year ended December 31,
 
 
 
2024
   
2023
   
2022
 
Jocasta Neuroscience, Inc. 
  $
—   $
—   $
236 
 
  $
—   $
—   $
236 
 
Jocasta Neuroscience, Inc. was deemed a related party at the effective time the agreement was made on December 17, 2021.
License Agreement with Jocasta Neuroscience, Inc.
In December 2021, the Company signed a License Agreement with Jocasta Neuroscience, Inc. (“the Jocasta Agreement”) to exclusively license its rights in 
the α-Klotho asset for development and commercialization, and included a sublicense agreement under the original license agreement with the University 
of California, San Francisco. Under the Jocasta Agreement, the Company received a $5.0 million upfront cash payment from Jocasta Neuroscience, Inc. 
The Company may also receive additional payments based on development milestones, approval milestones, and 
(1)
(1)

 
115
sales-based royalties, per indication. The Jocasta agreement is recognized in accordance with ASC 606, Revenue from Contracts with Customers, and is 
classified under License Revenue.
Promises that the Company concluded were distinct performance obligations in the License Agreement included: (1) the license of intellectual property and 
delivery of know-how, and (2) the transfer of licensed compounds and materials.
In order to determine the transaction price, the Company evaluated all the payments to be received during the duration of the contract. Fixed consideration 
exists in the form of the upfront payment. Regulatory milestones and royalties were considered variable consideration. The estimated variable consideration 
is constrained until the Company determines it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur in 
future periods. Milestone payments are constrained and not included in the transaction price due to the uncertainties of research and development. The 
Company will re-evaluate the transaction price, including the estimated variable consideration included in the transaction price and all constrained 
amounts, in each reporting period and as uncertain events are resolved or other changes in circumstances occur. The Company determined that the initial 
transaction price consists of the upfront payment of $5.0 million. The allocation of the transaction price is performed based on standalone selling prices, 
which are based on estimated amounts that the Company would charge for a performance obligation if it were sold separately. The transaction price 
allocated to the license of intellectual property and delivery of know-how was recognized upon grant of license and delivery of know-how. The transaction 
price allocated the transfer of licensed compounds and materials, will be recognized over time as the materials are delivered. Consideration received in 
advance are recorded as deferred revenue and will be recognized as the performance obligations are satisfied. 
For each of the years ended December 31, 2024 and 2023, the Company had no license revenue related to the Jocasta Agreement. For the year ended 
December 31, 2022, the Company recognized $0.2 million of license revenue related to the Jocasta Agreement. The deferred revenue balance was zero for 
each of the years ended December 31, 2024, 2023 and 2022.
License Agreements with Research Institutions
In May 2019, the Company entered into a license agreement with The Regents of the University of California on behalf its San Francisco campus 
(collectively, “UCSF”) which provides the Company the rights to certain patents and related know-how to make, use, sell, offer for sale and import certain 
products and practice certain methods for use in the development of human therapeutics, which excludes the provision of services to third parties for 
consideration of any kind. The license to the Company is subject to UCSF’s reserved rights under the licensed intellectual property for educational and 
non-commercial research purposes and a requirement to substantially manufacture any licensed products in the United States. The Company is obligated to 
use diligent efforts to develop and obtain regulatory approval for at least one product commercialized pursuant to the agreement, and must meet certain 
regulatory and development milestones. The Company is obligated to pay an annual license maintenance fee and may be obligated to make milestone 
payments or issue up to an additional 3,400 shares of its common stock upon the occurrence of specified development events, up to aggregate milestone 
payments of $13.6 million for each product licensed under the agreement, and upon commercialization, to make royalty payments in the low single digit 
percentages (subject to a specified minimum annual royalty) based on net sales of products commercialized pursuant to the agreement. None of these 
events had occurred and no milestone payments or royalty payments had been recognized as of December 31, 2024. In December 2021, the Company 
entered an agreement to exclusively license its rights in the α-Klotho asset to Jocasta Neuroscience, Inc. for development and commercialization. Under the 
license agreement, Jocasta Neuroscience, Inc. is, in addition to the payments due to the Company, required to make all payments due to UCSF from the 
Company under the UCSF License. 
The Company has also entered into license agreements with various research institutions which have provided the Company with rights to patents, and in 
certain cases, research “know-how” and proprietary research tools to research, develop and commercialize drug candidates. In addition to upfront 
consideration paid to these various research institutions in either cash or shares of the Company’s common stock, the Company may be obligated to make 
milestone payments, payable in cash and/or the issuance of shares of the Company’s common stock upon achievement of certain specified clinical 
development and/or sales events. The contingent consideration liability considered to be a derivative associated with the potential issuance of common 
stock related to these license agreements was not 

 
116
significant at December 31, 2024 and 2023. To date, none of these events has occurred and no contingent consideration, milestone or royalty payments 
have been recognized.
Ascentage Commercial Agreements
The Company was a party to three agreements (the "Commercial Agreements") with Ascentage Pharma: (a) a compound library and option agreement 
executed in February 2016, the Library Agreement, granting the Company the right to research and nominate an active compound from Ascentage’s library 
of BCL compounds and subsequently nominate a development candidate from any active compound in order to begin GLP toxicology work for indications
outside of oncology, which expired in February 2022; (b) a license agreement executed in February 2016 granting the Company rights to an Ascentage 
Pharma compound known as APG1252, or the APG1252 License Agreement, which the Company terminated in July 2020 due to the Company’s decision 
to prioritize the progression of UBX1325; and (c) a second license agreement executed in January 2019 granting the Company world-wide rights to 
develop and commercialize UBX0601, the active parent molecule of our lead drug candidate UBX1325, outside of Greater China, or the Original BCL 
Agreement, for indications outside of oncology. 
The Commercial Agreements referenced above include cash payments of up to $70.3 million as well as the equity payments of up to an aggregate of (a) 
93,333 shares of common stock in the event there is only one licensed product, and (b) 133,333 shares of common stock in the event there are two or more 
licensed products, in each case to be issued based on the Company’s achievement of certain preclinical and clinical development and sales milestone 
events. The Company is required to make 80% of all equity payments to Ascentage Pharma and the remaining 20% to an academic institution from whom 
Ascentage Pharma had previously licensed the technology. The milestones include the advancement of additional compounds into Investigational New 
Drug application (“IND”) enabling studies, the filing of an IND, the commencement of clinical studies, Food and Drug Administration (“FDA”) and/or 
European Medicines Agency approval, and a net sales threshold. The Original BCL License Agreement also includes tiered royalties in the low-single 
digits based on sales of licensed products. To date, no royalties were due from the sales of licensed products. The Company issued no shares pursuant to 
these agreements during the year ended December 31, 2024. 
 
7. Balance Sheet Components 
 
Prepaid Expenses and Other Current Assets
 
Prepaid expenses and other current assets consist of the following (in thousands): 
 
 
 
December 31,
 
 
 
2024
   
2023
 
Prepaid research and development expenses
 
$
39   
$
415 
Prepaid insurance expenses
 
 
354 
  
541 
Tax credit receivable
 
 
—   
 
1,493 
Interest receivable
 
 
139   
 
84 
Other prepaid expenses and current assets
 
 
505   
 
871 
 
 
$
1,037   
$
3,404 
Property and Equipment, Net 
Property and equipment, net, consists of the following (in thousands): 
 
 
 
December 31,
 
 
 
2024
   
2023
 
Laboratory equipment
 
$
2,995   
$
3,894 
Computer equipment
 
 
319   
 
303 
Furniture and fixtures
 
 
616   
 
627 
Leasehold improvements
 
 
8,765   
 
9,519 
Total property and equipment
 
 
12,695   
 
14,343 
Less: accumulated depreciation and amortization
 
 
(9,239)  
 
(9,261)
Total property and equipment, net
 
$
3,456   
$
5,082 
 

 
117
 
Depreciation and amortization expense related to property and equipment was $0.9 million, $1.2 million and $2.2 million for the years ended December 31, 
2024, 2023 and 2022, respectively. The Company incurred an impairment loss to its leasehold improvements associated with its Right-of-Use Asset. Refer 
to Note 9 for additional information.
Accrued and Other Current Liabilities 
Accrued and other current liabilities consist of the following (in thousands): 
 
 
 
December 31,
 
 
 
2024
   
2023
 
Operating lease liability - current portion
  $
3,830    $
3,451 
Accrued research and development
   
2,168 
  
839 
Liability related to early exercise shares
   
—     
10 
Accrued other
   
169     
319 
 
  $
6,167    $
4,619 
 
8. Government Assistance Program
Under the CARES Act, the Company met eligibility criteria and was approved for a $1.5 million refundable employee retention credit in 2023. The 
Company recorded contra-expense to personnel related costs within general and administrative expense of $0.4 million and research and development 
expense of $1.1 million for the year ended December 31, 2023. No such amounts were recorded for the year ended December 31, 2024. The employee 
retention credit receivable due from the U.S. Department of Treasury of $1.5 million was received as of December 31, 2024.
9. Commitments and Contingencies 
Leases 
In February 2019, the Company entered into a lease agreement for new office and laboratory space in South San Francisco, California. The term of the 
lease agreement commenced in May 2019. The lease has an initial term from occupancy of approximately ten years ending on December 31, 2029 with an 
option to extend the term for an additional eight years at then-market rental rates. The total base rent payment escalates annually based on a fixed 
percentage beginning from the 13th month of the lease agreement. The Company will also be responsible for the operating expenses and real estate taxes 
allocated to the building and common areas. Pursuant to the lease agreement, the landlord provided the Company with a tenant improvement allowance of 
$10.7 million, which was included in deferred rent and leasehold improvements on the balance sheet at December 31, 2019. In connection with the 
execution of the lease agreement, the Company delivered a letter of credit of approximately $0.9 million to the landlord. The Company had a total 
operating lease liability of $23.5 million as of December 31, 2024 and $27.0 million as of December 31, 2023. Current operating lease liability was $3.8 
million as of December 31, 2024 and $3.5 million as of December 31, 2023, which is included in "Accrued and other current liabilities" on the Balance 
Sheet.
The Company’s operating leases include various covenants, indemnities, defaults, termination rights, security deposits and other provisions customary for 
lease transactions of this nature.
 
The following table summarizes the components of lease expense, which are included in operating expenses in the Company’s Statements of Operations 
and Comprehensive Loss (in thousands):
 
 
 
Year ended December 31,
 
 
 
2024
   
2023
   
2022
 
Operating lease expense
  $
3,644    $
3,739    $
4,264 
Variable lease expense
   
1,018     
748     
1,318 
Sublease income
   
(4,859)    
(3,988)    
(4,317)
Total lease expense
  $
(197)   $
499    $
1,265 
 
Variable lease payments include amounts relating to common area maintenance, real estate taxes and insurance and are recognized in the Statements of 
Operations and Comprehensive Loss as incurred. 

 
118
 
The following table summarizes supplemental information related to operating leases (in thousands):
 
 
 
Year ended December 31,
 
 
 
2024
 
 
2023
 
 
2022
 
Cash paid for amounts included in the measurement of lease liabilities
  $
4,964 
  $
4,810 
  $
6,283 
Weighted-average remaining lease term (years)
   
5.0 
   
6.0 
   
7.0 
Weighted-average discount rate (percentage)
   
6.0%    
6.0%    
6.0%
 
The following table summarizes the maturities of lease liabilities as of December 31, 2024 (in thousands):
 
 
 
Amount
 
2025
 
$
5,123 
2026
 
 
5,287 
2027
 
 
5,457 
2028
 
 
5,633 
2029
 
 
5,801 
Total future minimum lease payments
 
 
27,301 
         Less: Amount representing interest
 
 
(3,762)
Present value of future minimum lease payments
 
 
23,539 
         Less: Current portion of operating lease liability
 
 
(3,830)
     Noncurrent portion of operating lease liability
 
$
19,709 
In February 2021, the Company entered into an agreement to sublease the first floor of the Brisbane, California facility (the Company's previous offices
and laboratory space), consisting of approximately 27,000 square feet, to Zymergen, Inc., through August 31, 2022. The base sublease rent rate is $3.53 per 
rental square foot per month and will increase by 3% on March 1, 2022 through expiration of the agreement. Additionally, the subtenant is required to pay 
approximately 41% of operating expenses and property management fees that the Company is required to pay under the lease for the Brisbane, California 
facility. In May 2021, the Company entered into an agreement to sublease the second floor of the Brisbane, California facility, consisting of approximately 
11,500 square feet, to CareDx, Inc., through September 30, 2022. The base sublease rent rate is $1.00 per rental square foot per month through expiration 
of the agreement. Additionally, the subtenant is required to pay approximately 30% of operating expenses and property management fees that the Company 
is required to pay under the lease for the Brisbane, California facility. The Company incurred initial direct costs of $0.1 million in sublease commissions 
related to entering into the agreements to sublease the Brisbane, California facility. To account for the commissions, the Company capitalized the total 
commissions amount and will amortize the balance over the term of the sublease. Sublease income from this facility was zero for each of the years ended 
December 31, 2024 and 2023 and $1.3 million for the year ended December 31, 2022, which was offset against total rent expense. 
In June 2021, the Company entered into an agreement to sublease a portion of the first floor of the South San Francisco facility, consisting of 
approximately 23,000 square feet, to Freenome Holdings, Inc., through July 31, 2024. The base sublease rent rate is $6.25 per rental square foot per month 
and will increase annually by 3.5% through expiration of the agreement. Additionally, the subtenant is required to pay approximately 37% of operating 
expenses and property management fees that the Company is required to pay under the lease for the South San Francisco, California facility. The Company 
incurred initial direct costs of $0.2 million in sublease commissions related to entering into the agreements to sublease the South San Francisco, California 
facility. To account for the commissions, the Company capitalized the total commissions amount and will amortize the balance over the term of the 
sublease. Sublease income related to this facility and this specific sub-tenant was $1.5 million, $2.3 million and $2.2 million for the years ended December 
31, 2024, 2023 and 2022, respectively, which was offset against total rent expense.
In May 2022, the Company entered into an agreement to sublease a portion of the second floor of the South San Francisco, California facility, consisting of 
approximately 15,000 square feet, to Initial Therapeutics, Inc. ("Initial Therapeutics"). The original sublease term commenced on July 1, 2022 and 
continued through June 30, 2024 and further extended through June 30, 2026 upon execution of an amendment as defined below. The base sublease rent 
rate is $7.80 per rental square foot per month and will increase by 3.5% annually through the expiration of the agreement. Additionally, the subtenant is 
required to pay approximately 24% of operating expenses and property management fees that the Company is required to pay under the lease for the South 
San Francisco, California facility. The Company incurred initial direct costs of $0.1 million in sublease commissions related to entering into the 

 
119
agreements to sublease the South San Francisco, California facility. To account for the commissions, the Company capitalized the total commissions 
amount and will amortize the balance over the term of the sublease. 
On September 15, 2023, the Company entered into an amendment with Initial Therapeutics to sublease the remainder of the second floor of the South San 
Francisco, California facility, consisting of an additional 17,000 square feet. The sublease term commenced on October 1, 2023 and extends the existing
sublease agreement that commenced on July 1, 2022 through June 30, 2026. The additional space will be subleased at a monthly rent rate of $1.00 per 
square foot starting a month after Initial Therapeutics first takes possession of the additional space through June 30, 2024. Starting July 1, 2024, the rent 
rate for the entirety of Initial Therapeutics' subleased space will be $6.02 per rental square foot per month and will increase 3.5% on December 1, 2024 and 
2025. Additionally, Initial Therapeutics will be required to pay approximately 51% of operating expenses and property management fees that the Company 
is required to pay under the lease for the South San Francisco, California facility. The Company incurred initial direct costs of $0.3 million in sublease 
commissions. Sublease income related to this amendment was $3.3 million and $1.7 million, for the years ended December 31, 2024 and 2023, 
respectively, which was offset against total rent expense.
On September 15, 2023, the Company entered into a sublease agreement with GT Biopharma, Inc. to sublease a portion of its first floor at 8000 Marina 
Boulevard, Brisbane, California, consisting of 4,500 square feet. The sub-sublease term commenced on October 6, 2023 and expired on June 30, 2024. The 
space was subleased at a rent rate of $2.00 per rent square feet. Sublease expense for this facility was $0.1 million and immaterial, for the years ended 
December 31, 2024 and 2023, respectively.
Impairment of Operating Lease Right-of-Use Asset and Other Long-Lived Assets
As the Company is subleasing its South San Francisco facility through June 30, 2026, the Company's market capitalization was below its net assets of the 
Company and determined an impairment indicator was present. The Company determined all of its long-lived assets represent entity wide asset group for 
the purpose of the long-lived asset impairment assessment. The Company concluded that the carrying value of the entity wide asset group was not 
recoverable as it exceeded the future net undiscounted cash flows that are expected to be generated from the use and eventual disposition of the assets 
within the asset group. To allocate and recognize the impairment loss, the Company determined the fair value of the Company using the adjusted net asset 
method under the cost approach. The implied allocated impairment loss shall not reduce the carrying amount of that asset below its fair value. To determine 
the fair value of the individual assets, the Company utilized the discounted cash flow method using the income approach. Based on this analysis, the 
Company recognized a non-cash impairment charge of $5.6 million, including $4.0 million for the right-of-use asset and $1.6 million for the leasehold 
improvements during the year ended December 31, 2023. Calculating the fair value of the assets involves significant estimates and assumptions. These 
estimates and assumptions include, among others, projected future cash flows, risk-adjusted discount rates and market rental rates. Based on current market 
conditions at the time of impairment, the proportionate operating costs (e.g., common area maintenance, real estate taxes, property insurance) is carried for 
three months and sublease base rentals is expected to commence in October 2026, at a rent per square foot of approximately 90% of the fixed rent per 
square foot that the Company is obligated to pay under the head lease. The anticipated sublease income is assumed to have annual escalations of 3% and 
the cash flows are discounted using a risk-adjusted market rate of return of 10%, which differs from the Company’s entity-specific incremental borrowing 
rate used to measure the head lease. Changes in the factors and assumptions used could materially affect the amount of impairment loss recognized in the 
period the asset was considered impaired.
During 2024, the Company determined that there was a fundamental change to a certain space within the Company's leased facility in South San Francisco, 
CA. This space is vacant and is currently being actively marketed for sublease for the remainder of the South San Francisco facility head lease term. The 
Company historically included all of its long-lived assets within its entity wide asset group. Due to the change in how this portion of space is being used, 
the identifiable cash flows pertaining to it are now largely independent of the cash flows of the Company’s other assets and liabilities. The operating lease 
right-of-use asset and leasehold improvements pertaining to the 15,379 square feet now represent a separate asset group for the purpose of the long-lived 
asset impairment assessment. The Company concluded that the carrying value of the asset group was not recoverable as it exceeded the future net 
undiscounted cash flows that are expected to be generated from the use of the assets within the asset group. 
To determine the fair value, the Company utilized the expected discounted cash flow method using the income approach. Based on this analysis, the 
Company recognized a non-cash impairment charge of  $2.7 million, which was allocated the right-of-use asset and the related leasehold improvements 
within the asset group on a pro rata basis using the relative carrying amounts of those assets, which resulted in write-downs of $1.9 million and $0.8 
million, respectively, during the year ended December 31, 2024. Calculating the fair value of the asset group involves 

 
120
significant estimates and market participant assumptions. These estimates and assumptions include, among others, projected future cash flows, risk-
adjusted discount rates and market conditions. Subleasing the space for office and laboratory space is the highest and best use and, based on current market 
conditions, the proportionate operating costs (e.g., common area maintenance, real estate taxes, property insurance) will be carried for twelve months and 
sublease base rentals are expected to commence in May 2026, after a four month rent abatement period, at a rent per square foot of approximately 50% of 
the fixed rent per square foot that the Company is obligated to pay under the head lease. The anticipated sublease income is assumed to have annual 
escalations of 3% and the cash flows are discounted using a risk-adjusted market rate of return of 9%, which differs from the Company’s entity-specific 
incremental borrowing rate used to measure the head lease. There are often risks and uncertainties associated with the intent to sublease office and 
laboratory space. Consequently, the eventual realized sublease income may vary from estimates as of the impairment testing date and adjustments may 
occur in future periods.
Indemnifications 
The Company indemnifies each of its officers and directors for certain events or occurrences, subject to certain limits, while the officer or director is or was 
serving at the Company’s request in such capacity, as permitted under Delaware law and in accordance with the Company’s amended and restated 
certificate of incorporation and bylaws. The term of the indemnification period lasts as long as an officer or director may be subject to any proceeding 
arising out of acts or omissions of such officer or director in such capacity. 
The maximum amount of potential future indemnification is unlimited; however, the Company currently holds director and officer liability insurance. This 
insurance allows the transfer of risk associated with the Company’s exposure and may enable the Company to recover a portion of any future amounts paid. 
The Company believes that the fair value of these potential indemnification obligations is minimal. Accordingly, the Company has not recognized any 
liabilities relating to these obligations for any period presented.
10. Term Loan Facility
 
On August 3, 2020, the Company entered into a Loan and Security Agreement (as amended, restated, supplemented or otherwise modified, the "Hercules 
Loan Agreement") with Hercules Capital, Inc. (“Hercules”), as administrative agent and collateral agent for the lenders, and certain banks and other 
financial institutions or entities from time to time parties thereto, for an aggregate principal amount of up to $80.0 million secured term loan facility (the 
"Hercules Facility") subject to certain terms and conditions. The first tranche of $25.0 million was advanced to the Company on the date the Loan 
Agreement was executed. The maturity date under the Hercules Loan Agreement was August 1, 2024.
 
On September 6, 2023, the Company and Hercules entered into a payoff letter for a voluntary prepayment with respect to the Hercules Loan Agreement 
(the “Payoff Letter”). Pursuant to the Payoff Letter, the Company paid a total of $15.0 million to Hercules, representing the outstanding principal, accrued 
and unpaid interest, fees, costs and expenses due to Hercules under the Hercules Facility and the Hercules Loan Agreement and related loan documents, in 
repayment of the Company’s outstanding obligations under the Hercules Facility and the Hercules Loan Agreement and related loan documents, and 
thereby terminated the Hercules Loan Agreement and the Hercules Facility and related loan documents. Under the terms of the Hercules Loan Agreement, 
no early termination penalty was payable as a result of such prepayment and termination as of such date. The Company recorded a loss on extinguishment 
of debt of $0.5 million under "Other expense, net" in the financial statements for the year ended December 31, 2023 related to the write-off of the 
remaining balance of unamortized debt discount.
 
Pursuant to the Payoff Letter, the lenders’ commitments to extend further credit to the Company terminated. Hercules released and terminated all liens or 
security interests granted to secure the obligations under the Hercules Loan Agreement and the Company was unconditionally released from its respective 
guaranties and obligations under the Hercules Facility and the Hercules Loan Agreement and related loan documents without further action (other than with 
respect to customary provisions and agreements that are expressly specified to survive the termination). Hercules returned to the Company, for the benefit 
of the Company, all of the collateral that it had in its possession. 
Interest expense relating to the term loan, which is included in interest expense in the Statements of Operations and Comprehensive Loss was $2.5 million 
and $3.6 million for the years ended December 31, 2023 and 2022, respectively.

 
121
11. Related Party Transactions 
Licensing Revenue – Related Party
In December 2021, the Company entered into a license agreement with Jocasta Neuroscience, Inc. A member of the Board of Directors of the Company is 
also an affiliate of Jocasta Neuroscience, Inc. The agreement provides for an upfront fee of $5.0 million and the opportunity for future research and 
development services to be provided. The Company recognized zero in licensing revenue for each of the years ended December 31, 2024 and 2023, and 
$0.2 million in licensing revenue for the year ended December 31, 2022.
12. Equity Financing
On October 19, 2022, the Company effected a reverse stock split of its outstanding share of common stock at a ratio of 1-for-10 pursuant to a Certificate of 
Amendment to the Company's Certificate of Incorporation filed with the Secretary of State of the State of Delaware. The reverse stock split was reflected 
on the Nasdaq Global Select Market beginning with the opening of trading on October 20, 2022. All share amounts and per share amounts disclosed in this 
Annual Report on Form 10-K have been restated to reflect the reverse stock split on a retroactive basis in all periods presented.
The Company has 10,000,000 shares of convertible preferred stock authorized for issuance, par value of $0.0001 per share. As of December 31, 2024 and 
2023, no shares of preferred stock were issued and outstanding. 
The Company has 300,000,000 shares of common stock authorized for issuance, par value of $0.0001 per share. Holders of the Company’s common stock 
are entitled to one vote per share. As of December 31, 2024 and 2023, there were 16,865,201 and 16,784,969 shares, respectively, of common stock issued 
and outstanding.
Follow-On Offering 
In August 2022, the Company closed an underwritten offering (the “Follow-On Offering”) in which the Company issued and sold an aggregate of 
6,428,571 of the Company’s common stock together with warrants (the "Existing Warrants”) to purchase up to 6,428,572 of the Company’s common stock 
at an offering price of at an aggregate offering price of $7.00 per unit. The Existing Warrants have an exercise price of $8.50 per warrant. The gross 
proceeds to the Company were $45.0 million before deducting underwriting discounts and commissions and other offering expenses. The net proceeds of 
the Follow-On Offering were approximately $41.7 million.  
The Existing Warrants are exercisable at any time after their original issuance and on or prior to the five-year anniversary of the original issuance date. A 
holder of Existing Warrants may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number 
of shares of common stock outstanding immediately after giving effect to such exercise. As of December 31, 2024, 2,143,000 warrants have been 
exercised.
The Company recorded the Existing Warrants as liabilities based upon the guidance of ASC 480 and ASC 815. The Company evaluated the Existing 
Warrants under ASC 815-40 and concluded that they do not meet the criteria to be classified in stockholders’ equity. Specifically, the settlement value in a 
scenario of a fundamental transaction precluded the Existing Warrants from being indexed to the Company’s own stock and Company believes that the 
scope exception related to the occurrence of a fundamental transaction in ASC 815-40 is not met. Since the Existing Warrants meet the definition of a 
derivative, they are recorded as liabilities and measured at fair value at initial recognition. Any subsequent changes in their respective fair values are 
recognized in the Statement of Operations and Comprehensive Loss at each reporting date.
 
At issuance, the Company valued the Existing Warrants using a Monte-Carlo valuation model due to the more than de-minims probability of a fundamental 
transaction which triggered a settlement value that is not indexed to the Company's own stock. The Monte Carlo valuation model resulted in a fair value of 
$27.6 million on the Existing Warrant issuance date. The difference between the gross proceeds of $45.0 million and $27.6 million fair value of warrants 
issued, was recorded to the stockholders’ equity under Common stock and Additional paid-in capital. Additionally, the Company also incurred an issuance 
cost of $3.3 million which was allocated to Existing Warrants and common stock based on their relative fair value. The issuance cost of $1.4 million 
attributed to the Existing Warrants were expensed under "Other expense, net" in the Statement of Operations and Comprehensive Loss.  The 

 
122
remaining issuance cost of $1.9 million attributed to the common stock was recorded as a reduction to Additional paid-in capital.
 
At December 31, 2024 and 2023, the Company updated the estimated fair value of the outstanding Existing Warrants using a Monte-Carlo valuation model 
resulting in an estimated fair value of $0.8 million and $2.8 million (subsequent to the exercise of the Existing Warrants as described in the section below), 
respectively. The change in fair value for the years ended December 31, 2024, 2023 and 2022 of $3.7 million gain, $6.6 million gain and $16.8 million gain 
was recorded as the Gain on warrant liability in the Statements of Operations and Comprehensive Loss for the years ended December 31, 2024,  2023 and 
2022. 
Inducement Offer
On November 9, 2023, the Company entered into an inducement offer letter agreement (the “Inducement Offer”) with certain holders (collectively, the 
“Holders”) of the Company's Existing Warrants to purchase up to an aggregate of 2,143,000 shares of common stock. The Holders agreed to exercise for 
cash their Existing Warrants to purchase an aggregate of 2,143,000 shares of common stock at a reduced exercise price of $2.045 per share in consideration 
of the Company’s agreement to issue new unregistered common stock purchase warrants (the “New Warrants”) to purchase up to an aggregate of 2,143,000 
shares of the Company’s common stock.
Each New Warrant will have an exercise price equal to $1.92 per share. The New Warrants will be exercisable on or after the initial issue date until the 
five-year anniversary of such date. The exercise price and number of New Warrant Shares issuable upon exercise of the New Warrants is subject to 
appropriate adjustment in the event of stock dividends, stock splits, subsequent rights offerings, pro rata distributions, reorganizations, or similar events 
affecting the Company’s common stock and the exercise price. 
The Company engaged H.C. Wainwright & Co., LLC (the “Placement Agent”) to act as its exclusive placement agent in connection with the transactions 
summarized above. The Company also issued to the Placement Agent or its designees warrants to purchase up to 128,580 shares of common stock. The 
Placement Agent Warrants have substantially the same terms as the New Warrants, except that the Placement Agent Warrants have an exercise price equal 
to $2.5563 per share. 
 
The Company recorded the New Warrants and Placement Agent Warrants (together “2023 Warrants”) as liabilities based upon the guidance of ASC 480 
and ASC 815. The Company evaluated the 2023 Warrants under ASC 815-40 and concluded that they do not meet the criteria to be classified in 
stockholders’ equity. Specifically, the settlement value in a scenario of a fundamental transaction precludes the 2023 Warrants from being indexed to the 
Company’s own stock and Company believes that the scope exception related to the occurrence of a fundamental transaction in ASC 815-40 is not met. 
Since the 2023 Warrants are recorded as liabilities on the balance sheet at fair value, any subsequent changes in their respective fair values are recognized 
in the statement of operations and comprehensive loss at each reporting date.
The Company received aggregate gross proceeds of $4.4 million from the exercise of the Existing Warrants by the Holders (the “Exercise”), before 
deducting placement agent fees and other offering expenses payable by the Company. 
The Company issued common stock at fair value of $3.7 million and 2023 Warrants at fair value of $2.7 million and extinguished the Existing Warrants 
Liability of $1.4 million. The issuance costs related to 2023 Warrants and loss on extinguishment of Existing Warrants Liability of $1.0 million were 
expensed under "Other expense, net" in the Statement of Operations and Comprehensive Loss.
At December 31, 2024 and 2023, the Company updated the estimated fair value of the outstanding New Warrants using a Monte-Carlo valuation model 
resulting in an estimated fair value of $1.4 million and $3.1 million, respectively. The change in fair value for the years ended December 31, 2024 and 2023 
of $1.7 million gain and zero, respectively, was recorded as Gain on warrant liability in the Statements of Operations and Comprehensive Loss.
At-the-Market Offering
In June 2019, the Company filed a Registration Statement on Form S-3 (the “Shelf Registration Statement”), covering the offering of up to $250.0 million 
of common stock, preferred stock, debt securities, warrants and units. The Shelf Registration Statement included a prospectus covering the offering, 
issuance and sale of up to $75.0 million of the Company’s common stock from time to time through an “at-the-market” offering under the Securities Act of 
1933, as 

 
123
amended (the “Initial ATM Offering Program”). The SEC declared the Shelf Registration Statement effective on June 6, 2019.
In June 2019, the Company also entered into a sales agreement (the “June 2019 Sales Agreement”) with Cowen and Company, LLC (“Cowen”) (now TD 
Securities (USA) LLC) to sell shares of the Company’s common stock, from time to time, with aggregate gross sales proceeds of up to $75.0 million, 
through the ATM Offering Program under which Cowen acts as its sales agent. Cowen is entitled to compensation for its services equal to up to 3.0% of 
the gross proceeds of any shares of common stock sold through Cowen under the June 2019 Sales Agreement. During the year ended December 31, 2020, 
the Company issued and sold 500,226 shares of its common stock through its ATM Offering Program and received net proceeds of approximately $37.3 
million, after deducting commissions and other offering expenses of $1.3 million.
In July 2020, the Company filed an additional prospectus supplement to the Shelf Registration Statement. This prospectus supplement covers the offering, 
issuance and sale of up to an additional $50.0 million of the Company’s common stock from time to time through an additional “at-the-market” offering 
under the Securities Act of 1933, as amended (the “Additional ATM Offering Program”). The Initial ATM Offering Program and Additional ATM 
Offering Program are collectively called the “ATM Offering Programs”.
 
In July 2020, the Company entered into sales agreement (the “July 2020 Sales Agreements”) with Cowen to sell shares of the Company’s common stock, 
from time to time, with aggregate gross sales proceeds of up to $50.0 million, through the Additional ATM Offering Program under which Cowen will act 
as its sales agent. The issuance and sale of shares of common stock by the Company pursuant to the July 2020 Sales Agreement are also deemed an “at-the-
market” offering under the Securities Act of 1933, as amended (the “Securities Act”). Cowen is entitled to compensation for its services equal to up to 
3.0% of the gross proceeds of any shares of common stock sold through Cowen under the July 2020 Sales Agreement. During the year ended December 31, 
2021, there were 118,707 shares of the Company’s common stock sold through the Initial ATM Offering Program and 70,746 shares of the Company’s 
common stock sold through the Additional ATM Offering Program and received total net proceeds of approximately $10.4 million, after deducting 
commissions and other offering expenses of $0.3 million. 
In March 2022, the Company filed a Registration Statement on Form S-3 (the “March 2022 Shelf Registration Statement”), covering the offering of up to 
$125.0 million of common stock, preferred stock, debt securities, warrants, and units, which was declared effective by the SEC in May 2022. In March 
2022, the Company also entered into a sales agreement (the “March 2022 Sales Agreement”) with Cowen and Company, LLC ("Cowen") as sales agent to 
sell shares of the Company’s common stock, from time to time, with aggregate gross sales proceeds of up to $50.0 million pursuant to the March 2022 
Shelf Registration Statement as an “at-the-market” offering under the Securities Act (the "March 2022 ATM Offering Program"). Cowen is entitled to up to 
3.0% of the gross proceeds of any shares of common stock sold under the March 2022 Sales Agreement. For so long as its public float is less than $75.0 
million, it may not sell more than the equivalent of one-third of its public float during any 12 consecutive months pursuant to the "baby shelf" rules. During 
the year ended December 31, 2023, there were 274,781 shares of the Company's common stock sold pursuant to the March 2022 Sales Agreement and the 
Company received total net proceeds of approximately $1.0 million, after deducting commissions and other offering expenses which were insignificant. On 
August 17, 2022, the Company entered into Amendment No. 1 (the “Amendment”) to the March 2022 Sales Agreement, which Amendment decreased the 
amount of the Company’s common stock that can be sold by the Company through Cowen under the March 2022 Sales Agreement, from an aggregate 
offering of up to $50.0 million to an aggregate offering of up to $25.0 million. Following the Amendment, $14.6 million of shares of common stock 
remained available for sale under the March 2022 Sales Agreement, as amended, as of December 31, 2023. On March 17, 2023, the Company entered into 
Amendment No. 2 (the "Second Amendment"), accompanied by a prospectus supplement, to the March 2022 Sales Agreement. The Second Amendment 
added the limitations imposed on the Program by General Instruction I.B.6 of Form S-3 (“Instruction I.B.6”) to the Sales Agreement. Pursuant to 
Instruction I.B.6, in no event will the Company sell ATM Shares through the Program with a value exceeding more than one-third of the Company’s 
“public float” (the market value of the Company’s outstanding common stock held by non-affiliates) in any twelve-month period so long as the Company’s 
public float remains below $75.0 million. 
In October 2022, the Company filed a Registration Statement on Form S-3 (the “October 2022 Shelf Registration Statement”), covering the offering of up 
to $250.0 million of common stock, preferred stock, debt securities, warrants, and units. In October 2022, the Company also entered into a sales agreement 
(the “October 2022 Sales Agreement”) with Cowen as sales agent to sell shares of the Company’s common stock, from time to time, with aggregate gross 
sales proceeds of up to $50.0 million pursuant to the October 2022 Shelf Registration Statement as an “at-the-market” offering under the Securities Act. 
Cowen is entitled to up to 3.0% of the gross proceeds of any shares of common 

 
124
stock sold under the October 2022 Sales Agreement. During the year ended December 31, 2024, there were no shares of the Company's common stock sold 
pursuant to the October 2022 Sales Agreement.
Purchase Agreement
In September 2021, the Company entered into an equity purchase agreement (the “Purchase Agreement”) and a registration rights agreement with Lincoln 
Park Capital Fund, LLC (“Lincoln Park” or “Investor”) which provided for the sale to Lincoln Park up to $30,000,000 of shares (the “Purchase Shares”) of 
its common stock over the thirty-six (36) month term of the Purchase Agreement. The Purchase Agreement expired according to its terms in September 
2024.
13. Corporate Restructuring
In February 2022, the Company implemented a corporate restructuring to align its resources to focus on its UBX1325 program while further extending 
operating capital. The restructuring resulted in an elimination of 29 positions, or approximately 50% of the Company’s workforce, in the first nine months 
of 2022. The Company incurred a one-time employee benefits and severance charge of approximately $1.9 million in operating expenses which was 
primarily recorded in the first nine months of 2022. Restructuring charges incurred under this plan primarily consisted of employee termination benefits. 
Employee termination benefits include $1.6 million of severance costs, $0.2 million of employee-related benefits, $0.1 million of payroll taxes and 
supplemental one-time termination payments. Charges and other costs related to the workforce reduction and structure realignment, and non-cash share-
based compensation credits related to the forfeiture of stock options for $1.7 million, are included in operating expenses in the Statements of Operations 
and Comprehensive Loss. Of the total charge, $1.4 million was recorded to research and development expenses and $0.5 million was recorded to general 
and administrative expenses during the year ended December 31, 2022. 
In May 2023, the Company implemented a reduction in its workforce to align operations with the changes in its corporate strategy to focus on resource 
optimization to enable the initiation and advancement of key data readouts. The reduction decreased its headcount by nine employees, or approximately 
29% of the Company’s workforce, effective as of May 31, 2023. Six employees departed as of the effective date and three employees departed as of June 
30, 2023. The Company recognized the employee benefits and severance charge of approximately $0.6 million in operating expenses in the second quarter 
of 2023. Restructuring charges primarily consisted of employee termination benefits, which included $0.5 million of severance costs, $0.1 million of 
employee-related benefits, and a negligible amount of payroll taxes. Charges and other costs related to the restructuring, and non-cash share-based 
compensation credits related to the forfeiture of stock options were negligible and are included in operating expenses in the Statements of Operations and 
Comprehensive Loss. Of the total charge, $0.4 million was recorded to research and development expenses and $0.2 million was recorded to general and 
administrative expenses during the year ended December 31, 2023. 
14. Stock-Based Compensation 
Summary of Equity Incentive Plans 
In March 2018, the Company’s board of directors adopted the Company’s 2018 Incentive Award Plan (the “2018 Plan”). The 2018 Plan was approved by 
the Company’s stockholders in April 2018 and became effective in May 2018. The 2018 Plan initially reserved 428,994 shares for the issuance of stock 
options as well as any automatic annual increases in the number of shares of common stock reserved for future issuance under the 2018 Plan. Awards 
granted under the 2018 Plan expire no later than ten years from the date of grant. For stock options, the option price shall not be less than 100% of the 
estimated fair value on the day of grant. Options granted typically vest over a four-year period but may be granted with different vesting terms. Unvested 
options not exercised at the time of an employee’s termination of employment are added back to the 2018 Plan. 
As of December 31, 2024, there were in aggregate 3,002,964 shares of common stock authorized for issuance under the 2018 Plan.
Under the 2013 Plan, the Company permitted early exercise of certain stock options prior to vesting. These unvested shares are subject to repurchase by the 
Company at the original issuance price in the event the optionee’s employment is terminated either voluntarily or involuntarily. The amounts paid for 
shares purchased under an early exercise of 

 
125
stock options and subject to repurchase by the Company are reported as a liability and reclassified into additional paid-in capital as the shares vest. 
In March 2020, the Company’s board of directors approved the Company’s 2020 Employment Inducement Incentive Plan (“the 2020 Plan”), to provide for 
grants to newly hired employees as a material inducement for them to commence employment with the Company. The 2020 Plan initially reserved 110,000 
shares for the issuance of stock options, and in November 2020, the Company reserved an additional 150,000 shares of common stock for future issuance 
under the 2020 Plan. In February 2023, the Company reserved an additional 300,000 shares of common stock for future issuance under the 2020 Plan. 
Awards granted under the 2020 Plan expire no later than ten years from the date of grant. For stock options, the option price shall not be less than 100% of
the estimated fair value on the day of grant. Options granted typically vest over a four-year period but may be granted with different vesting terms. 
Unvested options not exercised at the time of an employee’s termination of employment are added back to the 2020 Plan. As of December 31, 2024, there 
were in aggregate 542,000 shares of common stock authorized for issuance under the 2020 Plan.
Equity Incentive Plan Activity
The following sections summarize activity under the Company’s equity incentive plans.
Stock Options and Restricted Stock Units (RSUs) Activity 
A summary of the Company’s stock option activity under the 2013 Plan, 2018 Plan and 2020 Plan for the year ended December 31, 2024 is as follows: 
 
 
 
Shares
Available
for Grant
   
Outstanding
Options
   
Weighted-
Average
Exercise 
Price
   
Weighted-
Average
Remaining
Contract
Term
   
Aggregate
Intrinsic
Value
 
 
 
 
   
 
   
 
   
(in Years)
   
(in thousands)  
Balance at December 31, 2023
   
786,836     
1,913,345    $
14.23     
7.1    $
5 
Shares added
   
839,248     
—     
—   
    
   
Granted
   
(791,834)    
791,834     
1.62   
    
   
Exercised
   
—     
—     
—   
    
   
Canceled
   
380,839     
(380,839)    
3.89   
    
   
Balance at December 31, 2024
   
1,215,089     
2,324,340    $
11.63     
7.3    $
— 
Vested and exercisable at December 31, 2024
 
      
1,497,467    $
16.97     
6.3    $
— 
Vested and expected to vest at December 31, 2024
 
      
2,324,340    $
11.63     
7.3    $
— 
 
The total intrinsic value of options exercised was zero for the years ended December 31, 2024 and 2023, respectively. The weighted-average estimated fair 
value of stock options granted was $1.62 and $2.79 for the years ended December 31, 2024 and 2023, respectively. 
The aggregate intrinsic value of options exercisable was zero as of December 31, 2024 and 2023. 
The following table summarizes the Company’s RSU activity for the year ended December 31, 2024:
 
 
 
Shares
   
Weighted-
Average
Grant Date
Fair Value
 
Unvested at December 31, 2023
 
 
41,225    $
30.18 
Granted
 
 
422,725    $
1.66 
Released
 
 
(22,120)   $
21.83 
Canceled
 
 
(62,459)   $
2.03 
Unvested at December 31, 2024
 
 
379,371    $
3.52 
 

 
126
As of December 31, 2024, the total stock-based compensation cost related to options and RSUs granted but not yet amortized was $1.0 million and will be 
recognized over a weighted-average period of approximately 0.7 years. The total grant date fair value of RSUs and RSAs vested during the years ended 
December 31, 2024 and 2023 was approximately $0.5 million and $0.3 million, respectively. 
Valuation of Stock Options
The Company uses the Black-Scholes option-pricing model for determining the estimated fair value and stock-based compensation related to stock options 
and ESPP awards. The fair value of stock options granted to employees was estimated on the date of grant using the Black-Scholes option pricing model 
using the following assumptions: 
 
 
 
Year ended December 31,
 
 
 
2024
   
2023
   
2022
 
Expected term of options (in years)
 
5.79
   
5.79
   
5.55
 
Expected stock price volatility
 
97.29%-98.58%
   
94.11%-98.92%
   
86.22%-93.17%
 
Risk-free interest rate
 
4.01%-4.28%
   
3.36%-4.13%
   
2.41%-4.01%
 
Expected dividend yield
   
—     
—     
— 
 
The valuation assumptions were determined as follows: 
Expected Term—The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified 
method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise 
history does not provide a reasonable basis upon which to estimate expected term.
Expected Volatility—Due to limited historical data, the Company estimates stock price volatility based on a combined weighted-average of the Company’s 
historical average volatility and that of a selected peer group of comparable publicly traded companies within the biotechnology and pharmaceutical 
industry that were deemed to be representative of future stock price trends over the expected life of the award. 
Risk-Free Interest Rate—The Company based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. 
Treasury securities with similar maturities as of the date of the grant.
Expected Dividend Yield—The Company has never paid any dividends and does not plan to pay dividends in the foreseeable future. Therefore, the
expected dividend yield is zero.
The fair value of ESPP awards was not material for all periods presented.
Performance Stock Units 
The PSUs, which were modified by the Company's board of directors in January 2021, are scheduled to vest as to 5,000 PSUs upon the attainment of (a) a 
volume-weighted average per share closing trading price of the Company’s common stock of at least $180.00 over a trailing 30-day period or (b) a change 
in control transaction in which the price per share to the holders of the Company’s common stock is at least $180.00 and as to 10,000 PSUs upon the 
attainment of (x) a volume-weighted average per share closing trading price of the Company’s common stock of at least $360.00 over a trailing 30-day 
period or (y) a change in control transaction in which the price per share to the holders of the Company’s common stock is at least $360.00, as determined 
by the Company’s board of directors.
For the PSU awards, the Company used the Monte-Carlo option pricing model to determine the fair value of awards at the date of grant. The Monte-Carlo 
option pricing model uses similar input assumptions as the Black-Scholes model; however, it further incorporates into the fair-value determination the 
possibility that the market condition may not be satisfied. Compensation costs related to awards with a market-based condition are recognized regardless of 
whether the market condition is ultimately satisfied. Compensation cost is not reversed if the achievement of the market condition does not occur. The total 
grant date fair value of the PSU awards was determined to be $0.7 million and will be recognized as compensation expense over the weighted-average 
derived service period of approximately 4.3 years. The incremental fair value of the PSUs on the modification date of $31,000 are added to the unamortized 
value of the original grant of $569,000 and will be amortized to expense over the new implied service periods of 1.63 years to 2.79 years.

 
127
2018 Employee Stock Purchase Plan
In March 2018, the Company’s board of directors adopted the Company’s 2018 Employee Stock Purchase Plan (the “2018 ESPP”). The 2018 ESPP was 
approved by the Company’s stockholders in April 2018 and became effective on May 2, 2018. The 2018 ESPP reserved 53,624 shares of common stock for 
issuance pursuant to future awards, as well as any automatic increases in the number of shares of the Company’s common stock reserved for future 
issuance under this plan.  
Under the 2018 ESPP, employees are offered the option to purchase the Company’s common stock at a discount during the offering periods, at semi-annual 
intervals, with their accumulated payroll deductions. The option purchase price will be 85% of the lower of the closing trading price per share at the 
beginning of the offering period or at the purchase date. The 2018 ESPP provides for consecutive offering periods and eligible employees may elect to 
withhold up to 15% of their compensation through payroll deductions during the offering period for the purchase of stock. The maximum number of shares 
that may be purchased by any one participant is limited to 15,000 shares in each offering period and $25,000 in fair market value during any calendar year 
per the Internal Revenue Code limits. The first offering period commenced on September 16, 2018. 
Stock-Based Compensation Expense 
The following table sets forth the total stock-based compensation expense for all options granted to employees and nonemployees and costs associated with 
the 2018 ESPP included in the Company’s statement of operations (in thousands):
 
 
 
Year Ended December 31,
 
 
 
2024
   
2023
   
2022
 
Research and development
 
$
575   
$
1,947   
$
3,526 
General and administrative
 
 
3,395 
  
5,472 
  
5,853 
Total
 
$
3,970   
$
7,419   
$
9,379 
Repricing 
On May 4, 2023, and in accordance with the terms of the Company’s 2018 Plan, the Company’s Board of Directors approved a stock option repricing (the 
“Repricing”) for employees and certain service providers  that were not affected by the reduction in its workforce, as well as affected employees and 
certain service providers entering into or subject to a continuing consulting agreement, as of May 11, 2023. Pursuant to the terms of the Repricing, the 
exercise price of each outstanding option to purchase shares of the Company's common stock granted under its 2018 Plan that had an original exercise price 
above $6.00, was reduced to an exercise price of $2.77, the closing price for the Company's common stock on May 11, 2023, the effective date of the 
Repricing. 
On the effective date of the Repricing, 26 employees and certain service providers held 444,273 shares of the Company's common stock under option 
grants that met the eligibility criteria. Eligible outstanding options continue to remain outstanding in accordance with their current terms and conditions. On 
the effective date of the Repricing, the Company recognized $0.2 million of additional stock-based compensation from 251,821 shares of its common stock 
under vested options. The Company anticipates an additional $0.1 million will be expensed over the period from the effective date of the Repricing through 
2025 relating to 170,189 shares of the Company's common stock under unvested options.
Stock option and awards modification
In connection with the corporate restructuring in 2023, the Company’s executed consulting agreements with five of the 9 employees that were terminated 
as part of the reduction in force. The consulting agreements allowed for the non-employee to continue vesting in their option and awards, resulting in a 
modification to all then vested and outstanding option and awards. The modification resulted in an incremental compensation charge recognized upfront on 
the date of modification of $0.3 million. These costs were recorded as part of the stock compensation expense within “Research and development” and 
“General and administrative” costs within the Statement of Operations and Comprehensive Loss. There was no material incremental compensation expense 
as a result of modifications during the year ended December 31, 2022.

 
128
15. Net Loss per Common Share 
Basic net loss per share is calculated by dividing net loss by the weighted-average number of shares outstanding for the period. Diluted net loss per share is 
calculated by dividing net loss by the weighted-average number of shares of common stock and potential dilutive common stock equivalents outstanding 
during the period if the effect is dilutive. 
The calculation of diluted earnings (loss) per share also requires the consideration of the effect of dilutive potential common shares outstanding during the 
period determined using the treasury-stock related to the warrants outstanding.
A reconciliation of the numerators and denominators used in computing net loss from continuing operations per share is as follows (in thousands, except 
per share amounts):
 
 
 
Year ended December 31,
 
 
 
2024
   
2023
   
2022 (Restated)
 
 
 
(in thousands, except share and per share amounts)
 
Numerator:
 
 
   
 
   
 
 
Net loss
  $
(25,990)  $
(39,860)  $
(44,469)
Denominator:
 
    
    
   
Weighted average number of shares outstanding—basic
   and diluted
   
16,827,038 
  
14,773,612 
  
9,494,421 
Net loss per share—basic and diluted
  $
(1.54)  $
(2.70)  $
(4.68)
 
The Company was in a net loss position for all periods presented, basic net loss per common share is the same as diluted net loss per common share as the 
inclusion of all potential securities outstanding would have been anti-dilutive. 
 
Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows: 
 
 
 
Year ended December 31,
 
 
 
2024
   
2023
   
2022
 
Options to purchase common stock
   
2,324,340     
1,913,345     
1,609,938 
Outstanding warrants to purchase common stock
   
6,557,152     
6,557,152     
6,428,572 
Early exercised common stock subject to future vesting
   
—     
3,336     
3,336 
RSUs subject to future vesting
   
379,371     
41,225     
146,333 
Shares subject to future vesting relating to the 2018 ESPP
   
125,539     
47,389     
65,939 
Total
   
9,386,402     
8,562,447     
8,254,118 
 
Up to 3,390 shares may be contingently issued, if certain performance conditions are met under the Company’s in-licensing agreements. See Note 6, 
“License Revenue, Agreements and Strategic Investment”.
16. Defined Contribution Plan 
The Company sponsors a 401(k) Plan that stipulates that eligible employees can elect to contribute to the 401(k) Plan, subject to certain limitations, on a 
pretax basis. In January 2019, the Company began to match 4% of employees’ salary. During the years ended December 31, 2024, 2023 and 2022, the 
Company recorded matching contributions of $0.2 million, $0.3 million and $0.4 million, respectively.
17. Income Taxes 
The Company has incurred net operating losses for all the periods presented. The Company has not reflected the benefit of any such net operating loss 
carryforwards in the accompanying financial statements. The Company has established a full valuation allowance against its deferred tax assets due to the 
uncertainty surrounding the realization of such assets. All losses to date have been incurred domestically as the Company has no international operations or 
subsidiaries. 

 
129
No provision for U.S. income taxes exists due to tax losses incurred in all periods presented. All losses incurred were U.S. based.
The effective tax rate for the years ended December 31, 2024, 2023 and 2022 is different from the federal statutory rate primarily due to the valuation 
allowance against deferred tax assets as a result of insufficient sources of income. The effective tax rate of the Company’s provision for income taxes 
differs from the federal statutory rate as follows: 
 
 
 
Year ended December 31,
   
 
 
2024
   
2023
   
2022
   
Taxes at the U.S. statutory income tax rate
   
21.0  %  
21.0  %  
21.0  %
State tax, net of federal benefit
   
12.0   
 
9.0   
 
9.1   
Other
   
(0.2)  
 
0.5   
 
(0.8)  
Warrant activity
   
3.0   
 
2.8   
 
7.3   
Stock-based compensation
   
(5.3)  
 
(2.5)  
 
(6.6)  
Research and development tax credits
   
1.1   
 
1.8   
 
2.9   
Rate change
   
(0.2)  
 
(8.8)  
 
4.7   
ASC 740-10
   
—   
 
—   
 
(7.5)  
Change in valuation allowance
   
(31.3)  
 
(23.7)  
 
(30.1)  
Total provision for income taxes
   
—  %  
—  %  
—  %
 
Deferred income taxes reflect the net tax effects of (a) temporary differences between the carrying amounts of assets and liabilities for financial reporting 
purposes and the amounts used for income tax purposes, and (b) operating losses and tax credit carryforwards.
The tax effects of significant items comprising the Company’s deferred income taxes are as follows: 
 
 
 
December 31,
 
 
 
2024
   
2023
 
 
 
(in thousands)
 
Deferred tax assets:
 
    
   
Federal and state operating loss carryforwards
 
$
88,837   
$
81,094 
Research and development tax credits
 
 
9,827   
 
9,552 
Stock-based compensation
 
 
4,515   
 
5,078 
Accruals and other
 
 
335   
 
320 
Intangibles
 
 
1,239   
 
1,343 
Section 174 capitalization research expenses
 
 
10,347   
 
10,117 
Operating lease liabilities
 
 
5,501   
 
6,280 
Total deferred tax assets
 
 
120,601   
 
113,784 
Deferred tax liabilities:
 
    
   
Operating lease right-of-use asset
 
 
(2,080)  
 
(3,041)
Fixed assets
 
 
(671)  
 
(1,033)
Total deferred tax liabilities
 
 
(2,751)  
 
(4,074)
Valuation allowance
 
 
(117,850)  
 
(109,710)
Net deferred tax assets
 
$
—   
$
— 
 
The tax benefit of net operating losses, temporary differences and credit carryforwards should be recorded as an asset to the extent that management 
assesses that their realization is "more likely than not." Realization of the future tax benefits is dependent on the Company's ability to generate sufficient 
taxable income within the carryforward period. Because of the Company's recent history of operating losses, management believes that recognition of the 
deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation 
allowance. 
Realization of the net deferred tax assets is dependent upon future taxable income, if any, the amount and timing of which is uncertain. Based on the weight 
of available positive and negative objective evidence, management believes it more likely than not that the Company’s deferred tax assets are not 
realizable. Accordingly, the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by $8.1 million and 
$9.4 million during the years ended December 31, 2024 and 2023, respectively.

 
130
Net operating losses and tax credit carryforwards as of December 31, 2024 are as follows:
 
 
 
Amount
(in thousands)
   
Expiration Years
Net operating losses, federal (post December 31, 2017)
  $
328,268   
Do Not Expire
Net operating losses, federal (pre January 1, 2018)
   
64,136   
2029 - 2037
Net operating losses, state
   
229,491   
2029 - 2044
Research and development tax credits, federal
   
9,002   
2034 - 2044
Research and development tax credits, California
   
7,199   
Indefinite
 
 
Federal and state laws impose restrictions on the utilization of net operating loss carryforwards and R&D credit carryforwards in the event of a change in 
ownership of the Company, which constitutes an 'ownership change' as defined by Internal Revenue Code Section 382 and 383. The Company experienced 
an ownership change in the past that impacts the availability of its net operating losses and tax credits. The amounts indicated in the above tables reflect the 
reduction of net operating losses and credit carryforwards as a result of previous ownership changes that the Company experienced. In August 2022, the 
Company's Follow-On Offering may have resulted in an ownership change, which could substantially restrict the ability to utilize existing net operating 
losses, credits and other attribute carryforwards as well. Based on the readily available information, the Company has determined that it is more likely than 
not that there was no significant ownership change, according to Section 382 and 383.
 
The Inflation Reduction Act 2022 which incorporates a Corporate Alternative Minimum Tax (CAMT) was signed on August 16, 2022. The changes will be 
effective for the tax years beginning after December 31, 2022. The new tax will require companies to compute two separate calculations for federal income 
tax purposes and pay the greater of the new minimum tax or their regular tax liability. The IRA also imposes a nondeductible 1% excise tax on a publicly 
traded corporation for the net value of certain stock that the corporation repurchases during the tax year. As the Company is in a net loss position during 
2024, the CAMT does not have an impact on the Company. Additionally, during 2024, the Company did not have any stock repurchase activities. 
Therefore, there is no Corporate Excise Tax.
The Company determines its uncertain tax positions based on a determination of whether and how much of a tax benefit taken by the Company in its tax 
filings is more likely than not to be sustained upon examination by the relevant income tax authorities.
The following table summarizes the activity related to the Company’s unrecognized tax benefits: 
 
 
 
Year ended December 31,
 
 
 
2024
   
2023
   
2022
 
 
 
(in thousands)
 
Gross unrecognized tax benefits at January 1
  $
17,457    $
17,605    $
13,221 
Additions for tax positions taken in the current year
   
33     
84     
4,395 
Reductions for tax positions taken in the prior year
   
—     
(232)    
(11)
Gross unrecognized tax benefits at December 31
  $
17,490    $
17,457    $
17,605 
 
If recognized, none of the unrecognized tax benefits as of December 31, 2024 and 2023 would reduce the annual effective tax rate, primarily due to 
corresponding adjustments to the valuation allowance. The Company will recognize both accrued interest and penalties related to unrecognized benefits in 
income tax expense. As of December 31, 2024 and 2023, no liability has been recorded for potential interest or penalties. The Company does not expect the 
unrecognized tax benefits to change significantly over the next 12 months. 
The Company files income tax returns in the U.S. federal jurisdiction and Arizona, California, Colorado, Delaware, Florida, Illinois, Massachusetts, Rhode 
Island and Washington. The Company is not currently under audit by the Internal Revenue Service or other similar state or local authorities. All tax years 
remain open to examination by major taxing jurisdictions to which the Company is subject.
18. Segment Reporting 
The Company has one reportable segment relating to the research and development of therapeutics to slow, halt, or reverse diseases of aging. The measure 
of segment assets is reported on the balance sheet as total assets.

 
131
The Company’s Chief Operating Decision Maker (the “CODM”), its Chief Executive Officer reviews the Company’s financial information on an 
aggregated basis for the purposes of evaluating financial performance and allocating resources. The Company's method for measuring profitability on a 
reportable segment basis is net profit or loss. When evaluating the Company’s financial performance, the CODM reviews total expenses and expenses by 
department and the CODM makes decisions using this information.
 
 
 
Year ended December 31,
 
 
 
2024
 
 
2023
 
 
2022
 
 
 
(in thousands)
 
Licensing Revenue - Related Party
 
$
— 
 $
— 
 $
236 
Operating Segments
 
   
 
   
 
   
Personnel
 
 
7,051   
 
9,584   
 
16,787 
Program
 
 
7,465   
 
10,023   
 
16,950 
Department 
 
 
13,105   
 
18,387   
 
22,183 
Other
 
 
3,550   
 
6,673   
 
1,888 
Total operating expenses
 
 
31,171   
 
44,667   
 
57,808 
Loss from operations
 
 
(31,171)  
 
(44,667)  
 
(57,572)
Interest income
 
 
1,733   
 
2,874   
 
1,220 
Interest expense
 
 
—   
 
(2,452)  
 
(3,558)
Gain on warrant liability
 
 
3,713   
 
6,215   
 
16,843 
Other expense, net
 
 
(265)  
 
(1,830)  
 
(1,402)
Net Loss
 
$
(25,990)  
$
(39,860)  
$
(44,469)
 
(1) Department segment expenses include corporate expenses, facilities, IT, and stock-based compensation.
(2) Other segment expenses includes depreciation & amortization and impairment of long-lived assets in 2024 and 2023.
(1)
 (2)

 
132
Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.
None.
Item 9A. Controls and Procedures. 
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our chief executive and financial officers, evaluated the effectiveness of our disclosures controls and procedures, 
as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, as of December 31, 2024. The term “disclosure controls and procedures,” as defined 
in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information 
required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within 
the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed 
to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and 
communicated to management, including its principal executive and principal financial officers, as appropriate, to allow timely decisions regarding 
required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable 
assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and 
procedures. 
Based on this evaluation, and as a result of the material weakness described below, our chief executive officer and chief financial officer concluded that, as 
of December 31, 2024, our disclosure controls and procedures were not effective at a reasonable assurance level.
Management’s Annual Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule 13a-
15(f) under the Securities Exchange Act of 1934. Our internal control over financial reporting is designed to provide reasonable assurance regarding the 
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting 
principles in the United States and includes those policies and procedures that:
•
Pertain to the maintenance of records that accurately and fairly reflect in reasonable detail the transactions and dispositions of the assets of our 
company;
•
Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with 
generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our 
management and directors; and
•
Provide reasonable assurances regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could 
have a material adverse effect on our financial statements.
Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2024. In making this assessment, 
management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission, or COSO, in Internal Control-
Integrated Framework (2013 framework). Based on this assessment, management concluded that the Company's internal control over financial reporting 
was not effective as of December 31, 2024 due to the material weakness discussed below.
Material Weakness
A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility 
that a material misstatement of a company’s annual and interim financial statements will not be detected or prevented on a timely basis.
As disclosed in the Company's Financial Statements as of December 31, 2023 and as described in Note 2 of these Financial Statements, the Company 
previously concluded that the Existing Warrants in 2022 were incorrectly classified as equity and should have been recorded as liabilities. 
Management had identified a material weakness in the design and operating effectiveness of the Company's review procedures related to complex security
transactions. The reviewer had insufficient technical resources supporting the 

 
133
assessment of the complex securities accounting model and review procedures were not performed at a level of precision to prevent or detect a material 
misstatement on a timely basis in the normal course of the review. Management continues to believe that our internal control over financial reporting was 
not effective as of December 31, 2024.
Remediation Measures
We have identified and begun to implement steps, as further described below, designed to remediate the foregoing material weakness. The elements of our 
remediation plan can only be accomplished over time, and we can offer no assurance that these initiatives will ultimately have the intended effects.
To remediate this material weakness, we are in the process of expanding and improving our review process for complex security transactions and related 
accounting standards. We plan to improve this process by specifically incorporating the review of the accounting conclusions for each significant relevant 
contractual term, by using a robust accounting literature tool, and engaging third-party subject matter experts with relevant experience to determine the 
appropriate accounting for complex security transactions.
While the foregoing measures are intended to effectively remediate the material weakness described in this Item 9A, it is possible that additional 
remediation steps will be necessary. As such, as we continue to evaluate and implement our plan to remediate the material weakness, our management may 
decide to take additional measures to address the material weakness or modify the remediation steps described above. Until this material weakness is 
remediated, we plan to continue to perform additional analyses and other procedures to help ensure that our financial statements are prepared in accordance 
with GAAP.
Changes in Internal Control over Financial Reporting 
Except for the material weakness noted above, there has been no change in the Company's internal control over financial reporting as defined in Rules 13a-
15(f) and 15d-15(f) that occurred during the quarter ended December 31, 2024 that have materially affected, or are reasonably likely to materially affect, 
our internal control over financial reporting.
Attestation Report of the Registered Public Accounting Firm
This Annual Report on Form 10-K does not include an attestation report of our registered public accounting firm because we are deemed a “non-
accelerated filer” and “smaller reporting company” within the definition of Rule 12b-2 of the Exchange Act, as our public float was below the specified 
thresholds as of June 30, 2024. Accordingly, this Annual Report on Form 10-K does not include an attestation report of our independent registered 
accounting firm.
Item 9B. Other Information. 
None.
Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. 
Not Applicable.

 
134
PART III 
Item 10. Directors, Executive Officers and Corporate Governance. 
Information required by this Item is incorporated herein by reference to the sections titled “Executive Officers,” “Election of Directors,” “Corporate 
Governance” and “Section 16(a) Beneficial Ownership and Reporting Compliance” in our Definitive Proxy Statement with respect to our 2025 Annual 
Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.
We have adopted insider trading policies and procedures governing the purchase, sale, and other dispositions of our securities by directors, officers, and 
employees that are designed to promote compliance with insider trading laws, rules, and regulations, and applicable Nasdaq listing standards, as well as 
procedures designed to further the foregoing purposes. A copy of our insider trading policy is filed with this Annual Report on Form 10-K as Exhibit 19.1.
 
Item 11. Executive Compensation. 
Information required by this Item is incorporated herein by reference to the section titled “Executive Compensation,” “Director Compensation” and 
“Corporate Governance”  in our Definitive Proxy Statement with respect to our 2025 Annual Meeting of Stockholders to be filed with the SEC within 120 
days after the end of the fiscal year covered by this Annual Report on Form 10-K.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. 
Information required by this Item is incorporated herein by reference to the section titled “Security Ownership of Certain Beneficial Owners and 
Management” and “Equity Compensation Plan Information” in our Definitive Proxy Statement with respect to our 2025 Annual Meeting of Stockholders to 
be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.
Item 13. Certain Relationships and Related Transactions, and Director Independence. 
Information required by this Item is incorporated herein by reference to the section titled “Certain Relationships and Related Party Transactions” and 
“Corporate Governance” in our Definitive Proxy Statement with respect to our 2025 Annual Meeting of Stockholders to be filed with the SEC within 120 
days after the end of the fiscal year covered by this Annual Report on Form 10-K.
Item 14. Principal Accounting Fees and Services. 
Information required by this Item is incorporated herein by reference to the section titled “Ratification of Selection of Independent Registered Public 
Accounting Firm” in our Definitive Proxy Statement with respect to our 2025 Annual Meeting of Stockholders to be filed with the SEC within 120 days 
after the end of the fiscal year covered by this Annual Report on Form 10-K.

 
135
PART IV 
Item 15. Exhibits, Financial Statement Schedules. 
(a)	 The following documents are filed as part of this report:
1. Financial Statements
See Index to Financial Statements in Part II Item 8 of this Annual Report on Form 10-K.
2. Financial Statement Schedules
All schedules are omitted because they are not applicable or the required information is shown in the financial statements or notes 
thereto.
3. Exhibits

 
136
Exhibit Index
 
 
 
 
 
Incorporated by Reference
Exhibit
Number
 
Description
 
Form
 
Number
 
Filing Date
 
Filed 
Herewith
 
   
 
 
 
 
 
 
 
 
3.1
  Amended and Restated Certificate of Incorporation of Unity Biotechnology, 
Inc.
 
8-K
 
3.1
 
5-7-18
 
 
3.2
  Certificate of Amendment to Amended and Restated Certificate of 
Incorporation of Unity Biotechnology, Inc.
 
8-K
 
3.1
 
10-19-22
 
 
3.3
  Amended and Restated Bylaws of Unity Biotechnology, Inc.
 
10-K
 
3.3
 
4-15-24
 
 
4.1
  Reference is made to exhibits 3.1 through 3.2.
 
 
 
 
 
 
 
 
4.2
  Form of Common Stock Certificate.
 
10-Q
 
4.2
 
11-8-22
 
 
4.3
  Form of Warrant.
 
8-K
 
4.1
 
8-22-22
 
 
4.4
  Form of New Warrant
 
8-K
 
4.1
 
11-13-23
 
 
4.5
  Description of Unity’s Securities Registered Pursuant to Section 12 of the 
Securities Exchange Act of 1934. 
 
10-K
 
4.5
 
3-15-23
 
 
10.1(a)
  Lease Agreement, dated as of May  13, 2016, by and between Unity 
Biotechnology, Inc. and BMR-Bayshore Boulevard L.P.
 
S-1
 
10.1(a)
 
4-5-18
 
 
10.1(b)
  First Amendment to Lease Agreement, dated as of May 23, 2017, by and 
between Unity Biotechnology, Inc. and BMR-Bayshore Boulevard L.P.
 
S-1
 
10.1(b)
 
4-5-18
 
 
10.2(a)
  Space License Agreement, dated as of October 20, 2016, by and between Unity 
Biotechnology, Inc. and BMR-Bayshore Boulevard L.P.
 
S-1
 
10.2(a)
 
4-5-18
 
 
10.2(b)
  First Amendment to Space License Agreement, dated as of December 5, 2016, 
by and between Unity Biotechnology, Inc. and BMR-Bayshore Boulevard L.P.
 
S-1
 
10.2(b)
 
4-5-18
 
 
10.2(c)
  Second Amendment to Space License Agreement, dated as of January 30, 2017, 
by and between Unity Biotechnology, Inc. and BMR-Bayshore Boulevard L.P.
 
S-1
 
10.2(c)
 
4-5-18
 
 
10.3(a)#
  2013 Equity Incentive Plan.
 
S-1
 
10.3(a)
 
4-5-18
 
 
10.3(b)#
  Form of Stock Option Agreement under 2013 Equity Incentive Plan.
 
S-1
 
10.3(b)
 
4-5-18
 
 
10.4(a)#
  2018 Incentive Award Plan.
 
S-1
 
10.4(a)
 
4-23-18
 
 
10.4(b)#
  Form of Stock Option Grant Notice and Stock Option Agreement under the 
2018 Incentive Award Plan.
 
S-1
 
10.4(b)
 
4-5-18
 
 
10.4(c)#
  Form of Restricted Stock Award Grant Notice and Restricted Stock Unit Award 
Agreement under the 2018 Incentive Award Plan.
 
S-1
 
10.4(c)
 
4-5-18
 
 
10.4(d)#
  Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Award 
Agreement under the 2018 Incentive Award Plan.
 
S-1
 
10.4(d)
 
4-5-18
 
 
10.5#
  2018 Employee Stock Purchase Plan.
 
S-1
 
10.5
 
4-23-18
 
 
10.6#
  Form of Indemnification Agreement for directors and officers.
 
S-1
 
10.7
 
4-5-18
 
 
10.7+
  Compound Library and Option Agreement, dated as of February 2, 2016, by and 
between Ascentage Pharma Group Corp. Ltd. and Unity Biotechnology, Inc.
 
10-K
 
10.14
 
3-23-21
 
 
10.8+
  APG1252 License Agreement, dated as of February 2, 2016, by and between 
Ascentage Pharma Group Corp. Ltd. and Unity Biotechnology, Inc.
 
10-K
 
10.15
 
3-23-21
 
 
10.9†
  Research Services Agreement, dated as of February 2, 2016, by and between 
Ascentage Pharma Group Corp. Ltd. and Unity Biotechnology, Inc.
 
S-1
 
10.16
 
4-5-18
 
 

 
137
10.10+
  Amendment to APG1252 License Agreement, dated as of March 28, 2018, by 
and between Ascentage Pharma Group Corp. Ltd. 
 
10-K
 
10.17
 
3-23-21
 
 
10.11+
  Amendment to Compound Library and Option Agreement, dated as of March 
28, 2018, by and between Ascentage Pharma Group Corp. Ltd. and Unity 
Biotechnology, Inc.
 
10-K
 
10.18
 
3-23-21
 
 
10.12(a)+
  Exclusive License Agreement, dated as of June 28, 2013, by and between the 
Mayo Foundation for Medical Education and Research and Unity 
Biotechnology, Inc.
 
10-K
 
10.19(a)
 
3-23-21
 
 
10.12(b)+
  Amendment No. 1 to Exclusive License Agreement, dated as of September 10, 
2014, by and between the Mayo Foundation for Medical Education and 
Research and Unity Biotechnology, Inc.
 
10-K
 
10.19(b)
 
3-23-21
 
 
10.12(c)†
  Amendment No. 2 to Exclusive License Agreement, dated as of November 17, 
2014, by and between the Mayo Foundation for Medical Education and 
Research and Unity Biotechnology, Inc.
 
S-1
 
10.19(c)
 
4-23-18
 
 
10.12(d)+
  Amendment No. 3 to Exclusive License Agreement, dated as of May 5, 2015, 
by and between the Mayo Foundation for Medical Education and Research and 
Unity Biotechnology, Inc.
 
10-K
 
10.19(d)
 
3-23-21
 
 
10.12(e)+
  Amendment No. 4 to Exclusive License Agreement, dated as of September 15, 
2016, by and between the Mayo Foundation for Medical Education and 
Research and Unity Biotechnology, Inc.
 
10-K
 
10.19(e)
 
3-23-21
 
 
10.12(f)+
  Addendum to Amendment No. 4 to Exclusive License Agreement, dated as of 
September 15, 2016, by and between the Mayo Foundation for Medical 
Education and Research and Unity Biotechnology, Inc.
 
10-K
 
10.19(f)
 
3-23-21
 
 
10.12(g)+
  Amendment No. 5 to Exclusive License Agreement, dated as of October 12, 
2016, by and between the Mayo Foundation for Medical Education and 
Research and Unity Biotechnology, Inc.
 
10-K
 
10.19(g)
 
3-23-21
 
 
10.13+
  Amended and Restated License Agreement, dated as of January 27, 2017, by 
and between the Buck Institute for Research on Aging and Unity 
Biotechnology, Inc.
 
10-K
 
10.20
 
3-23-21
 
 
10.14††
  License Agreement for APG1197, dated as of January 2, 2019, by and between 
Ascentage Pharma Group Corp. Ltd. and Unity Biotechnology, Inc.
 
10-K
 
10.22
 
3-6-19
 
 
10.15
  Lease Agreement, dated as of February 28, 2019, by and between Unity 
Biotechnology, Inc. and Bayside Area Development, LLC
 
10-K
 
10.23
 
3-6-19
 
 
10.16††††
  First Amendment to Compound License Agreement for APG1197, dated as of 
November 19, 2019, by and between Ascentage Pharma Group Corp. Ltd. and 
Unity Biotechnology, Inc.
 
8-K
 
10.1
 
11-25-19
 
 
10.17†††
  Second Amendment to APG1252 License Agreement, dated as of November 
19, 2019, by and between Ascentage Pharma Group Corp. Ltd. and Unity 
Biotechnology, Inc.
 
10-K
 
10.25
 
3-11-20
 
 
10.18††††
  Second Amendment to Compound Library and Option Agreement, dated as of 
January 8, 2020, by and between Ascentage Pharma Group Corp. Ltd. and 
Unity Biotechnology, Inc.
 
10-K
 
10.26
 
3-11-20
 
 
10.19#
  Amendment to Employment Agreement, dated March 9, 2020, by and between 
Unity Biotechnology, Inc. and Nathaniel E. David.
 
10-K
 
10.27
 
3-11-20
 
 
10.20#
  Employment Agreement, dated March 30, 2020, by and between Unity 
Biotechnology, Inc. and Anirvan Ghosh.
 
8-K
 
10.1
 
3-30-20
 
 

 
138
10.21†††
  Third Amendment to Compound License Agreement for APG-1197, dated June 
29, 2020, by and between Ascentage Pharma Group Corp. Ltd. and Unity 
Biotechnology, Inc. 
 
8-K
 
10.1
 
7-1-20
 
 
10.22#
  Employment Agreement, dated August 1, 2020, by and between Unity 
Biotechnology, Inc. and Lynne Sullivan.
 
10-Q
 
10.2
 
11-4-20
 
 
10.23#
  Amendment to Employment Agreement, dated September 1, 2020, by and 
between Unity Biotechnology, Inc. and Lynne Sullivan.
 
10-Q
 
10.3
 
11-4-20
 
 
10.24
  Purchase Agreement, dated September 29, 2021, by and between the Unity 
Biotechnology, Inc. and Lincoln Park Capital Fund, LLC.
 
8-K
 
10.1
 
9-29-21
 
 
10.25
  Registration Rights Agreement, dated September 29, 2021, by and between 
Unity Biotechnology and Lincoln Park Capital Fund, LLC.
 
8-K
 
10.2
 
9-29-21
 
 
10.26
  Sales Agreement, dated March 15, 2022, by and between Unity Biotechnology, 
Inc. and Cowen and Company , LLC.
 
S-3
 
1.2
 
3-15-22
 
 
10.27
  Amendment No. 1 to Sales Agreement, dated August 17, 2022, by and between 
Unity Biotechnology, Inc. and Cowen and Company, LLC.
 
8-K
 
1.1
 
8-19-22
 
 
10.28
  Sales Agreement, dated October 14, 2022, by and between Unity 
Biotechnology, Inc. and Cowen and Company, LLC.
 
S-3
 
1.2
 
10-14-22
 
 
10.29#
  Second Amended and Restated Non-Employee Director Compensation Program 
(effective March 17, 2023).
 
10-Q
 
10.3
 
5-9-23
 
 
10.30
  Amendment No. 2 to Sales Agreement, dated March 17, 2023, by and between 
Unity Biotechnology, Inc. and Cowen and Company LLC.
 
8-K
 
1.1
 
3-17-23
 
 
10.31
  Inducement Offer to Exercise Common Stock Purchase Warrants Issued in 
November 9, 2023
 
8-K
 
10.1
 
11-13-23
 
 
10.32#
  Third Amended and Restated Non-Employee Director Compensation Program.  
10-K
 
10.41
 
4-15-24
 
 
 
10.33#
  Employment Agreement, dated January 1, 2025, by and between Federico 
Grossi and Unity Biotechnology, Inc.
 
 
 
 
 
   
X
19.1
  Insider Trading Policy
 
 
 
 
 
   
X
23.1
  Consent of Independent Registered Public Accounting Firm
 
 
 
 
 
   
X
24.1
  Power of Attorney. Reference is made to the signature page.
 
 
 
 
 
   
X
  31.1
 Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 
15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to 
Section 302 of the Sarbanes-Oxley Act of 2002.
   
   
   
 
X
  31.2
 Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 
15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to 
Section 302 of the Sarbanes-Oxley Act of 2002.
   
   
   
 
X
  32.1**
 Certification of Principal Executive Officer and Principal Financial Officer 
Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the 
Sarbanes-Oxley Act of 2002.
   
   
   
 
X
  97.1
  Policy for Recovery of Erroneously Awarded Compensation
 
10-K
 
97.1
 
4-15-24
 
 
101.INS
 Inline XBRL Instance Document 
   
   
   
 
X
101.SCH
  Inline XBRL Taxonomy Extension Schema Document With Embedded 
Linkbase Document
   
   
   
 
X
104
  The cover page from the Company’s Annual Report on Form 10-K for the year 
ended December 31, 2024 has been formatted in Inline XBRL.
   
   
   
 
X
 

 
139
† Confidential treatment has been granted for certain information contained in this exhibit. Such information has been omitted and filed separately with the 
Securities and Exchange Commission.
†† Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment filed separately with the Securities and 
Exchange Commission.
††† Portions of this exhibit (indicated by asterisks) have been omitted pursuant to Regulation S-K, Item 601(b)(10). Such omitted information is not 
material and would likely cause competitive harm to the registrant if publicly disclosed.
†††† Portions of this exhibit (indicated by asterisks) have been omitted pursuant to Regulation S-K, Item 601(b)(10). Such omitted information is not 
material and would likely cause competitive harm to the registrant if publicly disclosed. Additionally, schedules and attachments to this exhibit have been 
omitted pursuant to Regulation S-K, Item 601(a)(5).
+ Certain confidential portions of this exhibit have been omitted from this exhibit in accordance with Regulation S-K 601(b)(10). Exhibit being refiled 
upon expiration of confidential treatment previously granted by the SEC.
# Indicates management contract or compensatory plan.
 
** The certification attached as Exhibit 32.1 that accompanies this Annual Report on Form 10-K is not deemed filed with the Securities and Exchange 
Commission and is not to be incorporated by reference into any filing of Unity Biotechnology, Inc. under the Securities Act of 1933, as amended, or the 
Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general 
incorporation language contained in such filing.
Item 16. Form 10-K Summary. 
None.

 
140
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this 
Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
 
 
Unity Biotechnology, Inc.
 
 
 
Date: March 7, 2025
By:
/s/ Anirvan Ghosh
 
 
Anirvan Ghosh, Ph.D.
 
 
Chief Executive Officer
 
POWER OF ATTORNEY
 
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Anirvan 
Ghosh, Alexander Nguyen, and Lynne Sullivan his or her true and lawful attorney-in-fact and agent, with full power of substitution, for him or her and in 
his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with 
all exhibits thereto, and other documents in connection therewith, with the U.S. Securities and Exchange Commission, granting unto said attorneys-in-fact 
and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection 
therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming that all said attorneys-in-fact and 
agents, or their, his or her substitutes or substitutes, may lawfully do or cause to be done by virtue hereof.
 
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed by the following
persons on behalf of the Registrant in the capacities and on the dates indicated.
 
Name
 
Title
 
Date
 
 
 
 
 
/s/ Anirvan Ghosh
 Chief Executive Officer and Director
(Principal Executive Officer) 
 
March 7, 2025
Anirvan Ghosh, Ph.D.
 
 
 
 
  
 
 
/s/ Lynne Sullivan
  Chief Financial Officer
(Principal Financial and Accounting Officer)
 
March 7, 2025
Lynne Sullivan
 
 
 
 
   
 
 
/s/ Keith R. Leonard Jr.
  Chairman
 
March 7, 2025
Keith R. Leonard Jr.
  
 
 
 
  
 
 
/s/ Paul L. Berns
  Director
 
March 7, 2025
Paul L. Berns
  
 
 
 
  
 
 
/s/ Nathaniel E. David
  Director
 
March 7, 2025
Nathaniel E. David, Ph. D.
  
 
 
 
  
 
 
/s/ Gilmore O’Neill
  Director
 
March 7, 2025
Gilmore O’Neill, M.B.
  
 
 
 
  
 
 
/s/ Margo Roberts
  Director
 
March 7, 2025
Margo Roberts, Ph.D.
  
 
 
 
  
 
 
/s/ Michael P. Samar
  Director
 
March 7, 2025
Michael P. Samar
   
 
 
 
   
 
 
/s/ Camille D. Samuels
  Director
 
March 7, 2025
Camille D. Samuels
  
 
 
 

 
1
 
 
Exhibit 10.33
UNITY BIOTECHNOLOGY, INC.
EMPLOYMENT AGREEMENT
This Employment Agreement (the “Agreement”), entered into as of January 1, 2025 (the “Effective Date”), is made by and between 
Unity Biotechnology, Inc., a Delaware corporation (the “Company”) and Federico Grossi (“Executive” and, together with the Company, the 
“Parties”). This Agreement supersedes in its entirety that certain offer letter by and between Executive and the Company dated as of 
December 13, 2025 (“Offer Letter”).
WHEREAS, the Company desires to assure itself of the continued services of Executive by engaging Executive to perform services 
as an employee of the Company under the terms hereof; 
WHEREAS, Executive desires to provide continued services to the Company on the terms herein provided; and
WHEREAS, the Parties desire to execute this Agreement to supersede the Offer Letter in its entirety and reflect certain changes to 
Executive’s employment with the Company effective as of the Effective Date. 
NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, including the respective 
covenants and agreements set forth below, the receipt and sufficiency of which are hereby acknowledged, the Parties hereto agree as follows:
1. Employment.
(a)
General.  The Company shall continue employ Executive upon the terms and conditions provided herein effective 
as of the Effective Date.  
(b)
Position and Duties.  Effective on the Effective Date, Executive: (i) shall serve as the Company’s Chief Medical 
Officer, with responsibilities, duties, and authority usual and customary for such position, subject to direction by the Company’s Chief 
Executive Officer (the “CEO”); (ii) shall continue to report directly to the CEO; and (iii) agrees promptly and faithfully to comply with all 
present and future policies, requirements, rules and regulations, and reasonable directions and requests, of the Company in connection with 
the Company’s business.  At the Company’s request, Executive shall serve the Company and/or its subsidiaries and affiliates in such other 
capacities in addition to the foregoing as the Company shall designate, provided that such additional capacities are consistent with 
Executive’s position as the Company’s Chief Medical Officer.  In the event that Executive serves in any one or more of such additional 
capacities, Executive’s compensation shall not automatically be increased on account of such additional service.  
(c)
Performance of Executive’s Duties.  During Executive’s employment with the Company, and except for periods of 
illness, vacation, disability, or reasonable leaves of absence or as discussed in Section 1(e) below, Executive shall devote Executive’s full 
time and attention to the business and affairs of the Company pursuant to the general direction of the CEO.  The rights of Executive under 

 
2
 
 
this Agreement shall not be affected by any change in the title, duties, or capacity of Executive during Executive’s employment with the 
Company.
(d)
Principal Office.  Executive will work principally from home with travel as agreed with the Company’s CEO to the 
Company’s facility located in South San Francisco, California.  
(e)
Exclusivity.  Except with the prior written approval of the CEO (which the CEO may grant or withhold in the 
CEO’s sole and absolute discretion), Executive shall devote substantially all of Executive’s working time, attention, and energies to the 
business of the Company, except during any paid vacation or other excused absence periods.  Nothing in this section prevents Executive from 
engaging in additional activities in connection with personal investments and community affairs. Executive may also serve as a member of
the board of directors or board of advisors of another organization provided (i) such organization is not a competitor of the Company; (ii) 
Executive receives prior written approval from the CEO; and (iii) such activities do not individually or in the aggregate interfere with the 
performance of Executive’s duties under this Agreement, violate the Company’s standards of conduct then in effect, or raise a conflict under 
the Company’s conflict of interest policies.  
2. Term.  The period of Executive’s employment under this Agreement shall commence on the Effective Date and shall continue 
until Executive’s employment with the Company is terminated pursuant to Section 5 below.  The phrase “Term of Employment” as used in 
this Agreement shall refer to the entire period of employment of Executive by the Company.
3.
Compensation and Related Matters.
(a)
Annual Base Salary.  During the Term of Employment, Executive shall receive a base salary at the rate of $500,000 
per annum (as may be increased from time to time, the “Annual Base Salary”), subject to withholdings and deductions, which shall be paid to 
Executive in accordance with the customary payroll practices and procedures of the Company.  Such Annual Base Salary shall be reviewed 
by the CEO and, as applicable, the Board of Directors of the Company (the “Board”) and/or the Compensation Committee of the Board, not 
less than annually.
(b)
Annual Bonus.  Executive shall be eligible to receive a discretionary annual bonus based on Executive’s 
achievement of performance objectives as mutually agreed between Executive and the CEO and as approved by the Board and/or the 
Compensation Committee of the Board, such bonus to be targeted at 40% of Executive’s Annual Base Salary (the “Annual Bonus”).  Any 
Annual Bonus approved by the Board and/or the Compensation Committee of the Board shall be paid at the same time annual bonuses are 
paid to other executives of the Company generally, subject to Executive’s continuous employment through the date of approval.
(c)
Benefits.  Executive shall be entitled to participate in such employee and executive benefit plans and programs as 
the Company may from time to time offer to provide to its executives, subject to the terms and conditions of such plans.  Notwithstanding the 
foregoing, nothing herein is intended, or shall be construed, to require the Company to institute or continue any, or any particular, plan or 
benefit.
(d)
Business Expenses.  The Company shall reimburse Executive for all reasonable, documented, out-of-pocket travel 
and other business expenses incurred by Executive in the performance of Executive’s duties to the Company in accordance with the 
Company’s applicable expense reimbursement policies and procedures as are in effect from time to time.  

 
3
 
 
(e)
Vacation.  Executive will be entitled to paid vacation in accordance with the Company’s vacation policy.
4. Equity Awards.
(a)
Existing Stock Option Grant.  It will be recommended to the Board of Directors that the Executive be granted an 
option (the “Option”) to purchase 150,000 shares of Company common stock pursuant to the Company’s 2020 Employment Inducement 
Incentive Award Plan, as amended (the “Plan”).  The Option shall vest and become exercisable as to 1/48th of the total number of shares of 
Company common stock underlying the Option on the one-month anniversary of January 1, 2025, and thereafter as to 1/48th of the total 
number of shares of Company common stock underlying the Option on each monthly anniversary thereof, in each case, subject to 
Executive’s continued employment through the applicable vesting date.  The Option is otherwise subject to the terms and conditions of the 
Plan and an agreement entered into between the Parties to evidence the Option (the “Option Agreement”).  In the event of any conflict 
between the terms of the Plan or the Option Agreement and the terms of this Agreement, the terms of this Agreement shall control.  
(b)
Future Equity Awards.  Executive shall be eligible for such additional stock options and equity awards as may be 
determined by the Board and/or the Compensation Committee of the Board, in their discretion.
5. Termination.        
(a)
At-Will Employment.  The Company and Executive acknowledge that Executive’s employment is and shall 
continue to be at-will, as defined under applicable law.  This means that it is not for any specified period of time and can be terminated by 
Executive or by the Company at any time, with or without advance notice, and for any or no particular reason or cause.  It also means that 
Executive’s job duties, title, and responsibility and reporting level, work schedule, compensation, and benefits, as well as the Company’s 
personnel policies and procedures, may be changed with prospective effect, with or without notice, at any time in the sole discretion of the 
Company (subject to any ramification such changes may have under Section 6 of this Agreement).  This “at-will” nature of Executive’s 
employment shall remain unchanged during Executive’s tenure as an employee and may not be changed, except in an express writing signed 
by Executive and a duly authorized officer of the Company.  If Executive’s employment terminates for any lawful reason, Executive shall not 
be entitled to any payments, benefits, damages, award, or compensation other than as provided in this Agreement.  
(b)
Notice of Termination.  During the Term of Employment, any termination of Executive’s employment by the 
Company or by Executive (other than by reason of death) shall be communicated by written notice (a “Notice of Termination”) from one 
Party hereto to the other Party hereto (i) indicating the specific termination provision in this Agreement relied upon, if any, (ii) setting forth 
in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive’s employment under the provision so
indicated, and (iii) specifying the Date of Termination (as defined below).  The failure by the Company to set forth in the Notice of 
Termination all of the facts and circumstances which contribute to a showing of Cause (as defined below) shall not waive any right of the 
Company hereunder or preclude the Company from asserting such fact or circumstance in enforcing their rights hereunder.

 
4
 
 
(c)
Termination Date.  For purposes of this Agreement, “Date of Termination” shall mean the date of the termination 
of Executive’s employment with the Company specified in a Notice of Termination.
(d)
Deemed Resignation.  Upon termination of Executive’s employment for any reason, Executive shall be deemed to 
have resigned from all offices and board memberships, if any, then held with the Company or any of its affiliates, and, at the Company’s 
request, Executive shall execute such documents as are necessary or desirable to effectuate such resignations.
6. Consequences of Termination.
(a)
Payments of Accrued Obligations upon all Terminations of Employment.  Upon a termination of Executive’s 
employment for any reason, Executive (or Executive’s estate or legal representative, as applicable) shall be entitled to receive, within thirty 
(30) days after Executive’s Date of Termination (or such earlier date as may be required by applicable law): (i) any portion of Executive’s 
Annual Base Salary earned through Executive’s Date of Termination not theretofore paid, (ii) any expenses owed to Executive under Section 
3(d) above, (iii) any accrued but unused paid time-off owed to Executive, (iv) any Annual Bonus approved by the Board or the Compensation 
Committee of the Board on or prior to the Date of Termination but unpaid as of the Date of Termination, and (v) any amount arising from 
Executive’s participation in, or benefits under, any employee benefit plans, programs, or arrangements under Section 3(c) above, which 
amounts shall be payable in accordance with the terms and conditions of such employee benefit plans, programs, or arrangements.  Except as 
otherwise set forth in Section 6(b) below, the payments and benefits described in this Section 6(a) shall be the only payments and benefits 
payable in the event of Executive’s termination of employment for any reason.  
(b)
Severance Payments upon Termination Without Cause or For Good Reason.
(i) Termination Other than During a Change in Control Period.  If, during the Term of Employment but outside 
the period beginning three months prior to and ending 18 months following a Change in Control (such period, a “Change 
in Control Period”), Executive’s employment is terminated by the Company without Cause or Executive resigns for Good 
Reason, then, in addition to the payments and benefits described in Section 6(a) above and subject to Executive’s delivery 
to the Company of a waiver and release of claims agreement in a form approved by the Company that becomes effective 
and irrevocable in accordance with Section 11(d) hereof (a “Release”):
(A)
During the three-month period commencing on the Date of Termination (the “Severance 
Period”), the Company shall continue to pay Executive the Executive’s Annual Base Salary, such payment to be 
made in accordance with the Company’s regular payroll procedures, with the first such installment to occur on 
the first payroll date following the date the Release becomes effective and irrevocable or as otherwise provided 
in Section 11(d) hereof and inclusive of any installments that would have been made had the Release been 
immediately effective and irrevocable.
(B)
Following positive 36-week data in the ASPIRE Study, and subject to financing by the 
Company’s to fund a pivotal trial in UBX1325, and subject to Board approval, this Section 6(b)(i)(B) shall 
supersede Section 6(b)(i)(A) such that during the nine-month period commencing on the Date of 

 
5
 
 
Termination (the “Severance Period”), the Company shall continue to pay Executive the Executive’s Annual 
Base Salary, such payment to be made in accordance with the Company’s regular payroll procedures, with the 
first such installment to occur on the first payroll date following the date the Release becomes effective and 
irrevocable or as otherwise provided in Section 11(d) hereof and inclusive of any installments that would have 
been made had the Release been immediately effective and irrevocable.
(C)
During the period commencing on the Date of Termination and ending on the last day of the 
Severance Period or, if earlier, the date on which Executive becomes eligible for comparable replacement 
coverage under a subsequent employer’s group health plan (in any case, the “COBRA Period”), subject to 
Executive’s valid election to continue healthcare coverage under Section 4980B of the Internal Revenue Code of 
1986, as amended (the “Code”) and the regulations thereunder, the Company shall, in its sole discretion, either 
(x) continue to provide to Executive and Executive’s dependents, at the Company’s sole expense, or (y) 
reimburse Executive and Executive’s dependents for coverage under its group health plan (if any) at the same 
levels in effect on the Date of Termination; provided, however, that if (1) any plan pursuant to which such 
benefits are provided is not, or ceases prior to the expiration of the continuation coverage period to be, exempt 
from the application of Section 409A under Treasury Regulation Section 1.409A-1(a)(5), (2) the Company is 
otherwise unable to continue to cover Executive or Executive’s dependents under its group health plans, or (3) 
the Company cannot provide the benefit without violating applicable law (including, without limitation, Section 
2716 of the Public Health Service Act), then, in any such case, an amount equal to each remaining Company 
subsidy shall thereafter be paid to Executive in substantially equal monthly installments over the COBRA Period 
(or remaining portion thereof).
(ii) Termination During a Change in Control Period.  If, during the Term of Employment and during a Change in 
Control Period, Executive’s employment is terminated by the Company without Cause or Executive resigns for Good 
Reason, then, in addition to the payments and benefits described in Section 6(a) above and subject to Executive’s delivery 
to the Company of a Release that becomes effective and irrevocable in accordance with Section 11(d) hereof:
(A)
The Company shall pay to Executive an amount equal to the sum of (i) Executive’s Annual Base 
Salary and (ii) Executive’s target Annual Bonus.  Such amount will be subject to applicable withholdings and 
payable in a single lump sum cash payment on the first regular payroll date following the date the Release 
becomes effective and irrevocable or as otherwise provided in Section 11(d) hereof. 
(B)
During the period commencing on the Date of Termination and ending on the first anniversary 
thereof or, if earlier, the date on which Executive becomes eligible for comparable replacement coverage under a 
subsequent employer’s group health plan (in any case, the “CiC COBRA Period”), subject to Executive’s valid 
election to continue healthcare coverage under Section 4980B of the Code and the regulations thereunder, the 
Company shall, in its sole discretion, 

 
6
 
 
either (x) continue to provide to Executive and Executive’s dependents, at the Company’s sole expense, or (y) 
reimburse Executive and Executive’s dependents for coverage under its group health plan (if any) at the same 
levels in effect on the Date of Termination; provided, however, that if (1) any plan pursuant to which such 
benefits are provided is not, or ceases prior to the expiration of the continuation coverage period to be, exempt 
from the application of Section 409A under Treasury Regulation Section 1.409A-1(a)(5), (2) the Company is 
otherwise unable to continue to cover Executive or Executive’s dependents under its group health plans, or (3) 
the Company cannot provide the benefit without violating applicable law (including, without limitation, Section 
2716 of the Public Health Service Act), then, in any such case, an amount equal to each remaining Company 
subsidy shall thereafter be paid to Executive in substantially equal monthly installments over the CiC COBRA
Period (or remaining portion thereof).
(C)
The Company shall cause any unvested equity awards, including any stock options, restricted 
stock awards and any such awards subject to performance-based vesting, held by Executive as of the Date of 
Termination, to become fully vested and, if applicable, exercisable, and cause all restrictions and rights of 
repurchase on such awards to lapse with respect to all of the shares of the Company’s Common Stock subject 
thereto.
(c)
No Other Severance.  The provisions of this Section 6 shall supersede in their entirety any severance payment 
provisions in any severance plan, policy, program, or other arrangement maintained by the Company except as otherwise approved by the 
Board.
(d)
No Requirement to Mitigate; Survival.  Executive shall not be required to mitigate the amount of any payment
provided for under this Agreement by seeking other employment or in any other manner.  Notwithstanding anything to the contrary in this 
Agreement, the termination of Executive’s employment shall not impair the rights or obligations of any Party. 
(e)
Definition of Cause.  For purposes hereof, “Cause” shall mean any one of the following: (i) Executive’s material 
violation of any applicable material law or regulation respecting the business of the Company; (ii) Executive’s conviction of, or plea of nolo 
contendere to, a felony or other crime involving moral turpitude; (iii) any act of dishonesty, fraud, or misrepresentation in relation to 
Executive’s duties to the Company which act is materially and demonstrably injurious to the Company; (iv) Executive’s willful and repeated 
failure to perform in any material respect Executive’s duties hereunder after fifteen (15) days’ notice and an opportunity to cure such failure 
and a reasonable opportunity to present to the Board Executive’s position regarding any dispute relating to the existence of such failure (other 
than on account of disability); (v) Executive’s failure to attempt in good faith to implement a clear and reasonable directive from the CEO or 
to comply with any of the Company’s policies and procedures which failure is either material or occurs after written notice from the CEO; 
(vi) any act of gross misconduct which is materially and demonstrably injurious to the Company; or (vii) Executive’s breach of fiduciary 
duty owed to the Company.
(f)
Definition of Change in Control.  For purposes of this Agreement, “Change in Control” shall mean (i) the 
acquisition by any person or group of affiliated or associated persons of more than fifty percent (50%) of the outstanding capital stock of the 
Company or voting securities representing more than fifty percent (50%) of the total voting power of outstanding securities of the Company; 
(ii) the consummation of a sale of all or substantially all of the assets of the Company to a third party; (iii) the 

 
7
 
 
consummation of any merger involving the Company in which, immediately after giving effect to such merger, less than a majority of the 
total voting power of outstanding stock of the surviving or resulting entity is then “beneficially owned” (within the meaning of Rule 13d-3 
under the Securities Exchange Act of 1934, as amended) in the aggregate by the stockholders of the Company, as applicable, immediately 
prior to such merger.  For the avoidance of doubt and notwithstanding anything herein to the contrary, in no event shall a transaction 
constitute a “Change in Control” if: (w) its sole purpose is to change the state of the Company’s incorporation; (x) its sole purpose is to create 
a holding company that will be owned in substantially the same proportions by the persons who held the Company’s securities immediately 
before such transaction; (y) it is effected primarily for the purpose of financing the Company with cash (as determined by the Board without 
regard to whether such transaction is effectuated by a merger, equity financing, or otherwise); or (z) it constitutes, or includes sales of shares 
in connection with, the initial public offering of the Company’s capital stock. Notwithstanding the foregoing, a “Change in Control” must 
also constitute a “change in control event,” as defined in Treasury Regulation §1.409A-3(i)(5).
(g)
Definition of Good Reason.  For purposes hereof, “Good Reason” shall mean any one of the following: (i) the 
material reduction of Executive’s base salary or target annual performance bonus, (ii) the assignment to Executive of any duties materially 
and negatively inconsistent in any respect of Executive’s position (including status, offices, titles and reporting requirements), authority, 
duties or responsibilities, or any other action by the Company which results in a material diminution in such position, authority, duties or 
responsibilities (including without limitation a requirement to report to any person or entity other than the CEO or the Board); or (iii) the 
Company’s material breach of this Agreement, provided, that, in each case, Executive will not be deemed to have Good Reason unless (1) 
Executive first provides the Company with written notice of the condition giving rise to Good Reason within thirty (30) days of its initial 
occurrence, (2) the Company or the successor company fails to cure such condition within thirty (30) days after receiving such written notice 
(the “Cure Period”), and (3) Executive’s resignation based on such Good Reason is effective within thirty (30) days after the expiration of the 
Cure Period. 
7. Assignment and Successors.  The Company shall assign its rights and obligations under this Agreement to any successor to all 
or substantially all of the business or the assets of the Company (by merger or otherwise).  This Agreement shall be binding upon and inure to 
the benefit of the Company, Executive, and their respective successors, assigns, personnel, and legal representatives, executors, 
administrators, heirs, distributees, devisees, and legatees, as applicable.  None of Executive’s rights or obligations may be assigned or 
transferred by Executive, other than Executive’s rights to payments hereunder, which may be transferred only by will, operation of law, or as 
otherwise provided herein.
8. Miscellaneous Provisions.  
(a)
Confidentiality Agreement.  Executive shall continue to be obligated by the At-Will Employment, Confidential 
Information, Invention and Assignment, and Arbitration Agreement entered into with the Company in connection with the Prior Agreement 
(the “Confidentiality Agreement”).  The Confidentiality Agreement shall survive the termination of this Agreement and Executive’s 
employment with the Company for the applicable period(s) set forth therein.  Notwithstanding the foregoing, in the event of any conflict 
between the terms of the Confidentiality Agreement and the terms of this Agreement, the terms of this Agreement shall prevail.
(b)
Non-Solicitation of Employees.  For a period of one (1)-year following Executive’s Date of Termination, Executive 
shall not, either directly or indirectly (i) solicit for employment by any individual, corporation, firm, or other business, any employees, 
consultants, independent contractors, or other service providers of the Company or any of its affiliates, or (ii) solicit any employee 

 
8
 
 
or consultant of the Company or any of its affiliates to leave the employment or consulting of or cease providing services to the Company or 
any of its affiliates; provided, however, that the foregoing clauses (i) and (ii) shall not apply to a general advertisement or solicitation (or any 
hiring pursuant to such advertisement or solicitation) that is not specifically targeted to such employees or consultants.
(c)
Governing Law.  This Agreement shall be governed, construed, interpreted, and enforced in accordance with its 
express terms, and otherwise in accordance with the substantive laws of the State of California, without giving effect to any principles of 
conflicts of law, whether of the State of California or any other jurisdiction, and where applicable, the laws of the United States, that would 
result in the application of the laws of any other jurisdiction.
(d)
Validity.  The invalidity or unenforceability of any provision or provisions of this Agreement shall not affect the 
validity or enforceability of any other provision of this Agreement, which shall remain in full force and effect.  
(e)
Counterparts.  This Agreement may be executed in several counterparts, each of which shall be deemed to be an 
original, but all of which together will constitute one and the same Agreement.  Signatures delivered by facsimile shall be deemed effective 
for all purposes.
(f)
Entire Agreement.  The terms of this Agreement, together with the Confidentiality Agreement, are intended by the 
Parties to be the final expression of their agreement with respect to the employment of Executive by the Company and supersede all prior 
understandings and agreements, whether written or oral, regarding Executive’s service to the Company, including without limitation, the 
Prior Agreement and the Offer Letter.  The Parties further intend that this Agreement, together with the Confidentiality Agreement, shall 
constitute the complete and exclusive statement of their terms and that no extrinsic evidence whatsoever may be introduced in any judicial, 
administrative, or other legal proceeding to vary the terms of this Agreement or the Confidentiality Agreement.  Notwithstanding the
foregoing, in the event of any conflict between the terms of the Confidentiality Agreement and the terms of this Agreement, the terms of this 
Agreement shall prevail.    
(g)
Amendments; Waivers.  This Agreement may not be modified, amended, or terminated except by an instrument in 
writing signed by Executive and a duly authorized representative of the Company.  By an instrument in writing similarly executed, Executive 
or a duly authorized officer of the Company, as applicable, may waive compliance by the other Party with any specifically identified 
provision of this Agreement that such other Party was or is obligated to comply with or perform; provided, however, that such waiver shall 
not operate as a waiver of, or estoppel with respect to, any other or subsequent failure.  No failure to exercise and no delay in exercising any 
right, remedy, or power hereunder shall preclude any other or further exercise of any other right, remedy, or power provided herein or by law 
or in equity.  
(h)
Dispute Resolution.  Executive and the Company affirm the Parties’ obligations under Section 12 of the 
Confidentiality Agreement and hereby agree that any dispute, claim or controversy arising under this Agreement shall be subject to Section 
12 of the Confidentiality Agreement as a dispute, claim or controversy arising from, relating to or resulting from Executive’s employment. 
(i)
Enforcement.  If any provision of this Agreement is held to be illegal, invalid, or unenforceable under present or 
future laws, such provision shall be fully severable; this Agreement shall be construed and enforced as if such illegal, invalid, or 
unenforceable provision had never comprised a portion of this Agreement; and the remaining provisions of this Agreement shall remain in 
full force and effect and shall not be affected by the illegal, invalid, or unenforceable provision or by its severance from 

 
9
 
 
this Agreement.  Furthermore, in lieu of such illegal, invalid, or unenforceable provision there shall be added automatically as part of this 
Agreement a provision as similar in terms to such illegal, invalid, or unenforceable provision as may be possible and be legal, valid, and 
enforceable.
(j)
Withholding.  The Company shall be entitled to withhold from any amounts payable under this Agreement any 
federal, state, local, or foreign withholding or other taxes or charges which the Company is required to withhold.  The Company shall be 
entitled to rely on an opinion of counsel if any questions as to the amount or requirement of withholding shall arise.
(k)
Whistleblower Protections and Trade Secrets.  Notwithstanding anything to the contrary contained herein, nothing 
in this Agreement prohibits Executive from reporting possible violations of federal law or regulation to any United States governmental 
agency or entity in accordance with the provisions of and rules promulgated under Section 21F of the Securities Exchange Act of 1934 or 
Section 806 of the Sarbanes-Oxley Act of 2002, or any other whistleblower protection provisions of state or federal law or regulation 
(including the right to receive an award for information provided to any such government agencies).  Furthermore, in accordance with 18 
U.S.C. § 1833, notwithstanding anything to the contrary in this Agreement: (i) Executive shall not be in breach of this Agreement, and shall 
not be held criminally or civilly liable under any federal or state trade secret law (x) for the disclosure of a trade secret that is made in 
confidence to a federal, state, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected 
violation of law, or (y) for the disclosure of a trade secret that is made in a complaint or other document filed in a lawsuit or other 
proceeding, if such filing is made under seal; and (ii) if Executive files a lawsuit for retaliation by the Company for reporting a suspected 
violation of law, Executive may disclose the trade secret to Executive’s attorney, and may use the trade secret information in the court 
proceeding, if Executive files any document containing the trade secret under seal, and does not disclose the trade secret, except pursuant to 
court order.
9. Prior Employment.  Executive represents and warrants that Executive’s acceptance of employment with the Company has not 
breached, and the performance of Executive’s duties hereunder will not breach, any duty owed by Executive to any prior employer or other 
person.  Executive further represents and warrants to the Company that (a) the performance of Executive’s obligations hereunder will not 
violate any agreement between Executive and any other person, firm, organization, or other entity; (b) Executive is not bound by the terms of 
any agreement with any previous employer or other party to refrain from competing, directly or indirectly, with the business of such previous 
employer or other party that would be violated by Executive entering into this Agreement and/or providing services to the Company pursuant 
to the terms of this Agreement; and (c) Executive’s performance of Executive’s duties under this Agreement will not require Executive to, 
and Executive shall not, rely on in the performance of Executive’s duties or disclose to the Company or any other person or entity or induce 
the Company in any way to use or rely on any trade secret or other confidential or proprietary information or material belonging to any 
previous employer of Executive.
10.Golden Parachute Excise Tax. 
(a)
Best Pay.  Any provision of this Agreement to the contrary notwithstanding, if any payment or benefit Executive 
would receive from the Company pursuant to this Agreement or otherwise (“Payment”) would (i) constitute a “parachute payment” within 
the meaning of Section 280G of the Code and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the 
“Excise Tax”), then such Payment will be equal to the Reduced Amount (as defined below).  The “Reduced Amount” will be either (A) the 
largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (B) the 
entire Payment, whichever amount after taking 

 
10
 
 
into account all applicable federal, state, and local employment taxes, income taxes, and the Excise Tax (all computed at the highest 
applicable marginal rate, net of the maximum reduction in federal income taxes which could be obtained from a deduction of such state and 
local taxes), results in Executive’ s receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of 
the Payment may be subject to the Excise Tax.  If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced 
Amount is determined pursuant to clause (A) of the preceding sentence, the reduction shall occur in the manner (the “Reduction Method”) 
that results in the greatest economic benefit for Executive.  If more than one method of reduction will result in the same economic benefit, the 
items so reduced will be reduced pro rata (the “Pro Rata Reduction Method”).  Notwithstanding the foregoing, if the Reduction Method or 
the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A (as defined 
below) that would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method and/or the Pro Rata Reduction 
Method, as the case may be, shall be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows:  (1) as a first 
priority, the modification shall preserve to the greatest extent possible, the greatest economic benefit for Executive as determined on an after-
tax basis; (2) as a second priority, Payments that are contingent on future events (e.g., being terminated without cause), shall be reduced (or 
eliminated) before Payments that are not contingent on future events; and (3) as a third priority, Payments that are “deferred compensation” 
within the meaning of Section 409A shall be reduced (or eliminated) before Payments that are not deferred compensation within the meaning 
of Section 409A. 
(b)
Accounting Firm.  The accounting firm engaged by the Company for general tax purposes as of the day prior to the 
Change in Control will perform the calculations set forth in Section 10(a) above.  If the firm so engaged by the Company is serving as the 
accountant or auditor for the acquiring company, the Company will appoint a nationally recognized accounting firm to make the 
determinations required hereunder.  The Company will bear all expenses with respect to the determinations by such firm required to be made 
hereunder.  The accounting firm engaged to make the determinations hereunder will provide its calculations, together with detailed 
supporting documentation, to the Company within thirty (30) days before the consummation of a Change in Control (if requested at that time 
by the Company) or such other time as requested by the Company.  If the accounting firm determines that no Excise Tax is payable with 
respect to a Payment, either before or after the application of the Reduced Amount, it will furnish the Company with documentation 
reasonably acceptable to the Company that no Excise Tax will be imposed with respect to such Payment.  Any good faith determinations of 
the accounting firm made hereunder will be final, binding and conclusive upon the Company and Executive.
11.Section 409A.
(a)
General.  The intent of the Parties is that the payments and benefits under this Agreement comply with or be 
exempt from Section 409A of the Code and the Department of Treasury regulations and other interpretive guidance issued thereunder, 
including without limitation any such regulations or other guidance that may be issued after the Effective Date, (“Section 409A”) and, 
accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith.  If Executive notifies the 
Company that Executive has received advice of tax counsel of a national reputation with expertise in Section 409A that any provision of this 
Agreement would cause Executive to incur any additional tax or interest under Section 409A (with specificity as to the reason therefor) or the 
Company independently makes such determination, the Company and Executive shall take commercially reasonable efforts to reform such 
provision to try to comply with or be exempt from Section 409A through good faith modifications to the minimum extent reasonably 
appropriate to conform with Section 409A, provided that any such modifications shall not increase the cost or liability to the Company.  To 
the extent that any provision hereof is modified in order to comply with or be exempt from Section 409A, such 

 
11
 
 
modification shall be made in good faith and shall, to the maximum extent reasonably possible, maintain the original intent and economic 
benefit to Executive and the Company of the applicable provision without violating the provisions of Section 409A.
(b)
Separation from Service.  Notwithstanding any provision to the contrary in this Agreement:  (i) no amount that 
constitutes “deferred compensation” under Section 409A shall be payable pursuant to Section 6(b) above unless the termination of 
Executive’s employment constitutes a “separation from service” within the meaning of Section 1.409A-1(h) of the Department of Treasury 
Regulations (“Separation from Service”); (ii) for purposes of Section 409A, Executive’s right to receive installment payments shall be treated 
as a right to receive a series of separate and distinct payments; and (iii) to the extent that any reimbursement of expenses or in-kind benefits 
constitutes “deferred compensation” under Section 409A, such reimbursement or benefit shall be provided no later than December 31st of the 
year following the year in which the expense was incurred.  The amount of expenses reimbursed in one year shall not affect the amount 
eligible for reimbursement in any subsequent year.  The amount of any in-kind benefits provided in one year shall not affect the amount of 
in-kind benefits provided in any other year.
(c)
Specified Employee.  Notwithstanding anything in this Agreement to the contrary, if Executive is deemed by the 
Company at the time of Executive’s Separation from Service to be a “specified employee” for purposes of Section 409A, to the extent 
delayed commencement of any portion of the benefits to which Executive is entitled under this Agreement is required in order to avoid a 
prohibited distribution under Section 409A, such portion of Executive’s benefits shall not be provided to Executive prior to the earlier of (i) 
the expiration of the six (6)-month period measured from the date of Executive’s Separation from Service with the Company or (ii) the date 
of Executive’s death.  Upon the first business day following the expiration of the applicable Section 409A period, all payments deferred 
pursuant to the preceding sentence shall be paid in a lump sum to Executive (or Executive’s estate or beneficiaries), and any remaining 
payments due to Executive under this Agreement shall be paid as otherwise provided herein.  
(d)
Release.  Notwithstanding anything to the contrary in this Agreement, to the extent that any payments due under 
this Agreement as a result of Executive’s termination of employment are subject to Executive’s execution and delivery of a Release, (i) the 
Company shall deliver the Release to Executive within ten (10) business days following Executive’s Date of Termination, and the 
Company’s failure to deliver a Release prior to the expiration of such ten (10) business day period shall constitute a waiver of any 
requirement to execute a Release, (ii) if Executive fails to execute the Release on or prior to the Release Expiration Date (as defined below) 
or timely revokes Executive’s acceptance of the Release thereafter, Executive shall not be entitled to any payments or benefits otherwise 
conditioned on the Release, and (iii) in any case where Executive’s Date of Termination and the Release Expiration Date fall in two separate 
taxable years, any payments required to be made to Executive that are conditioned on the Release and are treated as nonqualified deferred 
compensation for purposes of Section 409A shall be made in the later taxable year.  For purposes of this Section 11(d), “Release Expiration 
Date” shall mean the date that is twenty-one (21) days following the date upon which the Company timely delivers the Release to Executive, 
or, in the event that Executive’s termination of employment is “in connection with an exit incentive or other employment termination 
program” (as such phrase is defined in the Age Discrimination in Employment Act of 1967), the date that is forty-five (45) days following 
such delivery date.  To the extent that any payments of nonqualified deferred compensation (within the meaning of Section 409A) due under 
this Agreement as a result of Executive’s termination of employment are delayed pursuant to this Section 11(d), such amounts shall be paid 
in a lump sum on the first payroll date following the date that Executive executes and does not revoke the Release (and the applicable 
revocation period has expired) or, in the case of any payments subject to Section 11(d)(iii), on the first payroll period to occur in the 
subsequent taxable year, if later.

 
12
 
 
12.Employee Acknowledgement.  Executive acknowledges that Executive has read and understands this Agreement, is fully 
aware of its legal effect, has not acted in reliance upon any representations or promises made by the Company other than those contained in 
writing herein, and has entered into this Agreement freely based on Executive’s own judgment.
[Signature Page Follows]

 
 
 
 
IN WITNESS WHEREOF, the Parties have duly executed this Agreement as of the date and year first above written.	
	
	
UNITY BIOTECHNOLOGY, INC.
By:	 /s/ Anirvan Ghosh	
Name:  Anirvan Ghosh
Title: CEO
EXECUTIVE
By:	 /s/ Federico Grossi	
Name: Federico Grossi 
Address:
	
	
	
	
	
	
	
	
	
	
	
	

|
Exhibit 19.1
UNITY BIOTECHNOLOGY, INC.
INSIDER TRADING COMPLIANCE POLICY
(Adopted March 13, 2018 – effective as of the company’s initial public offering)

(Last updated: December 8, 2023)
This Insider Trading Compliance Policy (this “Policy”) consists of seven sections:
•
Section I provides an overview; 
•
Section II sets forth Unity Biotechnology, Inc.’s (the “Company”) policies prohibiting insider trading; 
•
Section III explains insider trading; 
•
Section IV consists of procedures that have been put in place by the Company to prevent insider 
trading; 
•
Section V sets forth additional transactions that are prohibited by this Policy; 
•
Section VI explains Rule 10b5-1 trading plans and provides information about Section 16 and Rule 
144; and
•
Section VII refers to the execution and return of a compliance certificate.
I.	
OVERVIEW
Preventing insider trading is necessary to comply with securities laws and to preserve the reputation and integrity of the 
Company as well as that of all persons affiliated with the Company. “Insider trading” occurs when any person purchases or sells 
a security (e.g., common stock) while in possession of “inside information” relating to the security. As explained in Section III 
below, “inside information” is information that is both “material” and “non-public.” Insider trading violates several laws, 
including civil and criminal laws. The penalties for violating insider trading laws include imprisonment, disgorgement of profits, 
civil fines, and significant criminal fines. Insider trading is also prohibited by this Policy, and violation of this Policy may result 
in Company-imposed sanctions, including removal or dismissal for cause.
This Policy applies to all officers, directors, employees and certain consultants of the Company and extends to all 
activities within and outside an individual’s duties at the Company. Individuals subject to this Policy are responsible for ensuring 
that their immediate family members and members of their households also comply with this Policy. This Policy also applies to 
any entities controlled by individuals subject to the Policy, including any corporations, partnerships or trusts, and transactions by 
these entities should be treated for the purposes of this Policy and 

|
applicable securities laws as if they were for the individual’s own account. Notwithstanding the foregoing, this Policy, including 
without limitation, the pre-clearance requirements, blackout periods and prohibited transactions, does not apply to venture capital 
entities or other institutional investors, and the related transaction in the Company’s equity securities by such entities, that may be 
affiliated with a director of the Company or for Company equity securities that a director may be deemed to have beneficial 
ownership of by virtue of such affiliation. 
This Policy extends to all activities within and outside an individual’s Company duties. Every officer, director and 
employee (and if designated by management, applicable consultants) must review this Policy.  
Questions regarding the Policy should be directed to the Company’s General Counsel (or the Chief Financial Officer in 
the absence of a General Counsel), or such other person as the Company’s Board of Directors (the “Board of Directors”) may 
designate from time to time (the “Compliance Officer”).
II.	
STATEMENT OF POLICIES PROHIBITING INSIDER TRADING
No officer, director, employee or consultant, or any immediate family member or any member of the household of any 
such person, shall purchase or sell any type of security while in possession of material, non-public information relating to the 
security, whether the issuer of such security is the Company or any other company.
Additionally, no officer, director, employee or consultant designated by the Compliance Officer as being subject 
to this policy (such consultants, the “Applicable Consultants”) listed on Schedule I (as amended from time to time by the 
Compliance Officer), or any immediate family member or any member of the household of any such person, shall 
purchase or sell any security of the Company during the period beginning at market close on the twenty-first day 
following the last day of any fiscal quarter of the Company and ending at market close on the first full trading day after 
the public release of earnings data for such fiscal quarter whether or not the Company or any of its officers, directors, 
employees or any of the Applicable Consultants is in possession of material, non-public information.
Additionally, from time to time, the Company, through the Board of Directors, the Company’s disclosure committee or 
the Compliance Officer, may recommend that some or all officers, directors, employees, Applicable Consultants or others 
suspend trading in the Company’s securities because of developments that have not yet been disclosed to the public. Individuals 
affected by such an event-specific blackout may be notified by the Company that they are subject to the blackout (or the 
Compliance Officer may determine in his or her discretion to rely instead on the pre-clearance requirement provided for in 
Section IV.B of this policy). Subject to the exceptions noted below, persons notified should not trade in our securities while the 
event-specific blackout is in effect, and in the event that a press release is issued by the Company in connection with the event 
that resulted in the event-specific blackout (or the event or circumstances go away), such suspension shall continue for one full 
trading day after the public release (or the event or circumstances go away).  Additionally, those subject to the event-specific 
blackout should not disclose to others that we have suspended trading, as the blackout itself is material non-public information. 
Events that may give rise to event-specific blackouts may include consideration of 

|
major strategic transactions (e.g., acquisitions, dispositions, joint ventures), product developments, interim earnings or sales 
releases, significant legal proceedings and other circumstances that potentially implicate material non-public information.
These prohibitions do not apply to:
•
purchases of the Company’s securities from the Company (e.g., Employee Stock Purchase Plan) or sales of the 
Company’s securities to the Company, or the surrender to, or withholding by, the Company of the Company’s 
securities (e.g., to cover withholding obligations upon the vesting or settlement of equity-based awards);
•
exercises of stock options or other equity awards or the surrender of shares to the Company in payment of the 
exercise price or in satisfaction of any tax withholding obligations in a manner permitted by the applicable 
equity award agreement, or vesting of equity-based awards, in each case, that do not involve a market sale of the 
Company’s securities (note that the “cashless exercise” of a Company stock option or other equity award 
through a broker does involve a market sale of the Company’s securities, and therefore would not qualify under 
this exception);
•
bona fide gifts of the Company’s securities, unless the individual making the gift knows, or is reckless in not 
knowing, the recipient intends to sell the securities while the donor is in possession of material non-public 
information about the Company; or
•
purchases or sales of the Company’s securities made pursuant to any pre-existing binding contract, specific 
instruction or written plan entered into while the purchaser or seller, as applicable, was unaware of any material, 
non-public information and which contract, instruction or plan (i) meets all requirements of the affirmative 
defense provided by Rule 10b5-1 (“Rule 10b5-1”) promulgated under the Securities Exchange Act of 1934, as 
amended (the “1934 Act”), (ii) was pre-cleared in advance pursuant to this Policy and (iii) has not been 
amended or modified in any respect after such initial pre-clearance without such amendment or modification 
being pre-cleared in advance pursuant to this Policy. For more information about Rule 10b5-1 trading plans, see 
Section VI below.
For the purposes of this Policy, a “trading day” is a day on which national stock exchanges are open for trading.
No officer, director, employee or consultant shall directly or indirectly communicate (or “tip”) material, non-public 
information to anyone outside the Company (except in accordance with the Company’s policies regarding the protection or 
authorized external disclosure of Company information) or to anyone within the Company other than on a need-to-know basis.
III.	 EXPLANATION OF INSIDER TRADING
“Insider trading” refers to the purchase or sale of a security by someone who is in possession of “material,” “non-public” 
information relating to the security.

|
“Insider” refers to employees, officers, directors and certain consultants of the Company and anyone else within the 
Company who has material, non-public information about the Company.
“Securities” includes stocks, bonds, notes, debentures, options, warrants and other convertible securities, as well as 
derivative instruments.
“Purchase” and “sale” are defined broadly under the federal securities law. “Purchase” includes not only the actual 
purchase of a security, but any contract to purchase or otherwise acquire a security. “Sale” includes not only the actual sale of a 
security, but any contract to sell or otherwise dispose of a security. These definitions extend to a broad range of transactions, 
including conventional cash-for-stock transactions, conversions, the exercise of stock options, gifts, and acquisitions and 
exercises of warrants or puts, calls, pledging and margin loans, or other derivative securities.
It is generally understood that insider trading includes the following:
•
trading by insiders while in possession of material, non-public information;
•
trading by persons other than insiders while in possession of material, non-public information, if the information 
either was given in breach of an insider’s duty to keep it confidential or was misappropriated; and
•
communicating or tipping material, non-public information to others, including recommending the purchase or 
sale of a security while in possession of such information.
A.
What Facts are Material?
The materiality of a fact depends upon the circumstances. A fact is considered “material” if there is a substantial 
likelihood that a reasonable investor would consider it important in making a decision to buy, sell or hold a security, or if the fact 
is likely to have a significant effect on the market price of the security. Material information can be positive or negative and can 
relate to virtually any aspect of a company’s business or to any type of security, debt or equity. Also, information that something 
is likely to happen in the future or even just that it may happen could be deemed material.
Examples of material information include (but are not limited to) information about the results of clinical trials; 
communications sent to or received from the U.S. Food and Drug Administration; dividends; corporate earnings or earnings 
forecasts; mergers, acquisitions, tender offers or dispositions; major new products or product developments; important business 
developments such as major contract awards or cancellations; management or control changes; significant borrowing or financing 
developments including pending public sales or offerings of debt or equity securities; defaults on borrowings; bankruptcies; 
cybersecurity or data security or protection incidents; and significant litigation or regulatory actions. Moreover, material 
information does not have to be related to a company’s business. For example, the contents of a forthcoming newspaper column 
that is expected to affect the market price of a security can be material.

|
A good general rule of thumb: When in doubt, do not trade.
B.	
What is Non-public?
Information is “non-public” if it is not available to the general public. In order for information to be considered public, it 
must be widely disseminated in a manner making it generally available to investors through such media as Dow Jones, Business 
Wire, Reuters, The Wall Street Journal, Associated Press, or United Press International (all of which generally are accessible via 
a nationally recognized service such as Global News Wire, Business Wire, or PR Newswire), a broadcast on widely available 
radio or television programs, publication in a widely available newspaper, magazine or news web site, a Regulation FD-
compliant conference call, or public disclosure documents filed with the Securities and Exchange Commission (the “SEC”) that 
are available on the SEC’s web site.
The circulation of rumors, even if accurate and reported in the media, does not constitute effective public dissemination. 
In addition, even after a public announcement, a reasonable period of time must lapse in order for the market to react to the 
information. Generally, one should allow one full trading day following publication as a reasonable waiting period before such 
information is deemed to be public.
C.	
Who is an Insider?
“Insiders” include officers, directors, employees and certain consultants of a company and anyone else within the 
Company who has material, non-public information about a company. Insiders have independent fiduciary duties to their 
company and its stockholders not to trade on material, non-public information relating to the company’s securities. All officers, 
directors, employees and consultants of the Company should consider themselves insiders with respect to material, non-public 
information about the Company’s business, activities and securities. Officers, directors, employees and consultants may not trade 
in the Company’s securities while in possession of material, non-public information relating to the Company, nor may they tip 
such information to anyone outside the Company (except in accordance with the Company’s policies regarding the protection or 
authorized external disclosure of Company information) or to anyone within the Company other than on a need-to-know basis.
Individuals subject to this Policy are responsible for ensuring that their immediate family members and members of their 
households also comply with this Policy. This Policy also applies to any entities controlled by individuals subject to the Policy, 
including any corporations, partnerships or trusts, and transactions by these entities should be treated for the purposes of this 
Policy and applicable securities laws as if they were for the individual’s own account.
D.	 Trading by Persons Other than Insiders
Insiders may be liable for communicating or tipping material, non-public information to a third party (“tippee”), and 
insider trading violations are not limited to trading or tipping by insiders. Persons other than insiders also can be liable for insider 
trading, including tippees who trade on material, non-public information tipped to them or individuals who trade on material, 
non-public information that has been misappropriated. Insiders may be held liable for tipping even if they 

|
receive no personal benefit from tipping and even if no close personal relationship exists between them and the tippee.
Tippees inherit an insider’s duties and are liable for trading on material, non-public information illegally tipped to them 
by an insider. Similarly, just as insiders are liable for the insider trading of their tippees, so are tippees who pass the information 
along to others who trade. In other words, a tippee’s liability for insider trading is no different from that of an insider. Tippees 
can obtain material, non-public information by receiving overt tips from others or through, among other things, conversations at 
social, business, or other gatherings.
E.	
Penalties for Engaging in Insider Trading
Penalties for trading on or tipping material, non-public information can extend significantly beyond any profits made or 
losses avoided, both for individuals engaging in such unlawful conduct and their employers. The SEC and Department of Justice 
have made the civil and criminal prosecution of insider trading violations a top priority. Enforcement remedies available to the 
government or private plaintiffs (e.g., the Company’s stockholders) under the federal securities laws include:
•
SEC administrative sanctions;
•
securities industry self-regulatory organization sanctions;
•
civil injunctions;
•
damage awards to private plaintiffs;
•
disgorgement of all profits;
•
civil fines for the violator of up to three times the amount of profit gained or loss avoided;
•
civil fines for the employer or other controlling person of a violator (i.e., where the violator is an employee or 
other controlled person);
•
criminal fines for individual violators; and
•
jail sentences.
In addition, insider trading could result in serious sanctions by the Company, including dismissal. Insider trading 
violations are not limited to violations of the federal securities laws. Other federal and state civil or criminal laws, such as the 
laws prohibiting mail and wire fraud and the Racketeer Influenced and Corrupt Organizations Act, also may be violated in 
connection with insider trading.

|
F.	
Size of Transaction and Reason for Transaction Do Not Matter
The size of the transaction or the amount of profit received does not have to be significant to result in prosecution. The 
SEC has the ability to monitor even the smallest trades, and the SEC performs routine market surveillance. Brokers and dealers 
are required by law to inform the SEC of any possible violations by people who may have material, non-public information. The 
SEC aggressively investigates and prosecutes even small insider trading violations.
G.	 Examples of Insider Trading
Examples of insider trading cases include actions brought against corporate officers, directors, employees and 
consultants who traded in a company’s securities after learning of significant confidential corporate developments; friends, 
business associates, family members and other tippees of such officers, directors, employees and consultants who traded in the 
securities after receiving such information; government employees who learned of such information in the course of their 
employment; and other persons who misappropriated, and took advantage of, confidential information from their employers.
The following are illustrations of insider trading violations. These illustrations are hypothetical and, consequently, not 
intended to reflect on the actual activities or business of the Company or any other entity.
Trading by Insider
An officer of X Corporation learns that earnings to be reported by X Corporation will increase dramatically. Prior to the 
public announcement of such earnings, the officer purchases X Corporation’s stock. The officer, an insider, is liable for 
all profits as well as penalties of up to three times the amount of all profits. The officer also is subject to, among other 
things, criminal prosecution. Depending upon the circumstances, X Corporation and the individual to whom the officer 
reports also could be liable as controlling persons.
Trading by Tippee
An officer of X Corporation tells a friend that X Corporation is about to publicly announce that it has concluded an 
agreement for a major acquisition. This tip causes the friend to purchase X Corporation’s stock in advance of the 
announcement. The officer is jointly liable with his friend for all of the friend’s profits, and each is liable for all civil 
penalties of up to three times the amount of the friend’s profits. The officer and his friend are also subject to criminal 
prosecution and other remedies and sanctions, as described above.
H.	 Prohibition of Records Falsification and False Statements
Section 13(b)(2) of the 1934 Act requires companies subject to the 1934 Act (such as the Company) to maintain proper 
internal books and records and to devise and maintain an adequate system of internal accounting controls. The SEC has 
supplemented the statutory requirements by adopting rules that prohibit (1) any person from falsifying records or accounts 
subject to the above requirements and (2) officers or directors from making any materially false, misleading, or incomplete 
statement to any accountant in connection with any audit or filing with the SEC. These 

|
provisions reflect the SEC’s intent to discourage officers, directors and other persons with access to the Company’s books and 
records from taking action that might result in the communication of materially misleading financial information to the investing 
public.
IV.	 STATEMENT OF PROCEDURES PREVENTING INSIDER TRADING
The following procedures have been established, and will be maintained and enforced, by the Company to prevent 
insider trading. Each of the officers and directors and certain of the employees and consultants are required to follow these 
procedures.
A.
Blackout Periods
No officer, director, employee or consultant listed on Schedule I (as amended from time to time by the 
Compliance Officer), or any immediate family member or any member of the household of any such person, shall 
purchase or sell any security of the Company during the period beginning at market close on twenty-first day following 
the last day of any fiscal quarter of the Company and ending at market close on the first full trading day after the public 
release of earnings data for such fiscal quarter of the Company or during any other trading suspension period declared 
by the Company, except for:
•
purchases of the Company’s securities from the Company or sales of the Company’s securities to the Company, 
or the surrender to, or withholding by, the Company of the Company’s securities (e.g., to cover withholding 
obligations upon the vesting or settlement of equity based awards);
•
exercises of stock options or other equity awards or the surrender of shares to the Company in payment of the 
exercise price or in satisfaction of any tax withholding obligations in a manner permitted by the applicable 
equity award agreement, or vesting of equity-based awards, in each case, that do not involve a market sale of the 
Company’s securities (note that the “cashless exercise” of a Company stock option or other equity award 
through a broker does involve a market sale of the Company’s securities, and therefore would not qualify under 
this exception);
•
bona fide gifts of the Company’s securities, unless the individual making the gift knows, or is reckless in not 
knowing, the recipient intends to sell the securities while the donor is in possession of material non-public 
information about the Company; and
•
purchases or sales of the Company’s securities made pursuant to any binding contract, specific instruction or 
written plan entered into while the purchaser or seller, as applicable, was unaware of any material, non-public 
information and which contract, instruction or plan (i) meets all requirements of the affirmative defense 
provided by Rule 10b5-1, (ii) was pre-cleared in advance pursuant to this Policy and (iii) has not been amended 
or modified in any respect after such initial pre-clearance without such amendment or modification being pre-
cleared in advance pursuant to this Policy.

|
Exceptions to the blackout period policy may be approved only by the Compliance Officer or, in his or her absence, the 
Chief Financial Officer.
From time to time, the Company, through the Board of Directors, the Company’s disclosure committee or the 
Compliance Officer, may recommend that some or all officers, directors, employees, Applicable Consultants or others suspend 
trading in the Company’s securities because of developments that have not yet been disclosed to the public. Individuals affected 
by such an event-specific blackout will be notified by the Company that they are subject to the blackout. Subject to the 
exceptions noted above, all those affected may not trade in Company securities while the suspension is in effect, and in the event 
that a press release is issued by the Company in connection with the event that resulted in the event-specific blackout (or the 
event or circumstances go away), such suspension shall continue for one full trading day after the public release.  Additionally, 
individuals affected by such an event-specific blackout should not disclose to others that the Company has suspended trading, 
because the blackout itself is material non-public information. For purposes of clarity, the Company shall periodically review and 
update Schedule I.
B.	
Pre-Clearance of All Transactions by All Officers and Directors and Certain Employees and Consultants
To provide assistance in preventing inadvertent violations of applicable securities laws and to avoid the appearance of 
impropriety in connection with the purchase and sale of the Company’s securities, all transactions in the Company’s securities 
(including without limitation, acquisitions and dispositions (including gifts) of Company stock, the “net” or “cashless” 
exercise of stock options and the sale of Company stock issued upon exercise of stock options) by all officers, directors, 
employees and consultants listed on Schedule II (as amended from time to time by the Compliance Officer), other than 
exercises of stock options with cash or other equity awards or vesting of equity-based awards that do not involve a market 
sale of the Company’s securities must be pre-cleared by the Compliance Officer. As part of the pre-clearance process, the 
individual requesting pre-clearance must confirm that he or she is not in possession of material, non-public information. Pre-
clearance does not relieve anyone of his or her responsibility under SEC rules. 
For clarity, transactions in the Company’s securities pursuant to a Rule 10b5-1 plan, which was approved in advance of 
entering into the plan, are considered pre-cleared. For purposes of clarity, the Company shall periodically review and update 
Schedule II.
C.	
Post-Termination Transactions
The insider trading laws continue to apply to transactions in the Company’s securities even after termination of service 
to the Company. If an individual is in possession of material, non-public information when his or her service terminates, that 
individual may not trade in the Company’s securities until that information has become public or is no longer material.

|
D.	 Information Relating to the Company
1.	
Access to Information
Access to material, non-public information about the Company, including the Company’s business, earnings or 
prospects, should be limited to officers, directors, employees and consultants of the Company on a need-to-know basis. In 
addition, such information should not be communicated to anyone outside the Company under any circumstances (except in 
accordance with the Company’s policies regarding the protection or authorized external disclosure of Company information) or 
to anyone within the Company on an other than need-to-know basis.
In communicating material, non-public information to employees of the Company, all officers, directors, employees and 
consultants must take care to emphasize the need for confidential treatment of such information and adherence to the Company’s 
policies with regard to confidential information.
2.	
Inquiries From Third Parties
Inquiries from third parties, such as industry analysts or members of the media, about the Company should be directed to 
the Compliance Officer, Chief Financial Officer or head of Investor relations.
E.	
Limitations on Access to Company Information
The following procedures are designed to maintain confidentiality with respect to the Company’s business operations 
and activities.
All officers, directors, employees and consultants should take all steps and precautions necessary to restrict access to, 
and secure, material, non-public information by, among other things:
•
maintaining the confidentiality of Company-related transactions;
•
conducting their business and social activities so as not to risk inadvertent disclosure of confidential 
information. Review of confidential documents in public places should be conducted so as to prevent access by 
unauthorized persons;
•
restricting access to documents and files (including computer files) containing material, non-public information 
to individuals on a need-to-know basis (including maintaining control over the distribution of documents and 
drafts of documents);
•
promptly removing and cleaning up all confidential documents and other materials from conference rooms 
following the conclusion of any meetings (including erasing any whiteboards or other viewable information);
•
disposing of all confidential documents and other papers, after there is no longer any business or other legally 
required need, through shredders when appropriate;

|
•
restricting access to areas likely to contain confidential documents or material, non-public information, 
including individual offices that may contain such information;
•
safeguarding laptop computers, mobile devices, tablets, memory sticks, CDs and other items that contain 
confidential information, including complying with Company IT policies to prevent unauthorized access to your 
devices and/or electronic information you have access to; and
•
avoiding the discussion of material, non-public information in places where the information could be overheard 
by others such as in elevators, restrooms, hallways, restaurants, public transportation, airplanes, ride-share 
vehicles, or taxicabs.
Personnel involved with material, non-public information, to the extent feasible, should conduct their business and 
activities in areas separate from other Company activities.
V.	 ADDITIONAL PROHIBITED TRANSACTIONS
The Company has determined that there is a heightened legal risk and/or the appearance of improper or inappropriate 
conduct if the persons subject to this Policy engage in certain types of transactions. Therefore, officers, directors, employees and 
the specified consultants shall comply with the following policies with respect to certain transactions in the Company securities:
A.	 Short Sales
Short sales of the Company’s securities evidence an expectation on the part of the seller that the securities will decline in 
value, and therefore signal to the market that the seller has no confidence in the Company or its short-term prospects. In addition, 
short sales may reduce the seller’s incentive to improve the Company’s performance. For these reasons, short sales of the 
Company’s securities are prohibited by this Policy. In addition, as noted below, Section 16(c) of the 1934 Act absolutely 
prohibits Section 16 reporting persons from making short sales of the Company’s equity securities, i.e., sales of shares that the 
insider does not own at the time of sale, or sales of shares against which the insider does not deliver the shares within 20 days 
after the sale.
B.	
Publicly Traded Options
A transaction in options is, in effect, a bet on the short-term movement of the Company’s stock and therefore creates the 
appearance that an officer, director, employee or consultant is trading based on inside information. Transactions in options also 
may focus an officer’s, director’s, employee’s or consultant’s attention on short-term performance at the expense of the 
Company’s long-term objectives. Accordingly, transactions in puts, calls or other derivative securities involving the Company’s 
equity securities, on an exchange or in any other organized market, are prohibited by this Policy.
C.	
Hedging Transactions
Certain forms of hedging or monetization transactions, such as zero-cost collars and forward sale contracts, allow an
insider to lock in much of the value of his or her stock holdings, often in exchange for all or part of the potential for upside 
appreciation in the stock. These 

|
transactions allow the insider to continue to own the covered securities, but without the full risks and rewards of ownership. 
When that occurs, the insider may no longer have the same objectives as the Company’s other stockholders. Therefore, hedging 
transactions involving the Company’s equity securities, including but not limited to zero-cost collars and forward sale contracts, 
are prohibited by this Policy.
D.	 Purchases of the Company’s Securities on Margin; Pledging the Company’s Securities to Secure Margin or Other 
Loans
Purchasing on margin means borrowing from a brokerage firm, bank or other entity in order to purchase the Company’s 
securities (other than in connection with a cashless exercise of stock options under the Company’s equity plans). Margin 
purchases of the Company’s securities are prohibited by this Policy. Pledging the Company’s securities as collateral to secure 
loans is prohibited. This prohibition means, among other things, that you cannot hold the Company’s securities in a “margin 
account” (which would allow you to borrow against your holdings to buy securities).
VI.	 RULE 10b5-1 TRADING PLANS, SECTION 16 AND RULE 144
A.	 Rule 10b5-1 Trading Plans  
1.	
Overview
Rule 10b5-1 provides an affirmative defense from insider trading liability under Rule 10b5-1 for transactions under a 
previously established contract, plan or instruction to trade in the Company’s stock (a “Trading Plan”) entered into in good faith 
at a time when he or she is not in possession of material, non-public information, and where he or she acted in good faith with 
respect to the Trading Plan, and in accordance with the terms of Rule 10b5-1 and all applicable state laws and such transactions 
will be exempt from the trading restrictions set forth in this Policy. The initiation or revocation of, and any modification to, any 
such Trading Plan will be deemed to be a transaction in the Company’s securities, and such initiation, revocation or modification
is subject to all limitations and prohibitions relating to transactions in the Company’s securities. Individuals may not adopt more 
than one Trading Plan at a time except under the limited circumstances permitted by Rule 10b5-1 (i.e., all transactions under the 
later adopted Trading Plan may only begin after all transactions under the earlier adopted Trading Plan have been completed or 
expired and after the observance of the applicable cooling-off period) and subject to preapproval by the Compliance Officer.
Plans that authorize sell-to-cover transactions to satisfy tax withholding obligations incident to the vesting of equity awards are 
permitted even if you have another Trading Plan in place, as long as the sell-to-cover plan authorizes an agent to sell only the 
securities necessary to satisfy the tax withholding obligations, and you do not otherwise control the timing of the sales.
Each such Trading Plan, and any modification or revocation thereof, must be submitted to and pre-approved by 
the Compliance Officer, who may impose such conditions on the implementation and operation of the Trading Plan as the 
Compliance Officer deems necessary or advisable. The Compliance Officer may prescribe certain forms of Trading Plans to 
which employees’ Trading Plans must conform. The Compliance Officer may also require that Trading Plans be arranged with a 
specified broker. However, compliance of the Trading Plan to 

|
the terms of Rule 10b5-1 and the execution of transactions pursuant to the Trading Plan are the sole responsibility of the person 
initiating the Trading Plan, not the Company or the Compliance Officer.
Trading Plans do not exempt individuals from complying with Section 16 short-swing profit rules or liability.
Rule 10b5-1 presents an opportunity for insiders to establish arrangements to sell (or purchase) Company stock without 
the restrictions of trading windows and blackout periods, even when there is undisclosed material information. A Trading Plan 
may also help reduce negative publicity that may result when key executives sell the Company’s stock. Rule 10b5-1 only 
provides an “affirmative defense” in the event there is an insider trading lawsuit. It does not prevent someone from bringing a 
lawsuit.
A director, officer, employee or consultant may enter into a Trading Plan only in good faith and only when he or she is 
not in possession of material, non-public information, and only during a trading window period outside of the trading blackout 
period. Although transactions effected under a Trading Plan will not require further pre-clearance at the time of the trade, any 
transaction (including the quantity and price) made pursuant to a Trading Plan of a Section 16 reporting person must be reported 
to the Company promptly on the day of each trade to permit the Company’s filing coordinator to assist in the preparation and 
filing of a required Form 4. 
The Company reserves the right from time to time to suspend, discontinue or otherwise prohibit any transaction in the 
Company’s securities, even pursuant to a previously approved Trading Plan, if the Compliance Officer or the Board of Directors, 
in its discretion, determines that such suspension, discontinuation or other prohibition is in the best interests of the Company. 
Any Trading Plan submitted for approval hereunder should explicitly acknowledge the Company’s right to prohibit transactions 
in the Company’s securities. Failure to discontinue purchases and sales as directed shall constitute a violation of the terms of this 
Policy and result in a loss of the exemption set forth herein. 
Officers, directors, employees and consultants may adopt Trading Plans with brokers that outline a pre-set plan for trading of 
the Company’s stock, including the exercise of options. Trades pursuant to a Trading Plan generally may occur at any time. 
However, the Company requires a cooling-off period under which no purchases or sales may occur for:
•
Section 16 reporting persons that extends to the later of 90 days after adoption or modification of a Trading Plan 
or two business days after filing of the Form 10-K or Form 10-Q covering the fiscal quarter in which the 
Trading Plan was adopted, up to a maximum of 120 days; and 
•
employees and any other persons, other than the Company, that extends 30 days after adoption or modification 
of a Trading Plan.
Please review the following description of how a Trading Plan works. 
Pursuant to Rule 10b5-1, an individual’s purchase or sale of securities will not be “on the basis of” material, non-public 
information if:

|
•
First, before becoming aware of the information, the individual in good faith enters into a binding contract to 
purchase or sell the securities, provides instructions to another person to sell the securities or adopts a written 
plan for trading the securities (i.e., the Trading Plan).
•
Second, the Trading Plan must either:
•
specify the amount of securities to be purchased or sold, the price at which the securities are to be 
purchased or sold and the date on which the securities are to be purchased or sold; or
•
include a written formula or computer algorithm for determining the amount, price and date of the 
transactions; and
•
prohibit the individual from exercising any subsequent influence over the purchase or sale of the 
Company’s stock under the Trading Plan in question.
•
Third, for Section 16 reporting persons, the Trading Plan must include a representation that the Section 16 
reporting person is (i) not aware of any material non-public information about the Company or its securities and 
(ii) adopting the Trading Plan in good faith and not as part of a plan or scheme to evade Rule 10b-5.
•
Fourth, the purchase or sale must occur pursuant to the Trading Plan and the individual must not enter into a 
corresponding hedging transaction or alter or deviate from the Trading Plan.
2.	
Revocation of and Amendments to Trading Plans
Revocation of Trading Plans should occur only in unusual circumstances. Effectiveness of any revocation, modification 
or amendment of a Trading Plan will be subject to the prior review and approval of the Compliance Officer. Revocation is 
effected upon written notice to the broker. You should note that revocation of a Trading Plan can result in the loss of an 
affirmative defense for past or future transactions under a Trading Plan. 
A person acting in good faith may modify a prior Trading Plan so long as such modifications are made outside of a 
quarterly blackout or other blackout period and at a time when the Trading Plan participant does not possess material, non-public 
information. Modifications of a Trading Plan that change the amount, price or timing of the purchase or sale of the securities 
underlying a Trading Plan will trigger a new cooling-off period (as described in Section IV.A.1 above).
A Trading Plan shall include provision for suspension or revocation in certain circumstances, such as the announcement 
of a merger or the occurrence of an event that would cause the transaction either to violate the law or be expected to have an 
adverse effect on the Company. The Compliance Officer or administrator of the Company’s stock plans is authorized to notify 
the broker in such circumstances, thereby insulating the insider in the event of suspension or revocation.

|
3.	
Discretionary Plans
Although non-discretionary Trading Plans are preferred, discretionary Trading Plans, where the discretion or control 
over trading is transferred to a broker, are permitted if pre-approved by the Compliance Officer.
The Compliance Officer of the Company must pre-approve any Trading Plan, arrangement or trading instructions, etc., 
involving potential sales or purchases of the Company’s stock or option exercises, including but not limited to, blind trusts, 
discretionary accounts with banks or brokers, or limit orders. The actual transactions effected pursuant to a pre-approved Trading 
Plan will not be subject to further pre-clearance for transactions in the Company’s stock once the Trading Plan or other 
arrangement has been pre-approved by the Compliance Officer. 
4.	
Reporting (if Required)
If required, an SEC Form 144 will be completed and filed by the individual/brokerage firm in accordance with the 
existing rules regarding Form 144 filings. A footnote at the bottom of the Form 144 should indicate that the trades “are in 
accordance with a Trading Plan adopted under 10b5-1.” For Section 16 reporting persons, Forms 4 are required to be filed before 
the end of the second business day following the date that the broker, dealer or plan administrator informs the individual that a 
transaction was executed, provided that the date of such notification is not later than the third business day following the trade 
date. A similar footnote should be placed at the bottom of the Form 4 as outlined above.
5.	
Options
Exercises of options for cash may be executed at any time. “Cashless exercise” option exercises are subject to trading 
windows. However, the Company will permit same day sales under Trading Plans. If a broker is required to execute a cashless 
exercise in accordance with a Trading Plan, then the Company must have exercise forms attached to the Trading Plan that are 
signed, undated and with the number of shares to be exercised left blank. Once a broker determines that the time is right to 
exercise the option and dispose of the shares in accordance with the Trading Plan, the broker will notify the Company in writing 
and the administrator of the Company’s stock plans will fill in the number of shares and the date of exercise on the previously 
signed exercise form. The insider should not be involved with this part of the exercise.
6.	
Trades Outside of a Trading Plan
During an open trading window, trading in the Company securities not pursuant to an approved Trading Plan is allowed 
as long as the trading instructions in the approved Trading Plan continue to be followed. 
7.	
Public Announcements
The Company may make a public disclosure or announcement that Trading Plans and non-Rule 10b5-1 trading 
arrangements are being adopted, modified or terminated as required by SEC rules or otherwise in the Company’s discretion. It 
will consider in each case whether a public disclosure or announcement of a particular Trading Plan should be made. It may also 
make public 

|
disclosures, announcements or respond to inquiries from the media as transactions are made under a Trading Plan.
8.	
Prohibited Transactions
The transactions prohibited under Section V of this Policy, including among others short sales and hedging transactions, 
may not be carried out through a Trading Plan or other arrangement or trading instruction involving potential sales or purchases 
of the Company’s securities.
9.	
Limitations on Liability
None of the Company, the Compliance Officer or the Company’s other employees will have any liability for any delay 
in reviewing, or refusal of, a Trading Plan submitted pursuant to this Policy. Notwithstanding any review of a Trading Plan 
pursuant to this Policy, none of the Company, the Compliance Officer or the Company’s other employees assumes any liability 
for the legality or consequences relating to such Trading Plan to the person adopting such Trading Plan.
B.	
Section 16: Insider Reporting Requirements, Short-Swing Profits and Short Sales (Applicable to Officers, 
Directors and 10% Stockholders)
1.	
Reporting Obligations Under Section 16(a): SEC Forms 3, 4 and 5
Section 16(a) of the 1934 Act generally requires all officers, directors and beneficial owners of more than ten percent of 
our outstanding stock (each, a “10% stockholder”) (each, a “Section 16 insider”), within 10 days after the Section 16 insider 
becomes an officer, director, or 10% stockholder, to file with the SEC an “Initial Statement of Beneficial Ownership of 
Securities” on Form 3 listing the amount of the Company’s stock, options and warrants which the Section 16 insider beneficially 
owns. Following the initial filing on Form 3, changes in beneficial ownership of the Company’s stock, options and warrants, 
including as a result of a disposition of equity securities by gift, must be reported on Form 4, generally within two business days 
after the date on which such change occurs, or in certain cases on Form 5, within 45 days after fiscal year end. The two-day Form 
4 deadline begins to run from the trade date rather than the settlement date (or for gifts, the date of the gift). A Form 4 must be 
filed even if, as a result of balancing transactions, there has been no net change in holdings. In certain situations, purchases or 
sales of Company stock made within six months prior to the filing of a Form 3 must be reported on Form 4. Similarly, certain 
purchases or sales of Company stock made within six months after an officer or director ceases to be an insider must be reported 
on Form 4.
2.	
Recovery of Profits Under Section 16(b)
For the purpose of preventing the unfair use of information which may have been obtained by a Section 16 insider, any 
profits realized by any officer, director or 10% stockholder from any “purchase” and “sale” of Company stock during a six-month 
period (so called “short-swing profits”) are subject to recovery by the Company. When such a purchase and sale occurs, good 
faith is no defense. The Section 16 insider is liable even if compelled to sell for personal reasons, and even if the sale takes place 
after full disclosure and without the use of any inside information.

|
The liability of an insider under Section 16(b) of the 1934 Act is only to the Company itself. The Company, however, 
cannot waive its right to short swing profits, and any Company stockholder can bring suit in the name of the Company. Reports 
of ownership filed with the SEC on Form 3, Form 4 or Form 5 pursuant to Section 16(a) (discussed above) are readily available 
to the public, and certain attorneys carefully monitor these reports for potential Section 16(b) violations. In addition, liabilities 
under Section 16(b) may require separate disclosure in the Company’s annual report to the SEC on Form 10-K or its proxy 
statement for its annual meeting of stockholders. No suit may be brought more than two years after the date the profit was 
realized. However, if the Section 16 insider fails to file a report of the transaction under Section 16(a), as required, the two-year 
limitation period does not begin to run until after the transactions giving rise to the profit have been disclosed. Failure to report 
transactions and late filing of reports require separate disclosure in the Company’s proxy statement.
Officers and directors should consult the Company’s “Short-Swing Profit Rule Section 16(b) Checklist”, in addition to 
consulting the Compliance Officer prior to engaging in any transactions involving the Company’s securities, including without 
limitation, the Company’s stock, options or warrants.
3.	
Short Sales Prohibited Under Section 16(c)
Section 16(c) of the 1934 Act prohibits insiders absolutely from making short sales of the Company’s equity securities. 
Short sales include sales of stock which the insider does not own at the time of sale, or sales of stock against which the insider 
does not deliver the shares within 20 days after the sale. Under certain circumstances, the purchase or sale of put or call options, 
or the writing of such options, can result in a violation of Section 16(c). Insiders violating Section 16(c) face criminal liability.
The Compliance Officer should be consulted if you have any questions regarding reporting obligations, short-swing 
profits or short sales under Section 16.
C.	
Rule 144 (Applicable to Officers, Directors and 10% Stockholders)
Rule 144 provides a safe harbor exemption to the registration requirements of the Securities Act of 1933, as amended, 
for certain resales of “restricted securities” and “control securities.” “Restricted securities” are securities acquired from an issuer, 
or an affiliate of an issuer, in a transaction, or chain of transactions, not involving a public offering. “Control securities” are any 
securities owned by directors, executive officers or other “affiliates” of the issuer, including stock purchased in the open market 
and stock received upon exercise of stock options. Sales of Company securities by affiliates (generally, directors, officers and 
10% stockholders of the Company) must comply with the requirements of Rule 144, which are summarized below:
•
Current Public Information. The Company must have filed all SEC-required reports during the last 12 months.
•
Volume Limitations. Total sales of Company common stock by a covered individual for any three-month period 
may not exceed the greater of: (i) 1% of the total number of outstanding shares of Company common stock, as 
reflected in the most recent report or statement published by the Company, or (ii) the average 

|
weekly reported volume of such shares traded during the four calendar weeks preceding the filing of the 
requisite Form 144.
•
Method of Sale. The shares must be sold either in a “broker’s transaction” or in a transaction directly with a 
“market maker.” A “broker’s transaction” is one in which the broker does no more than execute the sale order 
and receive the usual and customary commission. Neither the broker nor the selling person can solicit or arrange 
for the sale order. In addition, the selling person or Board member must not pay any fee or commission other 
than to the broker. A “market maker” includes a specialist permitted to act as a dealer, a dealer acting in the 
position of a block positioner, and a dealer who holds himself out as being willing to buy and sell Company 
common stock for his own account on a regular and continuous basis. 
•
Notice of Proposed Sale. A notice of the sale (a Form 144) must be filed with the SEC at the time of the sale. 
Brokers generally have internal procedures for executing sales under Rule 144 and will assist you in completing 
the Form 144 and in complying with the other requirements of Rule 144.
If you are subject to Rule 144, you must instruct your broker who handles trades in Company securities to follow the 
brokerage firm’s Rule 144 compliance procedures in connection with all trades.
VII.	EXECUTION AND RETURN OF CERTIFICATION OF COMPLIANCE
After reading this Policy, all officers, directors and employees and Applicable Consultants may be asked periodically to 
certify their compliance with the terms and provisions of this Policy.
 
* * * * *
 

 
 
SCHEDULE I
INDIVIDUALS SUBJECT TO BLACKOUT PERIODS
All directors and executive officers of the Company
All UNITY Employees
 
Applicable Consultants - Consultants that the Compliance Officer may include from time to time

 
 
SCHEDULE II
 
INDIVIDUALS SUBJECT TO PRE-CLEARANCE REQUIREMENT
 
 
ALL DIRECTORS
 
 
ALL EXECUTIVE OFFICERS
 
OTHER EMPLOYEES
All other employees with the title of “Vice 
President” or above. 
All employees within the legal and IP teams.
All employees within the development team
All executive assistants.
Other employees that the Compliance Officer may 
include from time to time.
APPLICABLE CONSULTANTS
Consultants that the Compliance Officer may 
include from time to time
 
 
 
 
 

Exhibit 23.1
 
Consent of Independent Registered Public Accounting Firm 
 
We consent to the incorporation by reference in the following Registration Statements:
 
(1)
Registration Statements (Form S-3 Nos. 333-275924, 333-267886, 333-263574) of Unity Biotechnology, Inc.,
(2)
Registration Statement (Form S-8 No. 333-270567) pertaining to the 2018 Incentive Award Plan, 2018 Employee Stock Purchase Plan and 2020 
Employment Inducement Incentive Award Plan, as amended of Unity Biotechnology, Inc.,
(3)
Registration Statements (Form S-8 Nos. 333-263576, 333-254619, 333-237088, 333-230086, 333-278679) pertaining to the 2018 Incentive 
Award Plan and 2018 Employee Stock Purchase Plan of Unity Biotechnology, Inc.,
(4)
Registration Statement (Form S-8 No. 333-250926) pertaining to the 2020 Employment Inducement Incentive Award Plan, as amended of Unity 
Biotechnology, Inc.,
(5)
Registration Statement (Form S-8 No. 333-237474) pertaining to the 2020 Employment Inducement Incentive Plan of Unity Biotechnology, Inc.,
(6)
Registration Statement (Form S-8 No. 333-224726) pertaining to the 2013 Equity Incentive Plan, 2018 Incentive Award Plan, and 2018 
Employee Stock Purchase Plan of Unity Biotechnology, Inc.
 
of our report dated March 7, 2025, with respect to the financial statements of Unity Biotechnology, Inc. included in this Annual Report (Form 10-K) of 
Unity Biotechnology, Inc. for the year ended December 31, 2024.
/s/ Ernst & Young LLP
San Mateo, California 
March 7, 2025
 

 
 
Exhibit 31.1
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Anirvan Ghosh, certify that:
1.
I have reviewed this Annual Report on Form 10-K of Unity Biotechnology, Inc. for the year ended December 31, 2024;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the 
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this 
report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the 
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in 
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-
15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to 
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those 
entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our 
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for 
external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the 
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent 
fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to 
materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to 
the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are 
reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal 
control over financial reporting.
 
Date: March 7, 2025
 By:
/s/ Anirvan Ghosh
 
  
Anirvan Ghosh, Ph.D.
 
  
Chief Executive Officer
(Principal Executive Officer)
 

 
 
Exhibit 31.2
CERTIFICATION PURSUANT TO
RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Lynne Sullivan, certify that:
1.
I have reviewed this Annual Report on Form 10-K of Unity Biotechnology, Inc. for the year ended December 31, 2024;
2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the 
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this 
report;
3.
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the 
financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in 
Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-
15(f)) for the registrant and have:
(a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to 
ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those 
entities, particularly during the period in which this report is being prepared;
(b)
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our 
supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for 
external purposes in accordance with generally accepted accounting principles;
(c)
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the 
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent 
fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to 
materially affect, the registrant's internal control over financial reporting; and
5.
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to 
the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are 
reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal 
control over financial reporting.
 
Date: March 7, 2025
 By:
/s/ Lynne Sullivan
 
  
Lynne Sullivan
 
  
Chief Financial Officer
(Principal Financial and Accounting Officer)
 

 
 
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Unity Biotechnology, Inc. (the “Company”) on Form 10-K for the year ending December 31, 2024 as filed 
with the Securities and Exchange Commission on the date hereof (the “Report”), I, Anirvan Ghosh, Chief Executive Officer of the Company, and Lynne 
Sullivan, Chief Financial Officer of the Company, do each hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-
Oxley Act of 2002, that:
(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the 
Company.
 
Date: March 7, 2025
 By:
/s/ Anirvan Ghosh
 
  
Anirvan Ghosh, Ph.D. 
 
  
Chief Executive Officer
(Principal Executive Officer)
 
Date: March 7, 2025
 By:
/s/ Lynne Sullivan
 
  
Lynne Sullivan
 
  
Chief Financial Officer
(Principal Financial and Accounting Officer)